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The development of antibody based therapeutics has come of age, being a profoundly significant 
and dominant technology for the pharmaceutical industry. Antibody based therapies treat a plethora 
of indications including cancers, infections and autoimmune diseases, with many under 
development for new or improved treatments. The specificity of antibodies to biological targets and 
their ability to elicit an immune response are the primary functions behind the treatment strategy. 
Biotechnological advancements have led to the strategic design of fragment, drug conjugated and 
fusion antibody platforms along with modulated affinity to biological targets and immune effector 
functions, for the development of highly tailored and more efficacious treatment strategies. 
To achieve improved antibody manufacturing outcomes and treatment strategies, considerations in 
drug design can address key challenges through the antibody discovery, production and formulation 
processes. Currently, the manufacture of antibody based therapeutics is costly, owing to production 
being limited to cell-based expression systems and loss of biologically active antibody in 
downstream processes that cause degradation and aggregation. Furthermore to achieve 100% 
bioavailability, antibody based therapeutics are currently limited to lyophilised and liquid based 
formulations for intravenous or subcutaneous delivery.  
In considering the current technologies being applied to antibody based therapeutics, along with the 
challenges faced in manufacture, formulation and treatment strategies, this body of work was 
directed towards the strategic design of model antibodies trastuzumab and adalimumab, for 
enhancing target affinity and reducing self-association and aggregation propensity. Mutations were 
designed in trastuzumab’s Fab region for enhanced affinity to target HER2, and N-linked 
glycosylation sites introduced for the steric hindrance of colloidal self-association interactions. The 
hyper-glycosylated mutations were transferred to adalimumab to demonstrate proof-of-concept in 
this strategy of reducing self-association. Prior to mutational project design, appropriate expression 
systems for lab-scale production of trastuzumab and adalimumab were established. Mutant libraries 
were designed, produced, expressed and characterised prior to stability profiling and binding kinetic 
analysis against their relevant biological targets and Fcγ receptors.  
The findings from this body of work demonstrated that in vitro assessment of affinity mutations 
corroborated with in silico predictions, highlighting the success of this approach for biobetter 
development through election of lead candidates by design. Furthermore, in vitro assessment of 
strategically hyper-glycosylated libraries produced several lead candidates with enhanced stability 
profiles. Moreover, the stability profiles were transferrable between the trastuzumab and 
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adalimumab mutants demonstrating the applicability and adaptability of this approach in 
engineering stability enhanced mAbs by design.  
The implications from the outcomes of this body of work show great potential in the use of in silico 
analysis for the strategic and efficient development of biobetters, with the aim of improving 
manufacture and treatment outcomes by design.  
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A brief overview of the chapters in this thesis is as follows: 
Chapter 1 is a comprehensive literature review that discusses the current knowledge and state of the 
art in the field of therapeutic antibodies, providing significant insight and grounding for the 
reasoning behind the projects pursued for this body of work. Chapter 2 reports on establishing an 
expression vector library for the lab scale production of trastuzumab and adalimumab, as model 
antibodies for engineering projects. Chapter 3 reports on the optimisation of expression and 
purification in the lead up to the design and implementation of antibody engineering projects for 
enhanced affinity (Chapter 4) and stability (Chapter 5 and Chapter 6). Chapter 7 is a 
comprehensive discussion of the results and outcomes from this body of work, further 
understanding and future perspectives that this work has contributed to current knowledge in the art. 
A more detailed overview of the chapters in this thesis is as follows: 
Chapter 1 discusses and highlights the clinical significance of antibody based immunotherapies, 
specific challenges, current platforms and future trajectories of the development of antibody based 
immunotherapies. Therapeutic antibodies trastuzumab and adalimumab are discussed specifically as 
model antibodies chosen for this body of work, representing current treatment strategies for cancer 
and autoimmune diseases. State of the art knowledge in antibody engineering is extensively and 
comprehensively discussed as a tool for addressing key challenges in the manufacture, formulation 
and administration of therapeutic antibodies. And finally, this chapter aims to highlight the rationale 
of the directions pursued in this body of work, of which trastuzumab and adalimumab are chosen as 
model antibodies for engineering to enhance affinity and stability for improving formulation and 
administration strategies. 
Chapter 2 reports on the development of a library of expression vectors that carry the genes for 
expression of trastuzumab and adalimumab in mammalian cell culture. Upon successful cloning, 
antibody expression was compared between the vectors in a pilot transient expression system to 
ascertain the most appropriate expression systems to proceed with for the chapters following. This 
was the crucial starting point from which antibody expression conditions were optimised in the lead 
up to the design and production of antibody mutant libraries for in vitro testing.  
Chapter 3 reports on establishing a high yielding stable trastuzumab expression system from which 
purification strategies were optimised, and further describes a simple format of adapting adherent 
cells to suspension in the lead up to expression. This protocol was developed to be simple, cost-
effective and reasonably high-yielding to express, purify and characterise trastuzumab in 
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preparation of producing mutant libraries. Chapter 3 was published in the Journal of Visualized 
Experiments: 
Elgundi, Z., Sifniotis, V., Reslan, M., Cruz, E., Kayser, V. (2017). Laboratory Scale Production and 
Purification of a Therapeutic Antibody. Journal of Visualized Experiments, 119: e55153. 
Chapter 4 reports on trastuzumab being used as a model antibody to investigate rationally designed 
residue substitutions for enhanced affinity to target HER2. These substitutions were predicted to 
enhance affinity based on in silico results reported to us from our collaborators from A/Prof Serdar 
Kuyucak’s Computational Biophysics Group, School of Physics, The University of Sydney. Several 
QuikChange™ (Agilent Technologies) whole-plasmid mutagenesis strategies were compared and 
optimised to produce a trastuzumab affinity mutant library in the lead up to in vitro testing of 
relative binding affinity and kinetics. In vitro and in silico results were in agreement suggesting that 
computational tools are useful and powerful in predicting and rationally designing lead antibody 
candidates with a tailored specificity to target. 
Chapter 5 reports on trastuzumab being used as a model antibody to investigate rationally designed 
residue substitutions that introduce N-linked glycans in the Fab region for enhancing stability and 
resistance to aggregation. Substitutions were identified as regions that had the potential to sterically 
hinder a reported aggregation-prone region. A trastuzumab glycosylation mutant library was 
produced through an optimised mutagenesis and transient expression system in the lead up to 
in vitro screening of stability enhancement and retention of biological functions. The library 
produced mutants of varying stabilities with 2 lead candidates elected for further investigation, 
demonstrating the effectiveness of this approach in designing antibodies with enhanced stability 
profiles. 
Chapter 6 reports on demonstrating the proof-of-concept in stability enhancement from the 
glycosylation project reported in Chapter 5 by transferring the glycosylation mutations in 
adalimumab for comparison. As per the trastuzumab glycosylation study, an adalimumab 
glycosylation mutant library was produced through an optimised mutagenesis and transient 
expression system in the lead up to in vitro screening of stability enhancement and retention of 
biological functions. Chapter 6 employed additional purification strategies and more rigorous 
stability data to validate the interpretation of stability enhancement in the mutant library. Chapter 6 
was prepared for publication, pending patent embargo, to the European Journal of Pharmaceutics 
and Biopharmaceutics: 
5 
 
Reslan, M., Sifniotis, V., Cruz, E., Sumer-Bayraktar, Z., Cordwell, S., Kayser, V. (2018). 
Enhancing the stability of adalimumab by engineering additional glycosylation motifs. European 
Journal of Pharmaceutics and Biopharmaceutics. 
Chapter 7 summarises and discusses the findings of this body of work, in reflection of the aims and 
challenges addressed. The success of strategic engineering approaches applied in this fbody of work 
is highlighted, demonstrating the success of this approach in elucidating lead candidates by design 
for more efficient biobetter development. The achieved outcomes are reiterated with consideration 
and further understanding of what this body of work has contributed to current knowledge in the art. 
And finally, further investigation of the elected lead candidates are discussed for consideration of 
future perspectives in biobetter development and formulation strategies.   
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Since thesis submission, Chapter 1 had been repurposed as a review article entitled  
“Current Advancements in Addressing Key Challenges of Therapeutic Antibody Development, 
Manufacture and Formulation”  
and is accepted for publication in Antibodies: 
Sifniotis, V., Cruz, E., Eroglu, B., Kayser, V., Current Advancements in Addressing Key 
Challenges of Therapeutic Antibody Design, Manufacture and Formulation. Antibodies (2019) 8, 
36. DOI: 10.3390/antib8020036  
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1 Whole Therapeutic Monoclonal Antibodies; Introduction and Significance 
Since the first therapeutic monoclonal antibody (mAb) Orthoclone OKT3® was approved by the 
FDA in 1986, whole antibody therapeutics have persistently remained the most dominant and 
significant biologic therapeutic platform in the pharmaceutical industry [1, 2]. To date, therapeutic 
antibodies treat a plethora of indications including cancers, infections, autoimmune, cardiovascular 
and neurological diseases [3]. The development of therapeutic antibodies has been revolutionary 
due to the specificity of antibodies to a biological target and their ability to elicit a response that 
engages the immunological destruction of the target. The whole antibody therapeutics platform is 
regarded as the most promising class of pharmaceutical technology to date; it is continually being 
applied to newly identified biological targets and implemented in many formats to produce 
strategically engineered next generation antibody therapeutics, otherwise termed “biobetters” [4-9]. 
The international ImMunoGeneTics information system® (IMGT®) database reveals that as of 
December 2018, 65 whole antibodies and 19 next generation fragment or recombinant fusion 
antibody based therapies are approved for clinical use, with hundreds more in clinical trials 
expected to reach market.  
Of the therapeutic whole antibodies approved for use, the majority (74%) are IgG1 isotype (Figure 
1A) owing to its superior ability to activate the complement pathway and mediate antibody-
dependant cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) 
whilst maintaining a long half-life (approximately 23 days) in patient serum [4]. IgG2 and IgG4 
therapeutic isotypes have also been developed despite their inferior immunological functions as 
compared to IgG1 and are thus applied as antagonists, blocking the activation of key disease 
bearing signalling pathways, and more recently as carriers for potent drugs that is ideal for their 
minimal engagement with immune effector cells [10-12].  
Originally derived from animal origins such as mouse and rat, humanisation of therapeutic mAbs 
was the first revolutionary step to improving the treatment platform, as animal derived mAbs 
exhibit immunogenicity and are less efficient than human mAbs at activating the human immune 
system [13]. Humanisation has become standard practice for the development of new mAb 
therapies, which has led to the majority of whole therapeutic mAbs as either humanised (41%) or 
wholly human (44%) approved for clinical use (Figure 1B). 
Whole therapeutic mAbs are presently the dominant antibody platform approved for clinical use 
(Figure 1C) although antibody engineering technologies have advanced in recent years to produce 
highly optimised, strategically engineered biobetter therapies, along with biosimilar mAbs reaching 
market to compete against their originator. Further whole mAb formats include antibody-drug 
conjugates (ADCs) that have exceptional potency, isotype switched and glyco-engineered whole 
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mAbs for modulated Fc effector function and bispecific mAbs with engagement to dual biological 
targets. Fragments of mAbs such as the crystallisable fragment (Fc), antigen binding fragment (Fab) 
and single-chain variable fragment (scFv) possess key functions such specificity to a biological 
target or immunological activation. The isolation of these fragments for fusion with other mAb 
Figure 1 Pie charts depicting the proportions of whole therapeutic mAb isotypes (A), whole 
therapeutic mAbs species (B) and therapeutic formats (C) approved for use as of December 2018, 
IMGT®.  
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fragments, biologically functional proteins, mediators, cytotoxic drugs or drug carriers has been the 
crux of ingenuity in developing the next generation of biobetter therapies [4-12, 14-16].  
1.1 Trastuzumab; Model Antibody for Cancer Therapy  
Breast cancer is the most diagnosed and has the highest morbidity of all cancers in females 
worldwide, and is the second most commonly diagnosed of all cancers, posing a substantial burden 
on global disease [17]. HER2-positive breast cancer is diagnosed in approximately 20% of breast 
cancers and is a particularly aggressive cancer that can progress to metastasis [18]. The 
development of therapeutic whole antibody trastuzumab (Herceptin®) has been revolutionary in the 
evolution of HER2-positive breast cancer treatment whereby adjuvant treatment in combination 
with chemotherapy dramatically improves prognosis and overall survival [18-22]. HER2 is a cell 
receptor that is overexpressed in HER2-positive breast cancers and contains an intracellular and 
extracellular region. Trastuzumab is a humanised IgG1/κ mAb and acts by binding to the 
extracellular domain of HER2 to promote ADCC of tumour tissue for direct elimination [21] and 
downregulate the PI3K/AKT pathways that promote tumour cell survival and proliferation, thereby 
dampening the tumours aggression and making chemotherapy more potent [22]. However, the 
binding of trastuzumab to HER2 induces cellular uptake, internalisation and catabolism of 
trastuzumab into the breast cancer tumour cells, which limits the effect of ADCC [23]. Kadcyla®, a 
trastuzumab-drug conjugate takes advantage of this internalisation pathway to induce tumour cell 
death through the targeted delivery and release of cytotoxic drug mertansine into HER2 
overexpressing cancerous tissue [24]. 
Despite the improved clinical outcomes of HER2-positive breast cancers through trastuzumab 
combination therapy, several challenges have arisen that require the need for additional treatment 
options. Resistance to trastuzumab therapy is observed in HER2-positive breast cancer patients 
either initially (de novo) or it becomes acquired over time which eventually leads to disease 
progression [25]. Furthermore, trastuzumab is reported to induce adverse side effects such as 
cardiotoxicity leukopenia, pulmonary toxicity and hypersensitivity [18, 20-22, 26-28]. Pertuzumab 
(Perjeta®) was developed as another whole mAb therapeutic that targets a different epitope of HER2 
to produce a similar clinical effect and enhanced efficacy in combination with trastuzumab; 
however, cardiotoxicity was displayed in pertuzumab suggesting a correlation of this adverse effect 
with targeting HER2 specifically [21, 22, 29]. Small molecule drugs that inhibit HER2 have also 
been developed for use following resistance to trastuzumab, such as lapatinib (Tykerb®), afatinib 
(Gilotrif®) and neratinib (Nerlynx®); however, adverse side effects are more prevalent in these 
treatment strategies, making trastuzumab the preferred first line treatment in combination with 
chemotherapy [20, 21, 26, 30]. 
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Trastuzumab was traditionally formulated as a lyophilised powder for intravenous (IV) 
administration, although more recently as a fixed dose in pre-filled syringe for subcutaneous (SC) 
injection, subject to FDA approval [31-33]. The IV formulation reconstitutes the lyophilised powder 
to a concentration of 21 mg/mL, to be further diluted for administration to 4 mg/kg as a loading 
dose, and 2 mg/kg for weekly maintenance doses [28]. In comparison, the fixed SC dose (600 mg, 5 
mL) is administered once every three weeks, regardless of patient weight [33]. Between the 
formulation strategies, SC administration produces more adverse side effects such as infections that 
may be attributed to the mode of administration, although it does not require preparation and 
patients reported that they preferred SC administration [20, 33]. 
Trastuzumab is produced in a stable chinese hamster ovary (CHO) expression system, with 
gentamicin selection [28]. The entire trastuzumab peptide sequences for the heavy and light chains 
are publicly available on the IMGT® (2D ID: 7637) and DrugBank® (ID: DB00072) databases [34, 
35]. Crystal structures of various trastuzumab fragments and mutant variants are publicly available 
on the Research Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB PDB®) [36]. 
Of notable interest, crystal structure of the HER2 extracellular domain complexed to trastuzumab 
Fab (PDB ID: 1N8Z) is useful for in silico analysis of target binding. 
1.2 Adalimumab; Model Antibody for Autoimmune Disorder Therapy 
Autoimmune disorders encompass a wide range of chronic diseases that are often associated with 
comorbidities; they pose a substantial global disability burden and are predominantly in the aging 
population [37]. Adalimumab (Humira®) is used to treat many types of autoimmune disorders and 
stands out globally as the single most lucrative drug, generating 18.4 billion US dollars in 2017 [1]. 
Many autoimmune disorders such as rheumatoid arthritis, osteoarthritis, psoriatic arthritis, Crohn’s 
disease and ulcerative colitis are hypersensitised to TNF-α levels making it a primary target for 
therapy [38-41]. TNF-α is a key cytokine produced and secreted in activated innate immune cells 
that induces systemic inflammation, in the context of autoimmune disorders inflammation is 
spontaneously activated and misdirected to healthy tissues leading to tissue degenerative diseases.  
Hypersensitisation to TNF-α could be due to a deregulation in TNF-α expression (TNF-α 
overexpression) or single-nucleotide polymorphisms in key downstream immune pathways causing 
a demodulated inflammatory response (increased sensitivity to TNF-α) [41, 42]. Adalimumab is one 
of five mAb based disease-modifying antirheumatic drugs (DMARDs) that specifically targets 
TNF-α and have been revolutionary in the treatment of autoimmune diseases as they elicit a rapid 
and sustained suppression of TNF-α induced inflammatory disease. Adalimumab acts by binding to 
both the secreted form of TNF-α (soluble homotrimeric) and to membrane-bound TNF-α to 
promote ADCC for direct elimination and block downstream inflammatory pathways [43]. 
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Adalimumab is a wholly human IgG1/κ therapeutic whole mAb, developed as a second generation 
antibody from its chimeric predecessor infliximab (Remicade®). Along with adalimumab and 
infliximab, additional mAb based anti-TNF-α DMARDs include wholly human mAb golimumab 
(Simponi®), recombinant Fc fusion protein to a TNF receptor (CD120b) etanercept (Enbrel®) and 
PEGylated humanized Fab certolizumab pegol (Cimzia®); however, adalimumab remains the 
dominating anti-TNF-α DMARD treatment option [40, 43, 44].  
As discussed with trastuzumab, resistance to treatment is an ongoing problem relating to all mAb 
therapies, which is more pronounced with chronic autoimmune diseases that require ongoing 
treatment until remission, with the potential to relapse [45, 46]. Adverse effects in adalimumab 
therapy, as with all anti-TNF-α based therapies is the increased risk of infection and delayed wound 
healing due to the dampened immune system, and a higher incidence of lymphoma. To mitigate risk 
of these challenges, mAb therapeutics are not issued as a first-line treatment and are primarily 
considered in combination with current effective small molecule DMARD therapies for a superior 
recovery strategy. In the instance of resistance to treatment over prolonged exposure, switching 
between mAb therapies is a common practice to prolong efficacy [40, 41, 44].  
Adalimumab is produced in a CHO expression system and is formulated as a fixed dose (40 mg, 0.8 
mL) in pre-filled syringe for SC injection, administered once every other week, regardless of patient 
weight [47]. The entire adalimumab peptide sequences for the heavy and light chains are publicly 
available on the IMGT® (2D ID: 7860) and DrugBank® (ID: DB00051) databases [34, 35]. Crystal 
structures of various adalimumab fragments are publicly available on RCSB PDB® [36], notably 
TNF-α complexed to adalimumab Fab (PDB ID: 3WD5) for in silico analysis of target binding. 
2 Pharmaceutical Development Challenges and Considerations 
Whole therapeutic mAbs require a mammalian expression system to produce the biologically 
functional product; however, mAb fragment and recombinant fusion mAb products with simplified 
(or lacking) glycosylation are suitable for lower organism expression platforms [48]. Unlike 
oligopeptides that can be chemically synthesised, whole therapeutic mAbs are considerably larger 
(monomer ranging from 140 – 160 kDa) and comprise of four peptide chains (two heavy and two 
light chains) bound together by disulphide bonds. Further to this, antibodies contain glycosylation 
in a conserved region of the Fc (N297) that contributes to its stability and immune effector 
functions [49]. Aside from peptide synthesis, cell machinery is required to glycosylate, fold, orient 
and covalently bind the antibody peptide chains in order to produce the complete, biologically 
functional antibody product for secretion and purification. Manufacturing biologically functional 
whole mAb product is therefore commercially unfeasible through chemical synthesis, and 
insufficient in lower organism expression platforms such as bacteria, yeast, insect and plant cells 
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that do not produce the equivalent tertiary structure and glycosylation profiles. In particular, 
bacteria are completely deficient in the machinery to add post-translational glycosylations, yeasts 
hyper-mannosylate glycans which causes immunogenicity, insect cells are deficient in sialylation 
machinery and produce immunogenic glycan structures [48]. Secretion of the mAb product for 
purification is suboptimal for several lower organism expression platforms such as E. coli due to 
poor productivity and harsh culture conditions promoting product degradation. Protein is therefore 
produced intracellularly as inclusion bodies and harvest involves further processing steps such as 
cell lysis, inclusion body recovery, protein solubilisation and renaturation prior to further 
downstream purification steps [50, 51]. Despite these pitfalls, development of lower organism 
expression systems is of high commercial interest due to the simplified culture conditions, cheaper 
media requirements, rapid organism growth and higher product yield as compared to mammalian 
expression systems.  
In considering the requirements through the entire process of mAb discovery, manufacture, 
formulation and disease treatment, several key challenges arise which have sparked overwhelming 
interest in pursuit of achieving better mAb manufacturing outcomes and treatment strategies. As 
with all biotherapeutics, mAbs and mAb based therapeutics are limited to production in cell-based 
expression systems which is considerably costly and inefficient, yield can vary depending on the 
product and expression system, and downstream processing is necessary to remove biological 
contaminants introduced from the expression system. Despite affinity chromatography being a 
robust technology for the initial capture of mAb for purification, the capture process and further 
downstream processes such as viral inactivation applies the mAb product to harsh pH and salt 
conditions, which can chemically degrade the mAb leading to product instability and loss [5, 52, 
53]. A common challenge as seen with all biotherapeutics, mAbs and mAb based therapeutics are 
currently restricted to lyophilised and liquid based formulations for IV or SC delivery to achieve 
100% bioavailability. Protein self-association and intrinsic stability drive this limitation, in that 
viscosity and propensity to aggregate is dependent on mAb concentration. Formulations are 
optimised to achieve the highest dosing concentration (minimum achievable volume) without 
compromising the quality of the mAb in formulation. Viscosity remains a key limiting factor for 
formulating as a SC administration, certain mAb therapies are suitable and others not based on their 
solubility, self-association and aggregation profiles. Alternative non-invasive administration 
strategies such as pulmonary delivery causes additional mechanical stress that contribute further to 
mAb instability and loss, and oral delivery is unsuitable due to chemical degradation and poor 
absorption in the gastric and intestinal environments [5, 54-58].   
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2.1 Discovery and Manufacture 
Traditional technology for whole therapeutic antibody discovery required the immunisation of 
animals, primarily mice with a target antigen for the generation of a mixed population of B-
lymphocytes producing antibody against the target. The B-lymphocytes would be isolated for 
immortalisation to produce monoclonal hybridoma cell lines that secrete antibody candidates of 
interest, for further panning through display technologies to isolate potential leads [5]. This method 
led to the generation of highly specific mAbs of non-human origin that were potentially 
immunogenic and less efficacious at eliciting an immune response as compared to wholly human 
mAbs. Technologies arose to address immunogenicity by producing chimeric and humanised 
antibodies through grafting of the variable domains (chimeric) or complementarity-determining 
region (CDR) residues (humanised) isolated from lead non-human antibodies to human antibody 
framework. To further improve the humanisation strategy, transgenic mice were developed with 
their murine antibody heavy and light chain genes replaced with equivalent human genes, 
consequently expressing wholly human antibodies for discovery [4-6].  
Phage display technology remains the most prominent selection technology for panning antibody 
gene pools for specificity to a target antigen, it effectively couples the expression of mAb proteins 
to the genes that encode them for panning of high affinity leads. mAb variable genes from B-
lymphocyte pools are isolated through PCR, cloned into a phage expression vector that presents the 
genes on the surface of the phage, the library of vectors is rescued in phage and the phage library 
screened against a specific target antigen. Phage pools undergo several rounds of selection to isolate 
high affinity candidates, the variable genes of the lead mAb candidates can then be isolated and 
sequenced for the design of a mAb drug format and development of a suitable expression platform 
[5, 59]. 
Expression from hybridoma cell line to cell line can vary quite substantially, so to meet the 
commercial need for high expression efficiency, scalability, quality and reproducibility, high 
yielding mammalian expression systems have been developed. mAb genes of interest are introduced 
into suitable expression vectors and transfected into highly efficient mammalian cell lines for 
antibody expression and secretion; mAb can then be directly captured from the culture supernatant 
through affinity chromatography. Currently the majority of mammalian expression systems for 
commercial whole therapeutic antibody expression are based on stable chinese hamster ovary 
(CHO), mouse myeloma (NS0) and mouse hybridoma (Sp2/0) cell lines [4, 5]. However, in the 
context of research and development, transient expression in human cell lines such as embryonic 
kidney (HEK 293), amniotic (CAP), hybrid of HEK 293 and lymphoma (HKB-11) and embryonic 
retina (PER.C6) are favoured over stable CHO expression due to the ease and speed of production 
14 
 
of workable quantities of antibody for preliminary studies [48, 60-64]. Candidates that show 
potential for further investigation would then be developed for high yielding stable expression and 
more rigorous characterisation leading up to therapeutic development. However, a drawback from 
changing from human to hamster expression systems is the difference in glycosylation profile. CHO 
expressed mAbs produce immunogenic non-human glycoform Neu5Gc and have a higher 
composition of sialylation which results in reduced ADCC. Therefore in the early stages of 
development, leads need to be identified and thoroughly characterised in the expression system to 
be developed for commercial manufacture before committing to industrial scale up [48, 60, 61]. 
Amongst other biotherapeutics, approved mAb Fc fusion therapeutics dulglutide (Trulicity®), 
efmoroctocog alpha (Eloctate®) and eftrenonacog alpha (Alprolix®) are manufactured in a HEK 293 
expression system, which is giving rise to the acceptance of human-based expression systems for 
the production of mAb based therapeutics [4]. However, HEK 293 expression systems are prone to 
inducing mAb aggregation in culture, which is detrimental to cell viability and loss of product 
during manufacture, hence HKB-11 and PER.C6 are the preferred commercial human cell line for 
mAb expression [48, 60, 62].  
Established lower organism expression systems for fragment or recombinant fusion mAb 
therapeutics include bacteria such as E. coli, yeast such as S. cerevisiae and P. pastoris, plant such 
as tobacco, algae and insect such as silkworm [5, 48, 65-67]. Expression platforms that use E. coli 
in particular are considered high risk due to potential endotoxin contamination in the mAb product; 
however, several approved mAb fragment and recombinant based therapies are produced in an E. 
coli based expression system including pegol conjugated Fab’ certolizumab pegol (Cimzia®), Fab 
ranibizumab (Lucentis®) and recombinant Fc fusion romiplostim (Nplate®). An emerging in vitro 
cell-free synthesis technology is being developed with bacterial and CHO cell lysates which have 
the potential to alleviate formation of undesirable biological byproducts, as the machinery from the 
cell lysates purely express protein from the mAb genes that are introduced to the system. Although 
this technology is not currently applicable for industrial scale manufacture, it holds much promise 
as an alternative to live culture in that culture maintenance and highly defined media are no longer 
necessary, reactions can run continuously or lysates can be recycled with reproducible results, 
unmodified linear DNA is suitable for the system alleviating a need for multiple cloning steps and 
additional enzymes can be introduced to the system for engineering specific post-translational 
modifications [68-73].  
Current bioprocess engineering and cell line development strategies have been crucial in enhancing 
the manufacturability of mAbs. Many current mAb therapeutic expression platforms make use of 
CHO cell lines that have been commercially developed with dihydrofolate reductase or glutamine 
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synthetase deficiency, for enhanced stability selection through resistance to methotrexate and 
methionine sulfoximine inhibition, respectively [64, 74]. Mammalian cell lines have been adapted 
to suspension culture as it supports higher cell densities and mAb titre in the absence of serum from 
the culture media, for large scale fed-batch, perfusion or continuous culture systems. Further to this, 
cell lines are continually being engineered for enhanced metabolic functions, introducing 
glycosylation pathways, superior secretion and resistance to apoptosis for prolonged survival, in 
efforts to generate super-producer cell lines that can sustain continuous culture [75-81].  
mAb gene and expression vector design and development are specifically tailored to the expression 
system to maximise mAb expression and cell line stabilisation, through host cell codon optimisation 
and the addition of highly efficient transcription, secretion, selection and integration elements [82-
86]. Vectors can contain a single site for gene insertion, for subsequent co-transfection of vectors 
with that carry the antibody heavy and light chains, or both chains can be cloned into a dual 
expression vector. In more elaborately designed recombinant mAb drug formats that require 
expression of several genes, vector technologies have implemented multicistronic expression to 
enhance the efficiency of the vector system. Stable or transient transfection of vectors is performed 
on highly viable cell cultures with high cell density. Antibody heavy and light chain ratios may 
require adjustment in transfection for optimising expression and secretion, a reporter vector that 
expresses green fluorescent protein is typically included to observe transfection efficiency during 
optimisation [87, 88]. Liposome mediated transfection is preferential over all other mammalian 
transfection strategies, induced chemically through the complexing of DNA to a cationic lipid prior 
to or during addition to culture. Polyethylenimine is the most prevalently used transfection reagent 
despite the development of superior reagents such as Lipfectamine™ 2000, Freestyle™ MAX, 
LyoVec™, FuGENE 6™ and TransIT-PRO®, owing to its lower cost and relative efficiency [86, 88-
91].  
The commercial manufacture of mAbs have transitioned to serum-free, chemically defined, animal-
free media which has removed a source of expression variability and has been driven particularly 
from the advent of mad cow disease [64, 92]. Several media supplements such as plant and yeast 
digests (peptones / hydrolysates), surfactants (e.g. Pluronic F-68), DNA methyltransferase 
(azacytidine) and histone deacetylase (sodium butyrate, valproic acid) inhibitors have been found to 
support cell viability and enhance mAb expression [92-97]. Mild hypothermia of the culture has 
also demonstrated to reduce cell expansion, support prolonged cell viability and enhance mAb 
expression [86, 98-102]. Further to this, continuous supplementation  in expression culture of 
uridine, manganese chloride and galactose demonstrated successful glycan engineering of expressed 
mAb, where mAb hyper-galactosylation was promoted to enhance CDC activity [103].  
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In the manufacturing process of fed-batch, perfusion and continuous culture systems, media is 
continuously fed in the culture system whilst parameters such as cell viability, cell density and 
metabolite levels are monitored in real time until the parameters indicate that it is optimal time to 
harvest the expressed mAb from the culture supernatant. In perfusion and continuous culture 
systems, a feed is removed from the culture simultaneously to the media addition, the difference 
being that the cell dilution rate in continuous culture is optimised to remain equal or higher than the 
cell growth rate, which allows the perpetuation mAb expression and requires continuous harvest of 
the supernatant [104-106]. Harvest of the supernatant requires clarification technologies such as the 
use of precipitants / flocculants (e.g. polyethylene glycol, diethylaminoethyl dextran, caprylic acid 
and polyethylenimine), high throughput centrifugation and filtration methods to remove cells and 
biological debris, for lowering the loading burden in the lead up to mAb capture through affinity 
chromatography [50, 107-112]. Centrifugation and filtration causes unavoidable mechanical 
stresses which induces mild mAb product loss through fragmentation and aggregation.  
Protein A-ligand based affinity chromatography is the most robust, efficient and prevalently used 
mAb capture technology, owing to its selectivity and high affinity to various human Fc, and 
efficient dissociation of captured mAb at low pH for reuse. mAb fragment and recombinant formats 
based on Fabs and single chain variable fragments (scFv) are unable to take advantage of Protein A 
affinity capture and alternatives have been developed such as capture to Protein G, M and L which 
bind at different mAb epitopes, ion exchange chromatography and  polyhistidine tagged capture 
through immobilised metal chromatography [112-114]. A further advantage of affinity 
chromatography in manufacture is the integration of a viral inactivation step by holding the low pH 
eluted mAb product prior to further purification steps; however, this applies the mAb product to low 
pH at high concentrations which can induce mild mAb instability, aggregation and formation of 
acidic variants [5, 52, 112, 115, 116].  
Post mAb capture, further polishing steps are required to remove further contaminants such as host 
cell proteins and DNA, leached affinity chromatography ligand and mAb degradation products such 
as fragments, aggregates and ionic variants. The polishing steps are designed based on the specific 
properties of the mAb product such as the isoelectric point and molecular weight (MW), to 
implement appropriate chromatographic technologies such as anion and cation exchange, 
hydrophobic interaction, multimodal and size exclusion that will separate the mAb product from the 
manufacture-introduced impurities [52, 112, 115]. The additional chromatographic steps 
unavoidably apply the mAb product to buffers of varying ionic strength and high concentrations, 
which can again induce mild mAb instability and aggregation. Post polishing steps, the purified 
mAb product undergoes a further viral removal step such as filtration, then buffer exchange and 
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concentration through ultrafiltration or diafiltration methods to prepare the bulk mAb product for 
formulation [112, 117]. 
2.2 mAb Drug Design and Formulation 
Strategies to improve formulation of mAbs and mAb based therapies continues to be an ongoing 
challenge, as is faced with all biotherapeutics. Firstly, whole therapeutic mAbs are unsuitable for 
non-invasive oral, nasal or pulmonary routes of administration as they are susceptible to chemical 
and enzymatic degradation in the gastrointestinal tract and bioavailability through these routes is 
poor, owing to mAbs polar surface charge and relatively large MW limiting transport through 
mucosal membranes. Fragment mAb platforms together with excipient and PEGylation 
technologies have been developed to help circumvent transportation limitations for pulmonary 
delivery specifically, although physical stresses applied to mAb (e.g. shear stresses from 
aerosolisation of liquid formulations for pressurised meter dose and nebulisation delivery, or from 
production of dry powder for inhalation) pose further challenges of mAb instability leading to 
degradation and reduced efficacy. [8, 55, 57]. Few biologics have been successfully approved for 
pulmonary delivery, most notably insulin formulation Afrezza®, and currently an erythropoietin-Fc 
fusion and a nanobody targeting respiratory syncytial virus are in clinical trials, showing promise 
for further development of this administration strategy for both systemic and localised delivery of 
mAb based therapeutics [5, 57]. Several drug carrier technologies such as microencapsulation, 
liposome and nanoparticle formulations inherently enhance the stability and control the release of 
mAbs which can prolong their half-life. These nanocarrier formulation strategies are of intense 
interest as they hold promise for developing less invasive inhaled formulations of mAb based 
therapeutics with superior attributes to currently established formulations [118].  
The majority of currently approved mAb therapeutics are formulated for IV although commercial 
interest has directed technologies to develop injectable mAb formulations which has seen success in 
many approved mAb therapies thus far, primarily SC for systemic delivery, along with few 
intravitreal and intramuscular formulations for tissue specific indications or larger dosing volume, 
respectively. Injectable administrations offers several advantages over IV administration, especially 
in the treatment of chronic disease in regards to reduced burden to allied health services, patient 
tolerance and adherence to treatment; however, the intrinsic physicochemical properties of mAbs 
may be undesirable for injectable formulation. In considering the low volume, injection pressure 
and the typically high (> 100 mg) effective dose of mAb for injectable delivery, viscosity and 
aggregation propensity of mAbs become key formulation challenges to address as they are 
dependent on mAb concentration. Certain mAb therapies are suitable and others not based on their 
solubility, viscosity, self-association, intrinsic stability, aggregation and precipitation profiles. mAb 
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injectable formulations can further be improved with the use of excipients to increase solubility, 
reduce viscosity and enhance the stability of mAbs, and co-formulated with recombinant human 
hyaluronidase specifically as a permeation enhancer for more efficient absorption into tissue, 
although the inclusion of this additional biologic adds further burden to the formulation’s viscosity 
and propensity to aggregate [5, 8, 33, 54-57, 119-121]. mAb therapies for IV administration are 
prepared as lyophilised powder for reconstitution and further dilution, and injectable 
administrations as liquid based formulations in pre-filled syringes. Liquid formulations of mAbs are 
more susceptible to physiochemical degradation, are less stable and have a reduced shelf-life as 
compared to lyophilised formulations. However, drying technologies to produce lyophilised 
formulations apply the mAb to physical stresses that again induce instability and degradation [122-
124].   
mAb therapies are currently restricted to invasive parenteral routes of administration for 100% 
bioavailability and systemic distribution, although local delivery to the specific target tissue such as 
tumours for cancer treatments continues to be a challenge. Penetration to tissue from blood vessels 
is again poor, owing to mAbs polar surface charge and relatively large MW limiting transport 
through physiological barriers and efficiency of tissue penetration is further influenced by systemic 
and local mAb clearance rates. Enhancement to mAbs affinity to their biological target through 
maturation and strategic mutation technologies have led to faster diffusion rates of mAb to target 
for increased efficacy. However, for tumourous tissue specifically, penetration through tumours is 
restricted by the tumour’s binding site barrier, in which antigens expressed on the tumours 
periphery capture the majority of mAb released to surrounding tissue and this effect is exaggerated 
with overexpressed antigen. Enhancement of whole mAbs affinity beyond 1 nM has specifically 
shown that there is no further improvement of tumour diffusion rates and tissue penetration and 
accumulation [125-127]. Increased affinity of mAbs to cellular targets also leads to increased 
uptake, internalisation and catabolism of mAbs which reduces ADCC and increases mAb clearance 
rate, this mechanism is exploited through the development of high affinity ADCs to target the 
delivery and release of potent drugs, inducing targeted cell death [125, 128, 129].  
Fragment mAb platforms have shown better tissue penetration and biodistribution than whole mAb 
therapeutics; however, a pitfall of peptides lacking an Fc region is the highly reduced in vivo half-
life and poor retention times. Technologies to improve the half-life of mAb fragments have been 
primarily through PEGylation, along with strategic Fc mutation and glycosylation engineering to 
enhance neonatal Fc receptor (FcRn) recycling. Furthermore, hyper-glycosylation technology has 
been applied successfully in other biotherapeutics, such as with glycosylated erythropoietin 
Aranesp®. Conversely, nanocarrier platforms that are relatively larger as compared to whole mAbs 
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have demonstrated superior pharmacokinetics and tumour retention, as well as previously 
mentioned enhanced stability and sustained, controlled release of mAbs. These enhanced properties 
have generated considerable interest in developing systemic delivery of mAb-nanoparticle 
platforms for superior tumour penetration, targeted and sustained therapeutic drug delivery. Further 
to nanocarriers, additional formulation strategies developed for the controlled release of mAbs 
include hydrogels and crystalline antibody, which have shown success as stable, injectable 
formulations for development [5, 8, 16, 23, 118, 125, 127, 130, 131]. In addition, to further enhance 
the stability and half-life of other biotherapeutics, recombinant technologies allowed their fusion to 
mAb Fc as to introduce FcRn recycling as a protection mechanism, which has innovatively 
expanded the applicability of mAb based therapeutic platforms [15, 126, 132].  
Modulation of mAbs effector functions through isotype switching, glycoengineering and strategic 
mutations have proved advantageous for the development of more effective mAb treatment 
strategies. mAb binding to Cq1 promotes the complement cascade, FcγR1/BA, FcγR2A and 
FcγR3A/B receptors activate immune effector functions, FcγR2B counter-balances the effector 
response and FcRn prolongs mAb half-life, mAb binding to these receptors is primarily through 
sites in the Chinge, CH2 and the conserved glycosylation region in the Fc (N297). IgG2 and IgG4 
mAbs have reduced effector function as compared to IgG1, and are thus used in instances where 
minimal engagement to the immune system is warranted to increase safety of the mAb therapy, for 
instance with ADCs reducing off-target cytotoxicity. Eculizumab (Soliris®) is the first (and thus far 
only) approved recombinant IgGκ 2(CH1/Chinge) – 4(CH2/CH3) hybrid whole mAb, and further 
cross-sub-class variant mAb therapies are in development with key amino acid substitutions from 
the IgG2 and IgG4 sub-classes introduced for intentionally suppressed effector functions [4, 12]. 
Removal of the conserved glycosylation site through amino acid substitution of N297 or T299 
(aglycosylation) has also demonstrated reduced effector function; however, at the expense of mAb 
stability and is therefore not a suitable strategy for whole mAb therapeutics [10, 15, 16, 133-135]. 
On the other hand, enhancing ADCC and CDC is useful for engaging the immune system to tumour 
tissues in the absence of a conjugated cytotoxic drug. Certain glycoengineered modifications to the 
conserved glycosylation region in the Fc such as deficiency in fucose (afucosylation) and hyper-
galactosylation have demonstrated enhanced mAb binding to FcγR3A specifically for an enhanced 
ADCC effect [12, 125]. Afucosylated mAbs benralizumab (Fasenra™) and mogamulizumab 
(Potleigeo®), and low fucose content mAb obinutuzumab (Gazyva®) are currently approved 
therapies, with several further in development which demonstrates the commercial interest and 
applicability of this technology in improving mAb therapeutics through enhancing ADCC. 
However, the significance of manipulating sialyation in mAb therapeutics is a controversial topic, 
20 
 
with several reports demonstrating a reduction in ADCC and CDC, whilst others reporting no 
observable difference, highlighting a clear need to characterise and define the in vivo efficacy of 
such manipulation [10, 12, 15, 125]. Although no currently approved mAb therapies contain amino 
acid substitutions for improved half-life through modulated binding properties to FcRn, improved 
CDC through binding to complement factor Cq1 or improved ADCC through enhanced binding 
affinity to FcγR1A and 3A, several mutations have been reported and are in development, 
demonstrating the commercial interest in this technology for improving mAb therapeutics [6, 12, 
15, 16, 126, 133, 136-138].  
And finally, the stability profiles of mAbs can be greatly affected by the amino acid composition, 
structure and potential glycosylation in their variable region CDRs that are isolated though the 
screening and maturation process. Elucidating the causes for reduced solubility or increased 
aggregation propensity have to be considered together with the molecular interactions between the 
mAb to biological target as to not compromise affinity. Computational tools have been developed to 
elucidate amino acids within the mAb CDR structure that have a high propensity to aggregate,  and 
strategies for improving solubility and aggregation profiles have been through direct amino acid 
substitutions and strategic addition of glycosylation sites [139-143]. Characterisation of mAb 
stability and target interaction for optimisation is considered a fundamental step as part of 
preliminary drug discovery, as the applicability for development, manufacture and formulation of 
the mAb therapeutic is governed by the mAbs stability profile. 
3 Computational Approaches for Prediction and Rational Design of mAbs  
The advancement of in silico analysis of mAb peptide sequences, structures, conformation and their 
associated biological interaction has been integral to the development of various computational 
tools for characterising, designing and optimising mAb based therapeutics. The generation and 
continued pursuit of mAb structural data for in silico analysis has led to the development of several 
integral databases, notably IMGT®, DrugBank® and PDB® serving as key resources for data mining 
[34-36, 144-146]. Molecular dynamic (MD) simulation analysis has driven the computational 
analysis of the discovery and characterisation of relevant molecular interactions within the mAb 
molecule, mAb binding to biological targets and mAb surface association with the surrounding 
environment. These interactions can infer intrinsic stability, target binding associations, solubility 
and aggregation propensity of the mAb. MD simulations and free energy calculations from crystal 
structures remain key for the highly specific elucidation of mAb-target intramolecular interactions 
that correlate to binding affinity, as significant interactions such as hydrogen-bond formation can be 
predicted and determine the strength of the molecular associations [147]. However, elucidation of 
mAb self-association, solubility and aggregation propensity have been driven by the development 
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of computational modelling and simulation tools that simultaneously analyse mAb topography and 
surface polarity. Notably, AGGRESCAN3D, TANGO and PASTA are the most prominent tools for 
predicting site specific aggregation propensity of mAbs [148, 149]. 
The preliminary elucidation of mAb structural data, that being amino acid sequences and higher 
order structure (HOS), is experimentally derived to produce crystal structures that model the solid-
state 3D structure of the mAb. Mass spectrometry technologies have come of age, to produce high 
throughput and orthogonal analysis to elucidate mAb peptide sequences, oxidation, deamidation 
and glycosylation heterogeneity, and more recently for native, destabilised and aggregated HOS 
elucidation [150, 151]. X-ray crystallography technologies have been the underlying workhorse for 
elucidating the crystal structure of mAbs. Producing crystalline mAbs is challenging owing to the 
complexity of mAb HOS and the degree of mAb conformational heterogeneity. However, 
cryogenic-electron microscopy and nuclear magnetic resonance spectroscopy have evolved as a 
complementing technologies to ascertain structure and interactions in recent years [149, 152-155]. 
Thus far, only four whole IgG antibodies have a successfully determined crystal structure (PDB ID: 
1HZH, 1IGT, 1IGY and 5DK3), notably 1HZH as a wholly human IgG1, and 5DK3 as a humanised 
IgG4/κ, which have been used as model structures for MD simulations [156]. mAb fragments yield 
much higher success with producing crystal structures, which has led to much pursuit and 
contribution in generating mAb fragment and target complexing crystal structure libraries for data 
mining and in silico analysis [36, 157].  
Upon obtaining relevant crystal structures for a candidate mAb, detailed crystal structure and MD 
simulation analysis has been extensively used to elucidate the mAbs intermolecular interactions that 
confer intrinsic stability and intramolecular interactions to confer interactions to biological targets 
and self-association. The particular binding interface of interest is analysed, amino acids in the mAb 
structure are identified for substitution that can disrupt molecular interactions in the interface in the 
instance of diminishing target binding, or identify potentially unutilised bonding sites and polarity 
mismatches in the interface that can be improved in the instance of enhancing target binding. MD 
simulations are then carried out for the native and substituted mAb structures to elucidate any 
relevant bond formations and more favourable binding free energy produced by the substituted 
structure, of which promising candidates can be synthesised and validated through in vitro analysis. 
This predictive approach has been successfully applied to identify mutations in mAbs for 
modulating effector functions, target binding and optimise affinity capture for manufacturing, and 
more recently for designing antibodies de novo from targets of interest [15, 158-162]. mAb 
mutations have been specifically identified for enhanced binding to FcγR2A, FcγR3A and Cq1, and 
reduced binding to FcγR2B for a more pronounced ADCC and CDC effect, enhanced binding to 
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FcRn for extended half-life, and reduced binding to FcγRs and Cq1 for a diminished ADCC and 
CDC effect, all of which are transferrable to mAbs of the same isotype sub-class. Further to this, the 
molecular interactions of glycoengineered mAb variants to FcRs have been characterised through 
MD simulations to corroborate predictions with the modulated effector functions observed [12, 16, 
133, 136, 137].  
mAb self-association, solubility and aggregation propensity are further evaluated by computational 
modelling tools that specifically characterise the topography and surface polarity of mAbs, 
concurrently analysing the local spatial arrangement of amino acids in the mAb structure, solvent 
accessibility and local surface charge [5]. In particular, surface exposed hydrophobicity is sought as 
the lead mechanism for protein self-association driving aggregation propensity, in which 
aggregation-prone regions (APRs) are identified in the mAb structure. Substitution of identified 
APRs to gatekeeper (i.e. polar) amino acids has experimentally demonstrated resistance to 
aggregation and improved solubility, which validates this strategy for improving mAb stability 
[163-170]. The majority of APRs identified are located in biologically relevant mAb regions, that 
being the CDRs and the Fc. Specifically targeting these APRs through mutation may disrupt 
important biological functions and mAb structure. Analysis of the mAbs intermolecular interactions 
are necessary to validate the intrinsic stability of substituted mAb variants, if conformational 
fluctuations are elucidated then the biologically active interface is likely disrupted. Interestingly, 
mutations for enhancing biological functions have demonstrated a negative impact on mAb 
solubility and stability, further suggesting that the self-association profile of mAbs is linked to its 
biological activity [139, 165, 171].  
Aside from direct residue substitution in mAb structures, other strategies reported to profoundly 
interfere with the effects of APRs include isotype switching and the strategic addition of N-linked 
glycans [139, 168, 172, 173]. Additionally, N-linked glycosylation in the CDR regions of mAbs 
although uncommon, have demonstrated improved solubility and stability profiles of mAbs without 
impacting their target affinity, as compared to the same mAb with removed CDR glycans [139, 
174]. The rationale behind strategic glycan addition is based on the election of N-linked 
glycosylation sites that have apparent spacial proximity to APRs, the introduced glycan therefore 
sterically hindering the APR from self-association interactions. The benefits of extending mAb half-
life with strategic glycan addition as seen with hyper-glycosylated biotherapeutics, as well as 
improving mAb solubility and stability for improved formulation strategies, has yet to be realised 
and suggests a very intriguing and highly relevant technology for perusal. 
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4 Perspectives, Aims and Objectives 
In considering the current technologies being applied to mAb based therapeutic platforms, along 
with the challenges faced in manufacture, formulation and treatment strategies, this body of work 
was directed towards the strategic design and development of antibodies for enhancing target 
affinity, and reducing self-association and aggregation propensity. The modulation of a mAbs 
affinity to its target is an imperative part of the drugs design, where mAb fragment and ADC 
platforms take advantage of high target affinity. For diseases such as cancers, tumour tissue 
penetration, retention and immunological engagement are necessary considerations for improved 
treatment design and take advantage of mAb platforms with reduced target affinity (although 
retained specificity), including nanocarrier delivery strategies. Further to this, mAb self-association 
and aggregation propensity seems an ongoing challenge throughout the manufacture process 
leading to product loss and reduced quality, and through limiting formulation strategies for 
efficacious treatment. Specifically designed modifications in a mAbs framework for considerable 
stability enhancement can be transferrable to other mAb platforms in the same isotype sub-class, 
and would be of great commercial benefit for the whole class of biotherapeutics. 
In this body of work, trastuzumab and adalimumab were elected as model antibodies for the design, 
expression and in vitro analysis of mutational projects for enhanced affinity and reduced self-
association. Specifically, mutations were designed in trastuzumab for enhanced affinity to target 
HER2 and N-linked glycosylation sites introduced for steric hindrance of APRs, the glycosylation 
mutations transferred to adalimumab to demonstrate proof-of-concept in reduced self-association. 
Prior to mutational project design, appropriate expression systems for lab-scale production of 
trastuzumab and adalimumab were established. Several cloning strategies were implemented as to 
ascertain the most appropriate expression vector platforms for optimising antibody expression and 
purification, prior to mutagenesis optimisation and the expression of mutant libraries. Mutant 
libraries were designed based on in silico analysis of crystal structures, the trastuzumab affinity 
mutations were based on results from our collaborators from A/Prof Serdar Kuyucak’s 
Computational Biophysics Group, School of Physics, The University of Sydney, and the 
glycosylation mutations based on literature search of reported APRs. Mutant libraries were then 
produced and characterised before in vitro assessment of modulated target affinity, comparison of 
retained biological functions and stability profiling, to determine lead candidates for further 
investigation.  
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Chapter 2  
Vector Design and Cloning for 
Expression of Trastuzumab and 
Adalimumab 
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Scope and Aims 
This chapter reports on the development of a library of expression vectors that carry the genes for 
expression of trastuzumab (Tmab) and adalimumab (AdmAb) in mammalian cell culture. Upon 
successful cloning, antibody expression was compared between the vectors in a pilot transient 
expression system to ascertain the most appropriate expression systems to proceed with for the 
chapters following. This was the crucial starting point from which antibody expression conditions 
were optimised in the lead up to the design and production of antibody mutant libraries for in vitro 
testing.  
Here we report on the cloning strategies applied to the assembly of Tmab and AdmAb expression 
vectors for expression in transient 293F culture. Tmab genes were cloned into a library of vectors 
and the expression yield was compared in a preliminary transient expression experiment. Variable 
region gene switching was then performed on the vector library to produce AdmAb expression 
vectors which was again expressed transiently for comparison. The cloning strategies for 
introducing genes into vectors was relatively simple in design, had low background and error rate to 
yield successfully cloned isolates. Between the vector systems, the dual expression vector 
pVITRO1_Trastuzumab_ IgG1/κ and single expression vectors gWiz TH/TL expressed Tmab 
readily and were selected for further cloning, expression optimisation and mutagenesis in the further 
chapters. The cloning strategy for variable gene switching involved more scrupulous design, had 
high background with the gWiz vector system and cloning into the dual gene pVITRO1 vector 
system was unsuccessful. The single gene expression vectors gWiz AH/AL expressed AdmAb 
readily therefore they were adopted for mutagenesis in the further chapters.   
1 Introduction; Expression Vector Library 
The library of expression vectors sourced for this study were derived from three suites of vectors; 
that being pVITRO1 (InvivoGen, USA), mAbXpress (Acyte Biotech, Australia) and gWiz 
(Genlantis, USA).  
The pVITRO1 suite of vectors are empty dual expression vectors with the capacity for stable 
transfection in mammalian culture [175-177]. Dodev et al from Dr Andrew Beavil’s research group, 
School of Medicine, King’s College London successfully developed a library of antibody 
expression vectors from an empty pVITRO1 vector that possessed Hygromycin selection [178]. 
Beavil’s library of vectors have the capacity for stable and transient expression and have been made 
available through the international plasmid repository AddGene. 
The mAbXpress suite of vectors are single gene expression vectors containing the antibody constant 
region of either heavy or light chain [179]. This suite of vectors was designed for cloning in 
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antibody variable regions of interest through SacI digestion [180]. Successfully cloned mAbXpress 
heavy and light chain vector pairs would then be suitable for co-transfection in mammalian culture 
with the capacity for stable transfection.  
The gWiz vector is an empty single gene expression vector, with no capacity for stable transfection. 
For antibody expression, cloning of the whole antibody heavy or light chain genes would be 
required and transient expression through co-transfection of successfully cloned gWiz heavy and 
light chain vector pairs.  
The pVITRO1 and gWiz vectors were originally commercially sourced, whereas the mAbXpress 
vectors were developed by the National Biologics Facility at the Australian Institute for 
Bioengineering and Nanotechnology, for the specific applications of their partner, Acyte Biotech. 
The mAbXpress vectors are patented by Acyte Biotech and are not commercially available, 
although they have been made available for research purposes only. 
1.1 pVITRO1 
pVITRO1_Trastuzumab_IgG1/κ was the pVITRO1 vector sourced for this study, a kind donation 
from Dr Andrew Beavil’s research group. pVITRO1_Trastuzumab_IgG1/κ was developed from the 
commercial vector pVITRO1_hygro_mcs vector (pvitro1-mcs, InvivoGen) which is a dual 
expression vector with Hygromycin resistance [175].  Dodev et al produced 
pVITRO1_Trastuzumab_IgG1/κ as part of a library of different antibody expression vectors that 
contained paired antibody heavy and light chain genes in the one vector. This library was produced 
firstly by cloning gene cassettes of secretion signal peptide (SP) coupled with whole antibody genes 
into pVITRO1_hygro_mcs, and subsequently by replacing different combinations of antibody 
constant and variable regions in the expression vector by PIPE cloning method [178]. All vectors in 
the pVITRO1 suite were high yielding, capable of stable transfection and antibody was 
extracellularly secreted for ease of purification. pVITRO1_Trastuzumab_IgG1/κ was the 
subsequent vector produced for complete Tmab antibody expression (Table 1 and Figure 2). 
For the purposes of this study, pVITRO1_Trastuzumab_IgG1/κ contained the Tmab genes used for 
the cloning strategies of the other vectors produced. Moreover, the cloning strategy to produce an 
AdmAb dual chain expression vector was to exchange the Tmab variable region genes with AdmAb 
variable region genes of pVITRO1_Trastuzumab_IgG1/κ through an In-Fusion® cloning method 
(Clontech). A version of this vector with omitted variable regions (pVITRO1_dV_IgG1/κ) was used 
as a variable gene insert negative control. 
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Table 1  Summary of features of pVITRO1_Trastuzumab_IgG1/κ vector. 
Vector pVITRO1_Trastuzumab_IgG1/κ 
Size 8583 bp 
Bacterial Selection Hygromycin 
Mammalian Selection Hygromycin 
Gene Insert 1 SP coupled to Tmab IgG1 heavy chain 
Gene Insert 2 SP coupled to Tmab kappa chain 
Expression System Mammalian, secreted 
Transfection Stable and transient 
 
Figure 2 Vector map of pVITRO1-Trastuzumab-IgG1/κ. 
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1.2 mAbXpress 
The mAbXpress vectors sourced for this study were mAbX_hKappa and mAbX_hG1, a kind 
donation from Acyte Biotech [181]. mAbX_hKappa and mAbX_hG1 were produced as part of a 
library of expression vectors that contained a single expression cassette of a SP coupled to a SacI 
restriction enzyme (RE) site and an antibody constant region of either heavy or light chain. 
Specifically, mAbX_hKappa contains a SP coupled to SacI RE site, to the last 2 amino acids (aa) of 
the joining region to Cκ, and mAbX_hG1 contains a SP coupled to SacI RE site, to the last 4 aa of 
the joining region to the complete IgG1 constant regions CH1, hinge, CH2 and CH3 (Table 2 and 
Figure 3). This suite of vectors were designed to make antibody variable region insertion simple by 
SacI digestion of the vector and In-Fusion® cloning (Clontech) of the variable region of interest 
[179].  
Vector pairs of mAbXpress heavy and light chain would be suitable for co-transfection in 
mammalian culture. This suite of vectors was specifically designed and optimised for efficient 
cloning, transfection and high yielding expression in suspension CHO culture [179], although they 
can be applied to other mammalian expression systems.  
As the cloning strategy is SacI digestion based, the start and end codons for insertion of the variable 
region are restricted to glutamic acid (E) and leucine (L); i.e. E - variable insert - L. For the 
purposes of this study, the antibody variable regions were modified to suit the cloning strategy; 
however, they subsequently produced antibody with modified aa sequences to their reference 
product. The significance of modifying the aa sequences was not pursued. 
Table 2 Summary of features of mAbXpress vectors. 
Vector NBF304 mAbX_hKappa NBF305 mAbX_hG1 
Size 5064 bp 5742 bp 
Bacterial Selection Kanamycin 
Mammalian Selection G418 
RE site SacI 
Gene Insert 
SP coupled to SacI RE site, to 
human Cκ, from last 2 aa of 
joining region  
SP coupled to SacI RE site, to 
human IgG1, from last 4 aa of 
joining region 
Expression System Mammalian, co-expression (optimised for CHO) 
Transfection Stable and transient 
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1.3 gWiz 
The commercial gWiz blank vector sourced from this study was purchased from Genlantis, USA 
[182]. The gWiz expression vector contains a single multiple cloning site (MCS) for the cloning of 
either a heavy or light chain gene coupled to a SP, with subsequent expression in mammalian 
culture through co-transfection of vector heavy and light chain pairs (Table 3 and Figure 4). The 
gWiz vector does not possess any mammalian selection so is therefore only suitable for transient 
expression. 
Table 3  Summary of features of gWiz vector. 
Vector gWiz 
Size 5063 bp 
Bacterial Selection Kanamycin 
Mammalian Selection None 
RE site 1 MCS for gene insertion 
Expression System Mammalian 
Transfection Transient only 
 
Figure 3 Portions of the vector maps with cloning site for mAbX_hKappa (A) and mAbX_hG1 
(B). Portion of the vector sequence for mAbX_hG1 (C) highlighting the SacI RE site for cloning. 
 
 
 
A 
C 
B 
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For the purposes of this study, the strategy for cloning Tmab heavy and light chain genes into the 
gWiz vector was RE based, the strategy designed from the gWiz MCS. Subsequently, AdmAb 
expression vectors were cloned from the Tmab heavy and light chain gWiz vectors by exchanging 
the Tmab variable regions with AdmAb variable regions through an In-Fusion® cloning method 
(Clontech). 
 
A 
B
Figure 4 Vector map of gWiz blank vector (A) and portion of the gWiz sequence displaying 
the multiple cloning site with unique RE sites (B). *RE sites in grey are blocked by Dam or 
Dcm methylation for consideration of the cloning strategy. 
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2 Materials and Methods 
2.1 Instrumentation, Services and Software 
Cloning and colony PCR reactions were conducted on a Bio-Rad T100 thermal cycler, with heated 
lid. Agarose gels were prepared in Bio-Rad Mini-Gel casters and ran in a Bio-Rad Mini-Sub Cell 
GT system. Gel imaging was performed on a Bio-Rad Gel Doc XR system and analysed on Bio-
Rad Image Lab 5.2.1 software. DNA quantification was performed on a NanoDrop ND-1000 
spectrophotometer. 
Cloned isolate vectors were prepared as purified DNA samples and sent to AGRF for Sanger 
Sequence analysis. Sequencing results were analysed on Applied Biosystems Sequence Scanner 2 
software. 
The complete aa sequence of Tmab and AdmAb light and heavy chains were obtained from the 
DrugBank database (https://www.drugbank.ca). The corresponding nucleic acid sequences were 
obtained from the IMGT database (http://www.imgt.org). 
Visualisation and cloning plans of the vectors, genes and primers were performed on GSL Biotech 
SnapGene Viewer 4.0.5 software. Tm calculations were performed on NEB Tm calculator software 
(http://tmcalculator.neb.com). PCR product molar ratios were derived from Clontech molar ratio 
calculator software (http://bioinfo.clontech.com/infusion/molarRatio.do). Alignment of clone isolate 
sequences to designed vector DNA sequences were performed on the NCBI BLAST software 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi). 
Antibody was purified from culture supernatant on a GE HealthCare ÄKTApurifier 100 FPLC 
system, using Unicorn 5.11 system and analysis software. 
2.2 Molecular Biology Materials  
pVITRO1_Trastuzumab_IgG1/κ (61883) and pVITRO1_dV_IgG1/κ (52213) vectors were obtained 
from AddGene and mAbXpress NBF304 and NBF305 vectors were obtained from Acyte Biotech 
(Australia) through materials transfer agreements. gWiz blank expression vector (P000200) was 
purchased from Genlantis (USA). 
The primers designed for cloning mAbX_TH and mAbX_TL vectors and sequencing mAbX inserts 
were synthesised from Life Technologies (Australia). The primers designed for sequencing 
pVITRO1 and gWiz inserts and cloning gWiz_TH and gWiz_TL vectors were synthesised from 
Geneworks (Australia). The primers designed for cloning AdmAb heavy (AH) and light (AL) 
variable regions into all vectors, and the AH and AL variable region genes (gBlocks
® gene 
fragments) were synthesised from Integrated DNA Technologies (Singapore). 
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The SacI (1078A) RE and In-Fusion® cloning kit (38909) containing Stellar™ competent E. coli 
(636763), Nucleospin DNA purification kit (740609.1) and In-Fusion® HD Cloning mastermix 
(639648) were purchased from Scientifix (Australia). The Phusion high-fidelity PCR kit (E0553S), 
OneTaq® Quick-Load PCR mastermix (M0486L), high-fidelity SalI (R3138S) and BamHI 
(R3136S) RE, T4 DNA Ligase (M0202S), rSAP (M0371S), gel loading dye (B7025) and DNA 
ladders 1 kb (N3232S) and 100 bp (N3231S) were purchased from Genesearch (Australia). 
Biotechnology grade agarose (BIOD0012), PBS tablets (09-2051-100) and TAE 25x stock solution 
(PARTA82820) were purchased from Astral Scientific (Australia). SYBR® Safe nucleotide stain 
(S33102) was purchased from Life Technologies (Australia). Plasmid maxiprep kit (G221020) was 
purchased from Astral Scientific (Australia), miniprep (PLN70) and maxiprep (NA0310) kits were 
purchased from Sigma-Aldrich (Australia). 
2.3 Culture and Purification Materials 
Yeast extract (70161), Sodium chloride (S9888) and Kanamycin solution (K0254) were purchased 
from Sigma-Aldrich (Australia). Tryptone (LP0042B) and Geneticin® (10131-035) were purchased 
from Thermo Fisher Scientific Australia and agar (20767.232) was purchased from VWR 
International (Australia). Hygromycin B solution (ant-hg-1), Hygromycin agar (fas-hg-s) and 
Terrific Broth (fas-hg-l) sachets were purchased from Jomar Life Research (Australia). 
FreeStyle 293F cells were a kind donation from Dr Mario Torrado del Rey of Prof Joel Mackay’s 
research group, School of Life and Environmental Sciences, The University of Sydney. FreeStyle™ 
293 expression media (12338018) and OptiPRO™ Serum free media (12309050) were purchased 
from Life Technologies (Australia). Linear Polyethylenimine (PEI) 25 kDa (23966-2) was 
purchased from BioScientific (Australia). PBS tablets (09-2051-100) and 1 M Tris-HCl pH 9 
(BIOSD814) were purchased from Astral Scientific (Australia). Disposable baffled culture flasks 
(CLS431405), centrifuge tubes (CLS430291, CLS430791), vacuum systems (CLS430769), glycine 
hydrochloride (G2879), HiTrap® Protein A affinity column (GE17-0403-01) and Amicon® Ultracel 
50 kDa centrifugal filters (Z740177, Z740193) were purchased from Sigma-Aldrich (Australia).  
2.4 Cloning Strategies and Molecular Biology 
The cloning strategy for producing Tmab heavy and light chain mAbX and gWiz vectors was 
through a RE digestion and ligation method. Briefly for the mAbX vectors, the Tmab variable 
heavy and light chain genes were amplified from the pVITRO1_Trastuzumab_IgG1/κ vector by 
high fidelity PCR, with primers incorporating 16 – 17 bp homology of the SP upstream and 
constant region (Vjoin / Cjoin) downstream of the mAbX vectors for seamless cloning. The mAbX 
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vectors were linearised with SacI, then the linearised mAbX vectors and the Tmab variable PCR 
fragments were combined for an In-Fusion® ligation reaction and rescued in E. coli. 
Briefly for the gWiz vector, the complete Tmab heavy and light chain genes were amplified from 
pVITRO1_Trastuzumab_IgG1/κ by high fidelity PCR, with primers designed to flank the genes 
with unique RE sites for digestion. The PCR products were digested with the associated RE along 
with the gWiz vector. The digested PCR products and linearised vector were combined for a 
ligation reaction and rescued in competent E. coli.  
The cloning strategy for producing AdmAb heavy and light chain pVITRO1 and gWiz vectors was 
through an In-Fusion® insert switching method. Briefly, the entirety of the 
pVITRO1_Trastuzumab_IgG/κ, gWiz TH and gWiz TL vectors were amplified by high fidelity PCR 
with the Tmab VH and VL genes omitted from the PCR products through primer design. AdmAb VH 
and VL genes were synthesised, incorporating 20 bp homology of the SP upstream and constant 
region (Vκ / CH1) downstream of the vector backbones for seamless cloning. The linear vector 
backbones and AdmAb gene fragments were combined for an In-Fusion® ligation reaction and 
rescued in E. coli. 
In all cloning methods, single colony isolates were rescued and screened by colony PCR for the 
presence of gene insertion. Plasmid extractions were performed in isolates that screened insert 
positive, to then be prepared for sequence analysis. Isolates that were confirmed for successful 
cloning through sequence analysis were scaled up for a maxiprep plasmid extraction, in preparation 
of transfection. 
2.4.1 Cloning Tmab Variable Regions into mAbXpress Vectors 
The cloning strategy to produce mAbX Tmab light (mAbX TL) and heavy (mAbX TH) chain 
expression vectors was to isolate the genes for Tmab variable light (TVL) and variable heavy (TVH) 
chains and introduce them into the mAbX vectors through In-Fusion® cloning.  TVH and TVL were 
amplified from pVITRO1_Trastuzumab_IgG1/κ using a Phusion High Fidelity PCR kit (Table 4 
and  
Table 5) with the primers designed to introduce 16 – 17 bp homology up and downstream of the 
mAbX vectors for seamless cloning (Table 6). The PCR products were confirmed on a 0.8% 
agarose gel and purified using the Nucleospin DNA purification kit (Appendix 2.1.5).  
The mAbX hG1 and hKappa vectors were linearised through SacI digestion, incubated at 37 °C for 
1 hr. The linearised vectors were confirmed and separated on a 0.8% agarose gel and purified using 
the Nucleospin DNA purification kit (Appendix 2.1.5). The vector backbones were combined with 
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the Tmab variable region genes for In-Fusion® ligation reactions in a molar ratio of 2:1 gene to 
vector, incubated at 50 °C for 15 min. 2.5 µL of the ligation products were transformed into 
Stellar™ competent E. coli by heat-shock method, colonies were isolated in Luria-Bertani (LB) agar 
containing 50 µg/mL Kanamycin. Colony PCR was performed to rescue and screen for vector 
isolates containing intact single gene insertion. Positive isolates were purified and sequenced to 
confirm seamless integration of the TVH and TVκ genes, producing complete Tmab heavy (mAbX 
TH) and light (mAbX TL) chain expression vectors. 
Table 4 Reaction components for amplification of TVH. For amplification of TVL, the HC primer 
pair was replaced with the LC primer pair, all other components were equivalent. 
Component 
Reaction 
Concentration 
Volume 
(µL) 
5 x Phusion HF Buffer 1 x 10 
10 mM dNTP 200 µM 1 
10 µM   mAbX_HC_Trast_Fwd 0.5 µM 2.5 
10 µM   mAbX_HC_Trast_Rev   0.5 µM 2.5 
1 ng/mL pVITRO1_Trastuzumab_IgG1/κ 20 ng/mL 1 
Nuclease free H2O - 32.5 
Phusion DNA Polymerase 20 units/mL 0.5 
 
Table 5 Cycling conditions for PCR amplification of TVH and TVL. 
Cycle Step Cycles 
Temperature 
(°C) 
Time (sec) 
Initial denaturation 1 98 120 
Denaturation 
30 
98 40 
Annealing  55 40 
Extension 72 150 
Hold 1 12 ∞ 
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Table 6 List of designed primers for mAbX cloning and sequencing. Nucleotides with homology to 
mAbX vectors (underline), nucleotides with homology to Tmab genes in pVITRO1, including SP 
and join regions (bold). Tm calculated to pVITRO1_Trastuzumab_IgG1/κ with the Phusion PCR 
kit* and mAbX vectors with the OneTaq PCR kit#.   
 
Primer 
 
Sequence 
5’                                                             3’ 
Homology 
(bp) to 
mAbX  for 
In-Fusion® 
Tm 
(°C) 
mAbX_LC_Trast_Fwd 
mAbX_LC_Trast_Rev 
CCGGCGTGCACTCCGACATCCAGATGACC 
GCCACGGTCCGCTTGATCTCCACCTTGGT 
16 
16 
48* 
51* 
mAbX_HC_Trast_Fwd 
mAbX_HC_Trast_Rev 
CAGGTGTCCACTCCGAGGTGCAGCTGGTG 
GCGGAGGACACGGTGACAAGAGTACCT 
17 
16 
73* 
71* 
mAbX_SeqF 
mAbX_Seq-hKapR 
mAbX_Seq-hG1-hG2-R 
TAACACCGCCCCGGTTTTCC 
GTTCAGCAGGCACACCACGG 
TCACCAGGCAGCCCAGAGCG 
N/A 
64# 
65# 
69# 
 
2.4.2 Cloning Tmab Whole Genes into gWiz 
The cloning strategy to produce gWiz Tmab light (gWiz TL) and heavy (gWiz TH) chain expression 
vectors was to isolate the whole genes for Tmab light and heavy chains from 
pVITRO1_Trastuzumab_IgG1/κ and introduce the genes into the gWiz vector through RE double 
digestion and ligation reactions.  
The complete Tmab genes from the pVITRO1_Trastuzumab_IgG1/κ vector were amplified using a 
Phusion High Fidelity PCR kit using a 2-step PCR cycling method (Table 7 and  
Table 8). Primers for amplifying the Tmab genes were designed to flank the genes with unique RE 
sites based on the gWiz MCS, SalI and BamHI were elected for the primers designed upstream and 
downstream, respectively (Table 9). It was found that a BamHI RE site was present at the beginning 
of the TH SP gene, hence the TH forward primer was further modified to remove that RE site, whilst 
preserving the aa sequence: R6 (arginine) AGG > AGA (Figure 5).  
The linear PCR products were confirmed on a 0.8% agarose gel and purified using the Nucleospin 
DNA purification kit (Appendix 2.1.5). SalI-BamHI double digestion reactions were performed on 
the PCR products and gWiz vector, incubated at 37 °C for a total of 90 min (Table 10). To prevent 
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religation of the linearised gWiz vector, the digestion product was further dephosphorylated by the 
addition of rSAP 30 min into the digestion reaction.  
The digested DNA products were again separately purified using the Nucleospin DNA purification 
kit (Appendix 2.1.5), then prepared for ligation with T4 DNA ligase in a molar ratio of 3:1 gene to 
vector, incubated O/N at room temperature (Table 11). 5 µL of the ligation products were 
transformed into Stellar™ competent E. coli by heat-shock method, cells containing intact vector 
were rescued in LB agar containing 50 µg/mL Kanamycin. Colony PCR was performed to rescue 
and screen for vector isolates containing intact, single gene insertion. Positive isolates were purified 
and sequenced to confirm seamless integration of the Tmab IgG1 gene (gWiz TH) or kappa gene 
(gWiz TL).  
Table 7 Reaction components for amplification of TH. For amplification of TL, the TH primer pair 
was replaced with the TL primer pair, all other components were equivalent. 
Component Concentration Volume (µL) 
5 x Phusion HF Buffer 1 x 10 
10 mM dNTP 200 µM 1 
10 µM  Fwd pVitro TH into gWiz 0.5 µM 2.5 
10 µM  Rev pVitro TH into gWiz  0.5 µM 2.5 
1 ng/ mL pVITRO1_Trastuzumab_IgG1/κ 20 ng/mL 1 
Nuclease free H2O - 32.5 
Phusion DNA Polymerase 20 units/mL 0.5 
 
Table 8 Cycling conditions for 2-Step PCR amplification of TH and TL. 30 cycles were run for TH 
PCR with 45 sec extension time*, 25 cycles were run of the TL PCR with 20 sec extension time
+. 
Cycle Step Cycles 
Temperature 
(°C) 
Time (sec) 
Initial denaturation 1 98 30 
Denaturation 
30*/25+ 
98 10 
Annealing and Extension 72 45* / 20+ 
Final Extension 1 72 300 
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Table 9 List of primers designed for gWiz TH/TL cloning and sequencing. SalI/BamHI RE sites 
(underlined) and nucleotides with homology to Tmab genes (bold). Tm calculated to 
pVITRO1_Trastuzumab_IgG1/κ with the Phusion PCR kit* and gWiz vectors with the OneTaq 
PCR kit#.   
Primer 
Sequence 
5’                                                                                3’ 
Tm 
(°C) 
Fwd pVitro TH into gWiz 
Rev pVitro TH into gWiz 
GGTGGTGTCGACATGGACTGGACCTGGAGAATCCTCTTCTTG 
GGTGGTGGATCCTCATTTACCCGGAGACAGGGAGAG 
76* 
73* 
Fwd pVitro TL into gWiz 
Rev pVitro TL into gWiz 
GGTGGTGTCGACATGTTGCCATCACAACTCATTGGG 
GGTGGTGGATCCCCTAACACTCTCCCCTGTTGAAGC 
71* 
70* 
SeqF gWiz MCS 
SeqR gWiz MCS 
AGTACTCGTTGCTGCCG 
ATGGCTGGCAACTAGAAGG 
58# 
58# 
 
Table 10 Reaction components for double-digestion of TH, TL and blank gWiz vector. The entire 
quantity of TH and TL purified PCR products was digested. 
*rSAP was added to the gWiz digestion 
reaction after 30 min incubation. 
TH/TL gWiz 
Component Concentration Volume (µL) 
TH/TL  PCR product (purified) - 28 - 
122 ng/µL blank gWiz vector 40 µg/mL - 16.5 
10 x CutSmart Buffer 1 x 5 
Sal-HF 400 units/mL 1 
BamHI-HF 400 units/mL 1 
rSAP 20 units/mL - 1* 
Nuclease free H2O - 15 25.5 
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Table 11 Ligation reaction components for cloning gWiz TH and gWiz TL vectors.  
gWiz TH gWiz TL 
Component Reaction Quantity 
10 x T4 DNA Ligase Buffer 1 x 
Linearised gWiz vector (purified) 84 ng 
Digested TH product (purified) 72 ng - 
Digested TL product (purified) - 36 ng 
T4 DNA Ligase 20 units/µL 
Nuclease free  H2O Up to 20 µL 
 
2.4.3 AdmAb Variable Region Gene Switching 
The cloning strategy to produce AdmAb light (gWiz AL), heavy (gWiz AH) and dual 
(pVITRO1_Adalimumab_IgG1/κ) chain expression vectors was through variable region gene 
switching of pVITRO1_Trastuzumab_IgG1/κ, gWiz TL and gWiz TH. Each of the vectors was 
linearised using a Phusion High Fidelity PCR kit (Table 12 and Table 13), with primers designed to 
specifically omit the variable regions of the Tmab genes (Table 14). Two vector fragments were 
produced in separate PCRs for the pVITRO1_Trastuzumab_IgG1/κ that contained the heavy 
(pVITRO1 H/sL) or light (pVITRO1 L/sH) constant regions (Figure 6), whereas a single vector 
backbone fragment was produced from the gWiz TH (gWiz CH) and gWiz TL (gWiz CL) PCRs. The 
linear PCR products were confirmed on a 0.8% agarose gel and purified using the Nucleospin DNA 
purification kit (Appendix 2.1.5).  
 
Figure 5 Portion of the pVITRO1_Trastuzumab_IgG1/κ sequence highlighting the BamHI RE 
site in the SP of the TH gene. Primer Fwd pVitro TH into gWiz was designed to remove the 
BamHI site in the SP as to make BamHI a unique RE site to be introduced after the stop codon 
with the reverse primer. 
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gWiz CH gWiz CL 
pVITRO1 
H/sL 
pVITRO1 
L/sH 
Component 
Reaction 
Concentration 
Volume (µL) 
5 x Phusion HF Buffer 1 x 10 
10 mM dNTP 200 µM 1 
10 µM LinCH_IgG1_Fwd 0.5 µM 2.5 - 2.5 - 
10 µM LinCH_IgG1_Rev 0.5 µM 2.5 - - 2.5 
10 µM LinCL_kappa_Fwd 0.5 µM - 2.5 - 2.5 
10 µM LinCL_kappa_Rev 0.5 µM - 2.5 2.5 - 
1 ng/mL gWiz TH 20 ng/mL 1 - - - 
1 ng/mL gWiz TL 20 ng/mL - 1 - - 
1 ng/mL pVITRO1_Trastuzumab_IgG1/κ 20 ng/mL - - 1 1 
Nuclease free H2O - 32.5 
Phusion DNA Polymerase 20 units/mL 0.5 
 
Table 13 Cycling conditions for PCR linearisation of gWiz TH, gWiz TL and 
pVITRO1_Trastuzumab_IgG1/κ fragments, omitting the Tmab variable regions. 
Table 12 Reaction components for PCR linearisation of gWiz TH, gWiz TL and 
pVITRO1_Trastuzumab_IgG1/κ fragments, omitting the Tmab variable regions. 
gWiz CH gWiz CL 
pVITRO1 
H/sL 
pVITRO1 
L/sH 
Cycle Step Cycles 
Temperature 
(°C) 
Time (sec) 
Initial denaturation 1 98 30 
Denaturation 
25 
98 10 
Annealing  65 10 
Extension 72 100 90 60 70 
Final Extension 1 72 300 
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Table 14 List of primers designed for pVITRO1_Adalimumab_IgG1/κ, gWiz AH and gWiz AL 
cloning and sequencing. Tm calculated to the Tmab genes with the Phusion PCR kit
* and 
gWiz/pVITRO1 vectors with the OneTaq PCR kit# 
Primer 
Sequence 
5’                                                  3’ 
Tm (°C) 
LinCH_IgG1_Fwd 
LinCH_IgG1_Rev 
GCTAGCACCAAGGGCCCATC 
GGAGTGCGCGCCTGTG 
70* 
69* 
LinCL_kappa_Fwd 
LinCL_kappa_Rev 
GTACGGTGGCGGCGC 
ACCGCGGCTAGCTGGAAC 
68* 
68* 
SeqF gWiz MCS 
SeqR gWiz MCS 
AGTACTCGTTGCTGCCG 
ATGGCTGGCAACTAGAAGG 
58# 
58# 
pVITRO1_hFwd 
pVITRO1_hRev 
TTTTGAGCGGAGCTAATTCTCGGG 
AAAAAACCTCCCACACCTCC 
62# 
58# 
pVITRO1_kFwd 
pVITRO1_kRev 
GAGGCTAATTCTCAAGCCTC 
TCTAGACCTGGAAAGACCAG 
55# 
56# 
AL and AH genes were designed and custom synthesised to contain 20 bp homology of the SP 
upstream, and constant region (Vjoin / Cjoin) downstream of the vector backbones for seamless 
cloning. The vector backbones were combined with the AdmAb variable region genes for In-
Fusion® ligation reactions in a molar ratio of 2:1 gene to vector, incubated at 50 °C for 15 min 
(Table 15).  
 
 
 
 Figure 6: PCR products of pVITRO1-Trastuzumab-IgG1/κ for In-Fusion
® cloning pVITRO1 
H/sL (A) and L/sH (B). 
A 
B 
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2.5 µL of the ligation products were transformed into Stellar™ competent E. coli by heat-shock 
method, cells containing intact vector were rescued in LB agar containing 50 µg/mL Kanamycin for 
gWiz reactions, or 75 µg/mL Hygromycin for pVITRO1 reactions. Colony PCR was performed to 
rescue and screen for vector isolates containing intact, single gene insertion. Positive isolates were 
purified and sequenced to confirm seamless integration of the AdmAb variable regions producing 
complete AdmAb heavy and light chain expression vectors (gWiz AH, gWiz AL and 
pVITRO1_Adalimumab_IgG1/ κ). 
Table 15 In-Fusion® ligation reaction components for cloning gWiz AH, gWiz AL and 
pVITRO1_Adalimumab_IgG1/κ vectors. *Fragments chosen for reference to derive molar 
equivalent of other fragment. 
gWiz AH gWiz AL 
pVITRO1_ 
Adalimumab 
_IgG1/κ 
Component Reaction Quantity 
5 x In-Fusion HD Enzyme Premix 1 x 
AH gene 26.5 ng - 29.4 ng 
AL gene - 20.1 ng 26.4 ng* 
gWiz CH 200 ng - - 
gWiz CL - 150 ng - 
gWiz CH 200 ng - - 
pVITRO1 H/sL - - 150 ng* 
Nuclease free H2O Up to total reaction volume based on DNA volumes used 
 
2.5 Isolating Positive Clones and Sequence Analysis 
Ligation products were rescued in Stellar™ competent E. coli through a heat-shock method 
(Appendix 1.4), onto an LB agar plate containing selection antibiotic (50 µg/mL Kanamycin for 
mAbX and gWiz vector ligations, 75 µg/mL Hygromycin for pVITRO1 vector ligations). Single 
colonies were isolated for culture and screened for successful insertion through colony PCR (Table 
16 and Table 17). 5 µL of colony PCR products were loaded on 0.8 % agarose gel stained with 
SYBR® Safe nucleotide stain, imaged and analysed using the Bio-Rad Gel Doc XR system.  
Isolates that screened positive were prepared as glycerol stocks (Appendix 1.2) and plasmid 
miniprep extractions (Appendix 2.1.1) in preparation for sequencing (Appendix 2.2). Isolates that 
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screened positive for the clone insertion from sequence analysis were resuscitated and culture 
scaled up for plasmid maxiprep extraction (Appendix 2.1.3 - 2.1.4) in the lead up to preliminary 
expression studies. 
Table 16 Reaction components for colony PCR, probing for complete TH, TL, AH and AL genes in 
clone isolates. Primer pairs for the reactions were associated with the sequence primers for mAbX, 
gWiz and pVITRO1 vectors. 
Component 
Reaction 
Concentration 
Volume 
(µL) 
OneTaq QuickLoad 2x Master Mix 1 x 12.5 
Liquid o/n culture of isolate - 1 
10 µM Fwd Seq primer 0.2 µM 0.5 
10 µM Rev Seq primer 0.2 µM 0.5 
Nuclease free H2O - 10.5 
 
Table 17 Cycling conditions for colony PCR, probing for complete TH, TL, AH and AL genes in 
clone isolates. 
TH/AH TL/AL 
Cycle Step Cycles 
Temperature 
(°C) 
Time (sec) 
Initial denaturation 1 94 120 
Denaturation 
25 
94 15 
Annealing  55 30 
Extension 68 90 45 
Final Extension 1 68 300 
 
2.6 Transfection and Purification of Antibodies 
Successfully cloned vectors were prepared for transient transfection in suspension 293F culture. 24 
hr prior to transfection, 293F cells were passaged to a seeding density of 5 x 105 cells/mL in 
Freestyle 293 expression media. Transfection proceeded if the live cell concentration reached 0.8 – 
1.2 x 106 cells/mL and cell viability was ≥ 95% on the day of transfection. The total live cells of the 
culture was obtained and quantity of DNA and PEI were calculated as 2 µg PEI and 1 µg DNA per 
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106 cells in transfection culture. For co-transfection of light chain and heavy chain mabX or gWiz 
vectors, a 1:1 ratio of light chain to heavy chain vector was combined for transfection. Calculated 
quantity of DNA and PEI were separately diluted in OptiPRO SFM to total volumes of 600 µL and 
incubated at RT for 5 min. The diluted DNA and PEI solutions were combined, gently mixed and 
incubated at RT for 15 min prior to dropwise addition to transfection culture. Cultures were 
returned to incubate, 24 hrs post transfection the cultures were supplemented with 0.5% w/v 
tryptone to total culture volume, and again supplemented with 0.5% w/v tryptone on subsequent 
scale up at 48 hrs. Cell counts of the transfection cultures were taken daily to monitor progression 
and culture was harvested when the cell viability reached < 80%.  
In the instance of expression with the mAbX vectors, transfection was conducted in 30 mL culture 
and harvested 5 days post transfection. In the instance of expression with the pVITRO1 vector, 
transfection was conducted in 30 mL culture which was scaled up to 60 mL at 24 hrs, then 100 mL 
at 48 hrs post transfection; harvested 7 days post transfection. In the instance of Tmab and AdmAb 
expression with the gWiz vectors, transfection was conducted in 60 mL culture which was scaled up 
to 120 mL at 24 hrs, then 240 mL at 48 hrs post transfection; harvested 8 days post transfection. 
Culture supernatants were harvested by centrifugation (3,000 g, 15 mins), clarified and degassed by 
passing through a 0.22 μm vacuum filter. Secreted antibody was purified from the culture 
supernatant through Protein A affinity chromatography, using an ÄKTApurifier 100 FPLC system 
with a HiTrap® Protein A column (Appendix 4). Antibody was bound on the column with PBS as 
binding buffer, eluted from the column with 0.1 M glycine HCl pH 2.7 and elution fractions 
neutralised with 1 M Tris-HCl pH 9.  
FPLC chromatograms detected the protein content passing through the column with UV absorbance 
at 280 nm. Elution peaks from the FPLC chromatogram indicated the total protein content purified 
from each expression system. The chromatograms were analysed to determine the area under the 
elution peak for comparison, as a preliminary indicator of total protein yield. Fractions containing 
eluted antibody as indicated from the FPLC chromatograms were pooled, buffer exchanged to PBS 
and concentrated using 50 kDa centrifugal filters. UV absorption of the purified antibody samples 
was measured at 280 nm to derive total antibody yield using the Beer Lambert law and the 
extinction coefficients of Tmab and AdmAb. 
3 Results 
3.1 Cloning Tmab Variable Regions into mAbXpress Vectors 
The amplified Tmab variable region genes and SacI linearised mAbX vectors yielded fragments of 
their predicted size – TVH 376 bp, TVL 346 bp, linearised mAbX hKappa 5064 bp and linearised 
44 
 
mAbX hG1 5742 bp (Figure 7); however, the PCR products ran fairly broadly which suggests 
incomplete extension in the PCRs. Purification of the DNA products post RE digestions was high 
yielding and therefore did not compromise the ligation reaction setup conditions. 
Transformation of both ligation reactions successfully yielded many isolates for colony PCR 
screening, of which 4 mAbX TH and 2 mAbX TL tested isolates were positive (Figure 8). Blank 
mAbx hKappa and mAbX hG1 DNA were run for insert negative control. A consistent smear 
present in negative colony PCR samples (< 1000 bp) was attributed to the unreacted primers from 
the PCR mastermix. The 100 bp ladder was not resolved in the gels to quantify the PCR fragment 
sizes, although the difference between insert positive and negative was apparent. All colony PCR 
positive clones were prepared for sequencing. 
 
 
 
 
 
kb 
- 4
- 6
- 8
- 10 
- 0.5
- 1
- 1.5
- 2
- 3
  1          2         L1                                      3          4         L2           
bp 
- 1500 
- 1200 
- 1000 
- 500 
- 400 
- 300 
- 200 
- 100 
- 600 
- 700 
- 800 
A B 
350 bp → 
375 bp → 
5 kb → 
5.7 kb → 
Figure 7 0.8% Agarose gels of Tmab variable region gene PCR products (A) and SacI digested 
mAbX vectors (B). 100 bp DNA Ladder (L1) 1 kb DNA Ladder (L2), TVL PCR product (1), TVH 
PCR product (2), linearised mAbX hKappa (3), linearised mAbX hG1 (4). 2 µL ladder, 1.5 µL PCR 
and digestion products were loaded. 
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3.2 gWiz Cloning of Whole Tmab Genes 
The amplification of Tmab genes and linearisation of gWiz blank vector yielded fragments of their 
predicted sizes - TH 1,434 bp, TL 726 bp and linearised gWiz 5,016 bp (Figure 9); however, the 
products ran fairly broadly which suggests incomplete extension in the PCRs. Purification of the 
DNA products post RE digestions was high yielding and therefore did not compromise the ligation 
reaction setup conditions (Table 18).  
Transformation of both ligation reactions successfully yielded many isolates for colony PCR 
screening, of which 3 gWiz TH and 6 gWiz TL tested isolates were positive (Figure 10). 
L     1     2                                       L     3     4     5      6     7           
1 - 
3 - 
0.5 - 
10 - 
2 - 
1.5 - 
kb 
8 - 
0.5 - 
1.5 - 
1 - 
2 - 
6 - 
5 - 
3 - 
6 - 
5 - 
8 - 
kb 
10 - 
Figure 9 0.8% Agarose gels of reaction products for cloning Tmab whole genes TL (A) and TH (B) 
into gWiz vector. 1 kb DNA Ladder (L), TL PCR product (1), TL purified RE digestion product (2), 
TH PCR product (3), gWiz RE / rSAP product (4) TH purified RE digestion product (5), gWiz 
purified RE / rSAP product (6), 40 ng circular gWiz blank (7). 2 µL ladder, PCR and digestion 
products, and 1.5 µL purified samples were loaded. 
A B 
← 750 bp 
← 1.5 kb 
← 5 kb 
L    1    2    3    4    5    6    7    8    9   10   -H                         11      12      -L       L 
A B 
Figure 8 0.8% Agarose gels of colony PCR screening for positive insertion in mAbX TH (A) and 
mAbX TL (B) isolates. 100 bp DNA Ladder (L), 10 mAbX TH isolates (1 - 10), blank mAbX hG1 (-
H), 2 mAbX TL isolates (11 - 12) and blank mAbX hKappa (-L). 2 µL ladder and 5 µL PCR samples 
were loaded. 
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Additionally, pVITRO1_Trastuzumab_IgG1/κ DNA was run for a positive control, blank gWiz 
DNA for a negative control and PCR cocktail without DNA sample was run for a contamination 
control. A consistent band present in all colony PCR samples (< 100 bp) was attributed to the 
residual primers from the PCR mastermix. All colony PCR positive clones were prepared for 
sequencing.  
Table 18 Purified DNA digestion products for cloning Tmab whole genes into gWiz for ligation 
reaction setup. 
 gWiz TH gWiz TL 
Component Concentration Volume (µL) 
10 x T4 DNA Ligase Buffer 10 x 2 
Linearised gWiz vector (purified) 28.9  ng/µL 2.9 
Digested TH product (purified) 121.0  ng/µL 0.6 - 
Digested TL product (purified) 8.6  ng/µL - 4.2 
T4 DNA Ligase 400 units/µL 1 
Nuclease free  H2O - 13.5 9.9 
Figure 10 0.8% Agarose gels of colony PCR screening for positive insertion in gWiz TH (A) and 
gWiz TL (B) isolates. 1 kb DNA Ladder (L), 22 gWiz TH isolates (1 - 22), 11 gWiz TL isolates (23 - 
33), blank gWiz DNA (-), pVITRO1_Trastuzumab_IgG1/κ DNA (+) and PCR mastermix omitting 
DNA (C). 2 µL ladder and 5 µL PCR samples were loaded. 
kb 
kb 
L   1     2    3    4     5    6     7    8    9    10   11  12  13  14   15  16   17  18   19  20  21  22     -    +   C 
L   23   24   25   26    27   28   29   30   31   32   33     -     +     C 
0.5 - 
0.5 - 
1 - 
1.5 - 
6 - 
3 - 
10 - 
1 - 
1.5 - 
3 - 
6 - 
10 - 
1.6 kb → 
← 0.8 kb 
A 
B 
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3.3 Variable Region Gene Switching in gWiz and pVITRO1 Vectors 
The PCR reactions for linearising gWiz TH and gWiz TL vectors, and backbone fragments of 
pVITRO1_Trastuzumab_IgG1/κ yielded fragments of their predicted sizes – gWiz CH 6,072 bp, 
gWiz CL 5,401 bp and pVITRO1 H/sL 3,782 bp; however, pVITRO1 L/sH product was a much 
smaller fragment than the expected 5,401 bp (Figure 11). The fragment size could not be elucidated 
for pVITRO1 L/sH product although the fragment band spanned 700 – 1500 bp. PCR cocktail 
without DNA sample was run as a contamination control for all linearising PCRs. All PCR products 
ran broadly and were low yielding suggesting incomplete extension and suboptimal cycling 
conditions. Despite the low product yields as indicated from the agarose gel, purification of the 
DNA products yielded manageable quantities and In-Fusion® ligation reactions were adjusted 
accordingly, in keeping with the 2:1 molar ratio of gene to vector (Table 19).  
Transformation of gWiz In-Fusion® reactions successfully yielded many isolates for colony PCR 
screening, of which 7 gWiz AH and 8 gWiz AL tested isolates were positive (Figure 12A and B). 
However, transformation of pVITRO1 In-Fusion® reaction was unsuccessful, yielding 1 isolate that 
screened negative for both AL and AH colony PCRs (Figure 12A and C). Additionally, gWiz TH, 
gWiz TL and pVITRO1_Trastuzumab_IgG1/κ DNA were run for insert positive controls, 
pVITRO1_dV_IgG1/κ DNA was run for insert negative control and PCR cocktail without DNA 
sample was run for a contamination control. All colony PCR positive clones were prepared for 
sequencing. 
 
Figure 11 0.8% Agarose gels of PCR products for linearised gWiz TH, gWiz TL and 
pVITRO1_Trastuzumab_IgG1/κ. 1 kb DNA Ladder (L), pVITRO1 H/sL product (1), pVITRO1 
L/sH (2), gWiz CL (3), gWiz CH (4), PCR mastermix omitting DNA (1C - 4C). 2 µL ladder and 
1.5 µL linearising PCR products were loaded. 
kb 
1     1C    2     2C    3    3C     4     4C     L 
3.8 
kb 
→ 
5.5 
kb 
→ 
← 0.7 - 1.5 kb 
6.2 
kb 
→ 
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- 1 
- 1.5 
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- 10 
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Table 19 Purified linearised vector products for AdmAb variable region switching In-Fusion® 
ligation reactions. Reaction volumes were adjusted to maintain a minimum of 20 ng gene in the 
reaction, keeping in the 2:1 molar ratio of gene to vector. 
 
gWiz AH gWiz AL 
pVITRO1_ 
Adalimumab 
_IgG1/κ 
Component Concentration Volume (µL) 
5 x In-Fusion HD Enzyme Premix 5 x 3 2 4.5 
AH gene 8.6  ng/µL 3.1 - 3.4 
AL gene 8.6  ng/µL - 2.3 3.1 
gWiz CH 23.8 ng/µL 8.4 - - 
gWiz CL 29.4 ng/µL - 5.1 - 
pVITRO1 H/sL 24.9 ng/µL - - 5.5 
pVITRO1 H/sL 31.2 ng/µL - - 4.8 
Nuclease free  H2O - 0.5 0.6 1.2 
kb 
← 0.7 kb 
← 550 bp 
kb 
kb 
C 
L    1     2    3    4    5    6     7    8    9   10   11   p+ gH+ dV 
A 
L   12  13  14  15  16   17  18  19  20  21  gL+ p+ dV   C B L  22  p+ gL+ dV  C 
Figure 12 0.8% Agarose gels of colony PCR screening for positive insertion for full AH gene (A) 
and AL gene (B, C) in gWiz and pVITRO1 isolates. 1 kb DNA Ladder (L), 10 gWiz AH isolates (1 - 
10), 1 pVITRO1 isolate (11, 22), 10 gWiz AL isolates (12 - 21), pVITRO1_Trastuzumab_IgG1/κ 
DNA (p+), gWiz TH DNA (gH+), gWiz TL DNA (gL+), pVITRO1_dV_IgG1/κ DNA (dV) and PCR 
mastermix omitting DNA (C). 2 µL ladder and 5 µL PCR samples were loaded. 
8 - 
10 - 
6 - 
4 - 
3 - 
2 - 
1.5 - 
1 - 
0.5 - 
← 1.5 kb 
← 1.2 kb 
0.5 - 
1 - 
0.5 - 
1.5 - 
1 - 
2 - 
3 - 
2 - 
1.5 - 
4 - 
3 - 
4 - 
6 - 
6 - 
8 - 
10 - 
8 - 10 - 
← 800 bp 
← 550 bp 
← 800 bp 
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3.4 Sequence Analysis and Cloning Efficiency 
All sequence results were analysed for quality and robustness of base calling prior to BLAST 
alignment analysis. Robust isolate nucleotide sequences were aligned against the nucleotide 
sequences of the predicted vector products to determine the success of seamless insertion. Cloned 
isolates were confirmed through sequence analysis in both (forward and reverse) directions. 
An example of positive sequence analysis as shown in Figure 13, isolate gWiz TL1 forward 
sequence was aligned with the predicted nucleotide sequence for gWiz TL. Homology from 1874 – 
2589 bp in the gWiz TL sequence confirmed successful integration of the TL gene. No further 
alignments (i.e. one single alignment) confirmed a single, seamless gene insertion and a single 
vector backbone. Continued homology beyond the gene insertion confirmed a portion of the vector 
backbone. 
Through the sequencing analysis, it was realised that the primer design for the mAbX TL cloning 
produced a mismatch in the joining region that directly disrupted the SacI site and caused an aa 
substitution of Leucine 104 to Valine. This was observed in the sequencing of both mabX TL 
positive clones isolated. The significance of this bp and aa substitution was not investigated.  
The efficiency and accuracy between the different cloning methods were compared (Table 20). 
Efficiency is described as the percentage of isolates that screened insert positive by colony PCR and 
accuracy is described as the percentage of insert positive clones that were confirmed as successful 
cloning through sequence analysis.  
50 
 
 
 
 
   
Query  1819  AGCTGACAGACTAACAGACTGTTCCTTTCCATGGGTCTTTTCTGCAGTCACCGTCGTCGACATGTTGCCATCACAACTCATTGGGTTTCTGCTGCTCTGGGTTCCAGCTAGCCGCGGTGACATCCAGATGACCCAGTCTCCTTCTTCTCT  1968 
             ||||||| |||| | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8     AGCTGAC-GACT-ANAGACTGTTCCTTTCCATGGGTCTTTTCTGCAGTCACCGTCGTCGACATGTTGCCATCACAACTCATTGGGTTTCTGCTGCTCTGGGTTCCAGCTAGCCGCGGTGACATCCAGATGACCCAGTCTCCTTCTTCTCT  155 
 
Query  1969  TTCTGCTTCTGTTGGTGATCGTGTTACTATTACTTGTCGTGCTTCTCAAGATGTTAATACTGCTGTTGCTTGGTATCAACAAAAACCTGGTAAAGCTCCTAAActtcttatttattctgcttcttttctttattctggtgttccttctcg  2118 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  156   TTCTGCTTCTGTTGGTGATCGTGTTACTATTACTTGTCGTGCTTCTCAAGATGTTAATACTGCTGTTGCTTGGTATCAACAAAAACCTGGTAAAGCTCCTAAACTTCTTATTTATTCTGCTTCTTTTCTTTATTCTGGTGTTCCTTCTCG  305 
 
Query  2119  tttttctggttctcgttctGGTACTGATTTTACTCTTACTATTTCTTCTCTTCAACCTGAAGATTTTGCTACTTATTATTGTCAACAACATTATACTACTCCTCCTACTTTTGGTCAAGGTACCAAGCTGGAGATCAAACGTACGGTGGC  2268 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  306   TTTTTCTGGTTCTCGTTCTGGTACTGATTTTACTCTTACTATTTCTTCTCTTCAACCTGAAGATTTTGCTACTTATTATTGTCAACAACATTATACTACTCCTCCTACTTTTGGTCAAGGTACCAAGCTGGAGATCAAACGTACGGTGGC  455 
 
Query  2269  GGCGCCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGA  2418 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  456   GGCGCCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGA  605 
 
Query  2419  GAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAG  2568 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  606   GAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAG  755 
 
Query  2569  GGGAGAGTGTTAGGGGATCCAGATCACTTCTGGCTAATAAAAGATCAGAGCTCTAGAGATCTGTGTGTTGGTTTTTTGTGGATCTGCTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCC-TCCCCCGTG-CCTTCCTTGACCCTG  2716 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||||| ||||||||||||||| 
Sbjct  756   GGGAGAGTGTTAGGGGATCCAGATCACTTCTGGCTAATAAAAGATCAGAGCTCTAGAGATCTGTGTGTTGGTTTTTTGTGGATCTGCTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCCTCCCCCGTGCCCTTCCTTGACCCTG  905 
 
Query  2717  GAA-GGTGCC-ACTCCC-ACT-GTCCTTTCCTAATAAAATGA-GGAAA-TTGCATCGC-ATTGTC-TGAGT-AGGTGTCATT-CTATT-CTgggggg-tgggg  2807 
             ||| |||||| |||||| ||| ||||||||||||||||| || ||||| ||||||| | |||||| ||| | ||||||| || ||||| |||||||| ||||| 
Sbjct  906   GAAAGGTGCCCACTCCCCACTGGTCCTTTCCTAATAAAAAGAAGGAAAATTGCATCCCCATTGTCCTGAATNAGGTGTCCTTTCTATTTCTGGGGGGGTGGGG  1008 
Figure 13 Example of a BLAST sequence alignment demonstrating a positive sequence analysis result. gWiz TL1 positive isolate (Subjct) aligned to the 
predicted nucleotide sequence of gWiz TL (Query).  
51 
 
Cloning efficiency of the light chain for both Tmab and AdmAb appeared higher than the heavy 
chain, although compared to other isolates, only 2 mAbX TL isolates were tested which likely does 
not represent the efficiency derived. Regarding gene insertion, cloning accuracy was 100% for all 
strategies, yet accuracy with the variable gene switching strategy was highly reduced due to a high 
degree of background vector containing the original Tmab variable gene insert.  
Table 20 Comparison of cloning efficiencies between the different cloning strategies conducted in 
this study 
Vector 
Isolates 
Yielded 
Cloning 
Efficiency 
Cloning 
Accuracy 
mAbX TH 59 4/10 (40 %) 3/3 (100 %) 
mAbX TL 47 2/2 (100 %) 2/2 (100 %) 
gWiz TH 52 3/22 (13.6 %) 3/3 (100%) 
gWiz TL > 300 6/11 (54.5 %) 6/6 (100 %) 
gWiz AH > 300 7/10 (70 %) 1/7 (14.3 %) 
gWiz AL 285 8/10 (80 %) 1/8 (12.5 %) 
pVITRO1_Adalimumab_IgG1/κ 1 0/1 (0 %) N/A  
 
The variable gene switching strategy was unfortunately not successful for the dual 
pVITRO1_Adalimumab_IgG1/κ expression vector. This can be attributed to the incomplete 
linearised vector backbone product pVITRO1 L/sH truncating the vector re-assembly in the In-
Fusion® reaction. A truncated version of the pVITRO1_Adalimumab_IgG1/κ vector may have 
assembled in the In-Fusion® reaction although its rescue and isolation was not successful, 
suggesting that the assembly product was non-functional and therefore not useful. 
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3.5 Preliminary Transient Expression Study 
The expression of Tmab and AdmAb from the successfully cloned vector expression systems was 
compared through a pilot transient expression study in suspension 293F culture. 
pVITRO1_Trastuzumab_IgG1/κ dual expression vector was compared with the co-transfection of 
mAbX TH/TL, gWiz TH/TL and gWiz AH/AL single expression vectors. To further support the cell 
viability and protein expression prior to harvest, tryptone was supplemented to all transfection 
cultures and cultures were scaled up (aside from the mAbX expression system). The harvested 
culture supernatants were purified through an FPLC system using Protein A affinity 
chromatography and elution peaks from the FPLC chromatogram analysed to provide an indication 
of the total protein content purified from each expression systems.  
FPLC chromatograms indicated that the gWiz expression vectors were the highest yielding of the 
three vector expression systems (Figure 14), although the purification strategy between the two 
antibodies required optimisation. Insufficient column washing post sample injection and broad 
elution were observed with the gWiz expressed Tmab chromatogram (Figure 14C), which suggests 
inefficient elution of Tmab off the column. However, the similar peak area between both gWiz 
expression systems suggests that the quantity of antibody yielded was relatively consistent and that 
despite inefficient elution, Tmab yield was not compromised. It is noted that a pressure fluctuation 
in the gWiz AdmAb purification occurred during the column wash post sample loading, although 
this did not affect the elution of AdmAb.  
The pVITRO1_Trastuzumab_IgG1/κ and mAbX expression systems produced considerably less 
antibody (Figure 14A and B), although it is noted that seeding volume, total cells and quantity of 
DNA for these transfection reactions were exactly half of those prepared for the gWiz expression 
systems, and that the harvest time point slightly differed across the expression systems according to 
cell viability. However, in keeping the cells to DNA ratio consistent, the scale of transfection 
seeding correlates with protein expression, and that the majority of expression occurs within the 
first 96 hrs of transfection. It is also noted that the mAbX purification commenced on the FPLC 
system before the system had stabilised (as indicated by the negative baseline during elution), 
although this has no effect on the efficiency of the elution of Tmab, or determining the eluting peak 
area.  
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Figure 14 FPLC chromatograms of Tmab (blue) and AdmAb (red) purifications from pVITRO1 
(A), mAbX (B) and gWiz (C) expression systems. Elution peaks of each chromatogram (inset). 
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The purified antibody samples were buffer exchanged, concentrated and the total antibody yield 
derived from UV absorbance at 280 nm. Antibody yields correlated to the elution peak areas (Table 
21), further confirming that the gWiz expression system was the most efficient for transient 
expression of both Tmab and AdmAb. The Tmab yield from the pVITRO1 system was 18% of 
gWiz system after buffer exchange. The mAbX system yield was lost through the buffer exchange 
process and was therefore not determined. As the elution peak area for the mAbX system was 8-
fold lower than the pVITRO1 system, the theoretical yield could be approximated to 30 µg, which 
is 2% of the gWiz system.  
Table 21 Yield of Tmab and AdmAb generated from the expression vector library in the 
preliminary transient expression study. 
Vector Expression System 
Seed 
Volume 
(mL) 
Harvest 
Volume 
(mL) 
Peak Area 
(mL.mAU) 
Yield 
(µg) 
pVITRO1_Trastuzumab_IgG1/κ 
30  
100 31.04 235 
mAbX TH/TL 30 3.95 ND 
gWiz TH/TL 
60 240 
467.34 1300 
gWiz AH/AL 459.27 1175 
 
4 Discussion 
In developing the expression vector library for the expression of Tmab and AdmAb in mammalian 
culture, different cloning strategies were required for each vector suite. That is variable region gene 
switching in the pVITRO1 suite, variable region gene insertion in the mAbX suite and whole gene 
insertion then variable region gene switching in the gWiz suite. Of the cloning strategies conducted 
in this project, whole Tmab gene insertion into the blank gWiz vector using traditional restriction 
cloning and ligation was the least scrupulous and had the highest efficiency. AdmAb variable 
region gene switching into the gWiz suite was relatively unscrupulous also; however, the method 
requires optimisation to reduce the number of background isolates captured for sequencing. The 
gWiz Tmab and AdmAb vector suite produced the highest yield in the transient co-expression 
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system and was deemed the most suitable vector suite for transient expression optimisation leading 
up to mutagenesis projects. 
The cloning efficiency in producing gWiz AH/AL through the variable region gene switching 
strategy was considerably low, in that many isolates had captured the background vector containing 
the original Tmab variable gene insert. Unlike with the gene insertion strategies, colony PCR for the 
variable gene switching strategy is not indicative of the cloning efficiency. In this instance, colony 
PCR does not differentiate between the complete original Tmab genes and cloned AdmAb genes in 
order to exclude background vector, but rather it excludes the rare event of isolating incomplete 
gene/vector constructs. The isolated background vector is attributed to the gWiz TH/TL vectors from 
the linearising PCRs being retained in the purification of the linearised products, and therefore 
carried over in residual quantities in the subsequent In-Fusion® reactions. In considering 
improvement to this cloning method, a separation step of the linearised PCR products on agarose 
gel prior to purification would have substantially reduced vector background, as was demonstrated 
with the higher cloning efficiency of the mAbX variable gene insertion cloning strategy. However, 
with this currently reported cloning method, gWiz AH/AL vectors were successfully isolated and 
they readily expressed AdmAb in transient co-transfection. 
The mAbX variable gene insertion strategy was rather scrupulous; however, yielded high cloning 
efficiency and accuracy. Interestingly, as a dephosphorylation step was not included in this strategy 
as a method of preventing religation of linearised vector, a lower cloning efficiency was expected 
from what we reported. This further infers that agarose separation of linearised product is a more 
efficient way of removing non-linearised background vector in the final ligation product. 
Unfortunately primer design required revision before embarking on this strategy as an aa 
substitution was unintentionally introduced into the TL gene. Further to this, transient co-expression 
of Tmab using the mAbX system was poor yielding, hence it was determined that this system was 
not suitable for further investigation and optimisation. 
pVITRO1_Trastuzumab_IgG1/κ readily expressed Tmab in transient culture, and is a versatile 
vector in being able to produce stable cell lines. However, the variable gene switching strategy for 
producing pVITRO1_Adalimumab_IgG1/κ proved unsuccessful. Specifically, the amplification of 
pVITRO1 L/sH produced an incompletely amplified fragment that was smaller than predicted. 
Further investigation of the primer design did not give insight to the reason why the primers 
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produced a truncated product from pVITRO1_Trastuzumab_IgG1/κ, as no further binding sites 
were predicted when manipulating primer hybridization parameters such as primer length, CG 
content and minimum melting temperature. Considering that the primer set was designed with full 
homology in the Tmab genes, the primers were completely transferrable between the gWiz TH/TL 
and pVITRO1_Trastuzumab_IgG1/κ vectors. The incompletely amplified backbone product 
contained 20 bp homology to the synthetic AdmAb variable region genes as per the primer design, 
therefore the In-Fusion® reaction was expected to assemble a truncated version of 
pVITRO1_Adalimumab_IgG1/κ vector, with possible exclusion of the hygromycin resistance gene. 
It is likely that the outcome of the In-Fusion® reaction assembled a truncated version of 
pVITRO1_Adalimumab_IgG1/κ which may have lost function, replicability or hygromycin 
selectivity, rendering the ligation product incapable of being rescued and isolated.  
Upon successful cloning, a preliminary transient expression study was conducted in 293F culture to 
compare yield and quality of antibody produced from the different vector systems. The vector suites 
had different expression requirements that impact the further considerations for producing libraries 
of antibody variants. Unlike the pVITRO1 and mAbX vector suites, the gWiz vectors were limited 
to transient expression. Furthermore, unlike the pVITRO1 suite, the mAbX and gWiz vector suites 
were single gene vectors that required co-expression of both heavy and light chain vectors for the 
expression of complete antibody. Therefore, a fair comparison of antibody expression between the 
vector suites required that all expression systems remained transient and that the ratio of heavy to 
light chain genes and DNA to cells in transfection culture remained consistent. To further support 
cell viability and enhance expression, tryptone was supplemented to transfection cultures.  
Of the transient expressions conducted in this study, Tmab and AdmAb in the gWiz system was the 
highest yielding. Tmab expression in the pVITRO1 system was moderately yielding and in the 
mAbX system, poorly yielding. As the mAbX system was low yielding and the mAbX TL vector 
isolated for expression contained an aa mismatch due to primer design, we determined that this 
system was not suitable for further investigation and optimisation.  
Investigations reported in Chapter 3 and Chapter 4 expressed Tmab libraries through 
pVITRO1_Trastuzumab_IgG1/κ before progressing to gWiz TH/TL (Chapter 4 and Chapter 5) and 
AdmAb expression in gWiz AH/AL (Chapter 6) vector systems.  
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Chapter 3 was published in the Journal of Visualized Experiments: 
Elgundi, Z., Sifniotis, V., Reslan, M., Cruz, E., Kayser, V. (2017). Laboratory Scale Production and 
Purification of a Therapeutic Antibody. Journal of Visualized Experiments, 119: e55153. 
  
Chapter 3  
Laboratory Scale Production and 
Purification of a Therapeutic Antibody 
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Abstract  
Ensuring the successful production of a therapeutic antibody begins early on in the development 
process. The first stage is vector expression of the antibody genes followed by stable transfection 
into a suitable cell line. The stable clones are subjected to screening in order to select those clones 
with desired production and growth characteristics. This is a critical albeit time-consuming step in 
the process. This protocol considers vector selection and sourcing of antibody sequences for the 
expression of a therapeutic antibody. The methods describe preparation of vector DNA for stable 
transfection of a suspension variant of human embryonic kidney 293 (HEK-293) cell line, using 
polyethylenimine (PEI). The cells are transfected as adherent cells in serum-containing media to 
maximize transfection efficiency, and afterwards adapted to serum-free conditions. Large scale 
production, setup as batch overgrow cultures is used to yield antibody protein that is purified by 
affinity chromatography using an automated fast protein liquid chromatography (FPLC) instrument. 
The antibody yields produced by this method can provide sufficient protein to begin initial 
characterization of the antibody. This may include in vitro assay development or physicochemical 
characterization to aid in the time-consuming task of clonal screening for lead candidates. This 
method can be transferable to the development of an expression system for the production of 
biosimilar antibodies. 
1 Introduction  
The success of therapeutic antibodies continues to drive substantial investment into antibody 
development as a wave of next generation therapeutics begins. The antibody market is expected to 
be reshaped by antibody fragments [183], antibody-drug conjugates [184], bispecific antibodies 
[185] and engineered antibodies with favorable properties [186]. Another class gaining 
pharmaceutical interest are biosimilars. Biosimilar antibodies are ‘highly similar’ replicate products 
of a therapeutic antibody that has already received regulatory approval. A proposed biosimilar must 
be comparable with the originator antibody with respect to its structure, function, animal toxicity, 
clinical safety and effectiveness, human pharmacokinetics (PK), pharmacodynamics (PD) and 
immunogenicity [187, 188].  
The approval rates of biosimilar antibodies have been slow due to the strict constraints on the final 
quality of the product. The exact manufacturing processes such as specific cell lines and culturing 
conditions through to the final processing steps can remain proprietary. What is more, the 
manufacturing of antibodies inherently involves a degree of variability which can add to the 
59 
 
challenge of producing a highly similar product. A comprehensive physiochemical and biophysical 
characterization and comparison is quite difficult, yet a number of studies demonstrating the 
characteristics of biosimilar antibodies are emerging in the literature [189-191]. 
Generating a therapeutic antibody begins with transfection of mammalian host cells with a vector 
carrying the genes for the respective antibody. Vector design, cell line and culture conditions are 
key considerations for setting up the expression system.  
The DNA sequences of antibodies can be sourced from Drug Bank (www.drugbank.ca), IMGT 
(www.igmt.org) or research publications including patents. For example, the sequence of 
trastuzumab is available through Drug Bank (DB ID: DB00072). The amino acid sequence of the 
variable regions can undergo gene design and optimization for synthesis in the desired host species. 
It is important for a biosimilar antibody that no modification is made to the amino acid sequence. 
Once synthesized, antibody genes can be subcloned into the appropriate vector of choice.  
Human IgG antibodies consist of two identical heavy chains and two identical light chains. Tightly 
regulated expression of both chains is essential for optimal production of heterologous IgG protein 
in mammalian cells [192]. Intra- as well as inter-chain disulfide bonds have to be formed and a 
number of post-translational modifications have to be introduced during protein biosynthesis. A 
number of vectors are available that have been designed specifically to express antibody genes 
(refer to Table S1 in supplementary information). These antibody-specific vectors usually express 
the constant regions for both heavy and light chains so only the variable regions of each chain 
require cloning. 
Transfection of cells with two independent constructs (co-transfection) is the most common 
approach for delivering heavy and light chain-encoding genes. That is, each gene is driven by its 
own promoter and transcribed as separate antibody chains before being assembled in the 
endoplasmic reticulum. On the other hand, multi-cistronic vectors have internal ribosome entry site 
(IRES) elements incorporated that allow expression of multiple genes as a single mRNA transcript 
with translation permitted from internal regions of the mRNA [193]. In this instance, the heavy and 
light chain-encoding genes are coupled in an arrangement to achieve co-expression of both antibody 
chains [192, 194].  
While transiently transfected cells yield sufficient protein to perform a limited number of 
experiments, stably transfected cell lines that have undergone selection for genome integration can 
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deliver higher yields. Higher protein amounts allow for assay development relating to in vitro 
characterization and can provide an indication of antibody quality in consideration for downstream 
applications such as clonal cell line and lead candidate selection.  
The goal of this article is to describe the stable expression and purification of a therapeutic antibody 
produced in a mammalian expression system. Indeed, this method can be applied to the expression 
of a biosimilar antibody. The method can be used for the initial characterization of antibodies before 
proceeding on to the critical, albeit time-consuming steps of identifying a desirable clone for larger 
scale manufacturing. Moreover, this method can be used to express other proteins and not just 
antibodies. 
The following detailed protocol describes the expression of therapeutic antibody trastuzumab. This 
consists of preparation of vector DNA followed by stable transfection in HEK-293 cell line and 
purification of antibody protein by an automated chromatographic method.  
2 Protocol  
Note: A suitable mammalian expression vector must be used for this protocol. Here, a single 
construct containing two expression cassettes is used (i.e. heavy and light chain expression is driven 
by separate promoters). Trastuzumab heavy and light chains were previously cloned into the vector. 
This vector was a gift from Andrew Beavil, obtained through a not-for-profit plasmid repository 
[178].  
2.1 Recovery and Scale-up of Vector DNA  
Note: Vector DNA was received as a soft agar stab culture in Escherichia coli XL-1 Blue strain; 
vector carries hygromycin resistance.  
2.1.1 Insert a sterile inoculation stab or loop into the soft agar of the stab culture then streak a Luria 
Bertani (LB) agar plate prepared with 75 μg/mL hygromycin for isolated colonies. Incubate the 
plate at 37 °C for 18-24 h. 
2.1.2 Inoculate a single colony into 5 mL Terrific broth (TB) containing 75 μg/mL hygromycin. 
Incubate the culture at 37 °C for 18-24 h with 225 rpm shaking. 
2.1.3 Use the overnight culture to prepare a glycerol stock of vector DNA by gently mixing 800 μL 
of culture with 200 μL 80% glycerol in a cryovial and freeze at - 80 °C. 
2.1.3.1 Add 100 μL of the overnight culture to 100 mL TB containing 75 μg/mL hygromycin in a 
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baffled shaker flask (i.e. 1/1000 dilution). Incubate the culture at 37 °C for 18 - 24 hr with 225 rpm 
shaking. 
2.1.4 After overnight culture, extract and purify the DNA according to manufacturer’s instructions 
of midi/maxi preparation kit with the following exception; during the final step, elute or resuspend 
DNA with water (pH 7.0-8.5). 
2.1.5 Check concentration and purity of DNA by absorbance readings at 260 and 280 nm then store 
DNA at -20 °C. 
Note: Optional (highly recommended): Sequence DNA using vector-specific primers to confirm 
identity. 
2.2 Stable Transfection of HEK-293 Cells  
2.2.1 Grow and maintain HEK-293 cells (suspension cells) according to standard protocols in 
serum-free media supplemented with 0.1% non-ionic surfactant in baffled flasks. Maintain at 2x105 
cells/mL and subculture every fourth day. Culture cells at 37 °C with 5% CO2 and 120 rpm rotation.  
Note: Cells should have been in culture for no less than 4 days and no more than 4 weeks prior to 
transfection. HEK-293 cells grown as monolayers in serum-containing media can also be used for 
this procedure.  
2.2.2 On the day prior to transfection, seed HEK-293 cells at 3x105 cells/mL in wells of a 12-well 
plate in 2 mL of Dulbecco's Modified Eagle Media (DMEM) supplemented with 10% heat-
inactivated fetal bovine serum (FBS). On the day of transfection, check that cells have reached 80-
90% confluency  
2.2.3 Dilute DNA and polyethylenimine (PEI) separately in transfection media then mix together. 
2.2.3.1 Dilute 1.25 μg vector DNA per well (15 μg for 12 wells) in 300 μL transfection media. 
Incubate at room temperature for 5 min. 
2.2.3.2 Dilute 2.5 μL of 1 mg/mL PEI solution (30 μL for 12 wells; i.e. 1:2 ratio of DNA to PEI) 
in 300 μL transfection media. Incubate at room temperature for 5 min. 
2.2.3.3 Add diluted DNA to diluted PEI, gently mix and incubate at room temperature for 15 min. 
2.2.4 Add 50 μL of DNA/PEI mixture dropwise to each well of the plate. Rock the plate gently to 
distribute the transfection mixture then place the plate at 37 °C, 5% CO2 for 24 h. 
2.2.5 Add 50 μg/mL hygromycin B per well and return plate to 37 °C, 5% CO2 for 10 days. 
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Note: By Day 10, un-transfected cells will have died and detached from the surface of the plate, 
whereas stably-transfected cells will be viable and attached to the plate. 
2.2.6 Replace the media in wells with ¼ volume serum-free media and ¾ volume DMEM 
supplemented with 10% FBS (i.e. 0.5 mL serum-free media + 1.5 ml DMEM = 7.5% final serum 
concentration) and incubate for 4 days. 
2.2.7 Replace the media in wells with ½ volume serum-free media and ½ volume DMEM 
supplemented with 10% FBS (i.e. 1 mL serum-free media + 1 mL DMEM = 5% final serum 
concentration) and incubate for 4 days. 
2.2.8 Replace the media in wells with ¾ volume serum-free media and ¼ volume DMEM 
supplemented with 10% FBS (i.e. 1.5 mL serum-free media + 0.5 mL DMEM = 2.5% final serum 
concentration) and incubate for 4 days. 
2.2.9 Replace the media in wells with 2 mL of serum-free media supplemented with 0.1% non-ionic 
surfactant (i.e. 0% final serum concentration) and incubate for 4 days. 
Note: Maintain 50 μg/mL hygromycin B selective pressure on cells during serum-free adaptation. 
Cells adapted to serum-free media detach from the surface of wells and may cluster in suspension. 
Refer to step 2.2.1 for culture conditions with the additional supplement of 50 μg/mL hygromycin B. 
2.2.10 Using a pipette, gently mix the suspension cultures in the 12-well plate and pool cells into 
a separate tube. 
2.2.10.1 Using a hemocytometer, enumerate pooled cells and seed in 30 mL serum-free media in a 
baffled flask at 2x105 cells/ml. Culture cells at 37 °C with 5% CO2 and 120 rpm rotation. 
Subculture and expand every fourth day. 
2.2.11 Continue to expand culture size to required cell density to obtain 10 vials at 1x107 
cells/vial for cryopreservation in liquid nitrogen. Freeze the cells in serum-free media containing 
10% dimethylsulfoxide (DMSO). 
Note: Conditioned media containing antibody can be harvested at each subculture to confirm 
protein production or used to optimize purification conditions. To harvest conditioned media and 
maintain cells for subculture, centrifuge the culture at 300 x g for 5 min then filter-sterilize 
supernatant through a 0.22 μm filter. Filtered supernatant may be kept at 4 °C for 1-2 weeks or -20 
°C for longer term storage. 
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2.3 Large Scale Antibody Production from Batch Overgrow Culture 
Note: Antibody production can be followed on from step 2.2.11 where existing cells are expanded 
to the required cell density based on the batch overgrow culture volume to be setup. Otherwise, 
cells that have been thawed from cryopreservation begin at this stage once expanded to an 
appropriate cell density and volume. Various culture supplements may be used to optimize antibody 
production; the use of tryptone to increase antibody yield is demonstrated in this protocol. 
2.3.1 Seed cells at 2x105 cells/ml in 100 mL serum-free media in two baffled flasks (to compare 
antibody yields from un-supplemented and nutrient-supplemented cultures). Culture at 37 °C, 5% 
CO2 and 120 rpm. 
2.3.2 After 24 h, add tryptone to a final concentration of 0.5% to nutrient-supplemented culture. 
Equalize volume of un-supplemented culture with serum-free media. 
2.3.3 From day 8, perform cell counts of the cultures daily using a hemocytometer to monitor cell 
viability. Harvest the culture supernatants once cell viability is less than 80%. 
2.3.3.1 Harvest supernatant by centrifugation of the cultures at 3000 x g for 15 min then filter-
sterilize the supernatant (containing antibody) through a 0.22 μm filter. Store the supernatants at 4 
°C (short-term) or freeze at -20 °C (long-term). 
2.4 Antibody Purification by Affinity Chromatography Using an Automated Fast Protein 
Liquid Chromatography (FPLC) System  
Note: The following procedure can generally be applied to most automated systems. Purification 
can be performed at room temperature or at 4 °C (if FPLC system is kept in a cool room). A series 
of scouting tests can be performed to identify the optimal purification conditions including 
appropriate column matrix, binding buffer, elution buffer and pH to ensure maximum recovery of 
purified antibody from conditioned media (refer to Results section). The optimal conditions are 
dependent on the antibody or protein being purified. Purifications were performed on an automated 
FPLC system. Purifications were performed at room temperature using a 5 ml Protein A column. 
2.4.1 Prepare the following buffers using ultrapure water and adjust to the recommended pH then 
filter through a 0.22 μm filter. 
2.4.1.1 Prepare 1 L of phosphate buffered saline (PBS) pH 7.4 (binding buffer) by mixing the 
following: 0.14 M NaCl, 0.0027 M KCl, 0.01 M Na2HPO4 and 0.001 M KH2PO4. Adjust pH if 
necessary before filtering the buffer. 
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2.4.1.2 Prepare 500 mL of 0.1 M glycine-HCl pH 2.7 (elution buffer). Adjust pH before filtering 
the buffer. 
2.4.1.3 Prepare 50 mL of 1 M Tris pH 9.0 (neutralization buffer). 
2.4.2 Ensure all system power and communication connections with computer are made. Devices 
should be visible in the software ‘System Control’ module. Ensure UV cell is set at 280 nm 
wavelength. Optional: Calibrate pH meter if connected and to be used. 
2.4.3 Immerse inlet tubes of A, B and sample pump in ultrapure water to wash the system. Purge the 
pumps with a syringe if there is air in the tubing or a suspicion of air in the system. Wash the 
system with water by manual operation via the system controller or via an automated method. 
Observe that pressure, conductivity, UV280 tracing and pH remain consistent and that the pressure 
limit for the column is not exceeded as per manufacturer’s specification. 
Note: Abnormalities may indicate air or blockage in the system that should be addressed before 
proceeding. 
2.4.4 In the system controller module, start the flowrate at 1 mL/min manually via pump A in either 
load (bypassing sample loop) or inject (through the sample loop) position to begin connecting the 
column. Disconnect system tubing at the column position inlet and remove the stopper connected to 
the column inlet. 
2.4.4.1 Allow water to flow from the system tubing dropwise on top of the column then attach the 
system tubing to the column. Having the column inlet and inlet fitting overflowing with drops of 
water ensures a connection free of air bubbles. 
2.4.5 Attach the column outlet at the downstream outlet and verify all fittings are tightly fastened. 
With the column now attached to the system, do not exceed limits for maximum pressure limit and 
flowrate as outlined in column specifications. 
2.4.6 Wash column with 5 column volumes (CV) of water. If necessary, continue column wash until 
UV280 tracing has stabilized. 
2.4.7 Immerse inlet tubes of A in Binding buffer, B in Elution buffer and sample pump in Binding 
buffer to equilibrate the system in correct buffers. Fill the inlet tubes with buffer using PumpWash 
by manual operation. 
2.4.8 In the ‘Method Editor’ module of the software, use the method wizard to setup an affinity 
chromatography method for the column that is intended to be used. 
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Note: Automated FPLC systems come with methods pre-filled with the recommended settings (i.e. 
flowrate and pressure limit) and run steps based on the column (manufacturer, matrix and size) 
selected for purification. 
2.4.8.1 Use the following run steps for Protein A affinity chromatography: 
2.4.8.1.1 Equilibrate system with 5 CV of Binding buffer and collect flowthrough into waste 
container. 
2.4.8.1.2 Load sample onto the column (volume to be loaded is specified manually in the method) 
and collect flowthrough into a separate container. 
2.4.8.1.3 Wash system with 5 CV of Binding buffer and collect flowthrough into a separate 
container. 
2.4.8.1.4 Elute column with 5 CV isocratic fractionation using Elution buffer and collect purified 
antibody sample as fractions by fraction collector. 
2.4.8.1.5 Equilibrate system with 5 CV of Binding buffer and collect flowthrough into waste 
container. 
2.4.9 Once the method has been setup, specify the volume of conditioned media to be applied to the 
column and save the method. 
Note: The specified volume in the method should be 5-10 mL less than the actual volume to avoid 
introduction of air during the sample run. The specified volume used in this protocol is 90-120 mL. 
2.4.10  Submerge the sample pump tubing into the vessel containing the conditioned media. 
2.4.11 Prepare a separate container to collect sample flowthrough via the specified outlet tubing. 
Note: It is important to collect the flowthrough in the case an error occurs during the run or the 
binding capacity of the column is exceeded requiring the flowthrough to be reapplied to the column 
or the purification repeated. 
2.4.12  Prepare collection tubes in the fraction collector. Add 100 μL of neutralization buffer per 
1 mL fraction volume. The FPLC system will automatically elute the fractions into the collection 
tubes. 
2.4.13  In the ‘System Control’ module of the software, open the method to be run. 
Note: The method run is initiated in a series of pages that include checking the variables of the 
method, fraction collector setup and defining result file name and storage location. 
2.4.14  Click START to initiate the run. The run can be monitored in the ‘System Control’ 
module. 
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2.4.15  At the completion of the purification run, check the resulting chromatogram in the 
‘Evaluation’ module in the system software. 
2.4.16  Combine all protein-containing fractions into a separate tube, buffer exchange and 
concentrate in PBS using a centrifugal filter device with 30 kDa molecular weight cut off. Perform 
centrifugation steps according to manufacturer’s instructions. 
2.4.17  Measure antibody concentration using bicinchoninic acid assay (BCA) according to 
manufacturer’s instructions. 
2.4.18  If another purification run is to be performed, prime the sample pump tubing in Binding 
buffer and repeat steps 2.4.9-2.4.14. 
2.4.19  At the completion of purification runs, immerse inlet tubes of A, B and sample pump in 
ultrapure water and wash the system and column as performed in step 2.4.3. 
2.4.20  Submerge A, B and sample pump tubing in 20% ethanol and repeat wash procedure for 
storage of the system and column. 
2.4.21  Disconnect the column from the downstream outlet and replace column stopper, then 
disconnect column at the inlet and replace stopper, reconnect tubing to the system. Store the column 
at 4 °C. 
3 Representative Results 
Stable production of trastuzumab by transfected HEK-293 cells was confirmed using bio-layer 
interferometry (BLI) as presented in Figure 15. An IgG standard curve was generated by measuring 
the binding rate between an IgG antibody standard and protein A biosensor (Figure 15A). The 
crude supernatant sample was similarly measured, then its concentration interpolated from the 
standard curve (Figure 15B). The supernatant concentration was measured to be approximately 25 
μg/mL (sampled from 50 mL collected at subculture) two weeks after serum-free adaptation and 
prior to setting up cells for overgrow batch cultures. Supernatant collected at each subculture after 
serum-free adaptation was pooled and used to optimize purification conditions; scouting of binding 
and elution buffers was performed as shown in Figure 16. The steps of purification are depicted in 
Figure 16A based on UV280 signal. Once the Protein A column equilibrates, an increase in UV280 
signal represents sample loading; this increase is due to supernatant flowthrough passing through 
the column (containing unbound proteins which absorb UV light at this wavelength), while 
antibodies have been captured by the column. Once the sample has finished loading, the UV280 
signal returns to baseline as any remaining unbound proteins are washed away. Elution occurs as 
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pH decreases to the optimal pH to release the antibodies captured by the column, depicted by an 
increase in UV280 signal with eluted antibodies fractionated and collected by the fraction collector. 
Throughout the sample run, conductivity changes based on the salt concentration in the buffers 
whereas system pressure should remain relatively constant.  
Optimal elution, pH and buffer were scouted first (Figure 16B); it was observed that antibody 
eluted more efficiently off the column at lower pH using either 0.1 M glycine HCl or citric acid. 
However, below pH 2.7 there was no further improvement in the elution profile. In addition, elution 
peaks with 0.1 M glycine HCl appeared less broadened when compared with 0.1 M citric acid at 
similar pH (Figure 16B). Subsequently, 0.1 M glycine-HCl pH 2.7 buffer was used to optimize 
binding buffer conditions (Figure 16A). The effect of different binding buffers on elution was also 
compared (Figure 16A). It was observed that PBS pH 7.4 and 20 mM sodium phosphate pH 7 had 
comparable elution profiles, while the addition of 3 M NaCl to sodium phosphate buffer (to enhance 
antibody binding to the column) was not favorable. Due to the ease of PBS buffer preparation, PBS 
pH 7.4 was selected as the binding buffer for future purifications.  
The purification chromatograms of batch overgrow cultures are shown in Figure 17; tryptone-
supplemented culture is compared to un-supplemented culture. It was noted that the addition of 
tryptone to the supplemented culture resulted in an increased UV280 signal during the sample 
loading step, compared to the un-supplemented culture. The tryptone-supplemented culture yielded 
3.8 mg and the un-supplemented culture 1.7 mg of trastuzumab, based on protein recovered after 
buffer exchange and concentration. Quality control of the purified antibody was confirmed by 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (Figure 18). Trastuzumab 
grown in un-supplemented and tryptone-supplemented conditions results in similar antibody 
profiles under non-reducing and reducing conditions. As expected, a prominent band at 
approximately 150 kDa confirms correctly folded antibody; other bands represent fragmented forms 
of the antibody, a result of disulfide bond breakage and a method-induced artefact. Likewise, two 
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bands at 50 and approximately25 kDa confirm the presence of antibody heavy and light chains, 
respectively. 
 
Figure 15 Confirmation of protein production by stably transfected HEK293-F cells using BLItz 
(bio- layer interferometry). (A) BLItz sensorgrams of antibody standards analysed in a 1:1 binding 
model to determine binding rates at each concentration. Binding curves of standards (grey) and 
crude supernatant sample of PEI-transfected trastuzumab (PEI-Tmab; black) to protein A biosensor 
was measured over 120 seconds. (B) Antibody standard curve of concentration versus binding rate, 
used to interpolate concentration of antibody protein in crude supernatant. 
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Figure 16 Purification chromatograms of elution and binding buffer scouting experiments. (A) The 
steps of purification are depicted according to UV280 signal (blue, green or black lines); sample 
loading onto the column followed by column wash to wash away unbound proteins then elution of 
bound protein from the column. Measurement of pH (red line), conductivity (brown line) and 
system pressure (grey line) is monitored throughout the run. Three buffers were tested for optimal 
binding of trastuzumab to the column and washing away of unbound protein to maximize elution 
yield. (B) 0.1 M glycine-HCl (pH 2.5-3.3) and 0.1 M citric acid (pH 2.5-3.5) buffers were tested for 
optimal elution of trastuzumab from protein A column. 
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Figure 17 Purification chromatograms of trastuzumab (TmAb) batch overgrow cultures grown 
with no supplement or supplemented with tryptone. Stably transfected HEK-293 cells were setup 
at 2x105 cells/ml and cultured for 8 days either un-supplemented (120 mL; black line) or 
supplemented with 0.4% tryptone (90 mL; green line). After harvesting, supernatants were purified 
using PBS pH 7.4 (binding buffer) and 0.1 M glycine-HCl pH 2.7 (elution buffer). 
Figure 18 Analysis of purified trastuzumab by SDS-PAGE. Approximately 2 µg of trastuzumab 
purified from un-supplemented (-) or tryptone-supplemented (+) cultures was sampled by 10% 
SDS-PAGE under non-reduced or reduced conditions. The gel is stained with coomassie R-250.    
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4 Discussion 
This protocol details the transfection, stable expression and purification of a therapeutic antibody in 
HEK-293 cells. Stable expression of antibody genes is the first step in generating an antibody-
producing cell line for the development and manufacture of a therapeutic antibody. While Chinese 
hamster ovary (CHO) cells remain the expression platform of choice for therapeutic proteins, the 
HEK-293 cell line is gaining prominence with the realization that proteins produced in these cells 
are a closer match to naturally occurring human proteins, in terms of post-translational 
modifications and function [195, 196].  
Mammalian cell lines including CHO (for example, CHO-DG44 and CHO-K1) as well as non-
immunoglobulin secreting murine B cell lines NS0 and SP2/0 are predominantly used in 
biopharmaceutical production.  Expression systems based on these cell lines are based on selection 
processes whereby high producing clones are induced and selected through incremental addition of 
a specific selective drug [197, 198].  The selection process for a stable clone can therefore be 
arduous and time-consuming.  In comparison to these existing methods, the HEK-293 cell line 
robustly transfects with high efficiency, the selection process is simplified and very easily adapts to 
serum-free suspension culture, making it an ideal expression system for laboratory scale production 
of proteins [199]. 
A limitation of stable transfection is time in which a practical amount of protein can be produced 
and utilized in experiments.  To try and overcome this, the current protocol describes a culturing 
step that can achieve substantial amounts of protein within 3-6 weeks of transfection.  The batch 
overgrow cultures (large scale production) provide the opportunity to produce substantial amounts 
of antibody for the setup of in vitro characterization experiments in the lead up to selection of a 
clonal cell line and lead candidates. This has clear advantages over transient transfection which can 
require higher amounts of DNA and reagents, and protein yield is not reproducible from batch to 
batch since expression is only temporary and determined by transfection efficiency.  
The addition of tryptone in this protocol provided an increased yield in protein expression. Addition 
of tryptone to transfection cultures has previously been shown to improve protein synthesis [200, 
201]. The tryptone supplemented culture resulted in improved trastuzumab antibody yields of 40 
mg/L versus the un-supplemented culture of 14 mg/L (Figure 17). SDS-PAGE verified that: (1) the 
antibody was being produced correctly; and (2) the addition of tryptone did not alter structure based 
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on comparison of the antibody bands under non-reducing and reducing conditions (Figure 18). The 
addition of tryptone to the cultures is optional and is particularly used to achieve higher protein 
yields. Other supplements have been considered to enhance protein expression such as sodium 
butyrate and valproic acid [97, 202, 203]. 
The first checkpoint of the protocol is the confirmation that protein is being produced by the 
transfected cell line. This step may be performed any time after the two-week period of selective 
pressure used to select stable transformants. A number of methods may be used to confirm protein 
production including bio-layer interferometry (Figure 15) or the similar approach of an IgG ELISA. 
Alternatively, a western blot may be performed using an anti-IgG detection antibody to identify 
antibody protein in the crude supernatant or purified sample.  
Other researchers have shown that higher transfection efficiency is achieved using adherent cells in 
serum-containing media [204]. The presence of supplements from animal origin is undesirable for 
biopharmaceutical production therefore, the sequential adaptation to serum-free media is a critical 
step in the protocol requiring patience and careful monitoring of cell viability. The 4-day turnover 
period suggested in this protocol is a guide and so if problems are encountered at a certain serum 
concentration, it is recommended that the cells be subcultured 2-3 times in the previous ratio of 
serum-containing to serum-free media before continuing with the next ratio. Prior to setting up 
batch cultures and cryopreservation of cells, consider that most cell lines are deemed fully adapted 
after three subcultures in 100% serum-free media.  
One of the most crucial steps at the purification stage is the scouting for optimal conditions and 
buffers to ensure efficient binding of the antibody to the column and then complete elution off the 
column (Figure 16). The conditioned media collected at each subculture is useful for this purpose. 
In this case, the elution buffer of citric acid pH 3.5 generally recommended for protein A affinity 
chromatography was unsuitable for elution of trastuzumab from the column. The scouting 
experiment using two different elution buffers at various pH clearly showed that even within the 
narrow range of pH tested, the degree of elution was affected (Figure 16B). 
In terms of downstream processing of the antibody fractions after purification, the antibody can be 
buffer-exchanged using a desalting column either by manual or automated operation. Alternatively, 
dialysis membrane can also be used. Final protein concentration can be determined by other protein 
quantification methods including measurement of the absorbance signal at 280 nm with 
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concentration deduced from Beer Lambert’s Law based on the extinction coefficient of the 
antibody.  
This protocol has successfully produced antibody protein of trastuzumab by stable transfection of 
HEK-293 cells. The antibody was purified and characterized to confirm integrity. The steps in this 
protocol detailing DNA preparation, stable transfection followed by serum-free adaptation, large 
scale production and automated purification can be transferred to producing other proteins. 
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Chapter 4  
Rationalised Residue Substitution of 
Trastuzumab for Enhanced Affinity to 
Target HER2 
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Abstract 
This chapter reports on the development of a library of trastuzumab mutants that had predicted 
enhanced affinity toward target HER2 using in silico methods. Three of the reported five mutants 
were successfully produced in optimised transient 293F expression systems and tested in vitro for 
comparison of relative affinity and binding kinetics.  
Residue substitution predictions, molecular dynamic (MD) simulations, free energy perturbation 
and thermodynamic integration calculations were conducted by our collaborators from A/Prof 
Serdar Kuyucak’s Computational Biophysics Group, School of Physics, The University of Sydney. 
Their group reported highly promising residue substitutions in the trastuzumab CDRs and Fab 
region for experimental validation. We produced three of their reported candidates for screening; 
compared and optimised site-directed mutagenesis protocols in the lead up to expression of the 
trastuzumab affinity mutant library for in vitro testing. Trastuzumab affinity mutants were 
compared for binding to extracellularly expressed HER2 in a cell-binding titration assay and real-
time binding kinetics to immobilized HER2 through surface plasmon resonance.  
Interestingly, as in silico results were preliminary at the time of reporting lead candidates to our 
group for investigation, experiments gave varying results which were later validated with the 
completion of the in silico analysis. One mutation disrupted trastuzumabs affinity to HER2 quite 
considerably and the other two showed negligible affinity enhancement experimentally which 
confirmed the in silico results in that the mutations did not show conclusive affinity enhancement to 
HER2.  
The findings of this study suggest that in silico prediction correlates with in vitro analysis of an 
affinity disrupting mutation and that native inter and intramolecular interaction disruptions are a 
prerequisite part of MD simulation analysis for electing lead affinity mutation candidates. Two 
substitution mutations for affinity enhancement were unsuccessful after several rounds of 
mutagenesis and were therefore unable to corroborate a correlation between in silico prediction and 
in vitro analysis for affinity enhancement.   
1 Introduction; Trastuzumab Affinity to HER2 for the Treatment of HER2 Positive Breast 
Cancer 
As outlined in Chapter 1, Trastuzumab (Herceptin®) is a humanized IgG1/κ monoclonal antibody 
used therapeutically for the treatment of HER2 positive breast cancers [21, 22]. HER2 is a cell 
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receptor that is overexpressed in approximately 20% of breast cancers and contains an intracellular 
and extracellular region. HER2 can dimerize with several activated receptors and this dimerization 
activates downstream pathways that promote cell proliferation, motility and survival [18, 21, 22].  
Trastuzumab (Tmab) acts by binding to extracellular subdomain IV of HER2, which specifically 
inhibits HER2-HER3 dimerization, independent of HER3 ligand induction [22]. The consequence 
of this is the downregulation of the PI3K/AKT pathways that promote cell survival and proliferation 
[22]. Tmab being an IgG1/κ class antibody, its binding to the extracellular region of HER2 also 
specifically targets HER2 positive cancer cells for antibody-dependant cell-mediated cytotoxicity 
(ADCC) [21]. Tmabs relative binding affinity to the extracellular domain of HER2 has been 
screened through many assays, including cell-binding assays, enzyme-linked immunosorbent assays 
(ELISA), bio-layer interferometry (BLI) and surface plasmon resonance (SPR) [205-209]. The 
equilibrium binding constant (KD) for Tmab to HER2 has been experimentally determined to be 
very strong in the subnanomolar range, spanning from 19 pM – 1 nM [19, 205, 209].  
Interestingly, in the context of HER2 breast cancer treatment, in vivo studies have shown that 
biodistribution and tumour retention was poorer in anti-HER2 biotherapeutics of higher affinity [23, 
210, 211]. This association was confirmed with biotherapeutics that bound to the same HER2 
epitope, where affinity to HER2 was manipulated through mutation of the biotherapeutic [211-213]. 
Biodistribution was highly dependent on the molecular size of the biotherapeutic and cellular 
uptake was preferential in the tumour periphery for all biotherapeutics of high affinity [210, 211, 
214]. Specifically, biodistribution and tumour retention did not increase significantly in anti-HER 
single-chain Fv antibody fragments with an affinity stronger that 1 nM KD [213]. And similarly, the 
biodistribution of whole anti-HER2 antibodies of high affinity was confined to the tumour 
perivascular space as compared to lower affinity antibodies that had a broader distribution pattern 
and were achieving further penetration in the tumour [211].  
Manipulation of Tmabs relative affinity to HER2 is of ongoing interest, as different therapeutic 
platforms can be developed for improved treatment of HER2 positive breast cancers. Fragment 
Tmab and Tmab-drug conjugate platforms would favour enhanced relative affinity for efficient 
catabolism and delivery of cytotoxic drug to target cancer cells [23]. Tmab with enhanced ADCC 
functions, extended half-life, and Tmab decorated nanoparticles would favour a reduced relative 
affinity for better biodistribution and tumour retention leading to a more insistent ADCC effect.  
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This study was designed to produce lead Tmab mutant candidates with rationally designed residue 
substitutions to have enhanced relative affinity to HER2. The overall aim was to produce a Tmab 
affinity mutant library based on in silico analysis and to corroborate these results with in vitro 
experimental validation. 
1.1 In silico Substitution Predictions and Analysis of Tmab 
Preliminary in silico results produced from A/Prof Serdar Kuyucak’s Computational Biophysics 
Group (unpublished) were reported to us as warranted for experimental investigation. Firstly, their 
team analysed the binding interface of the crystal structure of Tmab Fab - HER2 fragment complex 
(PDB ID: 1N8Z) (Figure 19). Residues in the Tmab sequence that mismatch HER2 residues were 
identified as well as potential unutilised bonding sites of HER2 residues in close proximity to Tmab 
residues (Table 22). Suggested residue substitutions in the trastuzumab sequences were then trialled 
in MD simulations to detect the likelihood of newly formed bonds between the substitutions and 
HER2 residues. MD simulations were also conducted on the substitutions to confirm that the 
important intermolecular interactions from the complex were not disrupted and that intramolecular 
interactions within the Tmab Fab were not disrupted. For MD simulation results on substitutions 
that showed that newly formed bonds were likely, further free energy perturbation and 
thermodynamic integration calculations were conducted to determine the change in the binding free 
energy. 
Residues in the binding interface between Tmab Fab and HER2 that contribute to the binding 
between trastuzumab and HER2 is outlined in Figure 19. Several potential substitutions that were 
identified for investigation is outlined in Table 22. In one case (D28), a coulomb repulsion 
interaction was converted to an attraction interaction by replacing the Tmab amino acid (aa) residue 
to the opposite polarity; i.e. from acidic aspartic acid (D) to basic arginine (R) or lysine (K).  
In another case (S50), an introduction of electrostatic interaction or creation of a hydrophobic 
pocket was possible for the same site. In the instance of producing a hydrophobic pocket, 
surrounding aa in the Tmab sequence contained aromatic side chains which were predicted to cause 
steric hindrance at the binding interface with the addition of a further aromatic. Therefore the group 
proposed aa switching of tyrosine (Y) at position 49 and serine (S) at position 50 as opposed to the 
addition of a further aromatic in that region. In the instance of introducing an electrostatic 
interaction, the Tmab aa residue was replaced with an acidic aa residue; i.e. aspartic acid (D) or 
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glutamic acid (E); however, E was preferred as the longer sidechain would have closer proximity to 
HER2 aa residue to establish a hydrogen bond. In one further case (D102), this site being 
surrounded by aromatic residues from HER2 would create a hydrophobic pocket by replacing the 
Tmab aa reside to an aromatic i.e. phenylalanine (F). Unlike the case of S50, the Tmab aa sequence 
at the D102 site was not immediately surrounded by aromatics to be affected by steric hindrance, 
instead the residues at that site would directly interact and bury within the aromatics from a nearby 
loop of the HER2.  
Preliminary MD simulations indicated that all suggested mutations did not disrupt the important 
intermolecular interactions between the Tmab and HER2 in the complex (not shown). However, 
aside from S50>E substitution, all other substitutions did not disrupt the intramolecular interactions 
within the Fab (not shown). Unfortunately S50 had an intramolecular interaction with V33 that 
destabilised with the substitution to E (not shown).  
 
Figure 19 Portion of the crystal structure of the Tmab Fab – HER2 complex (1N8Z) zoomed in to 
the binding interface. TL Fab (yellow), TH Fab (orange), HER2 (green) and pairwise interactions 
between the contact residues (red dashed lines). 
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Table 22 Summary of reported Tmab aa substitutions identified for experimental validation. 
*Preferred aa due to the length of the sidechain. ^Additional electrostatic interaction identified. 
HER2  Tmab  Proposed Interaction and Comments 
Substitutions 
identified 
  E598 D28 
Remove coulomb repulsion interaction; replace 
acidic to basic aa 
R, K 
K593 
S50 
Introduce electrostatic interaction; replace to 
basic aa 
D, E* 
I591  
P571  
K593^ 
Create hydrophobic pocket (recruiting Y49, 
F53, G103 and F104); replace S50 to aromatic 
aa; consider steric hindrance in the region; 
switch Y49/S50 
Y 
F573  
V575  
Y588 
D102 
Create a hydrophobic pocket; replace to 
aromatic aa 
F 
 
MD simulations of Tmab electrostatic substitution residues to the aa residues in HER2 (Figure 20) 
showed that of all electrostatic interactions, only D28>R introduced new interactions, that being 
stable hydrogen bonds presented in the MD simulations as molecular distance stabilisation at 3Å 
(Figure 20C and D). However, molecular distance instability as presented in Figure 20A and B 
suggested no newly introduced interactions through the D28>K and S50>E substitutions, 
respectively. D28>R was a lead candidate for binding free energy calculations; D28>R was 
predicted to enhance the affinity of Tmab to HER2 by - 5.86 kcal/mol, which is a substantial 43% 
increase as compared to Tmab WT to HER2 of - 13.6 kcal/mol. 
MD simulations of Tmab aromatic substitution residues to the aa residues in HER2 showed that 
only Y49/S50>S49/Y50 introduced a stable hydrophobic and electrostatic interaction, along with 
key aa recruited for the hydrophobic pocket (Figure 21 and Table 23). HER2 I591 produced stable 
hydrophobic interactions with Tmab S50>Y and F104 (Figure 21A) and HER2 K593 produced 
stable hydrogen bonds with S50>Y and G103 (Figure 21B), presented in the MD simulations as 
molecular distance stabilisation at 4Å and 3Å, respectively. However, molecular distance instability 
as presented in Figure 21C suggested no newly introduced interactions through the D102>F 
substitution. The changes in molecular distances from key interactions observed for the mutations 
corroborate the MD simulation findings, in that Y49/S50>S49/Y50 introduced new interactions, 
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whereas D102>F did not (Table 23). Y49/S50>S49/Y50 is a lead candidate for binding free energy 
calculations that will be pursued as a future project with A/Prof Serdar Kuyucak’s Computational 
Biophysics Group. 
 
 
 
Time (ns) 
A 
Figure 20 MD simulations of Tmab electrostatic substitutions Tmab D28>K-NZ to HER2 E598-
OE2 (A), Tmab S50>E-O2 to HER2 K593-NZ (B), Tmab D28>R-N1 to HER2 E598-O1/2 (C) and 
Tmab D28>R-N2 to HER2 E598-O1/2 (D). Stability at 3Å for residues at R28 (C and D) suggests 
successful hydrogen bond formation. 
B 
C D 
0                5                10               15               20            25  0           5           10           15         20        25         30      35 
        
 0              10               20              30               40             50  0               10               20              30               40            50 
20 
 
15 
 
10 
 
5 
 
0 
7 
6 
5 
4 
3 
2 
15 
 
10 
 
5 
 
0 
M
o
le
cu
la
r 
D
is
ta
n
ce
 (
Å
) 
15   
 
10   
 
5   
 
0 
81 
 
Table 23 Summary of molecular distances between the residues of interest. Average molecular 
distances calculated from MD simulations, *introduced interactions through mutation, no data (ND). 
HER2  Tmab WT 
Crystal 
Structure 
Molecular 
Distance (Å) 
MD 
Average 
(Å) 
Tmab 
Mutants 
MD Average  
(Å) 
I591-Cδ 
P571-Cγ 
K593-NZ 
Y49-Cε1 
Y49-Cε2 
Y49-OH 
7.5 
11.0 
8.6 
4.7 ± 1.1 
13.3 ± 0.7 
9.4 ± 0.5 
Y50-Cε1 
Y50-Cε2 
Y50-OH 
4.7 ± 0.9* 
6.0 ± 0.6 
3.0 ± 0.2* 
F573-Cδ1 
V575-Cγ1 
Y588-Cε2 
D102-O2 
D102-O2 
D102-O2 
7.0 
8.7 
ND 
9.7 ± 1.4 
8.6 ± 2.1 
12.5 ± 1.9 
F102- Cε1 
F102- Cδ1 
F102- Cδ2 
7.5 ± 1.2 
6.5 ± 1.2 
9.3 ± 1.5 
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Figure 21 MD simulations of Tmab aromatic substitutions S50>Y-Cε1 (and F104-Cδ1) to HER2 E591-
Cδ (A), S50>Y-OH (and G103-O) to HER2 K593-NZ (B), and D102>F-Cδ1/ε1/δ2 to HER2 V575-Cγ1, 
F575-Cδ1 and Y588-Cε2 (C). Stability at 4Å for residue Y50 (A) suggests stable hydrophobic 
interaction and 3Å for residue at Y50 (B) suggests successful hydrogen bond formation. 
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1.2 Mutagenesis of Substitutions for Experimental Validation 
Based on the preliminary in silico results presented in 1.1, substitutions elected for experimental 
validation are listed in Table 24. Codons from the Tmab WT genes for mutagenesis were identified 
from the pVITRO1_Trastuzumab_IgG1/κ expression vector and mutations were designed based on 
minimum bp mismatching to Tmab WT codons. Mutagenesis reactions were designed and 
performed based on the QuikChange™ method (Agilent Technologies), that is whole plasmid, 
single-round PCR [215]. Overlapping primer pairs with introduced mutations were designed and the 
entire vector was amplified through high fidelity inverse PCR through a variety of cycling methods, 
including conventional 3-step PCR, a 2-step PCR and single-primer reactions in parallel [216]. 
Vectors containing successful mutations were expressed in transient 293F culture and purified 
through protein A affinity chromatography in the lead up to affinity and binding kinetic assays. The 
library was screened for extracellular binding of HER2 in a cell-based assay, and binding kinetics to 
HER2 through SPR. Furthermore, the library was screened for binding kinetics to model Fc 
receptor FcγR1A through SPR to demonstrate retention of other biological functions. For the 
purposes of this study, pVITRO1_Trastuzumab_IgG1/κ expression vector was used for 
experimental validation of D28>K and S50>E substitutions and the gWiz TH/TL expression vectors 
for all other substitutions. 
Table 24 Summary of Tmab aa substitutions elected for experimental validation. Codon bp that 
mismatch the WT gene codon for primer design consideration (bold). *Two primer pairs were 
designed with different mismatch codons for several mutagenesis attempts, ^simultaneous double 
substitution. 
 
Site WT Codon Substitution Mutation Codon 
D28 (Vκ) GAT 
K  
R  
AAG 
CGT/CGC* 
Y49 (Vκ) TAT S
^ TCT 
S50 (Vκ) TCT 
E  
Y^ 
GAG 
TAT 
D102 (VH) GAT F  TTT 
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2 Methods 
2.1 Instrumentation, Services and Software 
Site-directed mutagenesis (SDM) reactions were conducted on a Bio-Rad T100 thermal cycler, with 
heated lid. DNA quantification was performed on a NanoDrop ND-1000 spectrophotometer. Mutant 
isolate vectors were prepared as purified DNA samples and sent to AGRF for Sanger Sequence 
analysis. Sequencing results were analysed on Applied Biosystems Sequence Scanner 2 software. 
Overlapping primer pairs for mutagenesis were designed using GSL Biotech SnapGene Viewer 
4.0.5 software. Tm calculations were performed on NEB Tm calculator software with mismatched bp 
omitted (http://tmcalculator.neb.com). Alignment of mutant isolate sequences to vector DNA 
sequences were performed on the NCBI BLAST software (https://blast.ncbi.nlm.nih.gov/Blast.cgi). 
Mutant antibodies were purified from culture supernatant on a GE HealthCare ÄKTApurifier 100 
FLPC system, using Unicorn 5.11 system and analysis software.  
Flow cytometry was performed on a Merck Guava® easyCyte flow cytometer, using InCyte 3.1 
system and analysis software. SPR was performed on a GE HealthCare Biacore™ T200, using T200 
Control and Evaluation software.  
2.2 Materials 
pVITRO1-Trastuzumab-IgG1/κ vector (61883) was obtained from AddGene, gWiz TH and gWiz TL 
vectors were cloned from gWiz blank vector as described in Chapter 2.  The primers for D28>K 
and S50>E mutations were synthesised from Life Technologies (Australia). The primers designed 
for D28>R, Y49/S50>S49/Y50 and D102>F mutations were synthesised from Integrated DNA 
Technologies (Singapore). The primers designed for sequencing pVITRO and gWiz inserts were 
synthesised from Geneworks (Australia).  
The Phusion high-fidelity PCR kit (E0553S) and DpnI enzyme (R0176S) were purchased from 
Genesearch (Australia). Plasmid maxiprep kit (G221020) was purchased from Astral Scientific 
(Australia), miniprep (PLN70) and maxiprep (NA0310) kits were purchased from Sigma-Aldrich 
(Australia).  
Stellar™ competent E. coli (636763) was purchased from Scientifix (Australia), JM109 competent 
E. coli was prepared as per Appendix 1.3. Yeast extract (70161), Sodium chloride (S9888) and 
Kanamycin solution (K0254) was purchased from Sigma-Aldrich (Australia). Tryptone (LP0042B) 
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was purchased from Thermo Fisher Scientific Australia and agar (20767.232) was purchased from 
VWR International (Australia). Hygromycin B solution (ant-hg-1), Hygromycin agar (fas-hg-s) and 
Terrific Broth (fas-hg-l) sachets were purchased from Jomar Life Research (Australia). 
FreeStyle 293F cells were a kind donation from Dr Mario Torrado del Rey of Prof Joel Mackay’s 
research group, School of Life and Environmental Sciences, The University of Sydney. SK-BR3 
cells were a kind donation from A/Prof Thomas Grewal’s research group, Pharmacy School, The 
University of Sydney. FreeStyle™ 293 expression media (12338018), OptiPRO™ Serum free media 
(12309050), UltraPure™ 1M Tris-HCl pH 8.0 (15568-025), RPMI media (21870-076) and 
additional tissue culture reagents (Appendix 3.1) were purchased from Life Technologies 
(Australia). Linear Polyethylenimine (PEI) 25 kDa (23966-2 (POL)) was purchased from 
BioScientific (Australia), bovine serum albumin (BSA) (BSAS 0.1) was purchased from Bovogen 
(Australia) and T75 TC flasks (CORN430641U) were purchased from Bio-Strategy (Australia). 
PBS tablets (09-2051-100) and 1 M Tris-HCl pH 9 (BIOSD814) were purchased from Astral 
Scientific (Australia). Disposable baffled culture flasks (CLS431405), EDTA (E6758), FITC 
secondary antibody (F9512), isotype control antibody (I5154), centrifuge tubes (CLS430291, 
CLS430791), vacuum systems (CLS430769), glycine hydrochloride (G2879), HiTrap® Protein A 
affinity column (GE17-0403-01), HiTrap® MabSelect Sure column (29-0491-04) and Amicon® 
Ultracel 50 kDa centrifugal filters (Z740177, Z740193) were purchased from Sigma-Aldrich 
(Australia).  
Herceptin® was a kind donation from Genentech (USA), HER2 HIS-tagged receptor (SRP6405) 
was purchased from Sigma-Aldrich (Australia) and FcγR1A HIS tagged receptor (10256-H08H-5) 
was purchased from Life Technologies (Australia). CM5 chips (29-1049-88), Amine coupling kit 
(BR-1000-50) and Anti HIS capture kit (28-9950-56) were purchased from GE Healthcare 
(Australia). HEPES (54457), NaCl (S9888) and Tween 20 (P9416) were purchased from Sigma-
Aldrich (Australia). 
2.3 Site Directed Mutagenesis 
Overlapping mutagenesis primers were designed to incorporate mutagenic bp substitutions with a 
minimum of 8 bp homology upstream and downstream of the mutation site (Table 25). The primer 
lengths were varied due to GC content at the mutation site, and were adjusted to meet similar 
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predicted Tm values, a GC clamp of 2 C/G bp in the 3’ end of the primers and 40 – 60 % GC 
content in all primers for optimal annealing.  
Several PCR techniques were employed to optimise mutation efficiency (Table 26); inverse PCR 
(INV PCR) as 3-step and 2-step cycling conditions, differing number of cycles (18 and 25) and as 
single-primer reactions in parallel (SPRINP)[216]. The D28>K and S50>E mutations were 
performed on pVITRO1-Trastuzumab-IgG1/κ vector using the SPRINP and INV PCR 18 reaction 
conditions. The D102F mutation was performed on the gWiz TH vector and the D28>R mutation 
was performed on the gWiz TL vector using the INV PCR 25 and 2-step cycling conditions. The 
Y49/50>S49/Y50 mutation was performed on the gWiz TL vector using the 2-step cycling condition 
only. All reactions were performed using a Phusion High Fidelity PCR kit (Table 27). Unlike the 
INV PCR reactions, the SPRINP reactions were performed with a single primer in each reaction to 
produce single stranded vector DNA product. The SPRINP complementary single stranded DNA 
products were then combined and annealed in gradually cooling reaction to form the complete 
double stranded vector DNA (Table 28).  
Table 25 List of primers designed for TH and TL gene affinity mutations. Nucleotides that mismatch 
the Tmab genes aa sequence, introducing codon mutation (bold). Primer Tm was calculated to 
pVITRO1_Trastuzumab_IgG1/κ with the Phusion PCR kit, with mismatches omitted from the 
primer sequences. *1 G/C bp on 3’ end due to high GC content of sequence in the mutation site. 
Primer 
Sequence 
5’                                                                               3’ 
Tm 
(°C) 
SDMA TrasLC D28K Fwd 
SDMA TrasLC D28K Rev 
CGTGCTTCTCAAAAGGTTAATACTGCTGTTGCTTGG 
CCAAGCAACAGCAGTATTAACCTTTTGAGAAGCACG 75 
SDMA1 TrasLC D28R Fwd 
SDMA1 TrasLC D28R Rev 
CGTGCTTCTCAACGTGTTAATACTGCTGTTGCTTGG 
CCAAGCAACAGCAGTATTAACACGTTGAGAAGCACG 76 
SDMA2 TrasLC D28R Fwd 
SDMA2 TrasLC D28R Rev 
GTCGTGCTTCTCAACGCGTTAATACTGCTGTTGC 
GCAACAGCAGTATTAACGCGTTGAGAAGCACGAC* 72 
SDMA TrasLC S50E Fwd 
SDMA TrasLC S50E Rev 
GCTCCTAAACTTCTTATTTATGAGGCTTCTTTTCTTTATTCTGGTGTTCCTTCTCG 
CGAGAAGGAACACCAGAATAAAGAAAAGAAGCCTCATAAATAAGAAGTTTAGGAGC 78 
SDM TrasLC YS49/50SY Fwd 
SDM TrasLC YS49/50SY Rev 
GCTCCTAAACTTCTTATTCTTATGCTTCTTTTCTTTATTCTGGTGTTCC 
GGAACACCAGAATAAAGAAAAGAAGCATAAGAATAAGAAGTTTAGGAGC 76 
SDMA TrasHC D102F Fwd 
SDMA TrasHC D102F Rev 
CGTTGGGGTGGTTTTGGTTTTTATGCTATGG 
CCATAGCATAAAAACCAAAACCACCCCAACG 75 
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All PCR products were digested with DpnI at 37 °C for 1 hr to remove native vector from the PCR 
product. 5 µL of the digestion products were transformed in competent E. coli via heat-shock 
method (Appendix 1.4), cells containing intact vector were rescued in LB agar containing selection 
antibiotic (75 µg/mL Hygromycin for pVITRO1 reactions and 50 µg/mL Kanamycin for gWiz 
reactions). All digestion products aside from the Y49/50S>S49/Y50 and D28>R with SDMA1 
primer pair 2-step digestion products, were transformed into Stellar™ competent E.coli. The 
Y49/50S>S49/Y50 and D28>R with SDMA1 primer pair 2-step digestion products were 
transformed into in-house prepared JM109 competent E. coli (Appendix 1.4).  
Table 26 Cycling conditions for the different PCR reaction methods for TH and TL gene affinity 
mutations. *2-step reaction only, ^extension time only 
pVITRO1-Trastuzumab-IgG1/κ; D28>K, S50>E SPRINP INV PCR 18 
Cycle Step 
Temp 
(°C) 
Cycles 
Time 
(sec) 
Cycles 
Time 
(sec) 
Initial denaturation 98 1 120 1 30 
Denaturation 98 
30 
40 
18 
30 
Annealing  55 40 60 
Extension 72 150 150 
gWiz TH, gWiz TL; D102>F, D28>R, Y49/S50>S49/Y50* INV PCR 25 2-Step 
Cycle Step Cycles Time (sec) Temp (°C) 
Initial denaturation 1 30 98 98 
Denaturation 
25 
 10 98 98 
Annealing  10 65 
72^ 
Extension 120 72 
Final Extension 1 300 72 72 
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Table 27 Reaction components for TH and TL gene affinity mutations. Two SPRINP reactions were 
performed for each mutation; each reaction containing either the forward or reverse primer. 
Reaction Concentration Volume (µL) 
Component INV PCR SPRINP INV PCR SPRINP 
5 x Phusion HF Buffer 1 x 1 x 5 5 
10 mM dNTP 200 µM 200 µM 0.5 0.5 
10 µM   Forward primer 1.5 pM 
40 pM 
0.75 
4 
10 µM   Reverse primer   1.5 pM 0.75 
Vector DNA 0.6 ng/µL 20 ng/µL as needed 
Nuclease free H2O - to 25 µL 
Phusion DNA Polymerase 20 units/mL 50 units/mL 0.25 0.38 
 
Table 28 Cycling conditions for the annealing of complementary SPRINP products of TH and TL 
gene affinity mutations. 
Cycle step Temp (°C) Time (sec) 
Denaturation 95 300 
Gradual anneal 
90 
80 
70 
60 
50 
40 
60 
60 
30 
30 
30 
30 
Hold 37 ∞ 
 
Single colonies from transformations were isolated and cultured for glycerol stock preparation 
(Appendix 1.2) and plasmid miniprep extraction (Appendix 2.1.1) in preparation for sequencing 
(Appendix 2.2). Isolates that screened positive for the mutation from sequence analysis were 
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resuscitated and culture scaled up for plasmid maxiprep extraction (Appendix 2.1.3 - 2.1.4) in the 
lead up to production of the Tmab affinity mutant library through expression in transient 293F 
culture. 
2.4 Expression and Purification 
Successful pVITRO1-Trastuzumab-IgG1/κ and gWiz TH/TL mutant vectors were prepared for 
transient expression in suspension 293F culture. 24 hr prior to transfection, 293F cells were 
passaged to a seeding density of 5 x 105 cells/mL in Freestyle 293 expression media in 30 mL 
culture for pVITRO1-Trastuzumab-IgG1/κ transfections and 60 mL culture for gWiz TH/TL 
transfections. Transfection proceeded if the live cell concentration reached 0.8 – 1.2 x 106 cells/mL 
and cell viability was ≥ 95% on the day of transfection. Quantity of DNA and PEI were calculated 
as 2 µg PEI and 1 µg DNA per mL of transfection culture.  For co-transfection of light chain and 
heavy chain gWiz vectors, a 1:1 ratio of light chain to heavy chain vector was combined for 
transfection. Calculated quantity of DNA and PEI were separately diluted in OptiPRO SFM to total 
volumes of 2.25 mL for pVITRO1-Trastuzumab-IgG1/κ or 4 mL gWiz TH/TL transfections and 
incubated at RT for 5 min. The diluted DNA and PEI solutions were combined, gently mixed and 
incubated at RT for 15 min prior to dropwise addition to transfection culture. Cultures were 
returned to incubate and 24 hrs post transfection the cultures were supplemented with 0.5% w/v 
tryptone to total culture volume. 2 days post transfection, cultures were scaled up to double volume 
(i.e. 60 mL for pVITRO1-Trastuzumab-IgG1/κ and 120 mL for gWiz TH/TL transfections) and 
supplemented with 0.5% w/v tryptone in the gWiz cultures only. 3 days post transfection, cultures 
were further scaled up to double volume (i.e. 120 mL for pVITRO1-Trastuzumab-IgG1/κ and 240 
mL for gWiz TH/TL transfections) and again supplemented with 0.5% w/v tryptone in the gWiz 
cultures only.  
All transfection culture supernatants were harvested 8 days post transfection by centrifugation 
(3,000 g, 15 min), clarified and degassed by passing through a 0.22 μm vacuum filter. Secreted 
antibody was purified from the culture supernatant through Protein A affinity chromatography, 
using an ÄKTApurifier 100 FPLC system with a HiTrap® Protein A column for pVITRO1-
Trastuzumab-IgG1/κ expressed Tmab and mutants, and a HiTrap® MabSelect Sure column for 
gWiz TH/TL expressed Tmab and mutants (Appendix 4). Antibody was bound on the column with 
PBS as binding buffer, eluted from the column with 0.1 M glycine HCl (pH 2.7 with the Protein A 
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column or pH 3.0 with the MabSelect Sure column) and elution fractions neutralised with 1 M Tris-
HCl (pH 9 with the Protein A column or pH 8 with the MabSelect Sure column). FPLC 
chromatograms detected the elution peaks with UV absorbance at 280 nm and elution fractions 
containing antibody were pooled, buffer exchanged to PBS and concentrated using 50 kDa 
centrifugal filters. UV absorption of the purified antibody samples was measured at 280 nm to 
derive total antibody yield using the Beer Lambert law and the extinction coefficient of trastuzumab 
(Appendix 4.2). 
2.5 HER2 Cell-binding Assay  
The Tmab affinity mutant library was assessed for affinity of extracellularly expressed HER2 in a 
cell-binding end point HER2 affinity assay as detailed in Appendix 5.2. Tmab affinity mutant 
titrations were compared to Herceptin® buffer exchanged to PBS (PBS-Herc), Tmab WT expressed 
from the gWiz TH/TL vector system (Tmab gWiz) and expressed from the 
pVITRO1_Trastuzumab_IgG1/κ vector system (Tmab pVITRO1). 
Briefly, overexpressing HER2 cell line SK-BR3 was harvested non-enzymatically with Versene 
Solution, washed and incubated with Tmab sample titrations for 20 min, 4 °C. After incubation the 
cells were washed, resuspended with a FITC-secondary anti-human IgG1/κ antibody and further 
incubated for 20 min, 4 °C. The cells were again washed, resuspended and passed through flow 
cytometry to detect the amount of green fluorescence per cell in the single cell population. For each 
titration batch PBS-Herc was run as a positive control, a polyclonal IgG1/κ isotype was run as a 
negative control and dilution buffer was run as a wash control. The controls were used to define the 
cell populations detected on flow cytometry as positive or negative cell binding. All titration 
samples were measured through the control defined parameters in flow cytometry, with 5,000 
events collected in duplicate. For each sample, the positive fraction was calculated as the percentage 
of cells defined as positive (bound) amongst the entire count. The positive fraction of each sample 
was plotted against antibody concentration in a sigmoidal binding curve to extrapolate KD at 
equilibrium, that being antibody concentration at 50% positive fraction (bound).  
2.6 Binding Kinetics of Tmab Mutants to HER2 and FcγR1A  
The binding kinetics of Herceptin® buffer exchanged to PBS and Tmab affinity mutant library was 
assessed to HER2 and FcγR1A through surface plasmon resonance (SPR) as detailed in Appendix 
5.3. HER2 kinetics was measured to provide more insight to the results from the cell binding assay 
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and FcγR1A kinetics was measured to ensure that the mutations did not contribute to a loss of 
immunological functions. 
Briefly, a CM5 chip was prepared with anti-HIS antibody through amine coupling for the capture of 
HIS-tagged HER2 for FcγR1A receptor (4 nM, 5 µL/min for 5 min). Measurements were performed 
at 25 °C in HBS-T running buffer as single cycle kinetic assays. 2-fold serial dilutions of Tmab 
samples were prepared from 0.5 - 8 nM and 2.5 - 40 nM for HER2 and FcγR1A respectively. 
Increasing concentrations of Tmab sample was applied over the receptor captured surface 
(20 µL/min, 2 min) with dissociation times of 60 min and 30 min for HER2 and FcγR1A binding 
respectively.  
The sensorgrams were analysed globally using a Langmuir 1:1 binding model to determine Ka, Kd 
and KD. All samples were conducted in duplicate to obtain average values and standard deviation. 
Kinetic rate and binding constants determined from sensorgrams were accepted if the goodness of 
fit value (χ2) was within 5% of the maximum response level (Rmax) of the sensorgrams and KD was 
calculated as Kd/Ka. 
3 Results 
3.1 Mutation Efficiency and Expression 
Of the mutagenesis strategies implemented, three Tmab affinity mutant vectors were successfully 
isolated for expression. That being D28>K and S50>E mutations in the 
pVITRO1_Trastuzumab_IgG1/κ expression vector and D102>F mutation in the gWiz TH 
expression vector (Table 29). Of the mutagenesis strategies, the SPRINP and inverse PCR 2-step 
cycling methods were not successful. Both inverse PCR 3-step cycling methods were highly 
successful, with 25 cycles showing apparently higher efficiency for D102>F mutation specifically. 
Despite repeated attempts (of which several are not reported in this chapter), including re-design of 
primers for the D28>R mutation, isolation of a confirmed D28>R mutant was not achieved. One 
attempt was made at isolating mutation Y49/S50>S49/Y50 which was also unsuccessful.  
An example of positive mutation identified through sequence analysis as shown in Figure 22 isolate 
pVITRO1_Trast_S50E_INVPCR(3) forward sequence was aligned with the nucleotide sequence 
for pVITRO1_Trastuzumab_IgG1/κ. Homology from 5,710 – 6,411 bp of the for 
pVITRO1_Trastuzumab_IgG1/κ sequence confirms the complete TL gene with bp mismatch from 
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5914 – 5916 TCT > GAG confirmed for mutation S50>E. No further alignments and continued 
homology beyond site of mutation confirmed no further artefacts produced by primer ligation 
products.  
Transient expression and purification of the Tmab affinity mutant library was successful for all 
mutant vector expression systems. In keeping with previously reported results from Chapter 2 and 
Chapter 3, the gWiz TH/TL vector system produced significantly higher yield than the pVITRO1-
Trastuzumab-IgG1/κ vector system (not shown). All purified Tmab and affinity mutant samples 
were of workable yield and quality to proceed with subsequent characterisation and binding kinetics 
studies; that being Tmab pVITRO1 (700 µg), D28>K (430 µg), S50>E (150 µg), Tmab gWiz 
(1.65 mg) and D102>F (500 µg). 
Table 29 Comparison of efficiencies between the different mutagenesis strategies conducted in this 
study. Successfully isolated mutants and associated SDM method (bold). Inverse PCR SDM 
method performed using *SDMA1 and #SMDA2 primer pairs, +rescued from JM109 competent 
cells. 
Vector SDM method 
Isolates 
Yielded 
Mutation 
Efficiency 
pVITRO1_Tras_D28K 
SPRINP 
INV PCR 18 
> 300 
> 300 
0/4 (0 %) 
1/5 (20 %) 
pVITRO1_Tras_S50E 
SPRINP 
INV PCR 18 
> 300 
26 
0/5 (0 %) 
3/5 (60 %) 
gWiz TH D102F 
2-step 
INV PCR 25 
0 
> 300 
N/A 
2/3 (66.7 %) 
gWiz TL D28R 
2-step 
1*+ 
4# 
0/1 (0 %) 
0/3 (0%) 
INV PCR 25 
37* 
22# 
0/10 (0 %) 
0/10 (0 %) 
gWiz TL Y49/S50>S49/Y50 2-step 1+ 0/1 (0 %) 
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Query  5653  TTTCTAAACCCGTTTCCAGGTGTTGTGAAAGCCACCGCTAATTCAAAGCAATCCGGAATGTTGCCATCACAACTCATTGGGTTTCTGCTGCTCTGGGTTCCAGCTAGCCGCGGTGACATCCAGATGACCCAGTCTCCTTCTTCTCTTTCT  5802 
             ||||| | ||||||| ||||||||||| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8     TTTCT-AGCCCGTTT-CAGGTGTTGTG-AAGCCACCGCTAATTCAAAGCAATCCGGAATGTTGCCATCACAACTCATTGGGTTTCTGCTGCTCTGGGTTCCAGCTAGCCGCGGTGACATCCAGATGACCCAGTCTCCTTCTTCTCTTTCT  154 
 
Query  5803  GCTTCTGTTGGTGATCGTGTTACTATTACTTGTCGTGCTTCTCAAGATGTTAATACTGCTGTTGCTTGGTATCAACAAAAACCTGGTAAAGCTCCTAAActtcttatttattctgcttcttttctttattctggtgttccttctcgtttt  5952 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||   |||||||||||||||||||||||||||||||||||| 
Sbjct  155   GCTTCTGTTGGTGATCGTGTTACTATTACTTGTCGTGCTTCTCAAGATGTTAATACTGCTGTTGCTTGGTATCAACAAAAACCTGGTAAAGCTCCTAAACTTCTTATTTATGAGGCTTCTTTTCTTTATTCTGGTGTTCCTTCTCGTTTT  304 
 
Query  5953  tctggttctcgttctGGTACTGATTTTACTCTTACTATTTCTTCTCTTCAACCTGAAGATTTTGCTACTTATTATTGTCAACAACATTATACTACTCCTCCTACTTTTGGTCAAGGTACCAAGCTGGAGATCAAACGTACGGTGGCGGCG  6102 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||||||||||||| 
Sbjct  305   TCTGGTTCTCGTTCTGGTACTGATTTTACTCTTACTATTTCTTCTCTTCAACCTGAAGATTTTGCTACTTATTATTGTCAACAACATTATACTACTCCTCCTACTTTTGGTCAAGGTACCAAGCTGGARATCAAACGTACGGTGGCGGCG  454 
 
Query  6103  CCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGT  6252 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  455   CCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGT  604 
 
Query  6253  GTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGA  6402 
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| |||||||||||||||||| 
Sbjct  605   GTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCAC-AAGAGCTTCAACAGGGGA  753 
 
Query  6403  GAGTGTTAGGGATCCCGTACGCCTAGGAGCAGGTTTCCCCAATGACACAAAACGTGCAACTTGAAACTCCGCCTGGTCTTTCCAGGTCTAGAGGGGTAACACTTTGTACTGCGTTTGGCTCCACGCTCGATCCACTGGCGAGTGTTAGTA  6552 
             ||||||||||||||||||||||||||||||| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  754   GAGTGTTAGGGATCCCGTACGCCTAGGAGCA-GTTTCCCCAATGACACAAAACGTGCAACTTGAAACTCCGCCTGGTCTTTCCAGGTCTAGAGGGGTAACACTTTGTACTGCGTTTGGCTCCACGCTCGATCCACTGGCGAGTGTTAGTA  902 
 
Query  6553  ACAGCACTGTTGCTTCGTAGCGGAGCATGACGGCCGTGGGAACTCCTCCTTGGTAACAAGGACCCACGGGGCCAAAAGCCACGCCCACACGGGCCCGTCATGTGTGCAACCCCAGCACGGCGACTTTACTGCGAAACCCACTTTAAAGTG  6702 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| |||||||||||||||||| ||||||||||||||||||||||||| |||||||||| ||| 
Sbjct  903   ACAGCACTGTTGCTTCGTAGCGGAGCATGACGGCCGTGGGAACTCCTCCTTGGTAACAAGGACCCACGGGGCCAAAAGCCACGCCCACAC-GGCCCGTCATGTGTGCAA-CCCAGCACGGCGACTTTACTGCGAA-CCCACTTTAA-GTG  1048 
 
Query  6703  ACATTGAAACTGGTACCCACACACTGGTGACAGGCTAAGGATGCCCTTCAGGTACCCCGAGGTAACACGCGACACTCGGGATCTGAGAAGGGGACTGGGGCTTCTATAAAAGCGCTCGGTTTAAAAAGCTTCTATGCCTGAATAGGTGAC  6852 
             | |||||| || |||||||  ||||| |||| | ||||| ||||| | ||| ||||| ||| ||||  ||||  ||||  ||| | |||||  ||||||||||| ||||  |  |||| |  |||| ||| | |||| ||| |||   |  
Sbjct  1049  AMATTGAA-CT-GTACCCAMMCACTG-TGACTG-CTAAG-ATGCCGT-CAG-TACCC-GAG-TAACM-GCGAACCTCG--ATC-G-GAAGG--ACTGGGGCTTC-ATAA--GS-CTCGAT--AAAA-GCT-C-ATGC-TGA-TAGKA-A-  1169 
 
Query  6853  CGGAGGTCGGCACCTTTCCTTTGCAATTACTGACCC  6888 
             |||| |||||||| |||| ||  |||| || ||||| 
Sbjct  1170  CGGAAGTCGGCAC-TTTCGTTGCCAATAACKGACCC  1204 
Figure 22 Example of a BLAST sequence alignment demonstrating a positive mutation sequence analysis result.  Positive isolate 
pVITRO1_Trast_S50E_INVPCR(3) (Subjct) aligned to the pVITRO1_Trastuzumab_IgG1/κ complete nucleotide sequence (Query), mismatches at 
mutation site (circled). 
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3.2 Affinity and Binding Kinetics to HER2 and FcγR1A 
An example of Tmab sample titration detected through flow cytometry for the cell-binding assay as 
shown in Figure 23. A 10-fold increase in fluorescent intensity was observed in Herceptin® treated 
cells (positive control) versus IgG1/κ isotype treated cells (negative control) to clearly define 
positive and negative binding regions (Figure 23A). The titration of Tmab gWiz produced fractions 
from the cell population that migrated from the positive (bound) to the negative (unbound) region 
with reducing concentration of Tmab gWiz (Figure 23B). The cell-binding titrations from the Tmab 
affinity mutants as shown in Figure 24 prior to analysis. D28>K and D102>F titrations 
demonstrated retained affinity to extracellular HER2, whereas the S50>E titration spanned almost 
entirely in the negative (unbound) region. 
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Figure 23  Tmab gWiz titration detected through flow cytometry. Controls for defining positive and 
negative binding (A). Herceptin® treated (green), IgG1/κ isotype treated (aqua), dilution buffer 
treated (brown) and untreated cells (yellow). Tmab gWiz titration in 2-fold serial dilutions from 10 
µg/mL (B). 
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Figure 24  Cell-binding assay as detected on flow cytometry for titrations of Tmab affinity mutants 
D28>K (A), S50>E (B) and D102>F (C). 
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Binding curves and KD values derived from the flow cytometry data give a much clearer 
comparison of the binding between the Tmab affinity mutant library (Figure 25 and Table 30). The 
S50>E mutation was confirmed to have significantly diminished binding affinity to extracellularly 
expressed HER2, where the maximum concentration (10 µg/mL) reached 27% positive fraction and 
a KD value could not be determined. Between the control titrations, Tmab pVITRO1 binding was 
comparable to PBS-Herc; however, Tmab gWiz had an apparent 6-fold reduction in binding as 
compared to PBS-Herc. The D28>K mutation had an apparent 2-fold reduction in binding as 
compared to Tmab pVITRO1 and D102>F  had an apparent 4-fold increase in binding as compared 
to Tmab gWiz, its binding was also comparable to Tmab pVITRO1. 
In comparison, SPR derived binding kinetic values from the single cycle kinetic assay showed 
1000-fold stronger KD of the Tmab affinity mutant library binding to surface captured HER2 (pM) 
as opposed to the cell-based affinity assay (nM), as well as reporting KD values in the nM range for 
surface captured FcγR1A (Figure 26 and Table 31). As the Tmab gWiz performed poorly in the 
cell-binding assay, it was excluded from SPR analysis. 
 
 
Figure 25 Tmab affinity mutant library binding curves to SK-BR3 cells from the cell-binding 
HER2 affinity assay, detected on flow cytometry. 
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Table 30 KD values extrapolated from the cell-binding assay of the Tmab affinity mutant library. 
KD values were calculated as antibody concentration (µg/mL) at equilibrium (50% bound) and 
converted to nM for comparison with SPR data. 
 KD (µg/mL) KD (nM) 
PBS-Herc 0.2068 1.42 
Tmab pVITRO1 0.3039 2.09 
D28>K 0.5982 4.11 
S50>E ND ND 
Tmab gWiz 1.319 9.06 
D102>F 0.3442 2.37 
 
Tmab pVITRO1 has an apparent 4-fold reduction in binding (increase in KD) as compared to PBS-
Herc to surface captured HER2. Mutants D28>K and S50>E had a slight increase (1.3 – 1.5-fold) in 
binding (decrease in KD) and D102>F had a 2-fold decrease in binding (increase in KD) as compared 
to Tmab pVITRO1 to surface captured HER2. However, inspection of the SPR sensorgrams for 
Tmab affinity mutant library showed satisfactory curve fitting for affinity and dissociation 
calculations aside from mutations S50>E and D102>F (Figure 26A). Inspection of the residuals to 
the curve fitting further confirmed the case, with S50>E and D102>F data points distinctly 
exceeding the acceptable range during transitions through the association phase (Appendix 6.3). 
Mutation S50>E had the lowest maximum relative binding to the HER2 captured surface (Rmax = 
11.6) which infers a lower association constant (Ka) than calculated. Mutation D102>F had a high 
maximum relative binding to the HER2 captured surface (Rmax = 27.68) which was comparable to 
the PBS-Herc (Rmax = 29.08) and Tmab pVITRO1 (Rmax = 24.64) although it was the lowest Ka 
calculated. The dissociation constant (Kd) of both S50>E and D102>F didn’t adequately match the 
data against the curve fitting. The rapid decay in S50>E transitioning to a steady state in the 
dissociation phase more likely resembles a biphasic interaction. The dissociation of D102>F did not 
reach steady state during the cycling in the association phase, which again indicates a more complex 
interaction. In both mutations, the monophasic 1:1 binding model was an inadequate model to 
describe the interaction therefore the derived rate constants for these 2 mutants were not considered 
for reliable comparison.  
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Tmab pVITRO1 was comparable to PBS-Herc to surface captured FcγR1A. All mutants had an 
apparent increase (3 – 7-fold) in binding (decrease in KD) as compared to Tmab pVITRO1 to 
surface captured FcγR1A. Inspection of the SPR sensorgrams for Tmab affinity mutant library 
showed satisfactory curve fitting for affinity and dissociation calculations aside from mutations 
D28>K and S>50E (Figure 26B). Notably, D102>F had a comparable sensorgram curvature to 
PBS-Herc and Tmab pVITRO1 and had the highest maximum relative binding to the FcγR1A 
captured surface (Rmax = 88.35), which was approximately 2-fold of the PBS-Herc (Rmax = 51.36) 
and Tmab pVITRO1 (Rmax = 39.72). This is in agreement with the increased Ka and reduced KD 
calculated values for D102>F in comparison to PBS-Herc and Tmab pVITRO1. The Ka of both 
D28>K and S>50E didn’t adequately match the data against the curve fitting. In both mutations, 
association was overestimated in the association phase due to incorrect compensation of the bulk 
signal refractive index in the analysis software. This is further indicated as maximum relative 
binding to the FcγR1A captured surface for both mutants was 3 – 4.7-fold lower than Tmab 
pVITRO1 (D28>K Rmax = 13.07, S50>E Rmax = 8.47), which infers a lower Ka than calculated. In 
this instance, to adequately describe the interaction the monophasic 1:1 binding model requires 
refinement, therefore the derived rate constants for these two mutants were not considered for 
reliable comparison.  
Table 31 Binding kinetics of the Tmab affinity mutant library to surface captured HER2 and 
FcγR1A as measured through SPR. 
 
HER2 FcγR1A 
Ka 
(x 106) M-1.s-1 
Kd 
(x 10-5) s-1 
KD 
pM 
Ka 
(x 105) M-1.s-1 
Kd 
(x 10-4) s-1 
KD 
nM 
PBS-Herc 3.85 ± 0.09 1.10 ± 0.60 2.85 ± 1.49 2.75 ± 0.06 11.31 ± 0.10 4.11 ± 0.05 
Tmab pVITRO1 2.50 ± 0.03 3.03 ± 0.72 12.11 ± 2.72 2.11 ± 0.03 10.64 ± 0.56 5.05 ± 0.33 
D28>K 3.21 ± 0.19 2.51 ± 0.18 7.81 ± 1.02 16.62 ± 8.69 11.65 ± 2.79 0.70 ± 0.16 
S50>E 2.21 ± 0.02 1.95 ± 0.21 8.84 ± 0.87 4.88 ± 2.53 7.85 ± 0.14 1.61 ± 0.64 
D102>F 1.41 ± 0.21 3.33 ± 0.99 23.69 ± 3.52 3.09 ± 0.11 2.28 ± 0.04 0.74 ± 0.01 
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4 Discussion  
This study successfully produced three residue substituted Tmab mutants that were predicted from 
our collaborators as having enhanced affinity toward target HER2 through preliminary in silico 
analysis. The residue substitutions were confirmed for all mutants prior to in vitro biological assays 
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Figure 26 Analysed SPR sensorgrams from single cycle kinetic assays of the Tmab affinity 
mutation library to surface captured HER2 (A) and FcγR1A (B). Tmab samples PBS-Herc (1), 
Tmab pVITRO1 (2), D28>K (3), S50>E (4) and D102>F (5). Sensorgram data (red/green), curve 
fitting (black). 
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for determining relative affinity and binding kinetics. Results from the Tmab mutant library in vitro 
tests are in agreement with the completed in silico findings, in that mutation S50>E was disruptive 
to its affinity to HER2, and that D28>K and D102>F did not present conclusive affinity 
enhancement.  
The two further mutations that were not successfully produced for in vitro testing (i.e. D28>R and 
Y49/S50>S49/Y50) were reported as candidates that were very likely to have enhanced affinity to 
HER2 from in silico analysis. Although these mutations were not successfully isolated, they are of 
ongoing interest to be produced and tested for a future study. Tmab mutant D28>R had previously 
been tested and reported as 1.86-fold enhanced relative affinity compared to Tmab [217] through a 
cell-binding assay and an ELISA. This further highlights that D28>R is of interest for 
characterisation and profiling its binding kinetics to HER2, as the completed in silico findings (1.1) 
reported an increase of 43% in free binding energy of Tmab mutant D28>R as compared to native 
Tmab binding to HER2. Tmab mutant Y49/S50>S49/Y50 has not been reported experimentally 
thus far, and is of ongoing interest to calculate the free binding energies and compare these results 
with in vitro results. 
In comparing the SDM reactions for producing high yielding affinity mutants, the INV PCR 3-step, 
25 cycle reaction was the most efficient. INV PCR 25 yielded many isolatable colonies with a 67% 
mutation efficiency for the D102>F mutation; however, not yielding any successful D28>R isolate 
from the two sets of primer pairs designed (Table 29). The INV PCR 3-step, 18 cycle reaction was 
also very successful, although yielding 10-fold less isolates with D28>K mutation, and reduced 
(20%) mutation efficiency for the S50>E mutation. This was expected, as an increase in the number 
of cycles in the reaction produces a higher concentration of PCR product for isolation [218]. 
However, the SPRINP and INV PCR 2-step methods were not successful in yielding mutation 
positive vector isolates. A further attempt to isolate mutants D28>R and Y49/S50>S49/Y50 using 
INV PCR 3-step at 18 or 25 cycles, at 55 °C annealing temperature will most likely yield higher 
mutation efficiency. 
Strategies for preventing potential artefact primer ligation products was warranted for investigation 
as non-specific binding of elongated primers to self or template can occur at suboptimal annealing 
temperature [219]. Both the 2-step cycling method [218, 219] and the SPRINP method [216] are 
reported to minimise primer ligation artefacts and were trialled against the conventional 3-step 
cycling methods for improving mutation efficiency. Fortunately in this study, of all the isolates 
screened, no primer ligation artefacts were isolated.  
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The primer design for D28>K and S50>E mutants may be the attributing factor to the failure of the 
SPRINP method in producing mutant isolates (Table 25). The D28>K primer pair Tm was at the 
lowest recommended range (75 - 85 °C) and the S50>E primer pair exceeded the recommended 
flanking nucleotide length (10 – 20 bp) [216]. The primer design with the S50>E mutation 
specifically could not be helped due to the nucleotide sequence in that region having low GC 
content. The higher primer annealing temperature (72 °C) in the 2-step cycling method may be the 
attributing factor for its failure to produce mutant isolates, as the Tm of mutagenic primers 
containing mismatches can only be approximated against the template [220]. Use of the Phusion 
High fidelity PCR kit must also be considered, where components in the mastermix induce a higher 
primer Tm than predicted with conventional mastermixes [221]. It is likely that the predicted 
mutagenic primer Tms were overestimated and that a reduced annealing temperature of 10 – 20 °C 
was more suitable in designing the cycling reactions [220], rendering the 2-step cycling method 
inappropriate with the primers used in this study.  
Of the SMD reactions performed, successful mutants produced for in vitro testing included D28>K, 
S50>E in the pVITRO1_Trastuzumab_IgG1/κ expression system and D102>F in the gWiz TH/TL 
expression system. Along with the Tmab affinity mutants, native Tmab was produced from both 
expression systems for comparison against the reference product Herceptin®. All Tmab samples, 
including Herceptin® were buffer exchanged to PBS prior to in vitro assessment. Removal of the 
excipients in the Herceptin® formulation was necessary as to normalise Tmab sample biological 
activity and stability for comparison. 
SPR determined KD values of Tmab samples to HER2 were in the subnanomolar range which 
agrees with previous literature [19, 205, 209], as opposed to the nanomolar range derived from the 
cell-based affinity assay. The inconsistency of KD values between the cell-binding assay and SPR 
suggests that the cell-binding assay requires optimisation by extending the dissociation time to 
reach equilibrium [217, 222]. Due to the dilution series chosen to perform the cell-binding assay, 
the lowest Tmab dilution was 0.54 nM which was not sensitive enough to reach the subnanomolar 
range required for comparison with SPR. Another consideration limiting this technique is of Tmab 
internalisation and catabolism from binding to extracellular HER2 [23]. Discrepancies owing to 
internalised Tmab through the incubation time can be estimated with the use of an appropriate 
secondary antibody containing a fluorophore that can be quenched [223]. Estimation of non-
equilibrium system and internalisation discrepancies is necessary in order to ascertain appropriate 
optimisation parameters. In further consideration of optimising the cell-binding assay, minimization 
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of Tmab internalisation though a pre-treatment of the cells with 0.2% NaN3 [212] and a 1 hr 
dissociation incubation time [205, 206, 217] would likely yield results that are comparable to SPR.  
Interestingly, between the Tmab expression systems, Tmab pVITRO1 had higher biological 
similarity to PBS-Herc than the Tmab gWiz (Table 30 and Figure 25). The difference in relative 
affinity is likely due to varied content of acidic variants of the Tmab samples, caused by 
deamidation in the CDR [224] which mainly occurs in the production steps of expression and 
purification [225]. It was reported that Kd reduced 5-fold in Tmab sample containing 35.2% acidic 
variant compared to Tmab sample containing 14.9% acidic variant [224]. In further considering 
purification of the Tmab affinity mutant library for our study, assessing the Tmab samples for 
heterogeneity of charge variants through isoelectric focusing would have indicated whether a 
further ion exchange purification step was appropriate prior to commencing biological assays [205, 
224].  
Of the Tmab affinity mutant library produced for experimental investigation, S50>E clearly 
demonstrated a significant diminished relative affinity to extracellularly expressed HER2 through 
the cell-binding assay (Figure 25). SPR data for S50>E although unreliably calculated, did indicate 
a biphasic interaction in the dissociation phase which further confirmed a more complex 
dissociation than is described through a 1:1 binding model [226]. At the time of reporting 
preliminary in silico results of S50>E for experimental investigation, the previously described 
consideration of residue steric hindrance was not realised. The change in the crystal structure of the 
Tmab Fab-HER2 complex and the overall free energy of S50>E substitution was not further 
pursued by our collaborators. MD results demonstrated that the predicted electrostatic interaction 
did not produce a stable hydrogen bond with HER2 residue (Figure 20B) and an intramolecular 
interaction with V33 was destabilised which suggests conformational instability in the region. The 
experimental results for S50>E are in agreement with the in silico results, in that this mutation 
destabilised Tmabs conformation which inherently disrupted Tmabs relative affinity to HER2.  
In regards to the D28>K and D102>F mutants, in silico analysis did not confirm enhanced affinity 
to HER2 as predicted hydrogen bonds and electrostatic interactions were not produced (Figure 20A 
and Figure 21C). Relative affinity to extracellularly expressed HER2 of both mutants was similar 
to Tmab as demonstrated through the cell-binding assay (Figure 25). D28>K had a 2-fold reduced 
relative affinity to HER2 through the cell-based assay, and a 1.5-fold enhanced relative affinity 
through SPR as compared to Tmab-pVITRO1. D102>F had a highly similar relative affinity to 
HER2 through the cell-based assay, and a 2-fold reduced relative affinity through SPR as compared 
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to Tmab-pVITRO1 (Table 30 and Table 31). The deviations between these results suggest 
negligible differences in relative affinity that are in keeping with the results from in silico analysis 
in that the mutations did not demonstrate conclusive affinity enhancement to HER2. And, as 
previously discussed, assessment of charge variant content in all Tmab samples to determine if an 
ion exchange purification step was appropriate would have likely produced more robust relative 
affinity data for refined comparison.  
To validate that the mutations did not compromise further immunological activity, the Tmab 
affinity mutant library was further investigated for biological activity to high affinity IgG-receptor 
FcγR1A through SPR. Unexpectedly, analysis revealed that D102>F showed significant (6.8-fold) 
enhanced relative affinity to FcγR1A as compared to Tmab pVITRO1 (Table 31 and Figure 26B). 
As previously discussed, the curve fitting and values calculated for D28>K and S50>E were not 
reliable in which Ka and KD values were overestimated, although binding was apparent with all 
mutants which suggests a retention in biological activity. Binding curves to FcγR1A were similar as 
to previous investigations reporting on various other human IgG1 antibodies [227-231] which 
suggests that the mutations did not compromise further immunological activity. The enhanced 
relative affinity of D102>F also suggests a potentially enhanced ADCC effect that warrants further 
investigation.  
5 Concluding Remarks 
The findings of this study have shown that in silico analysis of predicted residue substitutions for 
Tmab affinity to HER2 correlates with in vitro investigation of an affinity disrupting mutation and 
of two mutations that did not show conclusive affinity enhancement. One of the mutations exhibited 
considerable enhanced affinity to FcγR1A which would likely result in a more pronounced ADCC 
effect, and is of interest for further investigation. Of the other predicted substitutions that were 
unsuccessfully isolated after several rounds of mutagenesis, the in silico results strongly suggest 
that they are lead candidates to pursue for enhanced relative affinity and are of further interest for 
investigation. 
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Chapter 5   
Rational Addition of Glycosylation 
Sites in Trastuzumab; 
Glycoengineering a Model Antibody 
for Enhanced Stability 
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Abstract 
This chapter reports on the design and development of a library of trastuzumab mutants with 
hypothesised enhanced stability, through the strategic addition of glycosylation sites within close 
proximity to a previously reported aggregation prone region. The trastuzumab glycosylation mutant 
library was designed to introduce N-linked glycosylation sites through residue substitution and the 
mutant library was expressed in an optimised transient 293F expression system. The mutant library 
was confirmed through mass spectrometry for successful residue substitution and glycosylation 
addition before proceeding with accelerated thermal stability, aggregation and monomer loss 
studies. Along with the stability screen, retention of biological function was confirmed for the 
mutant library to its target HER2 and effector immune receptors FcγR1A, FcγR2B and FcγR3A 
through a cell-based binding assay and surface plasmon resonance. The mutant library displayed 
varying stabilities, of which 2 mutants were elected as lead candidates, possessing enhanced 
thermal intrinsic stability and monomer retention. This demonstrates the success of this antibody 
engineering approach for the design of improved whole antibody and antibody-based therapeutics. 
1 Introduction; Stability and Aggregation Propensity in Whole Antibody Therapeutics 
Whole antibody therapeutics have persistently remained the most dominant and significant biologic 
therapeutic platform [1], for treatment of a plethora of indications including cancers, infections, 
auto-immune, cardiovascular and neurological diseases [3]. Aggregation remains one of the leading 
challenges in the development, manufacture and formulation of whole antibody therapeutics as it 
negatively affects the quality, efficacy and safety of the dosage form [5, 232, 233]. Aggregation is a 
highly complex process driven by self-association, in which interactions from surface exposed 
hydrophobic sites in antibodies lead to irreversible agglomeration, loss of higher order structure and 
biological activity [234]. As a consequence, aggregation leads to loss of the active antibody 
therapeutic and the presence of aggregates in the dosage form may elicit an adverse immunogenic 
response and resistance to treatment over time [233-236].  
Aggregation can occur either through native protein-protein interactions of the antibody, or through 
chemical or physical degradation of the antibody that leads to conformational instability, unfolding 
(reversible) and denaturation (irreversible). In either pathway, colloidal interactions of the protein 
species induce irreversible aggregation, the propensity of an antibody to aggregate is therefore 
concentration dependant [151, 232, 234, 237]. Antibodies follow the degradation pathway to 
aggregation when thermally or chemically stressed, where the intrinsic conformational stability of 
the protein is challenged with high ionic strength or energy [232]. Despite antibodies possessing 
relatively high intrinsic stability, much of their manufacturing process involves thermal and 
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chemical stress that is variable and cannot be compromised, such as cell culture conditions, affinity 
chromatography purification and viral inactivation steps [5, 64, 149]. In formulating the final 
therapeutic product for administration, the intrinsic stability of antibodies can be modestly enhanced 
with stabilising excipients and lyophilisation, to prevent aggregation from long term storage and 
handling [55, 120, 122, 123]. However, enhancement of whole therapeutic antibody intrinsic 
stability is of ongoing commercial interest to improve recovery and quality of antibody in the 
manufacture process, increase shelf life and accommodate for more versatile formulation options 
such as dry powder for inhalation [122, 238] and highly concentrated subcutaneous for injection 
[54, 55, 120]. 
Correlations between intrinsic stability, self-association, aggregation propensity, solubility and 
viscosity have been extensively researched through an array of experimental techniques and 
molecular dynamic simulations [166-170, 239-244]. Experimental findings have directed the 
development of an extensive array of computational tools to predict native protein-protein 
interactions of antibodies through amino acid (aa) sequence and native protein structure [5, 148, 
165, 245]. The current consensus for computational analysis of predicting sites of aggregation 
propensity in antibodies is in considering the native tertiary structure, the local spacial arrangement 
of aa residues, solvent accessibility and the density of surface exposed polarity versus 
hydrophobicity [5].  
For instance, the spacial-aggregation-propensity (SAP) computational tool has been reported to 
determine aggregation-prone regions (APR) in antibodies, experimentally confirmed by substitution 
of predicted surface exposed hydrophobic residues to polar aa residues [168, 169, 246]. This 
strategy has markedly demonstrated that removing APRs through directed single-point 
modifications to the antibody peptide sequence significantly improves its intrinsic stability and 
resistance to aggregation. This strategy has drawn significant attention to the continued discovery 
and characterisation of antibody APRs for enhancing stability through modification of the antibody 
peptide sequence. Stability enhancement would be translatable to the whole antibody class if 
modifications reside in any of the homologous antibody constant regions, although further 
considerations such as effector function may be compromised through such modifications. Pursuit 
of APR-removed antibodies is of ongoing commercial interest to derive strategically designed 
biobetter therapeutic antibodies with enhanced intrinsic stability and reduced aggregation 
propensity. 
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1.1 Strategic Addition of Glycosylation Sites  
In consideration of designing mutational projects for enhanced intrinsic stability and resistance to 
aggregation of a model antibody, literature had previously identified and experimentally confirmed 
APRs through direct residue substitution in Rituximab [169] and Bevacizumab [168]. Interestingly, 
it was previously found that the conserved glycosylation site in the Fc contributes to the intrinsic 
stability of antibodies, proposing the hypothesis that the glycans sterically hinder the interactions of 
APRs identified in close proximity to glycosylation site [247]. Additionally, residue substitution 
was applied to successfully introduce N-linked glycans to a poorly soluble antibody for increased 
solubility [173]. The direction of this mutational project design was therefore to identify surface 
exposed residues for substitution, to introduce N-linked glycans within close proximity (10 Å) to 
reported APRs as to sterically hinder APR colloidal associations. 
Further considerations with introduction of N-linked glycans to a model antibody was to not 
interfere with native antibody structure that: binds to target (specificity) in the CDRs, binds to Fc 
receptors (effector functions) and Protein A (purification) in the Fc region. Therefore identification 
of APRs and introduction of glycosylation sites was restricted to the Fab antibody regions excluding 
the CDRs, making the substitutions compatible with whole antibody and Fab based formats. 
Hyper-glycosylation has also been described with biotherapeutics as increasing solubility and 
extending half-life [118, 173], which is of further benefit to improving formulation and treatment 
strategies. Strategic glycosylation addition has the added advantage of orienting a specific 
functional group on the antibody for directed drug, dye, linker and nanoparticle conjugations. 
Beyond stability enhancement, the benefits for strategic addition of glycosylation sites in 
therapeutic antibodies are highly apparent for antibody engineering and is therefore of immense 
interest for investigation to uncover the full potential that can be exploited from this technology. 
1.2 Trastuzumab as a Model Antibody  
Trastuzumab (Tmab) was used as a model antibody to identify potential APR candidates from 
literature to design mutational projects. Each project was designed around a lead APR, with an 
additional project designed from a report of improved solubility, as summarised in Table 32. Visual 
inspection of substitutions listed in Table 32 to the crystal structure of Tmab Fab fragment 
complexed to extracellular domain of HER2 receptor (1N8Z) was performed to identify and 
confirm surface exposed APRs and residues for introducing glycosylation (Figure 27). 
Glycosylation site candidates were excluded from further consideration if the residue for 
substitution was a glycine or proline, as these residues are integral in the native antibody structure 
for flexibility and rigidity, respectively. Further exclusions to glycosylation site candidates were if 
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the solvent accessible area (SAA) of the substituted residue was predicted to be less than 15 Å, as it 
was hypothesised to be inaccessible to glycosylases in native structure for post-translational glycan 
addition [168, 169].  
Table 32 Surface exposed aa residues identified in Tmab Fab region for substitution. Mutations and 
project elected (bold), APR (underlined), *SAA of substitution predicted as less than 15 Å. 
Project 
aa Residue 
(Position) 
Region 
aa 
Substitution 
Proposed Function 
APR 1 
L (154) 
Cκ 
K/D Remove APR by introducing polar aa [168, 169] 
S/T Remove APR and introduce glycosylation site [168] 
L (175)* 
N Sterically hinder APR by introducing glycosylation site 
[168] 
P (204) 
APR 1/2 
G (157)* 
E (195) 
Q (160) S/T 
APR 2 
L (201) 
K Remove APR by introducing polar aa [168] 
N Remove APR and introduce glycosylation site [168] 
F (139)* S/T Sterically hinder APR by introducing glycosylation site 
[168] APR 2/3 G (200)* N 
APR 3 
V (110) K Remove APR by introducing polar aa [168] 
Y (140) S/T 
Sterically hinder APR by introducing glycosylation site 
[168] 
K (169) 
N D (170) 
K (107) Vκ 
APR 4 
L (177) CH1 
K/S Remove APR by introducing polar aa [168, 169] 
N 
Remove APR and introduce glycosylation site [168, 172] 
Q (160) 
Cκ 
Sterically hinder APR by introducing glycosylation site 
[168] 
S (176)* 
T (178)* 
L (115) 
Cjoin 
T (117) 
L (182) 
CH1 
Solubility/
APR 4 
Q (178)* 
Sterically hinder APR by introducing glycosylation site 
[168, 248] 
Solubility 
T (198) 
Improve solubility and sterically hinder self-association by 
introducing glycosylation site [166, 248] 
A (121) Improve solubility by introducing glycosylation site [248] 
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Interestingly, an excluded substitution identified from this research (Q178>N) had previously been 
produced successfully and demonstrated enhanced solubility [173] which indicated a potentially 
misguided rationale for exclusion. Of the mutational projects designed, the solubility and APR 
A B 
C 
D 
E 
Figure 27 Crystal structure 1N8Z of Tmab Fab fragment complexed to extracellular domain of 
HER2 receptor. Tmab VH/CH1 (blue), Vκ/Cκ (green), HER2 fragment (orange), APR (purple), 
surface exposed aa identified for substitution to an N-linked glycosylation site reported to increase 
solubility (red) or sterically hinder APR (pink). (A) Solubility Project, (B) APR Project 1, (C) APR 
Project 2, (D) APR Project 3, (E) APR Project 4 
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project 4 were pursued for this body of work with introduced glycosylations directing steric 
hindrance of APR L177; polar substitution L177>K was included for comparison (Figure 28).  
Residue substitutions elected for the Tmab glycosylation mutation library are listed in Table 33. 
Codons from the Tmab WT genes for mutagenesis were identified from the gWiz TH/TL expression 
vectors and mutations were designed based on minimum bp mismatching to Tmab WT codons. As 
previously described in Chapter 4, mutagenesis reactions were designed and performed based on 
the QuikChange™ method (Agilent Technologies). Overlapping primer pairs with introduced 
mutations were designed and the entire vector was amplified through high fidelity inverse PCR. 
Vectors containing successful mutations were expressed in transient 293F culture and purified 
through protein A affinity chromatography in the lead up to stability screening. For the purposes of 
this study, the gWiz TH/TL expression vectors were used for producing the Tmab glycosylation 
mutant library.  
Figure 28 Crystal structure 1N8Z, highlighting elected mutations pursued in this study based on 
Solubility Project and APR Project 4. Tmab VH/CH1 (blue), Vκ/Cκ (green), HER2 fragment 
(orange), APR (red) and surface exposed aa identified for substitution to an N-linked glycosylation 
site reported to sterically hinder APR (purple). 
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Further to screening for stability enhancement, the Tmab glycosylation mutation library binding 
kinetics to HER2 and a panel of FcγRs was screened to ensure that introduced mutations and 
glycosylation do not contribute to a loss of immunological functions. Tmab targets extracellular 
HER2 for the treatment of HER2 positive breast cancers [21, 22]. As with all IgG1 antibodies, 
Tmab binding to FcγR1A and FcγR3A induces immune response activation to the target to elicit an 
ADCC response, and binding to FcγR2B inhibits this immune response [12, 16, 133, 249].  
Table 33 Summary of Tmab aa substitutions elected for experimental validation. Codon bp that 
mismatch the WT gene codon for primer design consideration (bold) 
Site WT Codon Substitution Mutation Codon 
L177 (CH1) CTA 
K  
N 
AAA 
AAT 
Q160 (Cκ) CAG 
N 
AAT 
L115 ( Cjoin ) CTT AAT 
T117 ( Cjoin ) ACC AAC 
A121 ( CH1) GCT AAT 
Q178 ( CH1) CAG AAT 
L182 ( CH1) CTC AAC 
T198 ( CH1) ACC AAC 
 
2 Methods 
2.1 Instrumentation, Services and Software 
Crystal structure analysis for identification and confirmation of surface exposed N-linked 
glycosylation sites was performed on Dassault Systèmes Biovia Discovery Studio Visualizer 
v17.2.0.16349 software. Site-directed mutagenesis (SDM) reactions and accelerated thermal 
monomer loss studies were conducted on a Bio-Rad T100 thermal cycler, with heated lid. DNA 
quantification was performed on a NanoDrop ND-1000 spectrophotometer. Mutant isolate vectors 
were prepared as purified DNA samples and sent to AGRF for Sanger Sequence analysis. 
Sequencing results were analysed on Applied Biosystems Sequence Scanner 2 software. 
Overlapping primer pairs for mutagenesis were designed using GSL Biotech SnapGene Viewer 
4.0.5 software. Tm calculations were performed on NEB Tm calculator software with mismatched bp 
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omitted (http://tmcalculator.neb.com). Alignment of mutant isolate sequences to vector DNA 
sequences were performed on NCBI BLAST software (https://blast.ncbi.nlm.nih.gov/Blast.cgi). 
Mutant antibodies were purified from culture supernatant on a GE HealthCare ÄKTApurifier 100 
FLPC system, using Unicorn 5.11 system and analysis software. Liquid chromatography was 
performed on a Thermo Fisher Dionex™ 3500RS HPLC and mass spectrometry was performed in a 
Thermo Fisher Orbitrap Fusion™ Tribid™ MS using the Protein Metrics Byonic™ search engine. 
Flow cytometry was performed on a Merck Guava® easyCyte flow cytometer, using InCyte 3.1 
system and analysis software. SPR was performed on a GE HealthCare Biacore™ T200, using T200 
Control and Evaluation software.  
Accelerated thermal stability screening was performed and analysed on an Unchained Labs UNcle™ 
system and analysis V2.0 software. Size-exclusion high-performance liquid chromatography (SE-
HPLC) was performed on an Agilent Technologies Agilent™ 1200 Liquid Chromatography system, 
using ChemStation system and analysis software. 
2.2 Materials 
gWiz TH and gWiz TL vectors were cloned from gWiz blank vector as per described in Chapter 2.  
The primers for designed for mutagenesis and sequencing gWiz inserts were synthesised from 
Geneworks (Australia).  
The Phusion high-fidelity PCR kit (E0553S) and DpnI enzyme (R0176S) were purchased from 
Genesearch (Australia). Plasmid maxiprep kit (G221020) was purchased from Astral Scientific 
(Australia), miniprep (PLN70) and maxiprep (NA0310) kits were purchased from Sigma-Aldrich 
(Australia).  
Stellar™ competent E. coli (636763) was purchased from Scientifix (Australia), JM109 competent 
E. coli was prepared as per Appendix 1.3. Yeast extract (70161), Sodium chloride (S9888) and 
Kanamycin solution (K0254) was purchased from Sigma-Aldrich (Australia). Tryptone (LP0042B) 
was purchased from Thermo Fisher Scientific Australia and agar (20767.232) was purchased from 
VWR International (Australia).  
FreeStyle 293F cells were a kind donation from Dr Mario Torrado del Rey of Prof Joel Mackay’s 
research group, School of Life and Environmental Sciences, The University of Sydney. SK-BR3 
cells were a kind donation from A/Prof Thomas Grewal’s research group, Pharmacy School, The 
University of Sydney. FreeStyle™ 293 expression media (12338018), OptiPRO™ Serum free media 
(12309050), RPMI media (21870-076) and additional tissue culture reagents (Appendix 3.1) were 
purchased from Life Technologies (Australia). Linear Polyethylenimine (PEI) 25 kDa (23966-2 
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(POL)) was purchased from BioScientific (Australia), bovine serum albumin (BSA) (BSAS 0.1) 
was purchased from Bovogen (Australia) and T75 TC flasks (CORN430641U) were purchased 
from Bio-Strategy (Australia). PBS tablets (09-2051-100) and 1 M Tris-HCl pH 9 (BIOSD814) 
were purchased from Astral Scientific (Australia). Disposable baffled culture flasks (CLS431405), 
EDTA (E6758), FITC secondary antibody (F9512), isotype control antibody (I5154), centrifuge 
tubes (CLS430291, CLS430791), vacuum systems (CLS430769), glycine hydrochloride (G2879), 
HiTrap® Protein A affinity column (GE17-0403-01) and Amicon® Ultracel 50 kDa centrifugal 
filters (Z740177, Z740193) were purchased from Sigma-Aldrich (Australia).  
250 kDa Precision Plus™ molecular weight ladder (1610374) was purchased from Bio-Rad 
Laboratories (Australia) and all chemicals for reducing SDS-PAGE separation were purchased from 
Astral Scientific (Australia). Trypsin (T6567) chymotrypsin (11418467001) and C18 Ziptips 
(Z720070) were purchased from Sigma-Aldrich (Australia). PNGase F (P0708) was purchased from 
Genesearch (Australia) and all chemicals for LC-MS/MS were purchased from Sigma-Aldrich 
(Australia).  
The 20 cm × 75 μm Reprosil-Pur C18-AQ, 3 μm particle size 120 A in-house packed HPLC 
separating column (r13.aq) was purchased from Dr. Maisch GmbH (Germany). The 7.8 x 300 mm, 
5 µm particle size TSKgel® G3000SWXL HPLC column (0008541) and 6 x 40 mm TSKgel
® SWXL 
guard column (0008543) were purchased from Tosoh Bioscience GmbH (Japan). 
Herceptin® was a kind donation from Genentech (USA) and FcγR1A HIS-tagged receptor (10256-
H08H-5) was purchased from Life Technologies (Australia). HER2 HIS-tagged receptor 
(SRP6405), FcγR2B HIS-tagged receptor (SRP6396), FcγR3A HIS-tagged receptor (SRP6436), 
HEPES (54457), NaCl (S9888) and Tween 20 (P9416) were purchased from Sigma-Aldrich 
(Australia). CM5 chips (29-1049-88), Amine coupling kit (BR-1000-50) and Anti HIS capture kit 
(28-9950-56) were purchased from GE Healthcare (Australia).  
2.3 Site Directed Mutagenesis 
Overlapping mutagenesis primers were designed as described in Chapter 4, to incorporate 
mutagenic bp substitutions with a minimum of 8 bp homology upstream and downstream of the 
mutation site (Table 34). The primer lengths were varied due to GC content at the mutation site, and 
were adjusted to meet similar predicted Tm values, a GC clamp of 2 C/G bp in the 3’ end of the 
primers and 40 – 60 % GC content in all primers for optimal annealing. Mutagenesis was performed 
as an inverse PCR 2-step cycling condition to optimise mutation efficiency (Table 35) and minimise 
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primer ligation artefacts. All mutagenesis reactions were performed using a Phusion High Fidelity 
PCR kit (Table 36) on the gWiz TH/TL expression vector system.  
Table 34 List of primers designed for TH and TL glycosylation mutations. Nucleotides that 
mismatch the Tmab gene sequences, introducing codon mutation (bold). Primer Tm was calculated 
to gWiz TH/TL with the Phusion PCR kit, with mismatches omitted from the primer sequences. *1 
G/C bp on 3’ end due to high GC content of sequence in the mutation site. 
Primer 
Sequence 
5’                                                                   3’ 
Tm 
(°C) 
SDMC_TH1_L177K_Fwd 
SDMC_TH1_L177K_Rev 
CTTCCCGGCTGTCAAACAGTCCTCAGG 
CCTGAGGACTGTTTGACAGCCGGGAAG* 
76 
SDM2_TH1_L177N_Fwd 
SDM2_TH1_L177N_Rev 
CTTCCCGGCTGTCAATCAGTCCTCAGG 
CCTGAGGACTGATTGACAGCCGGGAAG* 
74 
SDM2_TkC_Q160N_Fwd 
SDM2_TkC_Q160N_Rev 
CAATCGGGTAACTCCAATGAGAGTGTCACAGAGC 
GCTCTGTGACACTCTCATTGGAGTTACCCGATTG* 
77 
SDM2_THV_L115N_Fwd 
SDM2_THV_L115N_Rev 
GGTCAAGGTACTAATGTCACCGTCTCCTCAGC 
GCTGAGGAGACGGTGACATTAGTACCTTGACC 
76 
SDM2_THV_T117N_Fwd 
SDM2_THV_T117N_Rev 
GGTACTCTTGTCAACGTCTCCTCAGCTAGC 
GCTAGCTGAGGAGACGTTGACAAGAGTACC 
71 
SDM0_TH1_A121N_Fwd 
SDM0_TH1_A121N_Rev 
CCGTCTCCTCAAATAGCACCAAGGGC 
GCCCTTGGTGCTATTTGAGGAGACGG 
74 
SDM0/2_TH1_Q178N_Fwd 
SDM0/2_TH1_Q178N_Rev 
CCGGCTGTCCTAAATTCCTCAGGACTCTACTCC 
GGAGTAGAGTCCTGAGGAATTTAGGACAGCCGG 
75 
SDM2_TH1_L182N_Fwd 
SDM2_TH1_L182N_Rev 
CCTACAGTCCTCAGGAAACTACTCCCTCAGCAGCG 
CGCTGCTGAGGGAGTAGTTTCCTGAGGACTGTAGG 
78 
SDM0_TH1_T198N_Fwd 
SDM0_TH1_T198N_Rev 
GCAGCTTGGGCAACCAGACCTACATC* 
GATGTAGGTCTGGTTGCCCAAGCTGC 
74 
 
All PCR products were digested with DpnI at 37 °C for 2 hr to remove native vector from the PCR 
product. 5 µL of the digestion products were transformed in competent E. coli via heat-shock 
method (Appendix 1.4), cells containing intact vector were rescued in LB agar containing 50 µg/mL 
Kanamycin as selection antibiotic. All digestion products were transformed into in-house prepared 
JM109 competent E. coli (Appendix 1.3). If mutants were not isolated from that round of 
transformation then digestion products were transformed again into commercial Stellar™ competent 
E. coli. 
113 
 
Single colonies from transformations were isolated and cultured for glycerol stock preparation 
(Appendix 1.2) and plasmid miniprep extraction (Appendix 2.1.1) in preparation for sequencing 
(Appendix 2.2). Isolates that screened positive for the mutation from sequence analysis were 
resuscitated and culture scaled up for plasmid maxiprep extraction (Appendix 2.1.3 - 2.1.4) in the 
lead up to production of the Tmab affinity mutant library through expression in transient 293F 
culture. 
Table 35 Cycling conditions for the mutagenesis inverse PCR 2-step reaction for TH and TL 
glycosylation mutations.  
Cycle Step Cycles Time (sec) Temp (°C) 
Initial denaturation 1 30 98 
Denaturation 
25 
10 98 
Annealing and Extension 120 72 
Final Extension 1 300 72 
 
Table 36 Reaction components for TH and TL glycosylation mutations.  
Component 
Reaction 
Concentration 
Volume 
(µL) 
5 x Phusion HF Buffer 1 x 5 
10 mM dNTP 200 µM 0.5 
10 µM   Forward primer 1.5 pM 0.75 
10 µM   Reverse primer   1.5 pM 0.75 
Vector DNA 0.6 ng/µL as needed 
Nuclease free H2O - to 25 µL 
Phusion DNA Polymerase 20 units/mL 0.25 
 
2.4 Expression and Purification 
Successful gWiz TH/TL mutant vectors were prepared for transient expression in suspension 293F 
culture. 24 hr prior to transfection, 293F cells were passaged to a seeding density of 5 x 105 
cells/mL in Freestyle 293 expression media in 60 mL culture. Transfection proceeded if the live cell 
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concentration reached 0.8 – 1.2 x 106 cells/mL and cell viability was ≥ 95% on the day of 
transfection. 120 µg PEI and 60 µg DNA (1:1 ratio of gWiz TH : gWiz TL) were separately diluted 
in OptiPRO SFM to total volume of 4 mL and incubated at RT for 5 min. The diluted DNA and PEI 
solutions were combined, gently mixed and incubated at RT for 15 min prior to dropwise addition 
to transfection culture. Cultures were returned to incubate, 24 hr post transfection the cultures were 
supplemented with 0.5% w/v tryptone to total culture volume. 2 days post transfection, cultures 
were scaled up to double volume (120 mL) and supplemented with 0.5% w/v tryptone. 3 days post 
transfection, cultures were further scaled up to double volume (240 mL) and again supplemented 
with 0.5% w/v tryptone. All transfection culture supernatants were harvested 8 days post 
transfection by centrifugation (3,000 g, 15 min), clarified and degassed by passing through a 
0.22 μm vacuum filter. Secreted antibody was purified from the culture supernatant through 
Protein A affinity chromatography, using an ÄKTApurifier 100 FPLC system with a HiTrap® 
Protein A column (Appendix 4). Antibody was bound on the column with PBS as binding buffer, 
eluted from the column with 0.1 M glycine HCl (pH 2.7) and elution fractions neutralised with 1 M 
Tris-HCl (pH 9). FPLC chromatograms detected the elution peaks with UV absorbance at 280 nm 
and elution fractions containing antibody were pooled, buffer exchanged to PBS and concentrated 
using 50 kDa centrifugal filters. UV absorption of the purified antibody samples was measured at 
280 nm to derive total antibody yield using the Beer Lambert law and the extinction coefficient of 
trastuzumab (Appendix 4.2). 
2.5 Mutations Confirmed through Mass Spectrometry 
Purified Tmab and glycosylation mutants were confirmed of the predicted aa sequence and 
successful introduction of a glycosylation site through site-specific liquid chromatography tandem 
mass spectrometry (LC-MS/MS) as detailed in Appendix 4.4.  Briefly, purified Tmab samples were 
separated on 10% reducing SDS-PAGE, the separated heavy and light chains were excised from the 
gel, washed and digested with trypsin and chymotrypsin. A fraction of the digestions were further 
treated with PNGase F for glycan release studies. Peptide digestions and glycan released peptide 
digestions were desalted in preparation of liquid chromatography separation. The digestion products 
were separated through HPLC using an in-house packed Reprosil-Pur C18-AQ column over a 90 
min 0 - 40% solvent gradient from 0.1% (v/v) formic acid to 80% (v/v) acetonitrile, 0.1% (v/v) 
formic acid, running at 300 nL/min, 60 °C. Tandem mass spectrometry was performed on the 
separated digested peptides using higher-energy collisional dissociation (HCD), collision induced 
dissociation (CID) and electron transfer dissociation (ETD) methods. The spectra were analysed by 
performing peptide spectrum matches (PSM) against the corresponding native or predicted mutation 
115 
 
aa sequence fasta file. Spectral annotations were manually validated and matches were compared 
between the HCD, CID and ETD methods to confirm and generate the complete aa sequences of the 
Tmab samples light and heavy chains. Successful introduction of a glycosylation site was confirmed 
through comparison of the glycan released sample fractions to their corresponding glycan intact 
samples.  
2.6 Accelerated Thermal Stability and Monomer Loss Screen 
The Tmab glycosylation mutant library was assessed through an accelerated thermal stability screen 
to derive melting temperature (Tm) and onset temperature of aggregation (Tagg) using the UNcle
™ 
system. The Tmab library was further assessed in an accelerated thermal relative monomer loss 
study as previously described [250], quantified by SE-HPLC. Prior to stability screening, Tmab 
sample concentrations were normalised to 1 mg/mL in PBS.  
Briefly for the stability screen, 9 µL of each Tmab samples was loaded on the UNcle™ system and a 
linear temperature ramp (15 – 95 °C) was applied at a ramp rate of 1 °C/min. A continuous scan for 
static light scattering (SLS) and intrinsic tryptophan fluorescence was measured through sample 
excitation at 266 nm, SLS intensity was further measured through sample excitation at 473 nm. The 
barycentric mean (BCM) of the Tmab samples were calculated through the UNcle™ analysis 
software (i.e. the mean fluorescence wavelength) and were plotted against temperature to generate 
thermal melting curves of the Tmab samples. Protein unfolding was observed as an increase in 
BCM, sudden or gradual increase reflected the rate of unfolding. Tms were calculated as the 
midpoint of the transition states (inflection points), identified through first differentials of the 
melting curves. Analysis and manual inspection of differentials was conducted using the UNcle™ 
analysis software.  
SLS intensity of the Tmab samples were plotted against temperature to generate thermal 
aggregation curves. Generation and accumulation of soluble aggregates in the sample was observed 
as an increase in SLS intensity with sensitivity to small particle formation at 266 nm and large 
particle formation at 473 nm. Sudden or gradual increase in intensity reflected the rate of 
aggregation. The midpoint of the transition state (inflection point) was identified through first 
differentials of the thermal aggregation curves. The temperature where signal intensity was 10% of 
the intensity at the inflection point was derived as the Tagg of the sample. Analysis and manual 
inspection of differentials was conducted using the UNcle™ analysis software.  
Briefly for the monomer loss study, three sets of Tmab samples were prepared to 30 µL. Tmab 
sample was either incubated in a thermal cycler with heated lid at 68 °C for 10 min or 30 min, or 
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prepared without incubation. Samples were immediately transferred to an ice bath after incubation, 
until injection into the HPLC system (25 µL) for characterisation and quantification. HPLC was 
performed on all samples as detailed in Appendix 4.5 using an Agilent 1200 liquid chromatography 
system with a TSKgel® G3000SWXL HPLC column coupled to a guard column. The HPLC system 
was running at 22 °C at a flow rate of 1 mL/min, with mobile phase of 150 mM potassium 
phosphate, pH 6.5. Total protein content of the sample was detected through UV absorption at 280 
nm to produce chromatograms that profiled the protein size distribution in the Tmab samples. 
Monomer peaks of the sample chromatograms were specifically quantified for the area under the 
curve (AUC) to derive a percentage of relative monomer loss against the AUC of its corresponding 
non-incubated sample. 
2.7 HER2 Cell-binding Assay  
The Tmab glycosylation mutant library was assessed for affinity of extracellularly expressed HER2 
in a cell-binding end point HER2 affinity assay as detailed in Appendix 5.2. The Tmab 
glycosylation mutant library titrations were compared to Tmab WT expressed from the gWiz TH/TL 
vector system (Tmab gWiz). As previously described in Chapter 4, overexpressing HER2 cell line 
SK-BR3 was harvested non-enzymatically with Versene Solution, washed and incubated with Tmab 
sample titrations for 20 min, 4 °C. After incubation the cells were washed, resuspended with a 
FITC-secondary anti-human IgG1/κ antibody and further incubated for 20 min, 4 °C. The cells were 
again washed, resuspended and passed through flow cytometry to detect the amount of green 
fluorescence per cell in the single cell population. For each titration batch Herceptin® buffer 
exchanged to PBS (PBS-Herc) was run as a positive control, a polyclonal IgG1/κ isotype was run as 
a negative control and dilution buffer was run as a wash control. The controls were used to define 
the cell populations detected on flow cytometry as positive or negative cell binding. All titration 
samples were measured through the control defined parameters in flow cytometry, with 5,000 
events collected in duplicate. The fraction of cells defined as positive (bound) in each sample was 
plotted against antibody concentration in a sigmoidal binding curve to extrapolate KD at 
equilibrium, that being antibody concentration at 50% positive fraction (bound).  
2.8 Binding Kinetics of Tmab Mutants to HER2 and FcγR 
The binding kinetics of PBS-Herc and Tmab glycosylation mutant library was assessed to HER2, 
FcγR1A, FcγR2B and FcγR3A through surface plasmon resonance (SPR) as detailed in Appendix 
5.3. HER2 kinetics was measured to complement results from the cell binding assay and FcγR 
kinetics was measured to ensure that the mutations did not contribute to a loss of immunological 
functions.  
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Briefly, a CM5 chip was prepared with anti-HIS antibody through amine coupling for the capture of 
HIS-tagged HER2 or FcγR (4 nM, 5 µL/min for 5 min). Measurements were performed at 25 °C in 
HBS-T running buffer as single cycle kinetic assays. 2-fold serial dilutions of Tmab samples were 
prepared from 0.5 - 8 nM, 2.5 - 40 nM and 25 – 400 nM for HER2, FcγR1A and FcγR2B/3A 
respectively. Increasing concentrations of Tmab sample was applied over the receptor captured 
surface (20 µL/min, 2 min) with dissociation times of 60 min and 30 min for HER2 and FcγR 
binding respectively. The sensorgrams were analysed globally using a Langmuir 1:1 binding model 
to determine Ka, Kd and KD. All samples were conducted in duplicate to obtain average values and 
standard deviation. Kinetic rate and binding constants determined from sensorgrams were accepted 
if the goodness of fit value (χ2) was within 5% of the maximum response level (Rmax) of the 
sensorgrams and KD was calculated as Kd/Ka. 
3 Results 
3.1 Mutation Efficiency and Expression 
Mutagenesis was performed on gWiz TH/TL expression vectors through an inverse PCR 2-step 
cycling condition to optimise mutation efficiency and minimise primer ligation artefacts. 
Mutagenesis was successful for the entire Tmab glycosylation mutant library; however, several 
mutants produced isolatable primer ligation artefacts (Table 37). The majority of mutants were 
isolated from commercial Stellar™ competent E. coli, several were due to an unsuccessful round of 
capture from in-house JM109 competent E. coli. Reactions L177>K, L177>N and Q160>N were 
rescued directly into Stellar™ cells, along with mutants L115>N, T117>N and Q178>N that were 
not isolated from the first round of transformation into JM109 cells. Of the reactions rescued in 
JM109, no isolates were rescued from the T117>N and Q178>N reactions, and only 1 isolate was 
rescued from the L115>N reaction that screened negative for the mutation and positive for a primer 
ligation artefact through sequence analysis (not shown).  
An example of positive mutation identified through sequence analysis is shown in Figure 29, and of 
a primer ligation artefact is shown in Figure 30. Nucleotide forward sequence of mutation positive 
isolate gWiz TL Q160>N(1) was aligned with the nucleotide sequence for gWiz TL (Figure 29). 
Homology from 1880 – 2581 bp in the gWiz TL sequence confirms the complete TL gene with bp 
mismatch from 2414 – 2416 CAG > AAT confirmed for mutation Q160>N. No further alignments 
and continued homology beyond site of mutation confirmed no further artefacts produced by primer 
ligation products. Nucleotide forward sequence of primer ligation artefact isolate gWiz TL 
Q160>N(2) was aligned with the nucleotide sequence for gWiz TL (Figure 30). Homology from 
1880 – 2413 bp in the  
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gWiz TL sequence confirms the TL gene until the mutation site, bp mismatch from 2414 – 2416 
CAG > AAT confirmed for mutation Q160>N; however, the primer sequence was repeated in the 
isolate nucleotide sequence before continued homology from 2417 bp. 
Transient expression and purification of the Tmab glycosylation mutant library was successful for 
all mutants, with varied yield amongst the mutants (not shown). Aside from gWiz Tmab (1.55 mg), 
the highest yielding Tmab mutants from the library were L177>K (1.95 mg), A121>N (1.32 mg) 
and L177>N (1.00 mg). The poorest yielding were L182>N (370 µg) and T117>N (190 µg). All 
purified Tmab glycosylation mutants were of good yield and quality to proceed with mutation and 
glycosylation confirmation, stability and binding kinetics studies. 
Table 37 Comparison of efficiencies between the different mutations conducted in this study, 
+rescued from in-house JM109 competent E. coli. 
Mutation 
Isolates 
Yielded 
Mutation 
Efficiency 
Primer Ligation 
Artefacts 
L177 > K > 300 1/5 (20 %) 3/5 (60%) 
L177 > N 31 5/5 (100%) 0/5 (0%) 
Q160 > N > 300 2/5 (40%) 3/5 (60%) 
L115 > N 222 1/1 (100%) 0/1 (0%) 
T117 > N 13 3/3 (100%) 0/3 (0%) 
A121 > N 13+ 2/3 (67%) 0/3 (0%) 
Q178 > N 126 2/3 (67%) 1/3 (33%) 
L182 > N 4+ 2/3 (67%) 0/3 (0%) 
T198 > N 9
+ 1/3 (33%) 2/3 (67%) 
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Query  1819  AGCTGACAGACTAACAGACTGTTCCTTTCCATGGGTCTTTTCTGCAGTCACCGTCGTCGACATGTTGCCATCACAACTCATTGGGTTTCTGCTGCTCTGGGTTCCAGCTAGCCGCGGTGACATCCAGATGACCCAGTCTCCTTCTTCTCT  1968 
             ||||||| |||| | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  9     AGCTGAC-GACT-ANAGACTGTTCCTTTCCATGGGTCTTTTCTGCAGTCACCGTCGTCGACATGTTGCCATCACAACTCATTGGGTTTCTGCTGCTCTGGGTTCCAGCTAGCCGCGGTGACATCCAGATGACCCAGTCTCCTTCTTCTCT  156 
 
Query  1969  TTCTGCTTCTGTTGGTGATCGTGTTACTATTACTTGTCGTGCTTCTCAAGATGTTAATACTGCTGTTGCTTGGTATCAACAAAAACCTGGTAAAGCTCCTAAActtcttatttattctgcttcttttctttattctggtgttccttctcg  2118 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  157   TTCTGCTTCTGTTGGTGATCGTGTTACTATTACTTGTCGTGCTTCTCAAGATGTTAATACTGCTGTTGCTTGGTATCAACAAAAACCTGGTAAAGCTCCTAAACTTCTTATTTATTCTGCTTCTTTTCTTTATTCTGGTGTTCCTTCTCG  306 
 
Query  2119  tttttctggttctcgttctGGTACTGATTTTACTCTTACTATTTCTTCTCTTCAACCTGAAGATTTTGCTACTTATTATTGTCAACAACATTATACTACTCCTCCTACTTTTGGTCAAGGTACCAAGCTGGAGATCAAACGTACGGTGGC  2268 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  307   TTTTTCTGGTTCTCGTTCTGGTACTGATTTTACTCTTACTATTTCTTCTCTTCAACCTGAAGATTTTGCTACTTATTATTGTCAACAACATTATACTACTCCTCCTACTTTTGGTCAAGGTACCAAGCTGGAGATCAAACGTACGGTGGC  456 
 
Query  2269  GGCGCCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGA  2418 
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| | || 
Sbjct  457   GGCGCCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCAATGA  606 
 
Query  2419  GAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAG  2568 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  607   GAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAG  756 
 
Query  2569  GGGAGAGTGTTAGGGGATCCAGATCACTTCTGGCTAATAAAAGATCAGAGCTCTAGAGATCTGTGTGTTGGTTTTTTGTGGATCTGCTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGG-  2717 
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| |||  
Sbjct  757   GGGAGAGTGTTAGGGGATCCAGATCACTTCTGGCTAATAAAAGATCAGAGCTCTAGAGATCTGTGTGTTGGTTTTTTGTGGATCTGCTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCNTGGA  906 
 
Query  2718  AAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCT-GAGTAGGTGTCATTCTATTCTgggggg--tgggg-t-gggg-C-AGCACA-GCAAGGGGG-A-GGATTGGG-AAGA-CAATAGCAGG-CAT  2854 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||  |||||||||||||||||||||||||||  ||||| | |||| | || |   ||||||||| | |||||||| || | ||||||| || ||| 
Sbjct  907   AAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCCGGAGTAGGTGTCATTCTATTCTGGGGGGGGTGGGGGTTGGGGNCNAGGAANNGCAAGGGGGGAAGGATTGGGGAANAACAATAGCCGGGCAT  1056 
 
Query  2855  GCTGGGG-A-TGCGGTGGG-CTCTATGGG-TACctctctctctctctctctctctctctctctctctctc  2920 
             ||||||| | ||||| ||| ||| ||||| |||||| ||||| |||| |||| | |||||||  |||||| 
Sbjct  1057  GCTGGGGGAATGCGGGGGGGCTCCATGGGGTACCTC-CTCTC-CTCTNTCTCCC-CTCTCTCCNTCTCTC  1123 
Figure 29 Example of a BLAST sequence alignment demonstrating a positive mutation sequence analysis result. gWiz TL Q160>N(1) positive 
isolate (Subjct) aligned to the complete nucleotide sequence of gWiz TL (Query), mismatch at mutation site (green, circled). 
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Query  1819  AGCTGACAGACTAACAGACTGTTCCTTTCCATGGGTCTTTTCTGCAGTCACCGTCGTCGACATGTTGCCATCACAACTCATTGGGTTTCTGCTGCTCTGGGTTCCAGCTAGCCGCGGTGACATCCAGATGACCCAGTCTCCTTCTTCTCT  1968 
             ||||||| |||| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  9     AGCTGAC-GACT-ACAGACTGTTCCTTTCCATGGGTCTTTTCTGCAGTCACCGTCGTCGACATGTTGCCATCACAACTCATTGGGTTTCTGCTGCTCTGGGTTCCAGCTAGCCGCGGTGACATCCAGATGACCCAGTCTCCTTCTTCTCT  156 
 
Query  1969  TTCTGCTTCTGTTGGTGATCGTGTTACTATTACTTGTCGTGCTTCTCAAGATGTTAATACTGCTGTTGCTTGGTATCAACAAAAACCTGGTAAAGCTCCTAAActtcttatttattctgcttcttttctttattctggtgttccttctcg  2118 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  157   TTCTGCTTCTGTTGGTGATCGTGTTACTATTACTTGTCGTGCTTCTCAAGATGTTAATACTGCTGTTGCTTGGTATCAACAAAAACCTGGTAAAGCTCCTAAACTTCTTATTTATTCTGCTTCTTTTCTTTATTCTGGTGTTCCTTCTCG  306 
 
Query  2119  tttttctggttctcgttctGGTACTGATTTTACTCTTACTATTTCTTCTCTTCAACCTGAAGATTTTGCTACTTATTATTGTCAACAACATTATACTACTCCTCCTACTTTTGGTCAAGGTACCAAGCTGGAGATCAAACGTACGGTGGC  2268 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  307   TTTTTCTGGTTCTCGTTCTGGTACTGATTTTACTCTTACTATTTCTTCTCTTCAACCTGAAGATTTTGCTACTTATTATTGTCAACAACATTATACTACTCCTCCTACTTTTGGTCAAGGTACCAAGCTGGAGATCAAACGTACGGTGGC  456 
 
Query  2269  GGCGCCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAG--  2416 
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| |    
Sbjct  457   GGCGCCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCAATGA  606 
                                                                                                                                                  * 
Query  2417  ---------------------------GAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTG  2539 
                                        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  607   GAGTGTCACAGAGCGGGTAACTCCAATGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTG  756 
                         * 
Query  2540  AGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAGGGGATCCAGATCACTTCTGGCTAATAAAAGATCAGAGCTCTAGAGATCTGTGTGTTGGTTTTTT-GT-GGATCTGCTGTG-CCTTCTAGTTGCCAGCCATCTGTTG-T  2685 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| || |||||||||||| ||||||||||||||||||||||||| | 
Sbjct  757   AGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAGGGGATCCAGATCACTTCTGGCTAATAAAAGATCAGAGCTCTAGAGATCTGTGTGTTGGTTTTTTTGTGGGATCTGCTGTGCCCTTCTAGTTGCCAGCCATCTGTTGGT  906 
 
Query  2686  TTGCCCC-TCCCCC-GTG-CCTTCCTTGACCCTGGAA-GGTGCC-ACTCCC-ACTG-TCCTTTCCTAATAAAA-TG-AGGAAATTGCATCGC-ATTGT-CTGAGTA-GGTGTC-ATTCTATT-CTggggggtggggtgggg  2812 
             ||||||| |||||| ||| |||||||||||||||||| |||||| |||||| |||| |||||||||||||||| || ||||||||||||| | ||||| | ||||| |||||| |||||||| |||||||| ||| ||||| 
Sbjct  907   TTGCCCCCTCCCCCCGTGCCCTTCCTTGACCCTGGAAAGGTGCCCACTCCCCACTGTTCCTTTCCTAATAAAAATGAAGGAAATTGCATCCCCATTGTTCGGAGTAAGGTGTCCATTCTATTTCTGGGGGG-GGG-TGGGG  1045 
Figure 30 Example of a BLAST sequence alignment demonstrating a primer ligation artefact sequence analysis result. gWiz TL Q160>N(2) primer 
ligation artefact (Subjct) aligned to the complete nucleotide sequence of gWiz TL (Query). Complete forward primer sequence (blue), mutation site in 
primer (red), repeated primer sequence (underlined) with * marking the first bp of the repeat sequence.  
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3.2 Confirmation of Successful Mutation and N-glycan Addition  
The Tmab glycosylation mutant library was separated on a 10% reducing SDS-PAGE for separation 
of the heavy and light chains in preparation for mass spectrometry (Figure 31). A primary 
indication of successful glycosylation was apparent from the gel analysis, with glycosylation 
mutants of the heavy chain (L115>N not shown) all migrating to 53 kDa, above the Tmab WT and 
non-glycosylated mutant L177>K heavy chain which migrated at 50 kDa. Glycosylation mutant of 
the light chain Q160>N (not shown) did not have an apparent difference in migration of the light 
chain through the gel as compared to the native Tmab light chain at 26 kDa, which suggested that 
glycosylation was not apparent in the light chain of this mutant. Gel analysis also showed that a 
proportion of non-glycosylated heavy chain species existed in T198>N (12%) and L182>N (7%). 
Residual fragment impurities of common size were observed in many of the purified Tmab samples 
(35 and 70 kDa) which match similarly to expected residual Protein A (42.0 kDa) fragment and 
HER2 (72.4 kDa) that had been captured together with the Tmab samples.  
Both the heavy and light chains of Tmab gWiz were excised from the gel in preparation for mass 
spectrometry. For all other Tmab mutants, the chain corresponding to its mutation was excised from 
the gel in preparation for mass spectrometry, i.e. the light chain for Q160>N and heavy chain for all 
other mutants.  
L        1         2          3         4         5         6        7          8   
kDa 
250 - 
150 - 
100 - 
75 - 
50 - 
37 - 
25 - 
← 50 kDa 
← 53 kDa 
← 26 kDa 
Figure 31 10% Reducing SDS-PAGE of Tmab glycosylation mutant library. Bio-Rad Precision 
plus Ladder (L), Tmab gWiz (1), L177>K (2), L177>N (3), Q178>N (4), T198>N (5), T117>N 
(6), L182>N (7) and A121>N (8). 
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LC-MS/MS analysis confirmed that the entire Tmab glycosylation mutant library had successful aa 
substitution (Appendix 6.1). Fragmentation techniques were further applied to HCD, ETD and CID 
to provide compositional glycan information of the mutation-introduced N-linked glycosylation 
sites. All Tmab glycosylation mutants aside for Q160>N and L177>K were found to contain an 
addition N-glycan compared to the corresponding native Tmab chain, demonstrating successful 
glycosylation of the mutation-introduced glycosylation sites. This result agrees with the previous 
SDS-PAGE analysis observing no difference in molecular weight between the light chain of 
Q160>N, or the heavy chain of L177>K to the native corresponding Tmab chains despite successful 
substitution.  
The MS glycan results for L177>K was as expected, as this substitution was not designed to 
introduce an N-linked glycosylation site. However, the lack of glycan addition to Q160>N was not 
expected as this substitution was designed to introduce an N-linked glycosylation site. This 
disagrees with previous literature that claims success in producing this particular glycosylated 
mutant in bevacizumab and that its performance indeed enhanced bevacizumab’s stability [168]. All 
further results obtained for this mutant is therefore due to the residue substitution alone. 
3.3 Accelerated Thermal Stability Screening 
The Tmab glycosylation mutation library was assessed on the UNcle™ system through an 
accelerated thermal stability screen to derive Tm and Tagg. Intrinsic tryptophan fluorescence was 
monitored at 266 nm excitation through the temperature ramp to observe protein unfolding events in 
the antibody samples, generating melting curves (Figure 32) from which Tms were calculated 
(Table 38). SLS was monitored to observe aggregate generation and accumulation in the samples 
through the temperature ramp at 266 nm for small particle formation (Figure 33) and 437 nm for 
large particle formation (Figure 34), generating thermal aggregation curves from which Tagg was 
calculated (Table 38).  
As glycan addition was not present with mutant Q160>N, it was excluded from this assay. The 
Tmab WT had highly similar Tms to the reference PBS-Herc, although interestingly the Tagg was 
measured as 3 °C higher in the Tmab WT than PBS-Herc (Table 38). Mutant T117>N produced a 
low signal through the stability screen, measurements reflected background noise of the system and 
therefore Tm and Tagg were not derived for this mutant. The aggregation events for all other samples 
in the Tmab glycosylation mutant library occurred concurrently with the second melting event. Of 
the thermal melting curve results, L177>N and L115>N was the most stabilising for the Tm1, 
L115>N and T198>N for the Tm2 as compared to the WT. The melting curve of L182>N showed 
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apparent stabilisation, with a delayed and reduced rate of melting from the Tm1 as compared to the 
WT; however, the Tm values calculated did not reflect this observation. Of the thermal aggregation 
curve data, precipitation of aggregates was observed for PBS-Herc and mutant A121>N in both the 
266 nm and 473 nm curves. Mutant L177>K had an apparent earlier onset of aggregation in both 
curves that was reflected in the calculated Tagg values. The aggregation curves of L115>N, L182>N 
and T198>N had an apparent resistance to aggregation as compared to WT.  
However, the Tagg values of L115>N did not adequately reflect what was observed from the curves, 
in which it presented as the most resistant to aggregation and having a reduced rate of aggregation 
as compared to WT. A deviation in the data set was observed for L182>N at 65 °C which caused an 
error in the calculation of Tagg and was therefore excluded from the results. The aggregation curves 
of L177>N, A121>N and Q178>N had apparent similar onset of aggregation to WT, although the 
calculated Tagg values reflect an improvement.  
The Tmab glycosylation mutant library was further assessed in an accelerated thermal relative 
monomer loss study. The Tmab mutants were incubated at 68 °C at 10 and 30 min time points. The 
amount of monomer remaining in the samples after incubation was quantified through SE-HPLC 
and compared against Tmab samples that were not incubated to produce a relative percentage of 
monomer loss. 
Table 38 Tm and Tagg values calculated from the thermal melting and aggregation curves of the 
Tmab glycosylation mutant library. 
 Tm1 (°C) Tm2 (°C) Tagg (°C) 266 nm Tagg (°C) 437 nm 
PBS-Herc 68.94 82.50 78.02 78.60 
Tmab WT 68.50 81.31 81.54 81.70 
L177 > K 69.00 79.27 78.51 80.59 
L177 > N 70.50 78.78 82.13 82.65 
L115 > N 71.00 81.92 74.15 75.90 
T117 > N ND ND ND ND 
A121 > N 69.60 80.50 82.41 82.78 
Q178 > N 69.40 80.50 82.22 82.50 
L182 > N 68.55 81.31 ND ND 
T198 > N 69.80 82.50 80.61 83.73 
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Figure 32 Melting curves of the Tmab glycosylation mutant library generated from the UNcle™ 
system. (A) Full temperature ramp of all samples highlighting the unfolding events in PBS-Herc that 
correspond to the calculated Tm1 and Tm2, (B) curve magnified over the melting regions for 
comparison of mutant Tms against Tmab WT (PBS-Herc excluded). 
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Figure 33 Thermal aggregation curves of the Tmab glycosylation mutant library generated from the 
UNcle™ system, measured at 266 nm. (A) Full temperature ramp of all samples highlighting the 
initiated aggregation event in PBS-Herc that correspond to the calculated Tagg, (B) curve magnified 
over the region where aggregation initiates for comparison of Tmab mutants Tagg against WT (PBS-
Herc and T117>N excluded). 
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Figure 34 Thermal aggregation curves of the Tmab glycosylation mutant library generated from 
the UNcle™ system, measured at 473 nm. (A) Full temperature ramp of all samples highlighting 
the initiated aggregation event in PBS-Herc that corresponds to the calculated Tagg, (B) curve 
magnified over the region where aggregation initiates for comparison of Tmab mutants Tagg against 
WT (PBS-Herc and T117>N excluded). 
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Due to sample limitations and poor performance from the stability screen, mutant T117>N was 
excluded from this assay. The accelerated monomer loss study performed at 68 °C demonstrated 
substantial differences in the Tmab glycosylation mutation library (Figure 35). Mutants L177>N 
and L182>N showed superior retention of monomer content as compared to WT. Mutants Q160>N, 
Q178>N and T198>N showed considerably (2 – 3 fold) reduced monomer content as compared to 
WT. Mutants L177>K, L115>N and A121>N also displayed reduced monomer content as 
compared to WT, but to a lesser extent. Mutants L177>N and L182>N possess apparent thermal 
stability as reflected in their melting curves, which appears effective at enhancing monomer 
retention under thermal stress. 
3.4 Retention of Biological Activity to HER2 and FcγRs 
The Tmab glycosylation library was screened for retention of biological activity to extracellularly 
expressed HER2 target in a cell-binding assay, detected through flow cytometry. Binding curves 
and KD values derived from the cell-binding assay revealed a retention of affinity to HER2 amongst 
the entire Tmab glycosylation mutant library (Figure 36 and Table 39), with most mutants 
performing similarly, if not demonstrating a modest increase in binding affinity compared to Tmab 
WT. Notably, mutant L177>K had the most significant increase  (2.5-fold) in binding as compared 
Figure 35 Relative monomer loss of the Tmab glycosylation mutation library at 68 °C, 10 min 
(solid) and 30 min (pattern) incubation time as quantified by SE-HPLC. 
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to WT, followed by mutant Q178>N (2-fold) and L115>N (1.7-fold). Mutants T117>N and 
A121>N exhibited a slight loss in binding affinity (1.1 – 1.3-fold) although the significance of this 
reduction is negligible. 
 
SPR single-cycle kinetic assays of the Tmab glycosylation mutant library (Appendix 6.2) produced 
sensorgrams of typical curvature for the panel of HER2 and FcγR receptors, as shown with Tmab 
WT in Figure 37. Inspection of the Tmab glycosylation library sensorgrams confirmed satisfactory 
curve fitting (Appendix 6.4) for calculated values as presented in Table 40 and Table 41. The SPR 
assay screening Tmab library against surface captured FcγR2B was not robust despite multiple 
attempts. T117>N mutation performed poorly in all SPR assays despite repeated attempts. As the 
kinetic values derived from T117>N SPR were not robust, all calculated values were excluded from 
the results presented.  
Tmab WT performed similarly to PBS-Herc on all receptors, aside from a 4-fold reduction in 
binding (increase in KD) to HER2. In comparing KD values to HER2 specifically, SPR derived 
kinetic values showed 1000-fold stronger KD of the Tmab glycosylation library binding to surface 
captured HER2 (pM) (Table 40) as opposed to the cell-based affinity assay (nM) (Table 39). Unlike 
Figure 36 Tmab glycosylation mutant library binding curves to SK-BR3 cells from the cell-binding 
HER2 affinity assay, detected on flow cytometry. 
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the results presented from the cell-binding assay, all Tmab glycosylation mutants exhibited a 
modest decrease in KD as compared to Tmab WT, notably that the dissociation constant (Kd) was 
the most drastically affected with mutants A121>N and T198>N. The entire Tmab glycosylation 
library KD to HER2 ranged from 30 – 84 pM, which was a 2.5 – 7-fold reduction in binding as 
compared to Tmab WT, with mutants T198N and L177>K performing poorest. 
Table 39 KD values extrapolated from the cell-binding assay of the Tmab glycosylation mutant 
library. KD values were calculated as antibody concentration (µg/mL) at equilibrium (50% bound) 
and converted to nM for comparison with SPR data. 
 KD (µg/mL) KD (nM) 
Tmab WT 1.63 11.22 
L177 > K 0.661 4.54 
L177 > N 1.131 7.77 
Q160 > N 1.028 7.06 
L115 > N 0.947 6.51 
T117 > N 2.169 14.90 
A121 > N 1.849 12.71 
Q178 > N 0.783 5.38 
L182 > N 1.220 8.38 
T198 > N 1.557 10.70 
 
SPR assays of the Tmab glycosylation mutant library binding to surface captured FcγR1A (Table 
40), FcγR2B and FcγR3A (Table 41) report on KD values in the nM range. All mutants possessed 
modest 1.5 – 4-fold increase in KD to FcγR1A as compared to Tmab WT, with mutants Q178>N and 
T198>N presenting as the most superior. Despite adequate curve fitting for several of the mutants, 
the kinetic values calculated to FcγR2B are not reliable and cannot be interpreted. For instance, 
mutants A121>N and Q178>N required longer dissociation times to achieve steady state, they had 
high relative binding to the FcγR2B captured surface (Rmax) values and curvature that matched 
similarly to Q160>N and L115>N (Appendix 6.2). This supports the sensorgram interpretation of 
similarity in association binding with a stronger dissociation. Sensograms also indicated that 
L182>N showed a drastic disruption to the binding kinetics with FcγR2B. Of the SPR screen to 
surface captured FcγR3A, mutant L177>K showed similarity in KD to Tmab WT, whereas all other 
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glycosylation mutants had a modest decrease (3.3 – 9.5-fold). However, inspection of the curve 
fittings suggested stronger Ka values than calculated for L177>N, L115>N and especially L182>N 
and T198>N due to their Rmax of 15.88, 25.15, 82.44 and 92.56 respectively. L177>N specifically 
had a slightly higher Rmax than L177>K (13.08), despite the 10-fold reduction in Ka calculated, 
therefore kinetic values calculated to FcγR3A are not entirely reliable for interpretation.  
Overall, SPR analysis demonstrated that relative binding to HER2 slightly decreased and FcγR1A 
slightly increased for the entire Tmab glycosylation library, aside from mutant T117>N. For 
FcγR2B and FcγR3A, results were varied and kinetic data was not robust for reliable interpretation. 
However, sensorgram interpretation showed that binding was similarly retained amongst the Tmab 
glycosylation library, aside from L182>N displaying drastic disruption in binding to FcγR2B and 
markedly enhanced affinity to FcγR3A, along with T198>N. 
Table 40 Binding kinetics of the Tmab glycosylation mutant library to surface captured HER2 and 
FcγR1A (± SD) as measured through SPR, 
*1 value only. 
 
HER2 FcγR1A 
Ka 
(x 106) M-1.s-1 
Kd 
(x 10-5) s-1 
KD 
pM 
Ka 
(x 105) M-1.s-1 
Kd 
(x 10-4) s-1 
KD 
nM 
PBS-Herc 3.85 ± 0.09  1.10 ± 0.60  2.85 ± 1.49 2.75 ± 0.06 11.31 ± 0.10 4.11 ± 0.05 
Tmab WT 2.50 ± 0.03  3.03 ± 0.72 12.11 ± 2.72 2.11 ± 0.03 10.64 ± 0.56 5.05 ± 0.33 
L177 > K  1.00 ± 0.25 7.28 ± 1.42 72.97 ± 3.64 2.73 ± 0.12 7.94 ± 0.36 2.91 ± 0.01 
L177 > N 1.84 ± 0.13 6.32 ± 0.08 34.28 ± 2.01 5.01 ± 0.18 15.04 ± 1.27 3.00 ± 0.15 
Q160 > N 0.83 ± 0.02 2.78 ±  1.26  33.53 ± 15.86 2.55 ± 0.02 6.62 ± 0.11 2.59 ± 0.02 
L115 > N  3.82 ± 3.80 18.16 ±  9.14 47.56 ± 25.89 1.79 ± 0.20 4.20 ± 0.06 2.34 ± 0.26 
A121 > N 4.40 ± 1.71 23.84 ± 4.35 54.24 ± 10.24 3.83 ± 0.36 8.77 ± 1.14 2.29 ± 0.08 
Q178 > N 1.35 ± 0.27 4.29 ± 0.67 31.88 ± 2.11 7.38 ± 0.11 9.23 ± 0.30 1.25 ± 0.02 
L182 > N 1.1 * 3.2 * 29.1 * 3.67 ± 0.55 12.37 ± 2.64 3.37 ± 0.22 
T198 > N 6.11 ± 1.17 50.97 ± 3.23 83.44 ± 77.77 4.71 ± 0.02 8.09 ± 0.10 1.72 ± 0.03 
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Figure 37 Representative analysed SPR sensorgrams of single cycle kinetic assays of Tmab WT to 
surface captured HER2 (A), FcγR1A (B), FcγR2B (C) and FcγR3A (D). Sensorgram data 
(red/green), curve fitting (black). 
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Table 41 Binding kinetics of the Tmab glycosylation mutant library to surface captured FcγR2B 
and FcγR3A (± SD) as measured through SPR. 
 
FcγR2B FcγR3A 
Ka 
(x 104) M-1.s-1 
Kd 
(x 10-4) s-1 
KD 
nM 
Ka 
(x 104) M-1.s-1 
Kd 
(x 10-4) s-1 
KD 
nM 
PBS-Herc 3.05 ± 0.04 1.99 ± 0.13 6.55 ± 0.35 10.51 ± 0.29  1.90 ± 0.54 1.81 ± 0.47 
Tmab WT 5.76 ± 1.01 4.75 ± 0.41 8.25 ± 0.69 11.41 ± 2.06 1.29 ± 0.64 1.13 ± 0.32 
L177 > K 7.61 ± 1.66 5.05 ± 0.91 6.63 ± 2.19 23.94 ± 2.69 2.39 ± 2.20 1.00 ± 0.25 
L177 > N 2.95 ± 1.82 6.88 ± 4.26 23.28 ± 44.62 2.83 ± 0.22  3.02 ± 0.05 10.67 ± 1.03  
Q160 > N 4.01 ± 0.32 1.85 ± 0.27 4.62 ± 0.32  21.17 ± 4.95 8.01 ± 2.95 3.78 ± 0.46 
L115 > N 0.65 ± 0.26 0.78 ± 0.44 11.92 ± 3.57 3.35 ± 0.85 2.74 ± 0.23 8.17 ± 1.60 
A121 > N 
ND ND ND 
2.78 ± 1.99 1.95 ± 0.43 7.01 ± 3.84 
Q178 > N 1.95 ± 0.20 0.98 ± 0.20 5.04 ± 1.47 
L182 > N 3.12 ± 0.25 1.95 ± 0.20 6.24 ± 1.30 
T198 > N 2.25 ± 0.14 0.86 ± 0.15 3.81 ± 0.41 
 
4 Discussion 
This chapter reports on the rational design of strategically introduced N-linked glycans to Tmab as a 
model antibody, to enhance intrinsic stability and reduce aggregation propensity through the steric 
hindrance of the APR identified at L177 in the CH1. Mutagenesis and expression was successful for 
the entire library designed; residue substitution and glycan addition was confirmed for the entire 
library aside from Q160>N. Stability screening revealed L177>N and L182>N as promising 
candidates for more rigorous investigation, possessing enhanced intrinsic stability and retention of 
monomer as comparted to Tmab WT. Biological screening generally demonstrated retained 
biological functions of the entire library aside from T117>N. Binding to target HER2 was modestly 
compromised and binding to FcγR1A and FcγR3A was modestly enhanced for the entire library, 
which warrants more rigorous investigation for the potential of modulating a more pronounced 
ADCC effect to HER2 positive tumorous tissue. 
In characterising the Tmab glycosylation mutant library, SDS-PAGE and LC-MS/MS analysis 
confirmed glycan addition for the entire library aside from Q160>N. The equivalent Q160>N 
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mutation had previously been produced in bevacizumab [168] reporting successful glycosylation 
addition through SDS-PAGE, which contradicts our findings in transferring this mutation to Tmab. 
Therefore the further stability and affinity data presented in this chapter from Tmab Q160>N is only 
in relation to the aa substitution, and not of an additional glycosylation site. This also highlights that 
N-glycan introducing mutations between antibodies of identical constant region sequences are not 
necessarily transferable.  
Due to the varied yield amongst the Tmab glycosylation mutation library, sample limitations 
restricted the stability screen to single measurements; however, the results presented show promise 
for further investigations with L177>N and L182>N as lead candidates. Mutant T117>N was 
specifically the poorest yielding of the library; the quality of T117>N produced was likely the 
contributing factor to its poor performance through the stability screen and biological assays and 
warrants reproduction. 
Of the stability screen, several mutants exhibited improved intrinsic stability as reflected through 
their melting curves (Figure 32), particularly mutants L177>N, L115>N, Q178>N, L182>N and 
T198>N. Several exhibited resistance to aggregation as reflected through their aggregation curves 
(Figure 33 and Figure 34), particularly mutants L177>N, A121>N, Q178>N, L182>N and 
T198>N. All mutations aside from A121>N and Q160>N (not tested) exhibited improved solubility 
as indicated from the precipitation of insoluble aggregates generated through the thermal ramp of 
the aggregation curves (Figure 33 and Figure 34). And finally mutants L177>N and L182>N 
exhibited superior retention of monomer content as reflected through the monomer loss study 
(Figure 35). Equivalent mutation of L177>K was previously reported to exhibit resistance to 
aggregation in bevacizumab [168] and promotes aggregation in rituximab [169]. Our findings 
demonstrate that in Tmab, L177>K modestly decreases Fab stability, promotes aggregation and 
monomer loss. L177>N and L182>N were elected as lead candidates from the stability screen as 
they possessed enhanced thermal stability and monomer retention.  
The stability screen profiling the glycosylation mutant library does not correlate resistance to 
aggregation with the retention of monomer. The correlation between thermal intrinsic stability, 
depletion of monomer and resistance to aggregation appears different with each Tmab glycosylation 
mutant, which highlights that profiling the stability for any individual protein is complex and 
requires orthogonal screening methods for thorough characterisation [251, 252]. As a minimum, 
repeating stability analysis in triplicate and longer term monomer loss studies would give more 
insight and robust information to the stability profiling of the Tmab glycosylation mutant library. 
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The transfer of these mutations to another antibody for equivalent stability profiling will 
demonstrate proof-of-concept that indeed, the strategic addition of N-linked glycans is a robust 
platform for enhancing intrinsic stability and resistance to aggregation of antibodies. 
In optimising mutation efficiency, despite the reduced amount of isolates yielded from the in-house 
JM109 competent cells, mutation efficiency was relatively high for those that were rescued. A first 
round of rescue with in-house JM109 competent E. coli was more cost-effective, in that the few 
isolates rescued have a high mutation efficiency and a reduced probability of capturing 
miscellaneous reaction construct / artefact than with the commercial competent E. coli. The 2-step 
PCR method was implemented to reduce the frequency of capturing primer ligation artefacts; 
however, mutations L177>K, Q160>N, L182>N and T198>N presented artefacts in the screening 
process demonstrating that primer design required refinement. The mutation strategy implemented 
for the Tmab glycosylation mutation library was the most successful of all strategies reported in this 
thesis, and all further mutational work was carried out with this method. In optimising production 
and purification, SDS-PAGE analysis revealed residual fragment impurities in many of the purified 
Tmab samples; predominantly at 35 and 70 kDa which match similarly to the expected impurities of 
leached Protein A (42.0 kDa) fragment from the affinity purification process [253] and host cell 
protein HER2 (72.4 kDa) captured from antibody during expression [254]. Although the proportion 
of impurities was residual, their presence was of concern for the stability studies as uncharacterised 
unfolding from the impurities may accelerate aggregation and monomer loss in the sample. 
Specifically, this is demonstrated with mutant T198>N that possessed the highest proportion of 
impurities (Figure 31) and appeared to have enhanced stability (Table 38), although detrimental 
monomer loss (Figure 35). This indicates a need for a polishing step such as ion exchange or size 
exclusion chromatography that will exclude these additional species from the purified antibodies. 
The presence of protein impurities leads to the overestimation of protein content in the purified 
antibody samples, which makes normalisation of samples for assays inadequate for characterisation. 
For the purposes of this study, the antibody yield was inadequate for optimising additional 
purification steps prior to stability and biological screening and remains to be addressed for 
additional investigation. 
Further to screening for stability enhancement, the Tmab glycosylation mutation library binding 
kinetics to HER2 and a panel of FcγRs was screened to ensure that introduced mutations and 
glycosylation do not contribute to a loss of immunological functions. Tmabs KD to HER2 is 
reported in the subnanomolar range, spanning 19 pM – 1 nM [19, 205, 209], IgG1 is reported to 
have a KD to FcγR1A of 1 – 10 nM, FcγR2B of 100 nM and FcγR3A of 10 µM [16, 133]. As per the 
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affinity and binding kinetics results presented in Chapter 4, KD values of the Tmab glycosylation 
mutant library derived from the cell-based assay resided in the nM range, unlike the SPR values that 
determined KD in the subnanomolar range. The SPR values of Tmabs binding kinetics to HER2 are 
in agreement with previous literature, which indicates that the cell-binding assay requires 
optimisation to achieve results that are in agreement with SPR, as previously discussed in Chapter 
4. The SPR values of Tmabs binding kinetics to HER2 and FcγR1A are in agreement with literature, 
unlike the values to FcγR2B and FcγR3A which are not robust for reliable interpretation. KD to 
HER2 was modestly reduced and KD to FcγR1A was moderately enhanced with the entire Tmab 
glycosylation mutant library in comparison to Tmab WT. Varied and unreliable kinetic rate 
constants were derived for the Tmab library binding to FcγR2B and FcγR3A. However, sensorgram 
interpretation demonstrated binding similarity amongst the Tmab glycosylation library. Significant 
deviations of sensorgram similarity of mutants to Tmab WT include L182>N and T198>N. L182>N 
displayed drastic disruption in binding to FcγR2B, both L182>N and T198>N displayed markedly 
enhanced affinity to FcγR3A (Appendix 6.2). 
Retention of the Tmab glycosylation mutation library’s affinity to HER2 is ideal; however, as 
comprehensively discussed in Chapter 1 and Chapter 4, manipulation of affinity to HER2 can 
become useful for different therapeutic platforms. Fragment Tmab and Tmab-drug conjugates 
favour enhanced affinity to promote efficient catabolism and delivery of cytotoxic drug to target 
cancer cells [23]. Tmab with enhanced ADCC functions, extended half-life, and Tmab decorated 
nanoparticles favour reduced affinity for better biodistribution and tumour retention leading to a 
more insistent ADCC effect. Also, the consequence of enhancing Tmab affinity to FcγR1A and 
FcγR3A or reducing Tmab affinity to FcγR2B would be an enhanced ADCC effect [16, 133]. The 
entire Tmab glycosylation mutant library appears to possess marginally adjusted receptor binding 
kinetics for an enhanced ADCC effect, however this needs to be extensively investigated to reach a 
satisfactory conclusion. However, the biological assays demonstrated that the addition of an N-
linked glycan to the Fab region of Tmab does not contribute to a significant disruption in binding of 
Tmab to HER2 or FcγR1A. Mutant L182>N appears a lead candidate due to the binding disruption 
to FcγR2B and enhancement to FcγR3A, warranting further investigation for the hypothesised 
enhanced ADCC effect. 
5 Concluding Remarks 
The findings of this study have shown that the strategic addition of N-linked glycans in the Fab 
region of Tmab can enhance intrinsic stability and resistance to aggregation through the steric 
hindrance of an aggregation prone region. Several of the glycosylation mutants displayed varying 
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stabilities and aggregation propensities, of which two were elected as lead candidates for further 
investigation. Addition of an N-linked glycan to the Tmab Fab was further demonstrated to retain 
antigen binding specificity and immunological functions. Enhanced ADCC effect, increase in 
solubility and longer half-life are further therapeutic benefits of glycan addition warranted for 
further investigation, alongside directed conjugations for alternative therapeutic formats. This study 
demonstrates the effectiveness of this approach in enhancing biotherapeutic stability for improved 
formulation and treatment options, warranting a proof-of concept study, as reported in Chapter 6. 
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Chapter 6  
Enhancing the Stability of Adalimumab 
by Engineering Additional 
Glycosylation Motifs 
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Abstract 
Monoclonal antibodies (mAbs) are of high value in the diagnostic and treatment of many 
debilitating diseases such as cancers, auto-immune disorders and infections. Unfortunately, protein 
aggregation is one of the ongoing challenges, limiting the development and application of mAbs as 
therapeutic products by decreasing half-life, increasing immunogenicity and reducing activity. We 
engineered an aggregation-prone region of adalimumab, the top selling mAb product worldwide - 
with additional glycosylations to enhance its resistance to aggregation by steric hindrance as a next 
generation biologic. We found that the addition of N-glycans in the Fab domain significantly 
enhanced its conformational stability, with some variants increasing the melting temperature of the 
Fab domain by more than 6 °C. The mutations tested had minimal impact on antigen binding 
affinity, or affinity to Fcγ receptors responsible for effector function. Our findings highlight the 
significant utility of this rational engineering approach for enhancing the conformational stability of 
therapeutic mAbs and other next-generation antibody formats.  
1 Introduction 
Monoclonal antibodies (mAbs) are amongst the top-selling therapeutic prescription products 
worldwide. In 2017, Humira® (adalimumab) alone, generated over 18 billion US dollars, 
maintaining its position as the top-selling drug worldwide [1, 255]. mAbs are revolutionary 
biopharmaceuticals used to treat cancers, auto-immune and inflammatory conditions, and even 
some types of asthma. Approximately 80 antibody products have been approved and marketed by 
the FDA and EMA with hundreds more in early and advanced clinical trials [9]. Advances in 
antibody engineering technology have led to the development of a multitude of novel, next-
generation antibody-derived products often termed biobetters, which include bispecifics, 
nanobodies, antibody-drug conjugates, and nanoparticles functionalised with antibodies [9, 256].  
Despite the four-decade-long progress and ever-growing interest in antibody research, one of the 
major challenges in the development of antibody therapeutics remains unsolved: protein 
aggregation [250, 256-258]. Protein aggregation is one of the most common form of antibody 
degradation, having significant implications for a therapeutic product under development; 
aggregation can result in reduced therapeutic efficacy, and may trigger severe immunogenic side 
effects when administered [259, 260]. Formulations of biologics including mAbs and other protein 
products are stabilized with the use of additives such as salts, sugars, amino acids and surfactants 
[261-263]. Some novel formulation additives have also been investigated to inhibit protein 
aggregation, including deuterated solvents [264], hydrogels [265, 266], peptide dendrons [267] and 
ionic liquids [268]. However, the type and amount of additives allowed in any given formulation is 
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limited, especially in parenteral formulations – which are often used to administer mAbs. Thus, 
other approaches to enhance the aggregation-resistance of mAbs are needed.  
Another approach to significantly enhance the stability of a mAb is to modify the antibody structure 
itself. A single amino acid mutation in an aggregation-prone region (APR) can be sufficient to 
significantly improve the stability of an antibody against aggregation and/or increase its melting 
temperature. Predictions of aggregation-prone regions are often aided by computational tools – 
these include TANGO, AGGRESCAN3D, SAP [269-271], docking studies and/or molecular 
dynamics simulations [272]. For instance, the spatial aggregation propensity (SAP) tool has 
previously been used to guide mutations of aggregation-prone motifs of rituximab. These motifs 
predicted by SAP were ‘neutralised’ by single-point mutations, and multiple mutations were then 
combined to increase the overall antibody stability [169].  
A variation of this approach, involves engineering an additional N-glycosylation site in a spatially 
proximate region to an APR, to sterically hinder aggregation in that APR [168, 273]. Naturally 
occurring N-linked glycans in the Fc domain are known to significantly influence antibody stability 
and effector function and to increase half-life in patient serum. The introduction of extra N-linked 
glycosylation sites in the Fab domain may not only improve resistance to aggregation, but also 
enhance solubility and conformational stability of the antibody, offering additional benefits to a 
single-point mutation in a hydrophobic region. 
Courtois, Agrawal, Lauer and Trout [168] recently tested a series of Fab-glycosylated bevacizumab 
variants and reported significant improvements in overall stability. Nakamura, Oda-Ueda, Ueda and 
Ohkuri [273] also tested a glycan-introducing mutation in the Fab of adalimumab expressed in 
Pichia pastoris and found that it inhibited protease digestion and precipitation under pH stress. 
However, its impact on soluble aggregation of the full antibody is not clear.  
In this study, we report on and discuss the stability of Fab-glycosylated adalimumab variants that 
have spatial proximity to a previously determined APR in the IgG1 CH1 region of rituximab [169] 
and bevacizumab [168]. Specifically, the amino acid of the APR transposed to the adalimumab 
IgG1 peptide sequence is leucine 178. The substitution of this hydrophobic amino acid to lysine in 
bevacizumab [168], or to serine in rituximab [169] in the equivalent position, had experimentally 
demonstrated increased stability. This amino acid can also be substituted with asparagine (e.g. 
L178N) to introduce an N-linked glycosylation site. For this study, surface exposed amino acids 
were identified that can be substituted to asparagine to introduce N-linked glycosylation sites i.e. 
Asn-X-Ser/Thr, where X is any amino acid except proline (Figure 38). All substitutions except 
140 
 
T199N, were previously identified to have 10 Angstrom spatial proximity to the APR of interest 
[168, 169]. T199N was specifically chosen as it had been reported to dramatically increase the 
solubility of a poorly soluble antibody [248], however it does not have spatial proximity to the 
APR. This particular substitution also has the potential to sterically hinder reversible self-
association [166] which warranted further investigation through this study.  
The substitutions that were identified and pursued for this study are listed in Table 42. In addition 
to studying the effect of these Fab N-linked glycosylations on the aggregation propensity of 
adalimumab, we also investigated the conformational stability of the variants, and characterised 
their binding affinity to TNF-, and Fcγ receptors (FcγRs) responsible for effector function, to 
understand the broader impact of these additional glycans.  
Table 42 Surface exposed amino acid (AA) residues identified in adalimumab Fab region for 
substitution 
 
AA 
Residue 
Position Region Mutation Proposed Function 
L 178 CH1 
K 
Remove APR by introducing polar amino acid 
[168] 
N 
Remove APR and introduce glycosylation site 
[168] 
Q 160 Ckappa 
Sterically hinder APR by introducing 
glycosylation site [168] 
L 116 
Cjoin 
T 118 
A 122 
CH1 
Improve solubility by introducing glycosylation 
site [248] 
Q 179 
Sterically hinder APR by introducing 
glycosylation site [168, 248] 
L 183 
T 199 
Improve solubility and sterically hinder self-
association by introducing glycosylation site 
[166, 248] 
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2 Materials and Methods 
2.1 Materials 
Humira® subcutaneous injections (40 mg/0.8 mL) were purchased from Symbion (VIC, Australia) 
and used as a reference. Adalimumab (AdmAb) wild-type (WT) and mutant variants were 
expressed transiently in FreeStyle™ human embryonic kidney cells adapted for serum-free media 
(HEK293F). The expression vector gWiz (blank) was obtained from Genlantis (CA, USA) and 
vector pVITRO1_Trastuzumab_IgG1/κ was a gift from Andrew Beavil (Addgene plasmid # 
61883). Primers and synthetic AdmAb variable region gene constructs were purchased from 
Integrated DNA Technologies (Singapore). In-Fusion cloning kit was obtained from Scientifix 
(Australia). FreeStyle™ 293 Expression Medium, OptiPRO™ Serum Free Medium (SFM) and 
HIS-tagged FcRγ1A receptor were purchased from Life Technologies Pty Ltd (VIC, Australia). 
Polyethylenimine (PEI), Linear, MW 25 kDa was purchased from BioScientific (Australia).  0.22 
µm PVDF filters), 50 kDa centrifugal filters, trypsin and chymotrypsin were purchased from Sigma 
T199 
L178 L116 
T118 
A122 
Q179 
Q160 
L183 
Figure 38 Crystal structure 3WD5 of adalimumab Fab fragment complexed to partial TNF- 
fragment. Adalimumab VH/CH1 (green), VL/CL (aqua), TNF- fragment (orange), APR site 
(purple) and surface exposed amino acids identified for substitution to an N-linked glycosylation 
site (pink). 
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Aldrich (Australia). PCR kits and all other enzymes were purchased from GeneSearch (Australia). 
Phosphate Buffered Saline (PBS) was purchased from Astral Scientific Pty Ltd (NSW, Australia). 
HiTrap MabSelect SuRe column, Biacore CM5 and ProA chips, amine coupling kit and HIS capture 
kit were purchased from GE Healthcare (Australia). All other receptors, chemicals, consumables 
and reagents were obtained from Sigma Aldrich (Australia). 
2.2 Cloning and Mutation of AdmAb WT and Variants 
The blank gWiz expression vector was used to construct separate AdmAb IgG1 and kappa chain 
expression vectors. The secretion signalling genes, IgG1 and kappa chain genes were sourced from 
genes contained in pVITRO1_trastuzumab_IgG1/κ vector; they were cloned separately into the 
empty gWiz vector through conventional restriction cloning techniques. The variable regions of 
AdmAb genes were designed and synthetically produced; they were exchanged with the 
trastuzumab variable regions in the gWiz vectors through In-Fusion cloning to produce gWiz 
AdmAb IgG1 and gWiz AdmAb kappa vectors.         
Mutations were then introduced to the gWiz AdmAb IgG1 and kappa vectors through high fidelity 
inverse PCR to produce a library of AdmAb mutant expression vectors. AdmAb WT and mutant 
variants were confirmed through sequencing and expressed through transfection of vector pair 
combinations. 
2.3 Expression and Purification of AdmAb WT and Variants  
AdmAb WT and mutants were transiently expressed in suspension HEK293F culture. HEK293F 
culture was maintained and transfected in Freestyle 293F media, 120 rpm, 37 °C, 5% CO2, 
humidified incubation conditions. 24 hr prior to transfection, HEK293F culture was seeded to 6 - 7 
x 105 cells/mL in a 60 mL culture and the culture was adjusted to 1 x 106 cells/mL on the day of 
transfection.  
The complexing DNA for transfection was prepared as 1 µg total DNA per 1 x 106 cells. The gWiz 
AdmAb IgG1 and kappa vectors were combined in a w/w ratio of 1:1, and the complexing w/w 
ratio of PEI to total DNA was 2:1. The vector DNA and PEI were separately diluted in OptiPRO 
SFM. The dilutions were combined and left to complex for 15 min before adding dropwise to the 
transfection culture.  
After 24 hr incubation of the transfection culture, the culture was scaled up to 120 mL with 
Freestyle 293F media and supplemented to a total concentration of 0.5% Tryptone w/v. After a 
further 24 hr of incubation, the culture was scaled up to 240 mL with Freestyle 293F media and 
supplemented to a total concentration of 0.5% Tryptone w/v. The transfection culture remained in 
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incubation for a total of 8 days before the media containing secreted antibody was harvested by 
centrifugation, and the culture supernatant was clarified by filtration. 
AdmAb WT and variants were purified from the culture supernatants using protein A affinity with a 
1mL HiTrap MabSelect SuRe column. PBS pH 7.4 was used as the binding and wash buffer, and 
glycine HCL pH 3 was used to elute bound antibody. Eluted antibody samples were neutralised in 1 
M Tris-HCl pH 8 and concentrated to <1 mL using 50 kDa centrifugal filters. To purify the samples 
from any aggregates and obtain pure monomer samples, concentrated samples were fractioned 
using size-exclusion chromatography (as per 2.6) and the monomer fractions were collected and 
concentrated in 150 mM potassium phosphate buffer, pH 6.5, for analysis.  
2.4 LC-MS/MS Analysis of AdmAb Variants  
Successful mutation and introduction of glycosylation motifs of the AdmAb variants was confirmed 
through site-specific liquid chromatography tandem mass spectrometry (LC-MS/MS). Briefly, 
AdmAb variants were separated on reducing SDS-PAGE and digested with trypsin and 
chymotrypsin. A fraction of the digestions was further treated with PNGase F for glycan release. 
The digestion products were analysed by LC-MS/MS using higher-energy collisional dissociation 
(HCD), collision induced dissociation (CID) and electron transfer dissociation (ETD) methods. 
The AdmAb variants (10 μg) were run on a reducing SDS-PAGE, in-gel trypsin digestion was 
performed on the heavy chain band (50 - 60 kDa) of variants L116N, T118N, A122N, L178K, 
L178N, Q179N, L183N, T199N and the light chain band (25 - 30 kDa) of Q160N. The bands were 
excised, diced and washed with 50% (v/v) acetonitrile (MeCN) in 100 mM NH4HCO3. The gel 
pieces were then reduced with 10 mM DTT at 56 °C for 45 min, followed by alkylation by addition 
of 55 mM iodoacetamide (IAA) in 100 mM NH4HCO3, and incubation at 25 °C for 30 min. The 
samples were subsequently washed with 50% (v/v) MeCN in 100 mM NH4HCO3. 
The alkylated polypeptides were incubated with trypsin (T6567) (1 μg trypsin per 50 μg antibody) 
in 50 mM NH4HCO3, pH 6.8 at 37 °C overnight. The resulting tryptic peptides were further 
digested with chymotrypsin (11418467001) in 100 mM Tris-HCl, 10 mM CaCl2, pH 7.8 at room 
temperature overnight.  
Glycan release was performed to confirm amino acid substitution; a fraction of the chymotryptic 
peptides (excluding L178K) was incubated with recombinant PNGase F (P0708S) (400 units per 1 
μg of peptide) in 50 mM sodium phosphate buffer pH 7.5 at 37 °C overnight. The chymotryptic 
peptides and the de-glycosylated fractions were desalted with C18 ZipTips (Millipore), eluted in 
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80% (v/v) MeCN, dried by vacuum centrifugation then redissolved in 0.1% formic acid (FA) for 
LC-MS/MS analysis. 
Glycopeptides and de-glycosylated peptides were separated on an in-house packed 20 cm × 75 μm 
Reprosil-Pur C18AQ (3 μm, 120 A; Dr. Maisch GmbH) column using a Dionex 3500RS HPLC 
over a 90-min 0-40% solvent B gradient at a flow rate of 300 nL/min, at 60°C (solvent A was 0.1% 
(v/v) formic acid; solvent B was 80% (v/v) acetonitrile and 0.1% formic acid). MS analysis was 
performed on an Orbitrap Fusion MS (Thermo Scientific) in positive mode. Instrument parameters 
were set up as follows: source voltage = 2.3 kV, S-lens RF level = 68%, and capillary temperature = 
275 °C. The initial MS scan was acquired in the Orbitrap mass analyzer (350–2000 m/z; MS AGC 
= 6 × 105) with a resolution of 60,000 at 400 m/z. MS1 was followed by data-dependent HCD using 
top speed, where as many dependant scans as possible are acquired in a specified time. HCD 
fragmentation was followed by re-isolation of the top two most intense precursors, and 
fragmentation with CID and ETD MS/MS. HCD parameters were as follows: activation time = 
0.1 ms, resolution = 30,000, maximum injection time = 200 ms, dynamic exclusion = enabled with 
repeat count 1, normalized energy = 40, exclusion duration = 20 s, default charge state = 2, and 
MSn AGC 2.0e5. CID parameters were as follows: 30,000 resolution in orbitrap, activation time = 
10 ms, max injection time = 300 ms, dynamic exclusion = enabled with repeat count 1, normalized 
energy = 35, exclusion duration = 20 s, default charge state = 2, and MSn AGC 5.0e4. ETD 
parameters were as follows: 30,000 resolution in orbitrap, 5.0e4 AGC, ETD reaction time = 50 ms, 
Max injection time = 300 ms. 
The peptide spectrum matches (PSM) were generated through a search against the corresponding 
fasta file (wild-type or variant Adalimumab amino acid sequence) utilising the search engine 
Byonic (Protein Metrics Inc.). Annotation of the HCD and ETD spectra were automated through 
Byonic and the PSM assignments were validated by manually annotating the aforementioned 
spectra and the complementary CID spectrum. Further confirmation of the identity assignment was 
achieved through analysis of the de-glycosylated chymotryptic peptides utilising the same LC-
MS/MS approach as for the glycosylated fraction. 
2.5 Accelerated Stability at Elevated Temperatures 
We performed accelerated studies at an elevated temperature as previously described [250]. Briefly, 
20 µL of each AdmAb sample (1 mg/mL) was pipetted into a 0.2 mL PCR vial and incubated at 65 
°C for 1, 2 or 3 hr in a Thermal Cycler (Applied Biosystems, CA, USA) to induce aggregation. 
Each experiment was repeated three times. A thermal cycler was used to minimize sample amount 
and prevent evaporation of the sample and consequent changes in antibody concentration during 
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incubation (lid/cover of thermal cycler is heated above incubation temperature). Following 
incubation, incubated samples were removed and immediately stored on ice to halt aggregation and 
then characterized by size-exclusion high-performance liquid chromatography (SE-HPLC).  
2.6 SE-HPLC Analysis of Monomer Loss 
Size-exclusion high-performance liquid chromatography (SE-HPLC) was used to quantify AdmAb 
monomer loss following incubation at elevated temperature as previously described [250]. Analysis 
was performed using an Agilent 1200 Liquid Chromatography system (Agilent Technologies, 
California, USA) with a Zorbax GF-250 column coupled to a guard column at 22 °C, using a 150 
mM potassium phosphate pH 6.5 mobile phase, and a flow rate of 0.5 mL/min. 5 μL of each 
incubated sample was then immediately injected and each injection was repeated three times. 
Monomer peaks were detected using an in-line UV signal detector set at 280 nm. The area under the 
curve (AUC) of the monomer peak was averaged over the three runs and the mean relative 
monomer % was calculated for each sample, by setting the monomer AUC of the non-incubated 
samples as 100% and calculating the change in monomer AUC accordingly. The standard 
deviations (SD) were plotted as error bars in the figures. 
2.7 AdmAb Melting Temperature (Tm) and Onset Temperature of Aggregation (Tagg) 
The Tm and Tagg of Humira
®, AdmAb WT, and variants were simultaneously measured using 
intrinsic tryptophan fluorescence and static light scattering (SLS), respectively, on the UNcle 
system (Unchained Labs, CA, USA). A linear temperature ramp from 15 to 95 °C at a 1 °C/min 
scan rate was performed whilst measuring tryptophan fluorescence and SLS simultaneously through 
laser excitation at 266 nm. 8.5 µL of each AdmAb sample (1 mg/mL) was pipetted undiluted into 
the UNcle UNI (a sample holding unit containing 16 quartz cells) in triplicates. A holding time was 
not used to maximise the frequency of measurements. Tm and Tagg were determined by the UNcle 
Analysis software. The barycentric mean (BCM) was used to plot the Tm curves, which is defined 
by the following equation: 
𝜆𝐵𝐶𝑀 =
∑ 𝜆𝐼(𝜆)𝜆
∑ 𝐼(𝜆)𝜆
 
The equation is defined over the range 300-450 nm; each wavelength value (λ) is multiplied by the 
tryptophan fluorescence intensity (I) at that wavelength, and the sum of that value for all 
wavelengths between 300-450 is divided by the sum of the intensities at those wavelengths. This 
results in an ‘averaged’ peak wavelength (λBCM) for a given spectrum.  
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2.8 Binding Kinetics (KD) to TNF-α and Fcγ receptors (FcγRs) 
The binding kinetics of Humira®, AdmAb WT and variants were assessed to TNF- and FcγR1A, 
2B and 3A through surface plasmon resonance (SPR) to confirm that the mutations did not 
contribute to a loss of biological function. Briefly, a Biacore T200 system (GE Healthcare, 
Australia) was used, running single cycle kinetic assays. Monomeric AdmAb samples were 
captured on a ProA chip and increasing dilutions of TNF- were injected, with a 60 min 
dissociation. HIS-tagged FcγR1A, 2B and 3A were captured on an anti-HIS chip and increasing 
dilutions of monomeric AdmAb samples were injected, with a 30 min dissociation. The sensograms 
were analysed to determine association (Ka), dissociation (Kd) and equilibrium binding constants 
(KD). All runs were performed at 25 °C with running buffer HBS-T (10 mM HEPES, 150 mM 
NaCl, 0.05% v/v Tween 20, pH adjusted to 7.4).  
Soluble homotrimeric TNF- (H8916) was assayed against monomeric AdmAb samples on a ProA 
chip under continuous flow rate of 20 µL/min. Monomeric AdmAb samples were prepared to 10 
nM and captured on the sensor chip surface with a contact time of 10 sec. TNF- was injected in 2-
fold increasing concentrations (2.5 – 40 nM) with a contact time of 120 sec at each concentration, 
then a dissociation time of 60 min. The chip surface was regenerated with 50 mM NaOH for 30 sec 
at a flow rate of 30 µL/min.  
Monomeric AdmAb samples were assayed against HIS tagged FcRγ receptors. Anti-HIS antibody 
was covalently attached to a CM5 biosensor chip using an amine coupling kit and HIS capture kit. 
HIS tagged FcγR1A (10256H08H), FcγR2B (SRP6396) and FcγR3A (SRP6436) were prepared to 4 
nM and captured to the sensor chip surface with a contact time of 300 sec at 5 µL/min flow rate. 
AdmAb samples were injected on FcγR1A coated surface in 2-fold increasing concentrations (2.5 – 
40 nM) at a flow rate of 20 µL/min with a contact time of 120 sec at each concentration, followed 
by 30-min dissociation time. AdmAb samples were injected on FcγR2B and FcγR3A-coated 
surfaces in 2-fold increasing concentrations (25 – 400 nM) at a flow rate of 10 µL/min with a 
contact time of 120 sec at each concentration, followed by 1800 sec dissociation time. The chip 
surface was regenerated with 10 mM Glycine HCl, pH 1.5 for 60 sec at a flow rate of 30 µL/min.  
The sensograms were analysed globally using a Langmuir 1:1 binding model to determine Ka, Kd 
and KD. All samples were conducted in duplicate to obtain average values and standard deviation. 
Kinetic rate and binding constants determined from sensograms were accepted if the goodness of fit 
value (χ2) was within 5% of the maximum response level (Rmax) of the sensograms and KD was 
calculated as Kd/Ka. 
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3 Results 
3.1 Confirmation of Mutation and Glycan Attachment through LC-MS/MS 
Detailed analysis of LC-MSMS data confirmed that all AdmAb variants had successful amino acid 
substitution. Incorporation of HCD, ETD and CID fragmentation techniques further provided 
compositional glycan information of the new N-glycosylation sites. Except for Q160N mutant, all 
other AdmAb glycosylation-site variants were found to contain an N-glycan (data not shown). 
Here, we show the characterization of glycan site-engineered AdmAb variant T199N as a 
representation of the analysis performed for all AdmAb variants. HCD spectrum of 
SLSSVVTVPSSSLGNQTY peptide observed at m/z 909.65(4+) showed b- and y-ion series 
confirming amino acid sequence and the asparagine substitution was shown specifically by y4-y11 
fragment ions (Figure 39A). HCD of T199N mutant also contained diagnostic HexNAc (m/z 
204.09) and HexNAcHex (m/z 366.14) oxonium ions, strongly indicating glycosylation on the 
mutant peptide (Figure 39A). ETD further confirmed the structure of T199N glycopeptide by 
multiple fragment ions corresponding to dissociated peptide backbone with intact glycan (Figure 
39B, c-15, c-16, c-17 and z-16 ions). Theoretical monosaccharide composition of the N-glycan was 
derived using Byonic (Protein Metrics) search results and GlycoMod (https://web.expasy.org). CID 
data in Figure 39C shows sequential loss of monosaccharides from glycopeptide fragments of 
T199N mutant and contains complementary oxonium ions m/z 366.14, m/z 528.19, and m/z 569.22 
of the observed glycan in the low mass region. Extensive glycosidic bond cleavages (Figure 39C, 
y-ions, m/z 1616.2(2+), m/z 1535.19(2+), m/z 1461.67(2+)) observed in CID confirmed that 
SLSSVVTVPSSSLGNQTY peptide is occupied by a complex type N-glycan with 
HexNAc5Hex4Fuc1 composition.  CID spectra of deglycosylated T199N peptide m/z 609.64(3+) 
showed enhanced peptide backbone fragmentation and provided additional information for the 
expected mass shift from threonine to asparagine (y4-y18 ions and b17 ion, Figure 40). Same ion 
series also displayed deamidation (+1Da) of the new asparagine residue which is a characteristic 
result of PNGaseF treatment of a formerly N-glycosylated peptide. 
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Figure 39 (A) HCD, (B) ETD and (C) CID spectra of chymotryptic T199N glycopeptide 
observed at m/z 909.65 (4+). Peptide sequence SLSSVVTVPSSSLGNQTY and attached 
complex type N-glycan HexNAc5Hex4Fuc1 are shown. Blue square; N-acetylglucosamine, 
red triangle; fucose, green circle; mannose, yellow circle; galactose, Hex; hexose, HexNAc; 
N-acetylhexosamine, M; precursor ion. 
Figure 40 CID spectrum of de-glycosylated chymotryptic T199N mutant peptide 
SLSSVVTVPSSSLGNQTY observed at m/z 609.64(3+). b- and y- ions show CID fragments 
of the peptide. 
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3.2 Monomer Loss following Accelerated Studies at Elevated Temperature 
Incubation at 65 °C revealed modest differences in aggregation propensity between the reference 
Humira®, WT and single-mutant variants (Figure 41). Variants L116N and T118N were completely 
degraded after one hr of incubation and were therefore not included in the figure (Figure 41). 
Variant Q160N had very similar monomer loss data at all incubation temperatures to the W T, while 
L183N had a noticeably higher monomer loss. Variants A122N, Q179N and T199N retained higher 
monomer content than the control at most incubation conditions, with A122N having the least 
monomer loss (Figure 41). While Q179N had comparable monomer loss after one hr, monomer 
loss was lower at two and three hr, when compared to the WT. Interestingly, variants L178N and 
L178K had comparable monomer loss profiles which were not significantly different to the WT 
(Figure 41). Humira® reference had slightly lower monomer loss than the WT.  
3.3 Tm and Tagg  
The WT AdmAb had a very similar Tm1 and Tm2 to the Humira
® reference product; a slightly lower 
Tm1 was measured at 69.6 °C (WT) compared with 70.8 °C (Table 43). Aside for Tm2, all SD 
observed between the AdmAb WT and Humira were relatively low and comparable, demonstrating 
insignificance of the sample variation and robustness of derived values. The SD observed for Tm2 
for Admab WT (1.4 °C) versus Humira (0.8 °C) showed more substantial sample variation, 
Figure 41 Monomer loss of Humira®, AdmAb wild-type (WT) and variants following incubation 
at 65 °C for one, two and three hours. Error bars represent the SD.  
 
150 
 
however; the derived mean Tm2 was comparable at 82 °C (WT) compared with 82.5 °C  (Humira
®). 
Variant Q160N had a similar melting profile to the WT, with an identical Tm1 and comparable Tm2 
of 69.6 and 82 °C, respectively. Variants T118N and L116N had a significantly lower Tm1 at 59.7 
and 63.6 °C, respectively; the Tm2 was also lower at 68 and 78.6 °C, respectively. Interestingly, a 
third Tm was recorded for variants T118N and L116N at 87.8 and 88.3 °C, respectively. Variants 
L178K, A122N and Q179N had similar Tms and were comparable to the WT. Variants T199N and 
L178N had similar Tm1 values to the WT (70.6 and 69.9 °C, respectively), but significantly higher 
Tm2 values (88.2 and 89.3 °C, respectively). Variant L183N had a similar Tm1 to the WT, but had a 
consistent minor unfolding event at ~65 °C (not shown); Tm2 was higher than the WT (88.3 °C, 
Table 2). The Tagg of the WT and variants ranged from 70.6 to 72.5 °C, except for variants T118N 
and L116N, which had significantly lower Tagg values (61.7 and 64.7 °C, respectively; Table 43). 
Most variants had a slightly higher Tagg than the WT (70.7 °C) by approximately 1 – 2 °C, while the 
Tagg of Q160N and L178K were unchanged. Compared with L178K, the Tagg of glycosylated variant 
L178N was 1.7 °C higher. Results presented in Table 43 are derived from analysed sample melting 
and aggregation curves as presented in Appendix 7.6. 
Table 43 The melting (Tm) and onset of aggregation temperatures (Tagg) of the AdmAb variants 
compared with the wild-type (WT) and reference Humira® product (± SD); ^see discussion 
AdmAb Tm1 (°C) Tm2 (°C) Tm3 (°C) Tagg @266 nm 
Humira® 70.8 ± 0.2 82.5 ± 0.8 - 71.3 ± 0.4 
WT 69.6 ± 0.5 82 ± 1.4 - 70.7 ± 0.1 
Q160N 69.6 ± 0.3 81.1 ± 1.4 - 71 ± 0.4 
T199N 70.6 ± 0.2 88.2 ± 2.2 - 71.7 ± 0.1 
T118N 59.7 ± 0.5 68 ± 0.7 87.8 ± 2.5 61.7 ± 0.6 
L178K 68.4 ± 0.6 83.5 ± 0.5 - 70.6 ± 0.3 
L178N 69.9 ± 0.5 89.3 ± 0.2 - 72.3 ± 0.3 
A122N 69.7 ± 0.5 83.4 ± 0.7 - 71.8 ± 0.4 
Q179N 69.4 ± 0.2 82.7 ± 0.9 - 71.7 ± 0.5 
L116N 63.6 ± 0.5 78.6 ± 0.5 88.3 ± 1.2 64.7 ± 0.3 
L183N 70^ ± 0.5 88.3 ± 1.1 - 72.5 ± 0.7 
 
151 
 
3.4 Binding Kinetics of AdmAb to TNF- and FcγRs 
The binding kinetics of reference Humira®, monomeric AdmAb WT and variants to TNF- and 
FcγR1A, 2B and 3A were assessed using SPR single cycle kinetic analysis. Samples were run in 
duplicate and sensograms were fitted to a Langmuir 1:1 binding model to obtain Ka, Kd and KD 
values for comparison as per previous studies [228, 231]. It was determined that in general, the 
majority of AdmAb variants did not experience a significant loss of biological activity.  
The KD range determined for monomeric AdmAb variants binding to soluble homotrimeric TNF- 
spanned 36.69 – 110.27 pM, while Humira® had a mean KD of 30.77 pM (Table 44). Monomeric 
AdmAb WT had a KD of 66.43 ± 2.37 pM which lies within the range, with no significant outlier 
(Table 44). Of all variants tested, T199N had the strongest KD to TNF- (36.69 pM) - 
approximately 1.8-fold stronger than the WT - while Q179N had the weakest KD (110.27 pM).  
Table 44 Kinetics and binding affinity of reference (Humira®) and monomeric AdmAb mutants to 
soluble homotrimeric TNF- (± SD). 
AdmAb 
TNF- 
Ka  
(x 105) M-1.s-1 
Kd  
(x 10-5) s-1 
KD  
(pM) 
Humira® 11.7 ± 0.01 3.59 ± 0.80 30.77 ± 6.83 
WT 6.08 ± 0.07 4.04 ± 0.10 66.43 ± 2.37 
L178K 4.84 ± 0.01 4.61 ± 0.64 95.33 ± 13.3 
L178N 5.33 ± 0.03 5.42 ± 0.67 101.7 ± 12.1 
Q160N 6.2 ± 0.07 2.86 ± 0.05 46.05 ± 1.31 
L116N 5.19 ± 0.09 2.84 ± 0.1 54.77 ± 2.87 
T118N 5.04 ± 0.02 3.59 ± 0.21 71.19 ± 4.50 
A122N 6.47 ± 0.03 2.87 ± 0.05 44.32 ± 0.57 
Q179N 5.02 ± 0.40 5.53 ± 0.1 110.3 ± 6.56 
L183N 5.58 ± 0.14 3.05 ± 0.03 55.37 ± 0.86 
T199N 7.15 ± 0.69 2.62 ± 0.01 36.69 ± 3.54 
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The KD range determined for FcγR1A binding to monomeric AdmAb variants spanned 2.1 – 6.81 
nM, while Humira® had a mean KD of 1.84 nM (Table 45). Monomeric AdmAb WT had a KD of 4.4 
± 0.01 nM which lies within the range with no significant outlier (Table 45). Of all variants tested, 
the strongest KD was recorded for mutant T118N (2.1 nM), while the weakest KD was recorded for 
L178N (6.81 nM).  
Due to sample limitations, monomeric AdmAb Q160N was not tested for the cycle assays against 
FcγR2B (Table 45). The KD range determined for FcγR2B binding to monomeric AdmAb variants 
spanned 1.81 – 9.61 nM, while Humira® had a mean KD of 2.55 nM. Monomeric AdmAb WT had a 
KD of 4.47 ± 0.1 nM which lies within the range with no significant outlier (Table 45). T199N had 
the strongest KD to FcγR2B (1.81 nM), while T118N had the weakest KD (9.61 nM). However, due 
to the large variation in KD values for the WT and several mutants, most differences were not 
deemed significant.  
Table 45 Binding affinity of reference Humira® and monomeric AdmAb mutants to FcγR1A, 
FcγR2B and FcγR3A (± SD), no data (ND). 
AdmAb 
KD (nM) 
FcγR1A FcγR2B FcγR3A 
Humira® 1.84 ± 0.18 2.55 ± 1.67 1.84 ± 0.68 
WT* 4.4 ± 0.01 4.47 ± 1.00 5.96 ± 1.62 
L178K 4.14 ± 0.06 9.16 ± 6.86 2.37 ± 1.19 
L178N 6.81 ± 0.45 3.67 ± 0.93 2.15 ± 0.73 
Q160N 5.3 ± 0.01 ND 16.2 ± 3.05 
L116N 3.87 ± 0.14 6.15 ± 1.10 6.71 ± 1.91 
T118N 2.1 ± 0.01 9.61 ± 1.38 13.3 ± 0.45 
A122N 5.58 ± 0.18 7.53 ± 2.74 18.01 ± 7.4 
Q179N 2.74 ± 0.01 5.27 ± 0.11 2.92 ± 0.16 
L183N 2.6 ± 0.04 2.52 ± 2.05 1.48 ± 0.84 
T199N 6.49 ± 0.06 1.81 ± 1.25 11.80 ± 0.2 
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The KD range determined for FcγR3A binding to monomeric AdmAb variants spanned 1.48 – 18.01 
nM, while Humira® had a mean KD of 1.84 nM. Monomeric AdmAb WT had a KD of 5.96 ± 1.62 
nM which lies within the range with no significant outlier (Table 45). The strongest KD was 
recorded for L183N (1.48 nM), while the weakest KD was recorded for A122N (18.01 nM) with 
large ranges. Overall, all differences in KD recorded compared to the WT, were no larger or smaller 
than 3-fold for TNF- and all receptors tested. All kinetic results presented in Table 44 and Table 
45 are derived from analysed sample sensograms as presented in Appendix 7.3 - 7.5. 
4 Discussion 
We rationally designed and produced a library of glycan-engineered AdmAb variants to enhance 
stability through steric hindrance of an APR. Successful mutation and glycan addition was 
confirmed for all mutants aside from Q160N, through LC-MS/MS. Consequently, the stability and 
binding kinetics results for the Q160N variant are directly related to the amino acid substitution 
alone. Since Q160N had identical stability and antigen binding affinity to the WT, it was concluded 
that the amino acid substitution did not have any significant impact on the antibody properties 
tested. The KD values for the AdmAb WT produced in our study (Table 44 and Table 45) are 
comparable to Humira® KD values observed, and as reported in the literature; TNF- (30 - 110 pM), 
FcγR1A (15 - 23 nM), FcγR2B (4.3 - 14.2 nM) and FcγR3A (5.8 - 7.9 nM) [274, 275]. 
Likewise, most measured KD values for the mutants tested lay within a close range to reported 
literature values for the reference AdmAb, showing that these mutations had minimal impact on 
binding properties.  
The highest improvement in resistance to aggregation was observed in mutant A122N with a slight 
increase in Tagg and reduction in monomer loss (Table 43 and Figure 41). The A122N mutation 
resulted in 1.5-fold increased binding affinity to TNF- with slightly reduced binding to FcγRs 
tested and with no impact on conformational stability. Pepinsky, Laura, A., Graham, Alexey, Lee, 
John, Allan, Sha, Christilyn and Ellen [248] reported that a mutation equivalent in position to 
AdmAb variant A122N significantly improved the solubility of an anti-LINGO antibody, with no 
impact on binding affinity or conformational stability. Improvements in solubility often correlate 
with reduced precipitation and insoluble aggregate formation. 
This may explain the minor improvement in Tagg we observed with mutant A122N which reflects a 
higher resistance to precipitation at higher temperatures. Although only a minor improvement in 
monomer loss, the improvement is consistent at higher concentrations tested (15 mg/mL, data not 
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shown) and is significant in a clinical setting, where typically no more than 5% of aggregates are 
considered acceptable by regulatory standards.  
No significant improvements in monomer loss were observed with other mutants (e.g. T199N and 
Q179N). Courtois, Schneider, Agrawal and Trout [169] hypothesised that a mutant equivalent in 
position to Q179N in bevacizumab could not be glycosylated as it was inaccessible to glycosylases. 
However, we confirmed that Q179N was glycosylated; likewise, Pepinsky, Laura, A., Graham, 
Alexey, Lee, John, Allan, Sha, Christilyn and Ellen [248] were able to express a glycosylated 
variant with a mutation in an equivalent position to Q179N which mildly improved antibody 
solubility. With the additional N-glycan, Q179N was expected to sterically hinder Fab-mediated 
aggregation in the targeted APR; while T199N was reported to significantly improve solubility 
[248] and sterically hinder self-association [166], however this was not observed for AdmAb. The 
Q179N mutation also mildly reduced antigen binding affinity by ~1.6-fold. Interestingly, Pepinsky, 
Laura, A., Graham, Alexey, Lee, John, Allan, Sha, Christilyn and Ellen [248] reported no change in 
the Tm of the mutation equivalent in position to AdmAb variant T199N, while we observed a 
significant improvement in Fab Tm with variant T199N (~6 degrees higher). Additionally, T199N 
had 1.8-fold improved KD to TNF- with minimal differences in KD to FcγRs. The lack of 
improvement in resistance to aggregation, despite the improvement in Fab stability, may be related 
to the mechanism of aggregation in AdmAb. Since the CH2 has the lowest Tm in most IgG1s, it is 
expected that most aggregation steps are at least initiated with unfolding of the CH2; thus, an 
improvement in Fab stability may not significantly impact overall resistance to soluble aggregation.  
Similarly, we observed an improvement in Fab Tm for mutants L178N and L183N. L178N is an 
interesting example, because when compared to the non-glycosylated variant L178K, there is an 
improvement in Tagg and Fab Tm through glycosylation. This emphasises the impact of the N-
glycans added via mutation on the conformational stability of the Fab and its resistance to 
precipitation, and highlights that these changes are not due to the amino acid substitution. The 
mutation significantly improved the conformational stability of the Fab domain. Furthermore, 
despite suppressing pH-induced precipitation when tested on the Fab alone [273], the L178N 
mutation had minimal impact on soluble aggregation when tested on the full AdmAb. Surprisingly, 
the non-glycosylated variant L178K which was reported to significantly suppress aggregation in 
bevacizumab [168], but enhance aggregation in rituximab [169], also had minimal impact on the 
stability of AdmAb. This finding highlights that framework regions differ significantly between 
IgG1 antibodies despite having identical sequences.  
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Variants L116N and T118N had multiple Tms, with a lower Tm1, higher Tm3 and a significantly 
reduced Tagg; additionally, they were completely degraded at 65 °C. The Tms of these mutants are 
harder to interpret, and do not necessarily represent the CH2, Fab and CH3 in that order. As 
previously reported [143], disturbances in the joining region between the Fab domains can create 
additional Tms for each separate domain. Thus, we expect that the Tm1 value of these mutants is 
representative of only part of the Fab (for e.g. the CH1 or VL); since the Tm of this part of the Fab is 
now less stable than the CH2, aggregation proceeded more rapidly at 65 °C. Again, our results do 
not correspond with findings reported for the mutation equivalent to AdmAb L116N in 
bevacizumab, which showed improved resistance to aggregation with no destabilization of the Fab 
[168]. Some perturbation in Fab stability was also observed with mutant L183N, resulting in 
increased monomer loss. The perturbation was minor and hard to detect; however consistently 
appeared in temperature ramps for Tm measurement. It is likely that the amino acid substation in 
this position impaired the conformational stability of part of the Fab domain as observed with 
mutants L116N and T118N.  
5 Conclusion 
Protein aggregation is a complex challenge hindering the development and long-term stability of 
therapeutic mAbs. Using advanced computational tools, we identified aggregation prone regions 
and engineered adalimumab, a marketed therapeutic mAb, with additional N-glycans in the Fab 
domain, with the aim to sterically hinder aggregation and increase long-term stability. Our glycan-
engineered variants displayed a range of different stabilities, with some mutations increasing 
susceptibility to aggregation, others enhancing the conformational stability of the Fab domain, and 
one showing minor improvements in resistance to aggregation.  This approach has potential 
application for other antibodies where the Fab domain has poor stability or is a pre-cursor to 
aggregation.  We demonstrated that the conformational stability of blockbuster therapeutic 
antibodies such as AdmAb can still be improved with glycan-engineering without compromising its 
antigen and Fc receptor binding affinity; these findings highlight the significant value of this 
engineering approach in the quest for developing more stable therapeutic mAbs with improved half-
lives and therapeutic outcomes.  
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Chapter 7  
Discussion; Outcomes, Reflections and 
Future Prospects 
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1 Summary of Aims and Outcomes 
In this body of work, mutational projects were designed for enhanced affinity and reduced self-
association and aggregation propensity, applied to Tmab and AdmAb as model mAbs for 
investigation. The rationale behind strategic mutagenesis for the successful modulation of Tmabs 
target affinity is the potential to reformat the antibody platform for a more efficacious therapeutic 
treatment. And similarly, the rationale behind strategic hyper-glycosylation for the successful 
reduction of self-association and aggregation propensity in both antibodies is the potential to 
improve manufacturability and formulation strategies, as well as prolonging mAb half-life for a 
more efficacious therapeutic treatment. The successful application of preliminary in silico analysis 
strategies to improve model mAbs by design for modulated functions can indeed be more broadly 
applied to other biotherapeutics, and is yet to be fully realised. The outcomes of this research has 
demonstrated the success of using in silico modelling and prediction for the preliminary elucidation 
and design of mAbs, having elected several lead mutants from the projects for further investigation. 
Before commencing the design of mutational projects, appropriate expression systems for the lab-
scale production of Tmab and AdmAb were required to be established and optimised. Several 
cloning strategies were implemented as to ascertain the most appropriate expression vector 
platforms for optimising antibody expression and purification, prior to biological assay and 
mutagenesis optimisation, and the design and expression of mutant libraries. Mutational projects 
were designed based on in silico analysis of crystal structures of the antibody Fabs complexed to a 
fragment of the target epitope. The Tmab affinity mutations were based on results from our 
collaborators from A/Prof Serdar Kuyucak’s Computational Biophysics Group, School of Physics, 
The University of Sydney, and the glycosylation mutations based on literature search of reported 
APRs, paying particular attention to spacial proximity of the APR and complexing interfaces. 
Mutant libraries were then produced and characterised before in vitro assessment to determine lead 
candidates for further investigation of modulated target binding for the affinity library specifically, 
or comparison of retained biological functions and stability profiling for the hyper-glycosylated 
libraries.  
In silico prediction of Tmab affinity mutations was in agreement with in vitro analysis, highlighting 
the applicability and impact of producing lead candidates by design for more economical and 
efficient discovery and biobetter development. Furthermore, strategic introduction of glycosylation 
sites identified through in silico analysis for the steric hindrance of an APR showed considerable 
stability enhancement without compromising biological functions in both Tmab and AdmAb, which 
demonstrates the potential transferability of this engineering approach in the pursuit of biobetter 
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design and development. The results from these mutational projects show that the preliminary 
design of mAbs based on relevant computational tools can successfully elucidate key strategic 
modifications for in vitro validation, which exemplifies this approach in the pursuit and design of 
next generation biologic therapeutics. 
2 Establishing Lab-Scale mAb Expression Platforms  
In order to design and produce mutational projects for in vitro assessment, the development of 
appropriate Tmab and AdmAb expression systems were required. The expression system for the 
mAb mutants was designed and optimised in a transient, serum-free, suspension 293F culture and 
captured through Protein A affinity chromatography. 
A library of mammalian expression vectors was developed for Tmab and AdmAb expression, as 
reported in Chapter 2. Several expression vectors requiring different cloning strategies were 
considered to design and apply the assembly of Tmab and AdmAb expression vectors for transient 
and stable expression. A pilot transient expression system was performed to compare antibody 
expression between the vector platforms. The gWiz platform was elected as the most suitable for 
optimisation of transient expression due to its superior yield and cloning efficiency, and the 
pVITRO1 platform elected as the most suitable for stable expression of Tmab alone.  
A high yielding stable Tmab expression system was established using the pVITRO1 platform, for 
preliminary characterisation and assay optimisations as reported in Chapter 3. The expression 
system was improved from traditional techniques through selection in adherent conditions prior to 
adaption to scaled-up serum free suspension culture, and the addition of surfactant and tryptone 
media supplements for enhanced protein expression and support of cell viability. The stable 
expression of Tmab was utilised to scout buffers for optimising the efficient capture of Tmab 
through Protein A affinity chromatography, and preliminary characterisation was performed to 
confirm the yield and purity of bulk Tmab product.  
However, the composition of host cell proteins and DNA, leached Protein A ligand, mAb 
fragments, aggregates and ionic variant contaminants were not specifically profiled from the bulk 
Tmab product to elucidate the necessity of any further polishing steps. The significance of these 
potential contaminants in the bulk mAb product can cause product instability and loss in biological 
activity, which affects in vitro assay results for interpretation. As extensively discussed in Chapter 
1, the profile of these contaminants can vary, being influenced by expression and capture 
conditions, and can be separated from the bulk mAb product with relevant ionic, hydrophobic and 
size-exclusion chromatographic technologies. Although not specifically addressed through the 
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Tmab mutant projects in Chapter 4 and Chapter 5, the AdmAb mutant project in Chapter 6 
optimised a further size-exclusion polishing step for the isolation of pure AdmAb monomer product 
prior to stability profiling and biological assays, for confident interpretation of the in vitro analysis 
between AdmAb mutant variants. 
As mAb mutant samples were equivalently produced using optimised expression conditions, 
variation in contaminant profiles between bulk mAb samples was likely minimal, hence mutation 
projects were comparable to their corresponding lab-produced wild-type mAb. In hindsight, 
profiling the contaminants in all mAb samples would have added value to provide more confidence 
behind the in vitro results from the Tmab mutation projects, to identify whether a polishing step was 
warranted and further ascertain the optimisation of mAb expression and capture conditions. 
However, this body of work has shown considerably interesting results from the Tmab mutation 
projects designed and expressed, with several lead candidates identified. Reproducing the Tmab 
projects with monomeric mAb samples would likely reflect similar in vitro properties as have been 
identified in the bulk mAb samples produced through this body of work; however, lead candidates 
warrant a further polishing step to reproduce and validate the current findings.  
3 In Pursuit of Modulating Target Affinity 
As extensively discussed in Chapter 1, the affinity of a mAb to its biological target is a crucial 
parameter to be considered for the design of biobetter antibodies. In considering disease 
presentation and treatment strategies, modulation of a mAbs target affinity can improve its efficacy 
with an appropriate mAb format. ADCs and fragment mAbs favour enhanced target binding 
affinity; disease treatments requiring ADCC, tissue penetration and retention favour reduced target 
binding. Further to modulating target binding, mAb half-life extension and modulation of immune 
effector function has been demonstrated through strategic manipulation of mAb binding to specific 
immune receptors. 
In this body of work, Tmab was used as a model antibody to design strategic mutations for 
modulated affinity to target HER2, as reported in Chapter 4. Our collaborators from A/Prof Serdar 
Kuyucak’s Computational Biophysics Group, School of Physics, The University of Sydney 
elucidated several substitutions in Tmabs Fab region that were predicted to modify its affinity to 
HER2 through in silico analysis. Specifically, substitution S50>E was disruptive to the Fab 
complex whilst reversal Y49/S50>S49/Y50 enhanced complex binding, substitutions D102>F and 
D28>K presented negligible alteration whilst D28>R showed considerable complex binding 
enhancement. Several mutagenesis strategies were implemented to optimise mutation yield and 
efficiency; however, of the five mutations designed only three were successfully produced for in 
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vitro validation, that being S50>E, D28>K and D102>F. Of the other predicted substitutions that 
were unsuccessfully isolated after several rounds of mutagenesis, the in silico results strongly 
suggest that they are lead enhanced affinity candidates to pursue for in vitro validation. 
The affinity mutant library was assessed for binding to extracellularly expressed HER2 in a cell-
binding titration assay, and surface plasmon resonance was performed to determine the binding 
kinetics of the affinity library to immobilized HER2 and FcγR1A. The findings from these results 
were in agreement to in silico prediction, in that substitution S50>E diminished binding to HER2, 
and that D28>K and D102>F showed negligible differences in binding to HER2 as compared to 
wild-type Tmab. Furthermore, binding to FcγR1A was assessed to validate that immunological 
activity was not compromised in the affinity mutant library. Interestingly, D102>F showed 
considerably enhanced binding to FcγR1A which would likely result in a more pronounced ADCC 
effect and is of interest for further investigation.  
From the findings of this project, the diminished affinity exhibited from mutant S50>E to HER2 is 
of considerable interest for continued investigation as a potential platform for improved cancer 
treatment by coupling this mutation with enhanced ADCC technologies. S50>E mutant warrants 
further effector function and stability profiling, in vivo assays to elucidate retention of specificity 
and enhancement of tumour penetration and retention, and x-ray crystallography of the Fab 
complex to HER2 to corroborate the structure of the binding interface with in silico predictions. 
Producing substitution D28>K and reversal Y49/S50>S49/Y50 mutations was unfortunately not 
achieved in this body of work. The in silico predictions of these reported mutations strongly 
indicate these as enhanced affinity candidates and are of continued interest for in vitro validation. 
4 In Pursuit of Reducing Self-Association and Aggregation Propensity  
As extensively discussed in Chapter 1, the propensity of a mAb to self-associate is a critical factor 
in its developability, as self-association induces mAb instability and irreversible aggregation 
leading to manufacturing loss, reduced efficacy and adverse immunogenicity in the drug product. 
mAb aggregation mainly occurs through the manufacture process, formulation development and 
long term storage, and remains a key challenge to be addressed for the design of biobetter 
formulations. Considerable efforts in determining self-association and APRs in mAbs have led to 
the design of in silico predictive tools that identify surface exposed hydrophobicity. The direct 
substitution of residues in APRs to remove hydrophobicity has shown considerably improved mAb 
stability and reduced aggregation propensity in vitro, validating this strategy of antibody 
engineering for the design of biobetters.  
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In this body of work, an extension of this mAb engineering technique was considered, in that the 
introduction of spatially proximate N-linked glycans to identified APRs would potentially sterically 
hinder colloidal APR associations and hence reduce self-association and aggregation propensity. 
Further to this, hyper-glycosylation technology has been utilised to increase solubility and enhance 
half-life of other biotherapeutics. Strategic hyper-glycosylation introduces orientated functional 
groups that can further be useful for conjugation technologies. Beyond self-association, the benefits 
for strategic hyper-glycosylation technology for biobetter mAb development are highly apparent 
and the potential is yet to be realised.  
Tmab was used as a model antibody to design mutations introducing strategic N-linked glycans in 
the Tmab Fab to sterically hinder APR associations, as reported in Chapter 5. Design of the 
mutational projects was based on literature search of identified APR that were experimentally 
validated through direct substitution. Spatially proximate surface exposed residue substitutions that 
introduce an N-linked glycan were considered for glycosylation projects. One consolidated 
glycosylation APR project was elected out of the several projects designed. To minimise the 
possibility of the introduced N-glycan diminishing important biological functions, the mutations 
were restricted to the Fab region excluding CDRs. To demonstrate proof-of-concept of the 
introduced glycans reducing self-association and aggregation propensity, the glycosylation mutant 
library was transferred into AdmAb as reported in Chapter 6.  
In both chapters, the mutation libraries were characterised through mass spectrometry to confirm 
the success of mutation and glycan addition, and interestingly one mutant (Q160>N) did not 
achieve glycosylation despite successful mutation in both mAbs and previous report of successful 
glycosylation of a bevacizumab mutant equivalent. Of the stability profiling, equivalent 
enhancement of intrinsic stability and aggregation resistance was observed between the Tmab and 
AdmAb libraries, although monomer retention was incomparable due to the markedly different 
parameters elected for the monomer loss studies. Tmab L177>N, L182>N and T198>N and the 
AdmAb equivalent L178>N, L183>N and T199>N mutants possessed enhanced intrinsic stability. 
Resistance to aggregation was observed in Tmab L177>N, A121>N, Q178>N, L182>N and 
T198>N the AdmAb equivalent L178>N, A122>N, Q179>N, L183>N and T199>N mutants. Tmab 
L115>N and T117>N and AdmAb equivalent L116>N and T118>N mutants equivalently 
performed poorly for intrinsic stability and resistance to aggregation. Highly accelerated monomer 
loss was performed on the Tmab library, of which candidates L177>N and L182>N exhibited 
superior monomer retention. Moderately accelerated monomer loss was performed on the AdmAb 
library, of which candidates A122>N and T199>N exhibited superior monomer retention, which 
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likely indicates a difference in the mechanism of aggregation. Tmab L177>N, L182>N and T198>N 
mutants and AdmAb L178>N, A122>N, L183>N and T199>N mutants were elected as lead 
candidates for more rigorous investigation.  
Further to stability profiling, retention of biological activity was screened amongst the libraries to 
ascertain retention of biological functions. In general, mutants binding to tested targets were within 
3-fold of the wild-type mAb, which may pose a small degree of significance; however, no real trend 
was observed between the two libraries. More specifically, Tmab mutant library binding to target 
HER2 and FcγR3A were modestly compromised, and binding to FcγR1A and was modestly 
enhanced. Unlike the Tmab mutant library, the AdmAb mutant library showed more variability, less 
significant difference and no trends in comparison to the wild-type mAb binding to target receptors. 
Interestingly, Tmab mutant L182>N displayed a drastic disruption in binding to FcγR2B and 
markedly enhanced affinity to FcγR3A, along with T198>N, which suggests a potentially enhanced 
ADCC effect. However, these modulations were not observed in the AdmAb equivalents, 
suggesting that the observed differences in binding may be negligible, although thorough in vivo 
assessment of modulated ADCC is warranted to clarify the case.  
From the findings of these projects, several mutations were elected as lead candidates for perusal of 
more thorough stability screening in the lead up to formulation development, demonstrating the 
success and applicability of this hyper-glycosylation approach in designing stability enhanced 
biobetters. Specifically, Tmab L177>N, L182>N and T198>N, AdmAb equivalents L178>N, 
L183>N and T199>N, and further AdmAb A122>N mutants were elected as lead candidates for 
further investigation. Proof-of-concept for the transference of this technology for reducing self-
association and aggregation propensity has been successfully demonstrated, in that three of four 
lead stability mutant candidates were elected from both antibody libraries. Characterisation of the 
addition of N-linked glycans was consistent between the two antibody libraries, further 
demonstrating the applicability of transference of this technology. The further size-exclusion 
polishing step in the AdmAb project provided more confidence behind the interpretation of the in 
vitro results to validate the current findings. The findings of the biological assays was marginally 
inconsistent between the two libraries, this is likely due to the additional size-exclusion purification 
step applied to the AdmAb library to produce monomeric species for robust in vitro results. In order 
to provide a more robust comparison, the Tmab library warrants reproduction following an 
appropriate polishing step to produce monomeric species. Following this, the lead stability mutant 
candidates warrant reproduction in several further antibodies for stability transferability 
comparison, in vivo assessment to observe retention of specificity and the potential for enhanced 
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half-life. X-ray crystallography of the glycosylated Fab is also warranted, to elucidate glycan 
orientation and structure for the potential to derive more significant findings through further in 
silico analysis. Furthermore, expression of the hyper-glycosylated mutants in different expression 
platforms for different glycan profiles is of further interest, to ascertain if particular glycosylation 
profiles may attribute to mAb stability, self-association and biological functions, in the aim of 
refining this technology for design-specific purposes. 
In considering the findings and outcomes from the completed hyper-glycosylation project, designed 
based on the self-association of one specific APR, the design and in vitro validation of further 
hyper-glycosylation projects is further warranted. It is entirely possible that a few key glycan 
additions in combination would achieve highly favourable stability and solubility profiles that can 
apply the mAb to alternative, less invasive formulations for a more efficacious treatment strategy. 
5 Concluding Remarks 
To recapitulate the findings from this body of work, in silico analysis was successfully applied to 
design model mAbs for a modulated affinity to biological target and disrupted colloidal self-
association interactions, through residue substitution and hyper-glycosylation strategies. In vitro 
assessment of affinity mutations corroborated with in silico predictions, highlighting the success of 
this approach in elucidating lead candidates by design for more efficient biobetter development. In 
vitro assessment of hyper-glycosylated libraries produced several lead candidates with enhanced 
stability profiles, demonstrating the applicability of this approach in engineering stability enhanced 
mAbs by design. Furthermore, transference was demonstrated of this hyper-glycosylation 
technology, which implies the potential adaptability of this approach to the whole IgG class in the 
pursuit of designing next generation biologic therapeutics. These strategies address two key 
challenges that arise in mAb development and can indeed be more broadly applied to the design of 
other biologic therapeutics, showing immense promise for the application of the presented 
engineering strategies for the strategic development of biobetter therapies.  
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1 E. coli Protocols  
1.1 Media and Culture Conditions 
In LB broth: 37 °C, 250 rpm O/N, on LB agar: 37 °C O/N. 
O/N (broadly means) 16 – 22 hrs 
Inoculate media using a sterile 10 µL inoculation loop.  
From a plate:  
Pick a single colony isolate. 
From liquid culture:  
Pick a loopful of liquid culture. 
To a plate:  
Over the surface of the agar plate, rub the inoculated loop in a small region towards the 
circumference. To one corner of the rubbed area, rub out in a separate region using the flipped side 
of the loop (first dilution). Making sure to only contact the edge of the prior rubbed region, rub 2 
further dilutions over the plate with a fresh loop. The final dilution to be a broad squiggle that takes 
the majority of the space of the plate, where single colonies can be isolated.  
To liquid media:  
Stir the loopful of liquid culture into the fresh media. For larger cultures, inoculate with larger 
volumes of liquid culture with a pipette (100 µL – 1 mL). 
Small scale (miniprep extraction):  
15 mL culture tube containing 3 – 5 mL LB broth 
Medium scale (midiprep extraction):  
50 mL centrifuge tube containing 15 – 35 mL LB broth 
Large Scale (maxiprep extraction): 
1L baffled culture flask containing 150 – 350 mL LB broth 
Luria-Bertani (LB) Broth  
Deionised H2O containing: 
 10 g/L tryptone (casein peptone) (LP0042B Thermo Fisher Scientific) 
 5 g/L yeast extract (70161 Sigma-Aldrich) 
 10 g/L NaCl (S9888 Sigma-Aldrich) 
Combine ingredients to the desired volume, adjust to pH 7.5 and autoclave.  
Keep media sealed and refrigerated until use.  
For antibiotic media, wait for the autoclaved media to cool to < 50 °C before adding desired 
antibiotic. 
LB Agar 
LB broth containing 15 g/L agar (20767.232 VWR International) 
Prepare media as per LB Broth section.  
Appendix 
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Once autoclaved, allow the media to cool to a lukewarm temperature for plate pouring. 
Approximately 15 – 20 mL media can be poured on a conventional sized plate (9 - 10 cm diameter), 
enough to cover the entire surface, having 5 – 7 mm depth. Allow a minimum of 20 min for the 
poured plates to set at room temperature.  
Once set, cover and label the plates. Refrigerate until use. 
For antibiotic media, wait for the autoclaved media to cool to < 50 °C before adding desired 
antibiotic. Mix gently to limit bubble formation before pouring plates. 
SOC Media 
Freshly prepare 100 x filter sterilised solutions in deionised H2O: 
 2 M glucose (G5767 Sigma-Alrich) 
 1 M MgCl2 (M4880 Sigma-Aldrich) 
 1 M MgSO4 (M2643 Sigma-Aldrich) 
SOC media preparation in deionised H2O containing: 
 20 g/L tryptone (casein peptone) (LP0042B Thermo Fisher Scientific) 
 5 g/L yeast extract (70161 Sigma-Aldrich) 
 0.5 g/L NaCl (S9888 Sigma-Aldrich) 
 20 mM glucose  
 10 mM MgCl2 
 10 mM MgSO4 
Combine tryptone, yeast extract and NaCl to the desired volume and autoclave.  
Once autoclaved, allow the media to cool to < 50 °C before adding freshly filter sterilised 2 M 
glucose, 1 M MgCl2 and 1 M MgSO4 solutions.  
Prepare as 1.2 mL aliquots in microfuge tubes, keep media aliquots at -20 °C until use.  
1.2 Glycerol Stock Preparation and Resuscitation 
Prepare 80% Glycerol solution (v/v) in deionised H2O and autoclave.  
Keep solution sealed and refrigerated until use.  
Glycerol stock preparation: 
To a labelled cryovial, add 200 µL of autoclaved 80% glycerol solution and 800 µL liquid culture. 
Mix gently but thoroughly via pipetting. Immediately transfer to -80 °C until use. 
Glycerol stock resuscitation:  
Take desired cryovial from -80 °C. Whist still frozen, use a sterile 10 µL inoculation loop to scrape 
some frozen stock from the vial and inoculate an appropriate agar plate as per 1.1. Immediately 
transfer the cryovial to -80 °C until further use; transfer the plate for O/N incubation as per 1.1. 
1.3 Calcium Chloride Preparation of Competent E. coli  
This method was adapted from Xiaowei, Li (2013) “An improved calcium chloride method 
preparation and transformation of competent cells” African Journal of Biotechnology 9(50) 8549-
8554 
This method was used on E. coli strain JM109, however this method can be applied to other E. coli 
strains. 
JM109 was a kind donation from Dr Fanfan Zhou (Pharmacy School, Faculty of Medicine and 
Health, The University of Sydney).  
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1.3.1 Reagents 
Prepare LB broth and LB agar (1.1). 
Prepare 15% glycerol solution (v/v) in deionised H2O for immediate use. 
Freshly prepare buffers and autoclave: 
Buffer 1: 75 mM CaCl2 (C4901 Sigma Aldrich) in deionised H2O. 
Buffer 2: 85 mM CaCl2 (C4901 Sigma Aldrich) in 15% glycerol solution. 
Keep media and buffers sealed and refrigerated until use.  
1.3.2 Calcium Chloride Method of Preparing In-house Competent JM109 
Inoculate a LB agar plate with JM109 for O/N culture. 
Isolate a single colony from the plate to inoculate 3 mL LB broth for O/N culture. 
Inoculate 200 mL LB broth with 2 mL of liquid culture and place in incubation for monitoring. 
After 1.5 hrs incubation, measure optical density at 600 nm (OD600) from the culture every 15 min 
until the culture OD600 resides between 0.35 – 0.45.  
When the OD is reached, remove the culture from incubation and transfer into an ice bath for 30 
min. Transfer the culture to chilled 50 mL centrifuge tubes and chill in an ice bath for 5 min.  
Pellet the cells (1,000 g, 5 min, 4 °C), resuspend the cells in 20 mL chilled Buffer 1 and chill on ice 
for 5 min. Pellet the cells (1,000 g, 5 min, 4 °C), resuspend the cells in 20 mL chilled Buffer 2 and 
chill on ice for 5 min.  
Pellet the cells (1,000 g, 5 min, 4 °C), resuspend the cells in fresh 4 mL chilled Buffer 2 and 
prepare as 100 µL aliquots in labelled 1.5 mL microcentrifuge tubes (keeping cells chilled on ice at 
all times).  
Immediately transfer aliquots to -80 °C for storage, aliquots to be thawed on ice for single use in 
heat-shock transformations. 
1.4 Transformation of Competent Cells by Heat-Shock method 
In-house JM109 competent cells and commercial Stellar™ competent E. coli were transformed 
using the following heat-shock method.  
Briefly per competent cell reaction, incubate 50 µL competent E. coli with product on ice for 30 
min. Heat-pulse the competent cell reaction in a 42 ºC waterbath for 45 sec, then return cells to ice 
for 2 min. Add 950 µL of pre-warmed (37 ºC) SOC media to the cells and incubate for 1 hr culture 
at 37 ºC, 250 rpm. After incubation, pellet the cells (12,000 g, 1 min) then resuspend the cells in 
200 µl fresh SOC media. Transfer the entire cell suspension and spread onto an LB agar plate 
containing appropriate selection antibiotic, for O/N incubation. 
2 DNA Protocols 
2.1 DNA Extraction Kits 
All plasmid preparations, purified PCR products and digestion products were eluted in H2O. All 
DNA elutions were quantified using a NanoDrop ND-1000 spectrophotometer and stored at 2 – 8 
°C for immediate use, or -20 °C for long term storage. 
For plasmid extraction, in the event that bacterial cell pellets could not be immediately prepared for 
extraction, the pellets were stored at -80 °C.  
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*Several different microcentrifuges were used depending on availability; top speed ranges from 
21,000 g to 30,000 g. 
The Sigma Refrigerated Centrifuge 4K15 was used for the larger volume high speed refrigerated 
centrifugation, located in W312, Anderson Stuart Building. 
2.1.1 GenElute™ Plasmid Miniprep Kit  
Plasmid minipreps were performed using the GenElute™ Plasmid Miniprep Kit (PLN70 Sigma-
Aldrich) as per manufacturer’s instructions. Resuspension Solution and Wash Solution were 
prepared before first use of the kit as per manufacturer’s instructions. All elutions were prepared in 
100 µL deionised, filter sterilized H2O. 
Briefly, 3 – 5 mL of O/N culture was pelleted (12,000 g, 1 min). The cell pellet was resuspended in 
200 µL Resuspension Solution, lysed with 200 µL Lysis Solution then neutralised within 5 min 
with the addition 350 µL of Neutralisation Solution. The sample was centrifuged at top speed* for 
10 mins to precipitate cell debris. A capture column was prepared in a sample tube by passing 500 
µL Column Preparation Solution through (12,000 g, 1 min). Once the sample had finished 
centrifugation, the entire lysate was carefully transferred to the column (omitting precipitate) and 
passed through (15,000 g, 1 min). The column was washed by passing 750 µL Wash Solution 
through the column (15,000 g, 1 min) followed by complete wash solution removal (15,000 g, 2 
min). The column was transferred to a clean microfuge tube, 100 µL H2O was added to the column 
and incubated at RT for 5 min before elution (15,000 g, 1 min).  
2.1.2 PureLink® HiPure Plasmid Midiprep Kit  
Plasmid midipreps were performed using the PureLink® HiPure Plasmid Midiprep Kit (K210004 
Life Technologies) as per manufacturer’s instructions. Resuspension Buffer and Wash Buffer were 
prepared before first use of the kit as per manufacturer’s instructions. The alcohol precipitation 
process was conducted in aliquots of microcentrifuge tubes due to accessibility of refrigerated 
microcentrifuges. All elutions were prepared as 3 x 100 µL aliquots in endotoxin free, 
commercially filter sterilized H2O that were pooled. 
Briefly, 10 mL of Equilibration Buffer was passed through a midi column via gravity flow, and 25 - 
40 mL of O/N culture was pelleted (15,000 g, 1 min). The cell pellet was resuspended in 4 mL 
Resuspension Buffer, lysed with 4 mL Lysis Buffer then neutralised within 5 min with the addition 
4 mL of Precipitation Buffer. The sample was aliquoted evenly to microfuge tubes and centrifuged 
at top speed* for 10 mins to precipitate cell debris.  
Once the sample had finished centrifugation, the entire lysate was carefully transferred to the 
column (omitting precipitate) and passed through via gravity flow. The column was washed twice 
with 10 mL Wash Buffer until completely dry. The column was transferred to a clean 15 mL tube, 5 
mL Elution Buffer was added to the column and the elution captured for alcohol precipitation. 
3.5 mL isopropanol was added to the elution, the elution was evenly distributed amongst 6 
microfuge tubes (i.e. 1.4 mL each tube) and centrifuged at top speed* at 4 °C for 30 min to pellet the 
plasmid DNA. The supernatant was carefully removed from the elution tubes, the DNA pellets were 
washed and pooled into 3 microfuge tubes in 70% (v/v) ethanol (total volume 3 mL i.e. 1 mL each 
tube). The elution tubes were again centrifuged at top speed* at 4 °C for 5 min and the supernatants 
carefully removed. The DNA pellets were left to air dry for 10 – 20 mins, then each tube 
resuspended in 100 µL H2O. Plasmid elutions of the same sample were pooled prior to 
quantification. 
2.1.3 JetStar® LFU Plasmid Maxiprep Kit 
Plasmid maxipreps from earlier work (Jan 2015 – Dec 2016) were performed using the JetStar® 
LFU Plasmid Maxiprep Kit (G221020 Astral Scientific) as per manufacturer’s instructions. Cell 
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Resuspending Buffer and Wash Buffer were prepared before first use of the kit as per 
manufacturer’s instructions. All elutions were prepared in 800 µL deionised autoclaved H2O. 
Briefly, 30 mL of Equilibration Buffer was passed through a maxi column / filter cartridge unit via 
gravity flow, and 100 - 250 mL of O/N culture was pelleted (3,000 g, 15 min). The cell pellet was 
resuspended in 10 mL Cell Resuspending Buffer, lysed with 10 mL Lysis Buffer then neutralised 
within 5 min with the addition 10 mL of Precipitation Buffer. The entire precipitated lysate was 
transferred to the column / filter unit and passed through via gravity flow. The column / filter unit 
was washed with 50 mL Wash Buffer until completely dry. The filter unit was disposed, the column 
was transferred to a clean 50 mL tube, 15 mL Elution Buffer was added to the column and the 
elution captured for alcohol precipitation. 10.5 mL isopropanol was added to the elution and 
centrifuged at 25,000 g, 4 °C for 30 min to pellet the plasmid DNA. The supernatant was carefully 
removed from the elution tube and the DNA pellet was washed in 5 mL 70% (v/v) ethanol. The 
elution tube was again centrifuged at 25,000 g, 4 °C for 5 min and the supernatant carefully 
removed. The DNA pellet was left to air dry for 10 – 20 mins, then resuspended in 800 µL H2O in a 
rotating mixer O/N at 2 - 8 °C. 
2.1.4 Genelute™ HP Plasmid Maxiprep Kit 
Plasmid maxipreps from later work (Jan 2017 onward) were performed using the Genelute™ HP 
Plasmid Maxiprep Kit (NA0310-1KT Sigma-Aldrich) as per manufacturer’s instructions. 
Resuspension Solution and Wash Solution 2 were prepared before first use of the kit as per 
manufacturer’s instructions. All elutions were prepared in 3 mL endotoxin free, commercially filter 
sterilized H2O.  
Briefly, 100 - 350 mL of O/N culture was pelleted (3,000 g, 15 min). The cell pellet was 
resuspended in 12 mL Resuspension Solution, lysed with 12 mL Lysis Solution then neutralised 
within 5 min with the addition 12 mL of chilled Neutralisation Solution. 9 mL of Binding Solution 
was added to the lysate and the entire precipitated lysate was transferred to a syringe / filter unit and 
left to stand at RT for 5 min, to separate cell debris aggregate from the solution. 12 mL of Column 
Preparation Solution was passed through a column (3,000 g, 2 min) then the cell lysate was passed 
through the syringe / filter unit into the column (3,000 g, 2 min). The column was washed with 12 
mL Wash Solution 1 (3,000 g, 2 mins) and 12 mL Wash Solution 2 (3,000 g, 5 min) until 
completely dry. The column was transferred to a clean 50 mL tube, 3 mL H2O was added to the 
column and incubated at RT for 5 min before elution (3,000 g, 5 min).  
2.1.5 Nucleospin® DNA Purification kit  
DNA purifications from PCR reactions, RE digestions or agarose gels were performed using the 
Nucleospin® DNA Purification kit (740609.1 Scientifix) as per manufacturer’s instructions. Buffer 
NT3 was prepared before first use of the kit as per manufacturer’s instructions. All elutions were 
prepared in 30 µL deionised, filter sterilized H2O. 
Briefly, DNA from PCR/digestion reaction, or excised from agarose gel bands were combined with 
equal volumes of Buffer NT1 and deionised, filter sterilized H2O. The sample was well mixed, then 
transferred and passed through a capture column (11,000 g, 30 sec). The column was washed twice 
by passing 700 µL Buffer NT3 through the column (11,000 g, 30 sec) followed by complete Buffer 
NT3 removal (11,000 g, 1 min). The column was transferred to a clean microfuge tube, 30 µL H2O 
was added to the column and incubated at RT for 1 min before elution (11,000 g, 1 min).  
2.2 Sample Preparation for Sequencing (AGRF) 
Plasmid elutions were prepared for Sanger Sequencing at AGRF as purified DNA (PD) samples as 
follows: 
 1 µL of [10 µM] sequence primer 
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 1 µg purified plasmid DNA (volume dependant on DNA concentration) 
 H2O up to total volume 12 µL 
AGRF additional recommendations for sample preparation:  
 0.6 – 1.5 µg total plasmid double stranded DNA. 
 Primer Tm to be between 55 – 60 °C. 
 Repetitive freeze-thaw of primers / template DNA causes degradation. 
 DNA quantitation via agarose is preferred over spectrophotometry as values from 
absorbance ratios can overestimate concentration in contaminated samples. 
Forward and reverse sequencing primers were prepared as 2 separate sequencing samples for each 
plasmid isolate.  
Few isolates had a very low DNA concentration and were prepared neat (i.e. 11 µL, no additional 
H2O) for sequencing. 
2.3 Agarose Gel Electrophoresis 
DNA fragments were analysed for size and quality using agarose gel electrophoresis. Equipment to 
cast and run the gels was sourced from the Bosch Institute, The University of Sydney. Bio-Rad 
Mini Gel casters were used to prepare gels.  
Gels were prepared as 0.8% - 1.2% (w/v) agarose in 1 x TAE buffer, stained with 0.004% (v/v) 
SYBR® Safe nucleotide stain (S33102 Life Technologies). 
A Bio-Rad Mini-Sub Cell GT system was used to perform electrophoresis, with the gels submerged 
in Tris-acetate-EDTA (1 x TAE) buffer, running at 70 - 80V for 15 - 30 mins. Gel electrophoresis 
was monitored and stopped when the samples gel loading dye migrated between ⅓ to ½ through the 
gel.  
Gels were imaged (1.5 sec exposure) on a Bio-Rad Gel Doc™ XR system and analysed using Bio-
Rad Image Lab 5.2.1 software. 
For resolution of larger fragments (1 – 10 kb; 10 kb ladder), 0.8% agarose was used. For resolution 
of smaller fragments (0.1 – 1 kb; 100 bp ladder), 1.2% agarose was used. Intermediate fragment 
sizes were run on 1 % agarose.  
Stock TAE buffer (25x) 
Deionised H2O containing: 
 1 M (121 g/L) Tris base (BIOTB0196 Astral Scientific) 
 25 mM (7.3 g/L) EDTA (E6758 Sigma-Aldrich) 
 0.5 M (28.6 mL/L) Glacial acetic acid (27225 Sigma-Aldrich) 
Combine ingredients to the desired volume. Keep stock buffer sealed until use.  
Prepare 1 x TAE buffer freshly for use to the desired volume in deionised H2O. 
2.3.1 Agarose Gel Casting  
Using clean, dry casting equipment, seal the sides of a mini-gel caster with masking and tape and 
place desired well combs into the caster holders. 
To a glass flask, add 25 mL 1 x TAE and agarose to the desired concentration i.e. 0.2 g (0.8 %), 
0.25 g (1 %) or 0.3 g (1.2 %). 
Microwave the solution in 30 sec increments until agarose fully dissolves and solution is gently 
bubbling (gently swirl the solution between increments). Take precautions for handling super-
heated fluid and glassware. 
190 
 
 
Set solution to cool on the bench until it can be handled by hand. Once cooled, add 1 µL SYBR® 
Safe nucleotide stain and gently swirl through the solution.  
Pour the solution into the casting tray, remove bubbles with a disposable pipette and allow the gel 
to set for 30 mins, RT. Once set, remove well combs and masking tape from gel.  
In preparation for electrophoresis, place gel in Mini-Sub Cell tank and fill tank with 1 x TAE until 
the gel is completely submerged. If the gel is not for immediate use, store the gel in a zip-lock bag 
with 20 mL 1 x TAE and refrigerate until use. 
2.3.2 DNA Preparation for Loading into Gels 
For a size and resolution reference in each prepared gel, 2 µL of prepared DNA ladder (i.e. 200 ng 
DNA) was directly loaded into gel wells. 100 bp (N3231S Genesearch) and 1 kb (N3232S 
Genesearch) DNA ladders were prepared to 100 ng/µL with 6 x gel loading dye (made to 1 x) and 
deionised H2O.  
Colony PCR products from OneTaq Quick-Load mastermix (M0486L Genesearch) may be loaded 
directly as the PCR mastermix contains loading dye that does not interfere with the PCR reaction. 5 
µL of colony PCR product was directly loaded into gel wells. 
Purified DNA samples and digestion/ligation products require to be mixed with 6 x gel loading dye 
(B7025 Genesearch) to be visualised in the gel through the electrophoresis run. 20 – 100 ng of 
purified sample DNA is clearly visible and resolvable; digestion/ligation products may be added 
without prior measurement. 
To prepare DNA samples for loading: 
On a sheet of parafilm load 1 µL of 6 x gel loading dye, an appropriate volume of DNA sample 
(e.g. 1.5 µL) and a volume of deionised H2O to make up to 6 µL. Mix well via pipette, then transfer 
the entire sample to be loaded into a gel well. 
3 Tissue Culture Protocols 
293F and CHOS cells were routinely cultured in suspension, serum free media (SFM) for protein 
expression. SK-BR3 and CHO-K1 cells were routinely cultured in adherent conditions, with 10% 
serum addition to media. For certain experiments, 293F and CHOS were also cultured in adherent 
conditions for stable transfection studies, and were adapted to suspension SFM culture. 
3.1  Maintenance Media, Reagents and Culture Conditions 
All tissue cultures were maintained at 37 °C, 5% CO2, humidified conditions. Suspension cultures 
were further maintained at 120 rpm on an orbital shaker.  
Suspension cultures were routinely maintained in 125 mL single use sterile baffled Erlenmeyer 
culture flasks (CLS431405 Sigma-Aldrich) or scaled up in pre-autoclaved, sealed 250 mL / 500 mL 
baffled flasks for protein expression experiments.  
Small scale (maintenance):  
125 mL flask containing 10 – 35 mL culture (routinely 30 mL) 
Medium scale (scale up):  
250 mL flask containing 40 – 80 mL culture (routinely 60 mL) 
Large Scale (protein expression):  
500 mL flask containing 90 - 150 mL culture (generally 120 mL) 
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Adherent cultures were routinely maintained in T75 flasks (CORN430641U Bio-Strategy), small 
volume work and resuscitation performed in T25 flasks and scale up for experiments and 
cryopreservation in T182 flasks. 
Small scale (resuscitation):  
T25 flask containing 3 - 8 mL culture (routinely 5 mL) 
Medium scale (maintenance):  
T75 flask containing 10 - 20 mL culture (routinely 15 mL) 
Large Scale (cryopreservation):  
T182 mL flask containing 25 - 50 mL culture (routinely 35 mL) 
100 x Surfactant Supplement: 
Prepare 10% (w/v) Kolliphor P 188 Lutrol F68 (Pluronic F-68) stock solution (K4894 Sigma-
Aldrich) in deionised H2O. Sterilize by passing through a 0.22 µm filter, keep sealed and refrigerate 
until use. 
Pen-Strep: 
Penicillin-Streptomycin (10,000 U/mL) solution (15140-122 Life Technologies). Prepare 5 mL 
aliquots and store at – 20 °C until use. 
L-Glutamine: 
GlutaMAX™ Supplement (35050-061 Life Technologies);  
i.e. 200 mM L-Glutamine. Store at – 20 °C until use. 
Trypsin-EDTA stock:  
Trypsin-EDTA (0.5%) solution (15400-054 Life Technologies). Store at – 20 °C until use. 
293F EM: 
FreeStyle™ 293 Expression Medium (12338018 Life Technologies) supplemented with: 
 Additional 1% (v/v) 100 x surfactant supplement 
 Additional 1% (v/v) Pen-Strep 
 
CHOS EM: 
FreeStyle™ CHO Expression Medium (12651014 Life Technologies) supplemented with: 
 Additional 1% (v/v) 100 x surfactant supplement 
 Additional 0.5% (v/v) Pen-Strep 
 Additional 8 mM L-Glutamine 
 
CD CHO EM: 
CD CHO Medium (10743029 Life Technologies) supplemented with: 
 Additional 1% (v/v) 100 x surfactant supplement 
 Additional 1% (v/v) Pen-Strep 
 Additional 6 mM L-Glutamine 
 
PBS: 
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Deionised H2O containing 1 phosphate buffered saline (PBS) tablet per 100 mL (09-2051-100 
Astral Scientific). Sterilize by autoclave or by passing through a 0.22 µm filter, keep sealed and 
refrigerate until use. 
1 x Trypsin-EDTA: 
Prepare PBS containing 10% v/v Trypsin-EDTA stock. Sterilize by passing through a 0.22 µm 
filter, keep sealed and refrigerate until use. 
 
RPMI: 
RPMI 1640 Medium (21870076 Life Technologies) supplemented with: 
 Additional 10% (v/v) FBS (10082-147 Life Technologies) 
 Additional 1% (v/v) Pen-Strep 
 Additional 6 mM L-Glutamine 
 
DMEM/F-12: 
Prepare 50% DMEM (11995-065 Life Technologies) and 50% Ham's F-12K Media (21127-022 
Life Technologies) supplemented with: 
 Additional 10% (v/v) FBS (10082-147 Life Technologies) 
 Additional 1% (v/v) Pen-Strep 
Keep all in use stocks and prepared media sealed and refrigerated until use.  
3.2 Cell Counting 
All cell counting was performed using trypan blue exclusion method, using 0.4% Trypan Blue 
solution (AMK940 Astral Scientific). Live cells are identified as clear with a halo against a light 
blue background, dead cells are stained dark blue. Live cells, dead cells, total cells and viability are 
calculated from cell counts. 
Cell counts from earlier work (Jan – Dec 2015) were performed on a Countess automated cell 
counter (Invitrogen) using Countess Chamber slides (C10228 Life Technologies).  
Briefly, an aliquot of cell suspension was mixed with an equal volume of trypan blue solution in an 
Eppendorf tube. 10 µL of stained cells was dispensed into a countess chamber and the chamber was 
loaded into the countess for measurement.  
The countess was turned on and focused prior to taking measurement; viability and total, live and 
dead cell concentration was reported directly from the machine. Measurements were conducted in 
duplicate to get an average set of values. 
Cell counts from later work (Jan 2016 onwards) were performed on a haemocytometer, read under a 
microscope at 10 x magnification. 
Briefly, 10 µL of cell suspension was mixed with an appropriate volume of trypan blue solution in 
an Eppendorf tube (the dilution factor to be noted for calculation). That is, routinely 40 µL for 
adherent cells, 90 µL for suspension maintenance cultures and 190 µL for transfection harvest 
cultures.  
The haemocytometer is set up with a coverslip, 10 µL of stained cells was added to a chamber of 
the haemocytometer and the chamber was examined under a microscope at 10 x magnification.  
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Of the 9 squares that comprise the grid pattern in the chamber, 4 full squares were examined and 
counted for live and dead cells to take average values and derive total cells and viability. To convert 
to concentration (cells/mL), the cell values were multiplied by 104, then by the dilution factor. 
Viability was calculated as the percentage of live cells from total cells. 
3.3 Suspension 293F / CHOS Culture Maintenance 
FreeStyle™ 293F cells (293F) were a kind donation from Dr Mario Torrado del Rey, Prof Joel 
Mackay’s research group.  
Freestyle™ CHO-S cells (CHOS) were purchased from Life Technologies (R80007). 
Suspension 293F and CHOS cells are passaged when cell density reaches 2 – 3 x 106 cells/mL, 
seeding the new culture at 2 – 3 x 105 cells/mL.  
293F culture has a 24 hr cell doubling rate, and is recommended to passage every 3 – 4 days at a 
seed of 3 x 105 cells/mL. 293F culture is maintained in 293F EM. 
CHOS culture has an 18 hr cell doubling rate and is recommended to passage every 2 – 3 days at a 
seed of 2 x 105 cells/mL. CHOS culture is maintained in CHOS EM and/or CD CHO EM. 
Maintenance culture (30 mL) passage protocol 
When a culture is due for passage: 
 Take a cell count to derive number of live cells per mL 
 Calculate the volume of culture required to seed a new passage (30 mL) 
 Transfer the volume of culture to a centrifuge tube 
 Pellet the cells via centrifugation (300 g, 5 min) 
 Remove the supernatant, agitate the cell pellet (flicking) 
 Resuspend the cell pellet in 5 mL fresh maintenance EM 
 Transfer the suspended cells to a new 125 mL flask with a further 25 mL fresh maintenance 
EM 
 Label the flask with cells, passage number, passage date, initial 
 Incubate the culture 
3.4 Suspension 293F / CHOS Cryopreservation and Resuscitation 
Suspension 293F and CHOS cells require to be preserved at 1 x 107 cells/mL in cryopreservation 
media. 
Cryopreservation media  
Maintenance EM containing 10% (v/v) DMSO; filter sterilised 
Suspension cells cryopreservation protocol 
For a culture that is ready to be cryopreserved: 
 Take a cell count to quantify the total amount of live cells in the culture 
 Pellet the cells of the entire culture via centrifugation (300 g, 5 min) 
 Remove the supernatant; agitate the cell pellet (flicking) 
 Calculate amount of cryopreservation media needed and prepare 
 Resuspend cells evenly in cryopreservation media 
 Aliquot 1 mL cell suspension into pre-labelled cryovials 
 Transfer cryovials to a Mr Frosty rack (prepared with fresh isopropanol) 
 Transfer the Mr Frosty rack to -80 °C freezer for O/N storage 
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 Transfer the vials from the -80 °C Mr Frosty rack to liquid nitrogen for long term storage 
For resuscitation of cells from a cryovial, the vial needs to be kept frozen (minimum in dry ice) 
until such time that it is ready for immediate thaw and transfer into media, as DMSO is toxic to 
cells and can reduce cell viability over prolonged exposure time. 
Resuscitation of cells for suspension culture protocol: 
 Prepare a tube with 4 mL pre-warmed maintenance EM 
 Retrieve vial from liquid nitrogen and thaw in 37 °C water-bath 
 Gently mix the thawed cell suspension with a pipette then transfer to the tube containing 
media 
 Pellet the cells via centrifugation (300 g, 5 min) 
 Remove the supernatant; agitate the cell pellet (flicking) 
 Resuspend the cell pellet in 5 mL fresh maintenance EM 
 Transfer the suspended cells to a new 125 mL flask with a further 10 mL (293F) or 20 mL 
(CHOS) fresh maintenance EM 
 Label the flask with cells, passage number, passage date, initial 
 Incubate the culture; monitor cell counts daily to determine next passage 
3.5 Adherent SK-BR3 / CHO-K1 WT Culture Maintenance 
SK-BR3 cells were a kind donation from A/Prof Thomas Grewal’s research group. 
CHO-K1 cells were a kind donation from Dr Alryel Yang, Dr Ingrid Gelissen’s research group. 
Adherent cultures have their media replenished when the media colour changes from red to 
orange/yellow and are passaged when confluency reaches 70 – 90%. 
SK-BR3 culture has a growth doubling rate of 7 days, and is recommended to replenish media after 
4 days and passage at 7 days at a 50% seed in RMPI. 
CHO-K1 culture has a growth doubling rate of 24 hrs, as is recommended to passage at 3 days at 
25% seed in DMEM/F-12. 
Maintenance culture (15 mL) passage protocol 
When a culture is due for passage: 
 Remove the culture media and wash the cell layer twice with 5 mL PBS 
 Add 3 mL 1 x Trypsin-EDTA to cell layer 
 Incubate flask at 37 °C for 5 min 
 Add 9 mL maintenance media to the flask 
 Gently dissociate the cell layer via pipette 
 Transfer seed amount of cell suspension to new T75 flask  
(i.e. 3 mL for 25% seed, 6 mL for 50%) 
 Add further maintenance media to flask to total 15 mL volume 
 Label the flask with cells, passage number, passage date, initial 
 Incubate the culture 
3.6 Adherent SK-BR3/CHO-K1 WT Cryopreservation and Resuscitation 
Adherent SK-BR3 and CHO-K1 cells require to be preserved at 3 x 106 cells/mL in 
cryopreservation media. 
Cryopreservation media:  
Maintenance media containing 5% (v/v) DMSO; filter sterilised 
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Adherent culture cryopreservation protocol 
For a culture that is ready to be cryopreserved: 
 Prepare cell suspension as outlined above for cell passage 
 Take a cell count to quantify the total amount of live cells in the culture 
 Pellet the cells of the entire culture via centrifugation (300 g, 5 min) 
 Remove the supernatant; agitate the cell pellet (flicking) 
 Calculate amount of cryopreservation media needed and prepare 
 Resuspend cells evenly in cryopreservation media 
 Aliquot 1 mL cell suspension into pre-labelled cryovials 
 Transfer cryovials to a Mr Frosty rack (prepared with fresh isopropanol) 
 Transfer the Mr Frosty rack to -80 °C freezer for O/N storage 
 Transfer the vials from the -80 °C Mr Frosty rack to liquid nitrogen for long term storage 
For resuscitation of cells from a cryovial, the vial needs to be kept frozen (minimum in dry ice) 
until such time that it is ready for immediate thaw and transfer into media, as DMSO is toxic to 
cells and can reduce cell viability over prolonged exposure time. 
Resuscitation of cells for suspension culture protocol: 
 Prepare a tube with 4 mL pre-warmed maintenance media 
 Retrieve vial from liquid nitrogen and thaw in 37 °C water-bath 
 Gently mix the thawed cell suspension with a pipette then transfer to the tube containing 
media 
 Pellet the cells via centrifugation (300 g, 5 min) 
 Remove the supernatant; agitate the cell pellet (flicking) 
 Resuspend the cell pellet in 1 mL fresh maintenance media 
 Transfer the suspended cells to a new T25 flask with a further 4 mL  fresh maintenance 
media 
 Label the flask with cells, passage number, passage date, initial 
 Incubate the culture; monitor cell counts daily to determine next passage 
3.7 Reagents for Protein Expression 
Commercial reagents for transfections include: 
OptiPRO™ Serum free media (SFM) (12309-050), Freestyle™ MAX Transfection reagent (16447-
100) and Lipfectamine™ 2000 Transfection reagent  (11668-027) from Life Technologies.  
 
Along with these commercial reagents, 1 mg / mL PEI solution is prepared for transfection as per 0.  
Reagents prepared as supplements to support cell viability and protein expression include Tryptone 
(0) and VPA (0), prepared as 40 x stock solutions. 
1 mg/mL Polyethylenimine, 25 kDa, linear (PEI)  
PEI is not readily dissolved in H2O at RT, it forms a white suspension. To prepare a PEI solution, it 
is recommended to heat the H2O up to 80 °C prior to addition of PEI and to adjust the suspension to 
pH 7.0 with HCl. 
Prepare a PEI (23966-2 BioScientific) 1 g/L stock solution in deionised H2O.  
Adjust to pH 7.0 with HCl and sterilize by passing through a 0.22 µm filter. 
Prepare as 1.2 mL aliquots in microfuge tubes, keep aliquots at -80 °C until use.  
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40 x Tryptone stock 
Prepare 20% (w/v) tryptone (casein peptone) (LP0042B Thermo Fisher Scientific) stock solution in 
PBS and autoclave.  
Keep stock solution sealed and refrigerated until use.  
40 x Valproic Acid (VPA) stock 
Prepare valproic acid sodium salt (P4543 Sigma-Aldrich) 140 mM stock solution in PBS and 
sterilize by passing through a 0.22 µm filter. 
Keep stock solution sealed and refrigerated until use.  
4 Antibody Purification and Characterisation Protocols 
Transfection cultures were harvested for antibody purification by centrifugation (3,000 g, 15 mins). 
The culture supernatant was decanted and further clarified by vacuum filtration, using Corning® 
0.22 μm bottle-top vacuum filter units (CLS430513 Sigma-Aldrich). 
Antibodies were purified from clarified supernatant through Protein A affinity chromatography, 
performed on an ÄKTApurifier 100 FLPC system using Unicorn 5.11 system and analysis software 
(GE Healthcare).  
Antibody purifications from earlier work (Jan 2015 – Mar 2018) were performed on a 5 mL 
HiTrap® Protein A High Performance column (GE17-0403-01 Sigma-Aldrich). Antibody 
purifications from later work (Apr 2018 – onwards) were performed on a 1 mL HiTrap® MabSelect 
Sure column (29-0491-04 GE Healthcare).  
Purified antibodies were buffer exchanged to PBS and concentrated in centrifugal filters prior to 
further characterisation, stability and biological assays. Antibody samples were quantified through 
UV absorption at 280 nm prior to normalisation of sample concentrations for assays. Antibody 
samples were characterised through reducing and non-reducing SDS-PAGE for purity, LC-MS/MS 
for confirmation of peptide sequence and glycosylation of antibody samples and SE-HPLC for size 
distribution analysis. 
4.1 FPLC Buffers and Protocol: 
The FPLC system was set up prior to purification with the method program, column connected to 
the system and washed, supernatant samples, buffers and elution collection tubes as detailed in 
Chapter 3.  
Antibody purification was performed on the FPLC system under the following conditions: 
 All system operations at 1 mL/min 
 Pass 5 column volumes (CV) of binding buffer through the system to equilibrate the column 
 Allowing 5 mL dead volume, pass the entire sample volume through the system; the 
antibody is captured in the column 
 Pass 5 CV of binding buffer through the system to wash the column 
 Pass 5 CV elution buffer through the system to disassociate the captured antibody from the 
column 
 Isocratic fractionation of elutions;  
 100 μL neutralisation buffer added to each elution collection tube in preparation of 
capturing the elution fractions 
 Pass 5 column volumes (CV) of binding buffer through the system to equilibrate the column 
FPLC was conducted with continuous monitoring of change in system pH, conductivity and UV 
absorption at 280 nm, producing chromatograms that demonstrate the performance of antibody 
capture and elution through the run. 
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Prepared buffers were sterilized and degassed by passing through a 0.22 µm vacuum filter unit prior 
to use on FPLC. 
Binding Buffer 
Deionised H2O containing 1 phosphate buffered saline (PBS) tablet per 100 mL (09-2051-100 
Astral Scientific), adjusted to pH 7.4. 
Elution Buffer 
Elution buffer for the HiTrap® Protein A column was deionised H2O containing 0.1 M glycine HCl 
(G2879 Sigma-Aldrich), adjusted to pH 2.7. 
Elution buffer for the HiTrap® MabSelect Sure column was deionised H2O containing 0.1 M 
glycine HCl (G2879 Sigma-Aldrich), adjusted to pH 3. 
Neutralisation Buffer 
Antibody purifications from earlier work (Jan 2015 – Apr 2017) used neutralisation buffer 1 M 
Tris-HCl pH 9 (BIOSD814 Astral Scientific). 
Antibody purifications from later work (May 2017 – onwards) used neutralisation buffer 1 M Tris-
HCl pH 8 (15568-025 Life Technologies). 
4.2 Buffer Exchange, concentration and quantification 
Elution fractions from FPLC runs were measured on a Shimadzu UV-Visible Spectrophotometer 
(UV-Vis); an absorbance peak at 280 nm indicated the presence of protein.  
Fractions that contained protein were pooled together (and the remainder discarded). Pooled 
fractions were buffer exchanged and concentrated in PBS using Amicon® 50 kDa centrifugal filters 
(Z740194, Z740177 Sigma-Aldrich) following manufacturing instructions for centrifugation 
conditions. 
Concentrated antibody elutions were measured on a UV-Vis for absorbance at 280 nm and their 
concentrations were derived from the Beer Lambert Law. 
 A = ε.c.ℓ    →    c = A/ε.ℓ   where: 
c = concentration (M)       A = absorbance (abs)  
ε = molar attenuation coefficient (M-1cm-1)  ℓ = pathlength (cm) 
For unit conversions from molarity to weight, the mass attenuation (aka extinction) coefficient for 
each species is derived by dividing ε by the species molecular mass (i.e. g-1L-1). 
The above formula was used with extinction coefficients 1.48 g-1L-1 for trastuzumab and 1.39 g-1L-1 
for adalimumab as reported from original patents and publications. 
Antibody samples were sterilized by passing through a 0.22 µm filter, prepared as small labelled 
aliquots in microfuge tubes and stored at -80 °C until use.  
The concentration of samples derived from the UV absorbance was used as reference for all further 
experiments. 
4.3 Purity Determined by SDS PAGE Analysis 
Purity of antibody samples (protein content) was determined by 10% (acrylamide) reducing and 
non-reducing SDS PAGE analysis and visualised with Coomassie Blue R-250 stain (786-498 Astral 
Scientific).  
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All SDS-PAGE chemicals were purchased from Astral Scientific. Gels were cast manually and 
separation performed on a Bio-Rad Mini-PROTEAN® Tetra Vertical Electrophoresis System. 
Imaging was performed on a Bio-Rad Gel Doc™ XR system and analysed using Bio-Rad Image Lab 
5.2.1 software. 
Antibody expected reduced bands at 50 – 60 kDa (TH/AH) and 25 - 30 kDa (TL/AL) and non-
reduced band at 150 - 165 kDa (whole antibody).  
Further bands indicate possible contaminants such as leached protein A, host cell protein and 
antibody degradation products.  
4.4 Sequence and Glycosylation Confirmed by LC-MS/MS Analysis 
Purified antibodies and mutants were confirmed of the predicted amino acid sequence and 
introduction of glycosylation motifs through site-specific liquid chromatography tandem mass 
spectrometry (LC-MS/MS).  
Briefly, purified antibody samples were separated on reducing SDS-PAGE and digested with 
trypsin and chymotrypsin. For glycosylated antibody mutants, a fraction of the digestions was 
further treated with PNGase F for glycan release. The digestion products were analysed by LC-
MS/MS using higher-energy collisional dissociation (HCD), collision induced dissociation (CID) 
and electron transfer dissociation (ETD) methods. 
4.4.1 Reducing SDS PAGE Separation and Peptide Digestion 
Trypsin 
Trypsin from porcine pancreas Proteomics Grade (T6567 Sigma-Aldrich) 
Incubate 1 µg trypsin to every 50 µg protein at 37 °C, O/N. 
Chymotrypsin 
Chymotrypsin Sequencing Grade from bovine pancreas (11418467001 Sigma-Aldrich) 
Incubate at RT, O/N. 
PNGase F 
PNGase F Recombinant (P0708 Genesearch) 
Incubate 400 units PNGase F to every 1 µg protein at 37 °C, O/N. 
10 μg samples were run on a 10% reducing SDS-PAGE and in-gel trypsin digestion was performed 
on the heavy and light chain bands. The bands were excised, diced and washed with 50% (v/v) 
acetonitrile (MeCN) in 100 mM NH4HCO3. The gel pieces were reduced with 10 mM DTT (56 °C, 
45 min) then alkylated with 55 mM iodoacetamide (IAA) in 100 mM NH4HCO3 (25 °C, 30 min).  
The alkylated polypeptide samples were washed with 50% (v/v) MeCN in 100 mM NH4HCO3, then 
incubated with trypsin in 50 mM NH4HCO3 pH 6.8. The tryptic peptides were further digested with 
chymotrypsin in 100 mM Tris-HCl, 10 mM CaCl2 pH 7.8.  
For glycosylation mutant samples, a fraction of the chymotryptic peptides was incubated with 
PNGase F in 50 mM sodium phosphate buffer pH 7.5.  
All chymotryptic peptides and de-glycosylated fractions were desalted with C18 Millipore Ziptips 
(Z720070 Sigma-Aldrich), eluted in 80% (v/v) MeCN, dried by vacuum centrifugation then 
redissolved in 0.1% formic acid (FA) for LC-MS/MS analysis. 
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4.4.2 LC-MS/MS Operation and Analysis 
Glycopeptides and de-glycosylated peptides were separated on an in-house packed 20 cm × 75 μm 
Reprosil-Pur C18-AQ column, 3 μm, 120 A (r13.aq Dr. Maisch GmbH) using a Thermo Fisher 
Dionex™ 3500RS HPLC over a 90-min 0-40% solvent B gradient at a flow rate of 300 nL/min, at 
60 °C (solvent A was 0.1% (v/v) formic acid; solvent B was 80% (v/v) acetonitrile and 0.1% formic 
acid).  
MS analysis was performed on an Orbitrap Fusion™ Tribid™ mass spectrometer (Thermo Scientific) 
in positive mode. The initial MS scan was acquired in the Orbitrap mass analyzer (350–2000 m/z; 
MS AGC = 6 × 105) with a resolution of 60,000 at 400 m/z. 
MS1 was followed by data-dependent HCD using top speed, where as many dependant scans as 
possible are acquired in a specified time. HCD fragmentation was followed by re-isolation of the 
top two most intense precursors, and fragmentation with CID and ETD MS/MS.  
Instrument parameters:  
 Source voltage = 2.3 kV 
 S-lens RF level = 68% 
 Capillary temperature = 275 °C 
 
HCD parameters:  
 Activation time = 0.1 ms 
 Resolution = 30,000 
 Maximum injection time = 200 ms 
 Dynamic exclusion = enabled with repeat count 1 
 Normalized energy = 40 
 Exclusion duration = 20 s 
 Default charge state = 2 
 MSn AGC 2.0e5 
 
CID parameters:  
 30,000 resolution in orbitrap  
 Activation time = 10 ms 
 Max injection time = 300 ms 
 Dynamic exclusion = enabled with repeat count 1 
 Normalized energy = 35 
 Exclusion duration = 20 s 
 Fefault charge state = 2 
 MSn AGC 5.0e4 
 
ETD parameters:  
 30,000 resolution in orbitrap 
 5.0e4 AGC 
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 ETD reaction time = 50 ms 
 Max injection time = 300 ms 
 
Peptide spectrum matches (PSM) were generated through a search against the corresponding fasta 
file (native antibody or predicted mutation amino acid sequence) utilising the search engine Byonic 
(Protein Metrics Inc.). Annotation of the HCD and ETD spectra were automated through Byonic 
and the PSM assignments were validated by manually annotating the aforementioned spectra and 
the complementary CID spectrum. Further confirmation of the identity assignment was achieved 
through analysis of the de-glycosylated chymotryptic peptides utilising the same LC-MS/MS 
approach as for the glycosylated fraction. 
4.5 Size Distribution of Antibody Samples Determined by SE-HPLC 
Antibody samples prepared for size distribution analysis were characterised by size-exclusion high-
performance liquid chromatography (SE-HPLC) performed on an Agilent™ 1200 Liquid 
Chromatography system, using ChemStation system and analysis software (Agilent Technologies). 
For earlier work (2015 – 2017) SE-HPLC was performed on a 7.8 x 300 mm, 5 µm particle size 
TSKgel® G3000SWXL HPLC column (0008541) coupled to a 6 x 40 mm TSKgel
® SWXL guard 
column (0008543 Tosoh Bioscience GmbH), at a flow rate of 1 mL/min. 
For later work (2018) SE-HPLC was performed on a 4.6 x 250 mm, 4 µm particle size Zorbax GF-
250 HPLC column (884973-701) coupled to a 4.6 x 12.5 mm, 6 µm particle size Zorbax Diol guard 
column (82095-911 Agilent Technologies) at a flow rate of 0.5 mL/min. 
SE-HPLC was performed on the Agilent™ 1200 LC system running at 22 °C, with a mobile phase 
buffer of 150 mM potassium phosphate, pH 6.5. Samples were loaded into the system at varied 
injection volume (5 – 100 µL) depending on the assay requirements.  
Total protein in the sample was detected through UV absorption at 280 nm, producing 
chromatograms where different sized protein species eluted separately through the system. Higher 
molecular weight species eluted ahead of smaller species; antibody soluble aggregates, dimers, 
monomers and fragments were separately distinguished on chromatograms for analysis. Protein 
content of individual chromatogram peaks was determined by the area under the curve (AUC). 
Relative comparisons of monomer content were made between the AUC of each species in the 
sample and between samples, described as relative percentage monomer content or monomer loss 
(%). 
4.5.1 Reagents for HPLC 
Stock Solution 1:  
Prepare 1.5 M potassium phosphate monobasic (AJA391Thermo Fisher Scientific) in deionised 
H2O 
Stock Solution 2: 
Prepare 1.5 M potassium phosphate dibasic (AJA391Thermo Fisher Scientific) in deionised H2O 
Mobile Phase Buffer (150 mM potassium phosphate, pH 6.5): 
Combine 66.3 mL Stock Solution 1 with 33.7 mL Stock Solution 2, dilute to 1L with deionised 
H2O and adjust to pH 6.5. 
Buffers were freshly prepared, sterilized and degassed by passing through a 0.22 µm vacuum filter 
unit prior to use on HPLC. Solutions were kept sealed and refrigerated until use.  
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5 Affinity and Binding Kinetic Assays 
5.1 ELISA  
Antibody samples such as transfection culture supernatant and bulk mAb product were quantified 
through an ELISA protocol. This protocol was derived from a commercial ELISA kit: Affymetrix 
Human IgG total ELISA Ready-SET-Go!® (88-50550-22 Jomar Life Research). Samples required 
appropriate dilution (within the range of 1 – 100 ng/mL) for robust fitting to standard curve. All 
samples were measured in duplicate, including the standard curve which was generated from 
Herceptin. ELISA was performed in batches, each batch including a 1:2 serial dilution of Herceptin 
standard (from 100 > 1.5625 ng/mL concentration). ELISAs were performed in Corning high 
protein binding 8-well microplate strips (734-1514 Bio-Strategy), shaking incubations conducted on 
a Biosan PSU-10i orbital shaker (Fisher Biotech) at 400 rpm, and photometric measurements 
conducted on a Victor X plate reader (Perkin Elmer) at 450 nm. All reagents and sample dilutions 
were prepared to slight excess, as to minimise loss or load inaccuracy through serial pipetting. 
ELISA antibodies were pre-aliquoted and stored at -20 °C until use, all working reagents were 
refrigerated until use. 
Coating Antibody 
Prepare anti-human IgG (Fab specific) antibody produced in goat (I9010 Sigma Aldrich) as a 
1:10,000 dilution in PBS to the total volume required for the batch of samples (i.e. 100 µL per 
sample).  
Wash Buffer 
Prepare PBS with 0.05% (v/v) Tween 20 (P9416 Sigma-Aldrich). Keep solution in squidgy bottle 
for efficient aspiration into wells. 
Stock Buffer 
Deionised H2O containing: 
 20 x PBS (09-2051-100 Astral Scientific)  
 1% (v/v) Tween 20 (P9416 Sigma-Aldrich) 
 10% w/v BSA (BSAS 0.1 Bovogen) 
This stock will be diluted for the further buffers used in this assay. 
Blocking Buffer 
Dilute 1:10 Stock Buffer in deionised H2O 
Assay Buffer 
Dilute 1:20 Stock Buffer in deionised H2O 
Detection Antibody 
Prepare anti-human IgG (Fc specific) − Peroxidase antibody produced in goat (A0170 Sigma 
Aldrich) as a 1:20,000 dilution in Assay Buffer to the total volume required for the batch of samples 
(i.e. 100 µL per sample).  
Substrate Solution 
TMB ELISA substrate solution (T4444 Sigma Aldrich); bring to RT before use. 
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Stop Solution 
1M H3PO4 in deionised H2O (i.e. 1.5 mL 85 % (w/v) phosphoric acid (695017 Sigma Aldrich) in 21 
mL deionised H2O. 
Herceptin® Preparation for Standard Curves; sample dilutions 
Herceptin® 21 mg/mL was a kind donation from Genentech (USA).  
Prepare 500 µL 100 ng/mL Herceptin in Assay Buffer, then perform 6 subsequent 1:2 serial 
dilutions in 250 µL Assay Buffer.  
Assay Buffer is included for a blank [0 ng/mL] sample, totalling 8 standard samples for the standard 
curve. 
Samples are diluted in Assay Buffer to a minimum volume of 220 µL for duplicate measurement. 
Appropriate dilutions for supernatants of good yield span 1:200 – 1:500, and bulk mAb product 
diluted to 50 ng/mL as calculated from UV measurement at 280 nm. However, if fairly uncertain of 
the sample concentration then perform several different dilutions for testing (e.g. 1:2, 1:20, and 
1:200).  
5.1.1 ELISA Protocol 
 Set up 8-well strips in a plate according the amount needed for the batch  
 Prepare appropriate volume of Coating Antibody, load 100 µL to each well 
 Seal the wells and refrigerate the plate 2 - 8 °C O/N 
 Aspirate wells, wash wells twice with Wash Buffer, aspirate and tap dry 
 Prepare appropriate volume of Blocking Buffer, load 250 µL to each well 
 Seal the wells and incubate at RT for 2 hrs (or 2 - 8 °C O/N) 
 Aspirate wells, wash wells twice with Wash Buffer, aspirate and tap dry 
 Prepare sample and standard dilutions in Assay Buffer 
 Load 100 µL standard / sample to designated wells  
 Seal the wells and incubate at RT for 2 hrs, 400 rpm 
 Aspirate wells, wash wells four times with Wash Buffer, aspirate and tap dry 
 Prepare appropriate volume of Detection Antibody, load 100 µL to each well 
 Seal the wells and incubate at RT for 1 hr, 400 rpm 
 Aspirate wells, wash wells four times with Wash Buffer, aspirate and tap dry 
 Add 100 µL Substrate Solution to each well, incubate at RT for 10 – 20 mins 
 Add 100 µL Stop Solution to each well, measure on plate reader at 450 nm 
5.1.2 ELISA Analysis 
Measurements on the Victor X plate reader will give absorbance values for each well as depicted in 
A, with columns 1 and 2 elected for the standard curve samples, descending in concentration from 
the top row. Absorbance directly correlates to concentration; samples are comparable to the 
standard curve in the same batch if their absorbance values reside within the absorbance range of 
the standard curve. However, due to variability with incubation and loading times, the standard 
curve of one batch cannot be compared to another, therefore a curve must be generated with each 
batch. 
 Calculate the average absorbance value of the blank samples, then subtract that blank value 
across all the sample values.  
 Produce a 4-PL sigmoidal curve of the blank subtracted standard values (absorbance versus 
concentration) as depicted in B 
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 Interpolate all blank subtracted sample values to the standard curve 
 Multiply the interpolated concentrations by the appropriate sample dilution factor, to derive 
the original sample concentration 
 
5.2 HER2 Cell-binding Assay Reagents and Protocols 
Binding of trastuzumab antibodies to extracellularly expressed HER2 was detected through a cell-
binding endpoint affinity assay. Overexpressing HER2 cell line SK-BR3 was used for the assay. 
Briefly, antibody samples were incubated with SK-BR3 cells, the cells were washed and tagged 
with a FITC-anti human IgG secondary antibody. The cells were again washed and ran though flow 
cytometry to detect the level of green fluorescence per cell. Cell populations were defined as 
positive or negative binding fractions and plotted against antibody concentration on a sigmoidal 
binding curve. 
Versene Solution 
Prepare EDTA (E6758 Sigma-Aldrich) 0.5 mM stock solution in PBS and sterilize by passing 
through a 0.22 µm filter. 
Keep stock solution sealed and refrigerated until use.  
Dilution Buffer 
Prepare 2 mM EDTA (E6758 Sigma-Aldrich), 0.5% (w/v) BSA (BSAS 0.1 Bovogen) stock 
solution in PBS. Sterilize and degas by passing through a 0.22 µm vacuum filter. 
Keep stock solution sealed and refrigerated until use.  
Secondary Antibody 
Prepare anti-Human IgG (Fc specific) − FITC antibody produced in goat (F9512 Sigma Aldrich) as 
a 1:200 dilution in Dilution Buffer to the total volume required for the batch of samples (i.e. 100 µL 
per sample).  
Isotype (negative) Control 
A B 
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Prepare 100 µL of IgG1, Kappa from human myeloma plasma purified immunoglobulin (I5154 
Sigma-Aldrich) to 20 µg/mL in Dilution Buffer. 
Herceptin (positive) Control 
Herceptin® was a kind donation from Genentech (USA).  
Herceptin was buffer exchanged from its formulation to PBS in preparation of experiments (PBS-
Herc). 
Prepare 100 µL of PBS-Herc to 20 µg/mL in Dilution Buffer. 
5.2.1 SK-BR3 Cell Harvesting and Preparation 
SK-BR3 cells were harvested for the HER2 binding assay when the culture was due for passage (as 
per 3.5). As the culture is a 50% split for passage, the other 50% was used for the assay. 
When a culture is due for passage and harvest: 
 Remove the culture media and wash the cell layer twice with 5 mL PBS 
 Add 3 mL Versene Solution to cell layer 
 Incubate flask at 37 °C for 5 min 
 Observe for detachment and single cell release under the microscope 
 Add 9 mL maintenance media to the flask 
 Gently dissociate the cell layer via pipette 
 From the cell suspension, prepare 50% split for passage: 
o Transfer 6 mL of cell suspension to new T75 flask  
o Add 9 mL maintenance media to flask (total 15 mL volume) 
o Label the flask with cells, passage number, passage date, initial 
o Incubate the culture 
 With the remaining 50% (6 mL) cell suspension: 
o Take a cell count, calculate the total number of cells  
o Transfer to centrifuge tube and pellet the cells at 300 g, 5 min 
o Remove the supernatant, agitate the cell pellet (flicking) 
o Resuspend the cell pellet in 5 mL Dilution Buffer 
o Repeat pellet and wash with dilution buffer as per the last 3 steps 
o Repeat pellet, remove supernatant and resuspend the cell pellet in Dilution Buffer to 
a total concentration of 2 x 106 cells/mL 
o Prepare 50 µL aliquots of cells for samples in assay 
o Keep cells on ice / in the fridge for the duration of the assay 
 
5.2.2 Antibody Titrations and Cell Binding Assay 
For each antibody tested, an 8 sample titration series was performed in 1:2 serial dilutions from 20 
µg/mL. All sample dilutions were prepared to 100 µL in Dilution Buffer. In each batch, PBS-Herc 
was prepared as a positive control and a polyclonal IgG1/κ isotype was prepared as a negative 
control.  
50 µL of each sample dilution was added to an aliquot (50 µL) of cells. An additional wash control 
was prepared by adding 50 µL Dilution Buffer to an aliquot of cells. All cell aliquots were 
incubated at 4 °C, 20 mins. 
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The cell aliquots were washed twice as follows: the cells were pelleted (300g, 5 mins), the 
supernatant removed and the cell pellet resuspended in 1 mL Dilution Buffer. After performing 2 
wash steps, the cells were again pelleted and supernatant removed. 
The secondary antibody was prepared as a 1:200 dilution in Dilution Buffer according to the 
volume required for the batch (i.e. 100 µL per sample). All cell pellets were resuspended in 100 µL 
diluted secondary antibody and were further incubated at 4 °C, 20 mins. 
The cell aliquots were washed twice as described previously. After performing 2 wash steps, the 
cells were resuspended in 250 µL for detection on flow cytometry. Cell suspension samples 
remained on ice for the duration of the measurements. 
5.2.3 Detection and Analysis with Flow Cytometry  
Flow cytometry measurements for the cell-binding assay were performed on a Guava® easyCyte 6-
2L benchtop flow cytometer using InCyte 3.1 analysis software (Merck). 
Prior to sample measurements on flow cytometry, excess SK-BR3 cells were used to calibrate the 
detection of the cells with the following parameters: 
Threshold: 1000 - 2000 
Forward scatter: 4 – 4.5 
Side scatter: 8.85 – 9.25 
Flow rate: Medium 
Collection: 5000 events 
The forwards and side scatter plot was used to gate the population of single cells (example as 
depicted in A, single cells gated in the red ellipse). The gated region was used for all further data 
collection. A histogram of cell counts versus log green fluorescence from the gated region was used 
to adjust the lasers for optimal detection of green fluorescence – i.e. the cell population was 
detected at 1 – 2 x 101 green fluorescence units emitted per cell. 
The control samples were assayed through flow cytometry. Successful batches were confirmed if 
the Herceptin treated cell population was detected at 1 – 3 x 102 green fluorescence units emitted 
per cell, and that the isotype and wash controls resided in the same region as the cells alone as 
detected through the calibration. The control samples were used to define regions in the histogram 
for positive and negative binding as depicted in B, Herceptin treated cells (green peak), IgG1/κ 
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isotype treated cells (aqua peak), dilution buffer treated cells (brown peak) and untreated cells 
(yellow peak). 
All other titration samples were assayed in the same parameters and data collection method to 
generate the percentage of cell population residing in the negative (unbound) or positive (bound) 
regions. A sigmoidal binding curve of antibody concentration was plotted against the percentage of 
fraction bound (positive counts) in a 5PL non-linear fit, to extrapolate KD at 50% positive. 
5.3 Binding Kinetic Assay Materials and Protocols 
Binding kinetic measurements were obtained though surface plasmon resonance (SPR) performed 
on a Biacore™ T200, using Biacore T200 Control and Evaluation software (GE HealthCare). All 
measurements were obtained through operation of single cycle kinetic assays at 25 °C with running 
buffer HBS-T. All receptors were prepared at 4 nM, and all antibody dilutions in Running Buffer 
HBS-T.  
Receptors as ligand were injected at 5 µL/min for 5 min for HIS-tagged capture. Antibody samples 
as analyte were injected at increasing concentrations at 20 µL/min for 2 min. The chip surface was 
regenerated with 10 mM glycine HC1 pH 1.5 at 30 µL/min for 1 min. 
Antibody sample as ligand was prepared as 10 nM and injected at 20 µL/min for 10 sec for ProA 
capture. TNF-α as analyte was injected at increasing concentrations at 20 µL/min for 2 min. The 
chip surface was regenerated with 50 mM NaOH at 30 µL/min for 30 sec. 
Analyte concentrations and disassociation times differed between the assays, each assay is detailed 
more thoroughly below. 
Stock Buffer 
Prepare PBS containing 0.1% (w/v) BSA (BSAS 0.1 Bovogen). 
Combine ingredients to the desired volume. Sterilise and degas by passing through a 0.22 µm 
vacuum filter. 
Keep buffer sealed and store at – 20 °C until use. 
Running Buffer (HBS-T) 
Deionised H2O containing: 
 10 mM HEPES (54457  Sigma-Aldrich) 
 150 mM NaCl (S9888 Sigma-Aldrich) 
 0.05% (v/v) Tween 20 (P9416 Sigma-Aldrich) 
Combine ingredients to the desired volume and adjust to pH 7.4. Sterilise and degas by passing 
through a 0.22 µm vacuum filter. 
Keep buffer sealed and refrigerated until use.  
ProA chip 
Series S Sensor Chip Protein A (29-1275-55 GE Healthcare) 
The ProA chip was used for the capture of antibody samples (adalimumab specifically) to screen 
against soluble homotrimeric TNF-α. 
CM5 chip 
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Series S Sensor Chip CM5 (29-1049-88 GE Healthcare) 
Amine Coupling Kit 
Amine Coupling Kit (BR-1000-50 GE Healthcare) 
Anti HIS capture Kit  
HIS Capture Kit (28-9950-56 GE Healthcare) 
CM5 chips were prepared for amine coupling with the anti-HIS capture kit (antiHIS chip) as per 
manufacturer’s instructions for the capture of HIS-tagged receptors: HER2, FcγR1a, FcγR2B, 
FcγR3A and FcγR3B. 
HIS-tagged HER2 receptor 
Prepare erbB2/HER2/CD340 human recombinant (SRP6405 Sigma-Aldrich) as 4 µM stock in 
Stock Buffer. 
HIS-tagged TNF-α receptor 
Prepare Tumor Necrosis Factor-α human TNF-α, recombinant (H8916 Sigma-Aldrich) as 4 µM 
stock in Stock Buffer. 
HIS-tagged FcγR1A receptor 
Prepare FCGR1A (CD64) Recombinant Human (10256-H08H-5 Life Technologies) as 4 µM stock 
in Stock Buffer. 
HIS-tagged FcγR2B receptor 
Prepare Fc-gamma RIIB/CD32b human recombinant (SRP6396 Sigma-Aldrich) as 4 µM stock in 
Stock Buffer. 
HIS-tagged FcγR3A receptor 
Prepare FCGR3A/CD16a human recombinant (SRP6436 Sigma-Aldrich) as 4 µM stock in Stock 
Buffer. 
HIS-tagged FcγR3B receptor 
Prepare Fc gamma RIIIB/CD16b human recombinant (SRP6451 Sigma-Aldrich) as 4 µM stock in 
Stock Buffer. 
Prepare all receptor stocks as 5 µL aliquots and store at – 80 °C until use. Keep in-use aliquots 
refrigerated, for use within 1 week. 
HER2 Captured Binding Assay 
HIS-tagged HER2 receptor was prepared as 4 nM and captured over an antiHIS chip at 5 µL/min 
for 5 min. Trastuzumab samples (specifically) were prepared as 2-fold serial dilutions from 0.5 – 8 
nM and injected over the HER2 captured surface in increasing concentrations at 20 µL/min for 2 
min, with dissociation time of 60 min. 
Soluble Homotrimeric TNF-a Binding Assay 
208 
 
Adalimumab samples (specifically) were prepared as 10 nM and captured over a ProA chip at 
20 µL/min for 10 sec. TNF-α was prepared as 2-fold serial dilutions from 2.5 – 40 nM and injected 
over the antibody captured surface at increasing concentrations at 20 µL/min for 2 min, with 
dissociation time of 60 min. 
FcγR1A Captured Binding Assay 
HIS-tagged FcγR1A receptor was prepared as 4 nM and captured over an antiHIS chip at 5 µL/min 
for 5 min. Antibody samples were prepared as 2-fold serial dilutions from 2.5 – 40 nM and injected 
over the FcγR1A captured surface in increasing concentrations at 20 µL/min for 2 min, with 
dissociation time of 30 min. 
FcγR2B, FcγR3A and FcγR3B Captured Binding Assays 
HIS-tagged FcγR2B, FcγR3A and FcγR3B receptors were prepared as 4 nM and captured over an 
antiHIS chip at 5 µL/min for 5 min. Antibody samples were prepared as 2-fold serial dilutions from 
25 – 400 nM and injected over the FcγR captured surfaces in increasing concentrations at 20 µL/min 
for 2 min, with dissociation time of 30 min. 
Analysis 
All sensograms were analysed globally using a Langmuir 1:1 binding model to determine Ka, Kd 
and KD. All samples were conducted in duplicate to obtain average values and standard deviation. 
Fluctuations produced from phase transitions through the cycle were excised from the sensograms 
to produce more robust curve fittings. Kinetic rate and binding constants determined from 
sensograms were accepted if the goodness of fit value (χ2) was within 5% of the maximum response 
level (Rmax) of the sensograms and KD was calculated as Kd/Ka. 
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6 Additional data for Chapter 4 and Chapter 5 
6.1 LC-MS/MS Representative Data of Tmab Glycosylation Library 
J 
Figure 42 Representative data; glycan release profiles of Tmab glycosylation library analysed through 
LC-MS/MS. Tmab WT (A), L115>N (B), T117>N (C), A121>N (D), Q160>N (E), L177>K (F), 
L177>N (G), Q178>N (H), L182>N (I), T198>N (J). Glycosylation was confirmed in all mutation sites 
aside for L177>K and Q160>N. 
A 
B 
C 
D 
E 
F 
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6.2 SPR Sensorgrams of Tmab Glycosylation Library 
 
 
 
 
 
 
 
Figure 44 Analysed SPR sensorgrams of single cycle kinetic assays of the Tmab glycosylation 
mutation library to surface captured FcγR1A. PBS-Herc (A), Tmab WT (B), L177>K (C), L177>N 
(D), Q160>N (E), L115>N (F), representative T117>N sensorgram of unreliable analysis (G), 
A121>N (H), Q178>N (I), L182>N (J) and T198>N (K). 
Figure 43 Analysed SPR sensorgrams of single cycle kinetic assays of the Tmab glycosylation 
mutation library to surface captured HER2. PBS-Herc (A), Tmab WT (B), L177>K (C), L177>N 
(D), Q160>N (E), L115>N (F), representative T117>N sensorgram of unreliable analysis (G), 
A121>N (H), Q178>N (I), single sensorgram of L182>N (J) and T198>N (K). 
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Figure 45 Analysed SPR sensorgrams of single cycle kinetic assays of the Tmab glycosylation 
mutation library to surface captured FcγR2B. PBS-Herc (A), Tmab WT (B), L177>K (C), L177>N 
(D), Q160>N (E), L115>N (F), representative sensorgram of unreliable analysis for T117>N (G), 
A121>N (H), Q178>N (I), L182>N (J) and T198>N (K). 
Figure 46 Analysed SPR sensorgrams of single cycle kinetic assays of the Tmab glycosylation 
mutation library to surface captured FcγR3A. PBS-Herc (A), Tmab WT (B), L177>K (C), L177>N 
(D), Q160>N (E), L115>N (F), representative T117>N sensorgram of unreliable analysis (G), 
A121>N (H), Q178>N (I), L182>N (J) and T198>N (K). 
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6.3 SPR Residual data of Tmab Affinity Library  
 
Figure 47 Residuals of analysed SPR sensorgrams from single cycle kinetic assays of the Tmab 
affinity mutation library to surface captured HER2 (A) and FcγR1A (B). Tmab samples PBS-Herc 
(1), Tmab pVITRO1 (2), D28>K (3), S50>E (4) and D102>F (5). Sensorgram data (red/green), 
curve fitting (black). 
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6.4 SPR Residual data of Tmab Glycosylation Library  
 
Figure 48 Residuals of analysed SPR sensorgrams of single cycle kinetic assays of the Tmab 
glycosylation mutation library to surface captured HER2. PBS-Herc (A), Tmab WT (B), L177>K 
(C), L177>N (D), Q160>N (E), L115>N (F), representative T117>N sensorgram of unreliable 
analysis (G), A121>N (H), Q178>N (I), single sensorgram of L182>N (J) and T198>N (K). 
 
Figure 49 Residuals of analysed SPR sensorgrams of single cycle kinetic assays of the Tmab 
glycosylation mutation library to surface captured FcγR1A. PBS-Herc (A), Tmab WT (B), L177>K 
(C), L177>N (D), Q160>N (E), L115>N (F), representative T117>N sensorgram of unreliable 
analysis (G), A121>N (H), Q178>N (I), L182>N (J) and T198>N (K). 
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Figure 50 Residuals of analysed SPR sensorgrams of single cycle kinetic assays of the Tmab 
glycosylation mutation library to surface captured FcγR2B. PBS-Herc (A), Tmab WT (B), L177>K 
(C), L177>N (D), Q160>N (E), L115>N (F), representative sensorgram of unreliable analysis for 
T117>N (G), A121>N (H), Q178>N (I), L182>N (J) and T198>N (K). 
 
Figure 51 Residuals of analysed SPR sensorgrams of single cycle kinetic assays of the Tmab 
glycosylation mutation library to surface captured FcγR3A. PBS-Herc (A), Tmab WT (B), L177>K 
(C), L177>N (D), Q160>N (E), L115>N (F), representative T117>N sensorgram of unreliable 
analysis (G), A121>N (H), Q178>N (I), L182>N (J) and T198>N (K). 
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7 Additional data for Chapter 6 
7.1 Primers; Mutation Efficiency of AdmAb Glycosylation Library 
 
Table 46 List of additional primers designed for AH /AL glycosylation mutations. Nucleotides that 
mismatch the AdmAb gene sequences, introducing codon mutation (bold).  
Primer 
Sequence 
5’                                                              3’ 
SDM2 AHV L116N Fwd 
SDM2 AHV L116N Rev 
GGCCAAGGTACCAATGTCACCGTCTCGAGTGC 
GCACTCGAGACGGTGACATTGGTACCTTGGCC 
SDM2 AHV T118N Fwd 
SDM2 AHV T118N Rev 
GGTACCCTGGTCAACGTCTCGAGTGC 
GCACTCGAGACGTTGACCAGGGTACC 
SDM0 AH1 A122N Fwd 
SDM0 AH1 A122N Rev 
CCGTCTCGAGTAATAGCACCAAGGGC 
GCCCTTGGTGCTATTACTCGAGACGG 
 
Table 47 Mutation efficiencies of the AdmAb glycosylation mutant library. 
Mutation 
Isolates 
Yielded 
Mutation 
Efficiency 
Primer Ligation 
Artefacts 
L178 > K 41 1/10 (20 %) 1/10 (10 %) 
L178 > N 281 1/6 (16.7 %) 0/6 (0 %) 
Q160 > N 2 1/2 (50 %) 0/2 (0 %) 
L116 > N 17 2/10 (20 %) 1/10 (10 %) 
T118 > N 91 3/6 (50 %) 0/6 (0 %) 
A122 > N > 300 2/4 (50 %) 0/4 (0 %) 
Q179 > N 45 1/10 (10 %) 1/10 (10 %) 
L183 > N > 300 1/9 (11 %) 0/9 (0 %) 
T199 > N 40 1/8 (12.5 %) 5/8 (62.5 %) 
 
 
 
7.2 LC-MS/MS Representative Data of AdmAb Glycosylation Library
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Figure 52 CID spectrum (A) and ETD spectrum (B) of the chymotryptic peptide NSGALTSGVHTFPAVK for L178>K AdmAb mutant confirming 
successful aa substitution. HCD spectrum (C) and ETD spectrum (D) of the chymotryptic peptide PAVNQSSGLY for L178>N AdmAb mutant 
confirming successful aa substitution.  
A 
B 
C 
D 
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Figure 53 HCD spectrum (C) and ETD spectrum (D) of the chymotryptic peptide KVDNALQSGNSNESSVTEQDSKDSTY for Q160>N AdmAb 
mutant confirming successful aa substitution; glycosylation of this mutant could not be confirmed. 
A 
B 
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Figure 54 HCD spectrum (A) and ETD spectrum (B) of the chymotryptic peptide LSTASSLDYWGQGTNVTVSSASTK for L116>N AdmAb 
mutant confirming successful aa substitution. HCD spectrum of the de-glycosylated chymotryptic peptide GQGTNVTVSSASTKGPAVFPLAPSSK 
for the L116>N AdmAb mutant (C) confirming successful glycosylation. 
A 
B 
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Figure 55 HCD spectrum (A) and ETD spectrum (B) of the chymotryptic peptide LSTASSLDYWGQGTLVNVSSASTK for T118>N AdmAb mutant 
confirming successful aa substitution. CID spectrum (C) and ETD spectrum (D) of the de-glycosylated chymotryptic peptide GQGTLVNVSSASTK 
for the T118>N AdmAb mutant confirming successful glycosylation. 
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Figure 56 HCD spectrum (A) and ETD spectrum (B) of the chymotryptic peptide GQGTLVTVSSNSTK for A122>N AdmAb mutant confirming 
successful aa substitution. CID spectrum (C) and ETD spectrum (D) of the de-glycosylated chymotryptic peptide 
LSTASSLDYWGQGTLVTVSSNSTK for the A122>N AdmAb mutant confirming successful glycosylation. 
A 
B 
C 
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Figure 57 HCD spectrum (A) and ETD spectrum (B) of the chymotryptic peptide NSGALTSGVHTFPAVLQSSGNY for L183>N AdmAb mutant 
confirming successful aa substitution. ETD spectrum of the chymotryptic peptide (C) and de-glycosylated chymotryptic peptide (D) 
SLSSVVTVPSSSLGNQTY for T198>N AdmAb mutant confirming successful aa substitution and glycosylation. 
In
te
n
si
ty
 
A 
B 
C 
D 
222 
 
7.3 SPR Sensorgrams of Monomer AdmAb Glycosylation Library 
 
 
 
Figure 58 Single cycle kinetic sensorgrams of monomeric AdmAb variants binding to soluble 
homotrimeric TNF-α. Humira® (A), AdmAb WT (B), L178K (C), L178N (D), Q160N (E), L116N 
(F), T118N (G), A122N (H), Q179N (I), L183N (J) and T199N (K). 
Figure 59 Single cycle kinetic sensorgrams of monomeric AdmAb variants binding to FcγR1A. 
Humira® (A), AdmAb WT (B), L178K (C), L178N (D), Q160N (E), L116N (F), T118N (G), 
A122N (H), Q179N (I), L183N (J) and T199N (K). 
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Figure 60 Single cycle kinetic sensorgrams of monomeric AdmAb variants binding to FcγR2B. 
Humira® (A), AdmAb WT (B), L178K (C), L178N (D), L116N (E), T118N (F), A122N (G), 
Q179N (H), L183N (I) and T199N (J). 
Figure 61 Single cycle kinetic sensorgrams of monomeric AdmAb variants binding to FcγR3A. 
Humira® (A), AdmAb WT (B), L178K (C), L178N (D), Q160N (E), L116N (F), T118N (G), 
A122N (H), Q179N (I), L183N (J) and T199N (K). 
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7.4 SPR Results and Sensorgrams of AdmAb Glycosylation Library, pre-SEC Purification 
Table 48 Binding kinetics of the AdmAb glycosylation mutant library to surface captured HER2 
and FcγRs 1A, 2B and 3A as measured through SPR (±SD), 
*one value only, no data (ND). 
 
TNF-α FcγR1A 
Ka 
(x 105) M-1.s-1 
Kd 
(x 10-5) s-1 
KD 
pM 
Ka 
(x 105) M-1.s-1 
Kd 
(x 10-4) s-1 
KD 
nM 
Humira 11.66 ± 0.01 3.59 ± 0.80 30.77 ± 6.83 5.83 ± 0.38 10.72 ± 0.33 1.84 ± 0.18 
AdmAb WT 11.63 ± 0.70 3.95 ± 0.30 33.98 ± 0.59 3.24 ± 0.04 8.63 ± 0.13 2.66 ± 0.08 
L178>K 8.91 ± 0.07 4.19 ± 2.20 47.02 ± 25.22 3.02 ± 0.07 9.34 ± 0.03 3.09 ± 0.08 
L178>N 9.38 ± 0.71 3.99 ± 0.59 42.56 ± 9.51 3.45 ± 0.09 9.26 ± 0.32 2.68 ± 0.16 
Q160>N 9.75 ± 0.58 3.32 ± 0.58 34.05 ± 3.96 3.04 ± 0.31 7.91 ± 0.04 2.61 ± 0.27 
L116>N 9.61 ± 0.57 3.69 ± 0.50 38.39 ± 2.88 2.71 ± 0.13 8.83 ± 0.40 3.26 ± 0.29 
T118>N 8.70 ± 0.90 6.29 ±  5.41 72.33 ± 75.75 2.59 ± 0.14 2.61 ± 0.16 1.01 ± 0.01 
A122>N 9.60 ± 0.02 5.61 ± 3.52 58.45 ± 36.09 3.25 ± 0.18 8.78 ± 0.10 2.70 ± 0.11 
Q179>N 12.04 ± 0.24 3.25 ± 2.17 27.01 ± 18.99 2.59 ± 0.16 10.06 ± 0.10 3.88 ± 0.27 
L183>N 8.87 ± 0.52 5.21 ± 3.84 58.74 ± 37.75 2.77 ± 0.13 9.23 ± 0.01 3.33 ± 0.16 
T199>N 11.25 ± 1.36 6.10 ± 0.38 54.19 ± 9.77 3.10 ± 0.12 8.24 ± 0.29 2.66 ± 0.01 
 
FcγR2B FcγR3A 
Ka 
(x 104) M-1.s-1 
Kd 
 (x 10-4) s-1 
KD 
nM 
Ka 
 (x 104) M-1.s-1 
Kd 
 (x 10-4) s-1 
KD 
nM 
Humira 56.28 ± 9.59 14.36 ± 8.04 2.55 ± 1.67 38.93 ± 5.41 7.16 ± 2.06 1.84 ± 0.68 
AdmAb WT 1.72 ± 0.85 1.64 ± 0.74 9.55 ± 15.96 3.98 ± 0.42 5.69 ± 0.21 14.30 ± 1.99 
L178>K 6.87 ± 0.14 8.75 ± 3.16 12.74 ± 4.34 4.00 ± 0.11 5.66 ± 0.19 14.13 ± 0.86 
L178>N 1.95* 1.17* 5.96* 4.06 ± 0.46 5.20 ± 0.30 12.81 ± 2.02 
Q160>N 1.95 ± 0.21 ND ND 4.30 ± 0.46 6.98 ± 0.59 16.24 ± 3.05 
T118>N 8.48 ± 0.36 1.96 ± 1.43 2.31 ± 1.81 9.77 ± 3.88 2.96 ± 0.14 3.03 ± 1.44 
A122>N 1.17 ± 0.12 0.88 ± 0.42 7.53 ± 2.74 2.32 ± 0.68 4.17 ± 0.55 18.01 ± 7.42 
L183>N 1.71 ± 0.57 0.92 ± 1.21 5.41 ± 9.67 ND ND ND 
T199>N 1.38  ± 0.12 1.13* 8.55* 2.51 ± 0.09 4.71 ± 0.17 18.75 ± 1.14 
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Figure 62 Single cycle kinetic sensorgrams of pre-SEC purification AdmAb variants binding to 
TNF-α. Humira® (A), AdmAb WT (B), L178K (C), L178N (D), Q160N (E), L116N (F), T118N 
(G), A122N (H), Q179N (I), L183N (J) and T199N (K). A deviation in binding and dissociation 
was observed for T118N, A122N, Q179N and L183N in the repeated cycle which affected the 
calculated values and SD. Values are as reported although they warrant repeat testing. 
Figure 63 Single cycle kinetic sensorgrams of pre-SEC purification AdmAb variants binding to 
FcγR1A. Humira
® (A), AdmAb WT (B), L178K (C), L178N (D), Q160N (E), L116N (F), T118N 
(G), A122N (H), Q179N (I), L183N (J) and T199N (K).  
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Figure 64 Single cycle kinetic sensorgrams of pre-SEC purification AdmAb variants binding to 
FcγR2B. Humira
® (A), AdmAb WT (B), L178K (C), L178N (D), Q160N (E), T118N (F), A122N 
(G), L183N (H) and T199N (I). T118N displayed markedly enhanced binding, FcγR2B assay 
requires optimisation. 
 
  
Figure 65 Single cycle kinetic sensorgrams of pre-SEC purification AdmAb variants binding to 
FcγR3A. Humira
® (A), AdmAb WT (B), L178K (C), L178N (D), Q160N (E), T118N (F), A122N 
(G), L183N (H) and T199N (I). 
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7.5 SPR Residual data of AdmAb Glycosylation Library 
 
Figure 66 Residuals of analysed SPR sensorgrams of single cycle kinetic assays of monomeric 
AdmAb variants binding to soluble homotrimeric TNF-α. Humira® (A), AdmAb WT (B), L178K 
(C), L178N (D), Q160N (E), L116N (F), T118N (G), A122N (H), Q179N (I), L183N (J) and 
T199N (K). 
 
Figure 67 Residuals of analysed SPR sensorgrams of single cycle kinetic assays of monomeric 
AdmAb variants binding to FcγR1A. Humira
® (A), AdmAb WT (B), L178K (C), L178N (D), 
Q160N (E), L116N (F), T118N (G), A122N (H), Q179N (I), L183N (J) and T199N (K). 
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Figure 68 Residuals of analysed SPR sensorgrams of single cycle kinetic assays of monomeric 
AdmAb variants binding to FcγR2B. Humira
® (A), AdmAb WT (B), L178K (C), L178N (D), 
L116N (E), T118N (F), A122N (G), Q179N (H), L183N (I) and T199N (J). 
 
Figure 69 Residuals of analysed SPR sensorgrams of single cycle kinetic assays of monomeric 
AdmAb variants binding to FcγR3A. Humira
® (A), AdmAb WT (B), L178K (C), L178N (D), 
Q160N (E), L116N (F), T118N (G), A122N (H), Q179N (I), L183N (J) and T199N (K). 
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Figure 70 Residuals of analysed SPR sensorgrams of single cycle kinetic assays of pre-SEC 
purification AdmAb variants binding to TNF-α. Humira® (A), AdmAb WT (B), L178K (C), L178N 
(D), Q160N (E), L116N (F), T118N (G), A122N (H), Q179N (I), L183N (J) and T199N (K). 
 
Figure 71 Residuals of analysed SPR sensorgrams of single cycle kinetic assays of pre-SEC 
purification AdmAb variants binding to FcγR1A. Humira
® (A), AdmAb WT (B), L178K (C), 
L178N (D), Q160N (E), L116N (F), T118N (G), A122N (H), Q179N (I), L183N (J) and T199N 
(K). 
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Figure 72 Residuals of analysed SPR sensorgrams of single cycle kinetic assays of pre-SEC 
purification AdmAb variants binding to FcγR2B. Humira
® (A), AdmAb WT (B), L178K (C), 
L178N (D), Q160N (E), T118N (F), A122N (G), L183N (H) and T199N (I). 
 
Figure 73 Residuals of analysed SPR sensorgrams of single cycle kinetic assays of pre-SEC 
purification AdmAb variants binding to FcγR3A. Humira
® (A), AdmAb WT (B), L178K (C), 
L178N (D), Q160N (E), T118N (F), A122N (G), L183N (H) and T199N (I). 
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7.6 Representative Thermal Melting and Aggregation curves of Monomer AdmAb 
Glycosylation Library 
 
Figure 74 Melting curves of the AdmAb glycosylation mutant library generated from the UNcle™ 
system. (A) Full temperature ramp of all samples highlighting the unfolding events in reference 
Humira® that correspond to the calculated Tm1 and Tm2, (B) curve magnified over the melting 
regions for comparison of mutant Tms against WT. 
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Figure 75 Thermal aggregation curves of the AdmAb glycosylation mutant library generated from 
the UNcle™ system, measured at 266 nm. (A) Full temperature ramp of all samples highlighting the 
initiated aggregation event in the reference Humira® that correspond to the calculated Tagg, (B) 
curve magnified over the region where aggregation initiates for comparison of Tagg of mutants 
against WT. 
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Abstract: Therapeutic antibody technology heavily dominates the biologics market and continues 
to present as a significant industrial interest in developing novel and improved antibody treatment 
strategies. Many noteworthy advancements in the last decades have propelled the success of 
antibody development; however, there are still opportunities for improvement. In considering such 
interest to develop antibody therapies, this review summarizes the array of challenges and 
considerations faced in the design, manufacture, and formulation of therapeutic antibodies, such as 
stability, bioavailability and immunological engagement. We discuss the advancement of 
technologies that address these challenges, highlighting key antibody engineered formats that have 
been adapted. Furthermore, we examine the implication of novel formulation technologies such as 
nanocarrier delivery systems for the potential to formulate for pulmonary delivery. Finally, we 
comprehensively discuss developments in computational approaches for the strategic design of 
antibodies with modulated functions. 
Keywords: therapeutic antibody; stability; aggregation; manufacture challenges; formulation 
 
1. Introduction 
Since the first therapeutic monoclonal antibody (mAb) Orthoclone OKT3® (Janssen Biotech, 
Horsham, PA, USA) was approved by the USA Food and Drug Administration in 1986, whole 
antibody therapeutics have become and persistently remain the most dominant and significant 
biologic therapeutic platform in the pharmaceutical industry [1,2]. To date, therapeutic antibodies 
treat a plethora of indications including cancers, infections, autoimmune disorders, and 
cardiovascular and neurological diseases [3]. The whole antibody therapeutics platform is regarded 
as the most promising class of pharmaceutical technology to date; it is continually being applied to 
newly identified biological targets and implemented in many formats to produce strategically 
engineered next generation antibody therapeutics, otherwise termed “biobetters” [4–9]. The 
international ImMunoGeneTics information system® (IMGT®, Montpellier, France) database reveals 
that as of December 2018, 65 whole antibodies and 18 next generation fragment or recombinant fusion 
antibody-based therapies are approved for clinical use, with hundreds more in clinical trials expected 
to reach market. 
Whole therapeutic mAbs are presently the dominant antibody platform approved for clinical 
use (Figure 1), although antibody engineering technologies have advanced in recent years to produce 
highly optimized, strategically engineered biobetter therapies, along with biosimilar mAbs reaching 
market to compete against their originator. Further whole mAb formats include antibody–drug 
conjugates (ADCs), bispecifics, isotype-switched, and glycoengineered. These additional formats 
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have been strategically designed to introduce exceptional potency, to engage dual biological targets, 
and to modulate Fc effector functions. Fragments of mAbs such as the crystallizable fragment (Fc), 
antigen binding fragment (Fab), and single-chain variable fragment (scFv) possess key functions such 
as specificity to a biological target or immunological activation. The isolation of these fragments for 
fusion with other mAb fragments, biologically functional proteins, cytotoxic drugs, or drug carriers 
has been the crux of ingenuity in developing the next generation of biobetter therapies [4–15]. Figure 
2 depicts several examples of prominent biobetter formats, providing a general representation of 
current fragment mAbs, whole mAb bispecifics, fragment mAb multispecifics, and fragment mAb 
fusion therapeutics. 
 
Whole mAb formats 65 
Naked whole mAbs 60 
ADCs 4 
Whole mAb bispecifics 1 
Fragment mAb formats 18 
Fabs 4 
Fc fusions 10 
scFv fusions 3 
scFv bispecifics (BiTE) 1 
Originator mAbs with 
approved biosimilars 6 
 
(a) (b) 
Figure 1. The proportions of therapeutic antibody formats approved for therapeutic use as of 
December 2018, IMGT® depicted through (a) a pie chart and (b) a table format. 
 
Figure 2. Schematic representation of a whole monoclonal antibody (mAb), a fragment mAb, and 
prominent fusion mAb formats that have been developed for strategic therapeutic uses. Proteins 
fused to mAb fragments are depicted as blue ovals for a general representation; however, fusion 
proteins may vary in size and structure. Fragment formats include the crystallizable (Fc), antigen 
binding (Fab and F(ab)2), and single-chain variable (scFv) fragments. Further whole mAb formats 
Naked Whole
mAbs
ADCs
Whole mAb
Bispecifics
Biosimilars
Fabs
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include the antibody–drug conjugate (ADC), triomab, dual variable domain immunoglobulin (DVD-
Ig), and immunoglobulin–scFv fusion (IgG-scFv). Multispecific fragment formats include the F(ab)2 
bispecific, bispecific T-cell engager (BiTE), dual affinity re-targeting molecule (DART), and tandem 
diabody (tandAb). 
2. Overview of mAb Production Challenges and Considerations 
Whole therapeutic mAbs require a mammalian expression system to produce the biologically 
functional product; however, a mAb fragment and recombinant fusion mAb products with simplified 
(or lacking) glycosylation are suitable for lower organism expression platforms [16]. Unlike 
oligopeptides, which can be chemically synthesized, whole therapeutic mAbs are considerably larger 
(with monomer ranging from 140–160 kDa) and comprise of four peptide chains (two heavy and two 
light chains) bound together by disulfide bonds and interchain non-covalent interactions. Further to 
this, antibodies contain glycosylation in a conserved region of the Fc (N297) that contributes to its 
stability and immune effector functions [17,18]. Aside from peptide synthesis, cell machinery is 
required to glycosylate, fold, orient, and covalently bind the antibody peptide chains in order to 
produce the complete, biologically functional antibody product. Manufacturing biologically 
functional whole mAb product is therefore commercially unfeasible through chemical synthesis and 
insufficient in lower organism expression platforms such as bacteria, yeast, insect, and plant cells that 
may not have the machinery to produce the equivalent tertiary structure and glycosylation profiles. 
In particular, many industrially relevant bacterial strains such as E. coli are completely deficient in 
the machinery to add post-translational glycosylations; yeasts hyper-mannosylate glycans, which 
cause immunogenicity; and insect cells which are deficient in sialylation machinery and produce 
immunogenic glycan structures [16]. A secretion of the mAb product for purification is suboptimal 
for several lower organism expression platforms such as E. coli due to poor productivity and harsh 
culture conditions that promote product degradation. Protein is therefore produced intracellularly, 
as inclusion bodies and harvest involves further processing steps such as cell lysis, inclusion body 
recovery, protein solubilization, and renaturation prior to further downstream purification steps 
[19,20]. Despite these pitfalls, the development of lower organism expression systems is of high 
commercial interest due to the simplified culture conditions, cheaper media requirements, rapid 
organism growth, and higher product yield as compared to mammalian expression systems [16,21]. 
In considering the requirements through the entire process of mAb discovery, manufacture, 
formulation, and disease treatment, several key challenges arise which have sparked overwhelming 
interest in pursuit of achieving better mAb manufacturing outcomes and treatment strategies. As 
with all biotherapeutics, mAbs and mAb-based therapeutics are limited to production in cell-based 
expression systems, which is considerably costly and inefficient, can have varied yields depending 
on the product and expression system, and requires downstream processing to remove biological 
contaminants introduced from the expression system. Despite affinity chromatography being a 
robust technology for the initial capture of a mAb for purification, the capture process and further 
downstream processes such as viral inactivation applies the mAb product to harsh pH and salt 
conditions, which can chemically degrade the mAb, leading to product instability and loss [5,22,23]. 
Many factors through the manufacture process influence glycosylation and charge heterogeneity 
of mAbs, which affects their biophysical and pharmacological properties. Though not specifically 
discussed in this review, the improvement and control mAb production technologies address these 
variations to reduce formulation heterogeneity and off-target cytotoxicities. 
A common challenge, as seen with all biotherapeutics, is that mAbs and mAb-based therapeutics 
are currently restricted to lyophilised and liquid-based formulations for intravenous (IV) or 
subcutaneous (SC) delivery to achieve maximum bioavailability. Protein self-association and intrinsic 
stability drive this limitation, in that viscosity and propensity to aggregate are dependent on mAb 
concentration. Formulations are optimized to achieve the highest dosing concentration at the 
minimum achievable volume for injection, without compromising the quality of the mAb in 
formulation [24]. Viscosity remains a key limiting factor for formulating as a SC administration—
certain mAb therapies are suitable and others not based on their solubility, self-association, and 
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aggregation profiles. Alternative non-invasive administration strategies such as pulmonary delivery 
causes additional mechanical stress that further contribute to mAb instability and loss. Furthermore, 
oral delivery is unsuitable due to chemical and enzymatic degradation, as well as poor absorption in 
the gastric and intestinal environments [5,25–29]. 
A brief overview of considerations through the different concept stages of therapeutic mAb 
development is depicted in Figure 3. The main challenges and considerations in the manufacture and 
formulation of mAb therapeutics are briefly summarized in Table 1. 
 
Figure 3. Schematic representation of the concept stages of mAb drug development in which 
considerations follow on from one process to the next in the design and manufacture of mAb-based 
therapeutics.
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Table 1. Summary of key technological advancements that address challenges and considerations in mAb design, manufacture, and formulation strategies. 
Challenges Advancements 
Manufacture Considerations 
Hybridoma technology produces immunogenic mAbs Humanization technologies [4–6] 
Yield from hybridoma technology is variable  
Commercial cell line development and recombinant technology [4–6]; lower organism systems for 
fragment mAbs, mammalian systems for whole mAbs, and Fc fusions [16,30,31] Significance of post-translational modifications and higher-order 
structure in mAb product 
CHO expressed mAbs contain an immunogenic glycosylation 
profile Human-based expression systems [16,30–32] 
HEK 293 expressed mAbs are prone to aggregation HKB-11 and PER.C6 cell lines [32] 
Undesirable byproducts produced in the manufacture process in vitro cell-free synthesis technology [33,34] 
Stability of mAb affects manufacture yield due to product loss 
through aggregation in downstream processing steps Enhancing mAb stability through framework mutations and hyperglycosylation [5,35–40] 
Treatment Considerations for Drug Design and Formulation 
Susceptibility of mAb to degradation limits delivery to 
intravenous and subcutaneous only Enhancing mAb stability through framework mutations, hyperglycosylation [5,35–40], and 
nanocarrier technologies [8,41] 
Stability of mAb limits concentration of formulation 
Concentration of mAb affects viscosity and injection pressure for 
subcutaneous delivery Excipients, fragment mAbs, PEGylation, and hyperglycosylation [25–27,41] 
Poor tissue penetration and biodistribution Fragment mAbs and nanocarrier technologies [8,41,42]; high affinity ADCs [43–45] 
Reduced half-life in low MW species 
PEGylation, hyper-glycosylation and Fc fusion proteins [8,41,46]; modulation of FcRn recycling 
through Fc mutation [11,13] 
Modulation of immunological engagement Isotype switching, glycoengineering, and Fc mutations [11,13,15,43,46] 
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3. mAb Discovery and Manufacture Technologies 
Traditional technology for whole therapeutic antibody discovery required the immunization of 
animals—primarily mice with a target antigen for the generation of a mixed population of B-
lymphocytes-producing antibody against the target. The B-lymphocytes would be isolated for 
immortalization to produce monoclonal hybridoma cell lines that secrete antibody candidates of 
interest for further panning through display technologies to isolate potential leads [5]. This method 
has led to the generation of highly specific mAb libraries of non-human origin that were potentially 
immunogenic and less efficacious at eliciting an immune response as compared to wholly human 
mAbs. Technologies arose to address immunogenicity by producing chimeric and humanized 
antibodies through the grafting of the variable domains (chimeric) or complementarity-determining 
region (CDR) residues (humanized) isolated from lead non-human antibodies to a human antibody 
framework. To further improve the humanization strategy, transgenic mice were developed with 
their murine antibody heavy and light chain genes replaced with equivalent human genes; they 
consequently expressed wholly human antibodies for discovery [4–6]. 
Phage display technology remains the most prominent selection technology for panning 
antibody gene pools for specificity to a target antigen, as it effectively couples the expression of mAb 
proteins to the genes that encode them for the panning of high affinity leads. Antibody variable genes 
from B-lymphocyte pools are isolated through polymerase chain reaction (PCR), and cloned into a 
phage expression vector that presents the expressed mAb on the surface of the phage, the library of 
vectors is rescued in phage, and the phage library is screened against a specific target antigen. Phage 
pools undergo several rounds of selection to isolate high affinity candidates, the variable genes of the 
lead mAb candidates can then be isolated and sequenced for the design of a mAb drug format and 
the development of a suitable expression platform [5,47]. Error-prone PCR-based mutagenesis has 
propelled display technology for the generation of enormous libraries for target affinity screening. 
Yeast surface display further improves these screening technologies, as glycosylation sites introduced 
in CDRs are expressed through this platform [5,48]. 
The expression, yield, and quality of a mAb can vary quite substantially in hybridoma cell lines. 
High yielding mammalian expression systems have been developed to meet the commercial need for 
high expression efficiency, scalability, quality, and reproducibility. Antibody genes of interest are 
introduced into suitable expression vectors and transfected into highly efficient mammalian cell lines 
for antibody expression and secretion; a mAb can then be directly captured from the culture 
supernatant through affinity chromatography. Currently, the majority of mammalian expression 
systems for commercial whole therapeutic antibody expression are based on stable chinese hamster 
ovary (CHO), mouse myeloma (NS0), and mouse hybridoma (Sp2/0) cell lines [4,5]. However, in the 
context of research and development, the transient expression in human cell lines such as embryonic 
kidney (HEK 293), amniotic (CAP), a hybrid of HEK 293 and lymphoma (HKB-11), and embryonic 
retina (PER.C6) are favored over stable CHO expression due to the ease and speed of production of 
workable quantities of antibody for preliminary studies [16,30–32,49,50]. The generated mAb library 
undergoes relevant in vitro testing along with formulation stability screening to exclude candidates 
that have poor manufacturability attributes [51]. Lead mAb candidates that show potential for further 
investigation would then be developed for high yielding stable expression and more rigorous 
characterization leading up to therapeutic development. However, a drawback from changing from 
human to hamster expression systems is the difference in glycosylation profile. CHO expressed mAbs 
produce immunogenic non-human glycoform Neu5Gc and have a higher composition of sialylation, 
which may result in reduced antibody-dependent cellular cytotoxicity (ADCC). Therefore in the early 
stages of development, leads need to be identified and thoroughly characterized in the expression 
system to be developed for commercial manufacture before committing to industrial scale up 
[16,30,32]. Amongst other biotherapeutics, approved mAb Fc fusion therapeutics dulglutide 
(Trulicity®, Eli Lilly, Indianapolis, IN USA), efmoroctocog alpha and eftrenonacog alpha (Eloctate® 
and Alprolix® , Biogen, Cambridge, MA, USA), are manufactured in a HEK 293 expression system, 
which is giving rise to the acceptance of human-based expression systems for the production of mAb-
based therapeutics [4]. However, HEK 293 expression systems are prone to inducing mAb 
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aggregation in cultures, which is detrimental to cell viability and creates a loss of product during 
manufacture. Hence, HKB-11 and PER.C6 are the preferred commercial human cell lines for mAb 
expression in human cell lines, specifically [16,31,32]. 
Established lower organism expression systems for fragment or recombinant fusion mAb 
therapeutics include bacteria such as E. coli, yeasts such as S. cerevisiae and P. pastoris, plants such as 
tobacco, algae, and insects such as silkworm [5,16,52–54]. Expression platforms that use E. coli in 
particular are considered high risk due to the potential endotoxin contamination in the mAb product, 
of which complete endotoxin removal requires further purification steps [19]. However, several 
approved mAb fragment- and recombinant-based therapies are produced in an E. coli-based 
expression system, including pegol conjugated Fab’ certolizumab pegol (Cimzia®, Celltech UCB, 
Brussels, Belgium), Fab ranibizumab (Lucentis®, Genentech, San Francisco, CA, USA), and 
recombinant Fc fusion romiplostim (Nplate®, Amgen, Thousand Oaks, CA, USA). Lower organism 
expression platforms such as E. coli and P. pastoris continue to be the preferred option for the 
manufacture of fragment mAb formats due to the relative ease, high yield, and reduced cost for 
manufacture as compared to mammalian expression platforms. 
An emerging in vitro cell-free synthesis technology is being developed with bacterial and CHO 
cell lysates which have the potential to alleviate formation of undesirable biological byproducts, as 
the machinery from the cell lysates purely express protein from the mAb genes that are introduced 
to the system. Though this technology is not currently applicable for industrial scale manufacture, it 
holds much promise as an alternative to live culture. For instance, culture maintenance and highly 
defined media are no longer necessary, reactions can run continuously, lysates can be recycled with 
reproducible results, unmodified linear DNA is suitable for the system (thus alleviating a need for 
multiple cloning steps), and additional enzymes can be introduced to the system for the engineering 
of specific post-translational modifications [33,34,55–58]. Despite the apparent advantages of this 
technology for mAb manufacture, cell lysates encounter the same challenges as their host cell 
expression system. That is, post-translational modifications of mAb product from lysates from lower 
level organisms are limited by the endogenous machinery of that host organism. Furthermore, 
preparation of mammalian cell lysates is challenging, and yield produced from these lysates is 
considerably low [59,60]. 
Current bioprocess engineering and cell line development strategies have been crucial in 
enhancing the manufacturability of mAbs. Many current mAb therapeutic expression platforms 
make use of CHO cell lines that have been commercially developed with dihydrofolate reductase or 
glutamine synthetase deficiency for enhanced stability selection through resistance to methotrexate 
and methionine sulfoximine inhibition, respectively [50,61]. Mammalian cell lines have been adapted 
to suspension culture, as they support higher cell densities and mAb titers in the absence of serum 
from the culture media, for large scale fed-batches, perfusion systems, or continuous culture systems. 
Further to this, cell lines are continually being engineered for enhanced metabolic functions, 
introducing glycosylation pathways, superior secretion, and resistance to apoptosis for prolonged 
survival, in efforts to generate super-producer cell lines that can sustain a continuous culture [62–68]. 
Gene and expression vector design and development are specifically tailored to the expression 
system to maximize mAb expression and cell line stabilization through host cell codon optimization 
and the addition of highly efficient transcription, secretion, selection, and integration elements [69–
73]. Vectors can contain a single site for gene insertion for the subsequent co-transfection of vectors 
that carry the antibody heavy and light chains, or both chains can be cloned into a dual expression 
vector. In more elaborately designed recombinant mAb drug formats that require the expression of 
several genes, vector technologies have implemented multicistronic expression to enhance the 
efficiency of the vector system. The stable or transient transfection of vectors is performed on highly 
viable cell cultures with high cell density. Antibody heavy and light chain ratios may require 
adjustment in transfection for optimizing expression and secretion. A reporter vector that expresses 
green fluorescent protein is typically included to observe transfection efficiency during optimization 
[74,75]. Liposome-mediated transfection is preferential over all other mammalian transfection 
strategies and is induced chemically through the complexing of DNA to a cationic lipid prior to or 
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during addition to a culture. Polyethylenimine is the most prevalently used transfection reagent 
despite the development of superior reagents such as Lipofectamine™ 2000 and Freestyle™ MAX 
(Thermo Fisher Scientific, Waltham, MA, USA), LyoVec™ (InvivoGen, San Diego, CA, USA), 
FuGENE 6™ (Promega, Madison, WI, USA), and TransIT-PRO® (Mirus, Madison, WI, USA), owing to 
its lower cost and relative efficiency [73,75–78]. 
The commercial manufacture of mAbs has transitioned to serum-free, chemically defined, and 
animal-free media which has removed a source of expression variability and has been driven 
particularly from the advent of mad cow disease [50,79]. Several media supplements such as plant 
and yeast digests (peptones/hydrolysates), surfactants (e.g., Pluronic F-68), DNA methyltransferase 
(azacytidine), and histone deacetylase (sodium butyrate, valproic acid) inhibitors have been found to 
support cell viability and enhance mAb expression [79–85]. Mild hypothermia of the culture has also 
demonstrated to reduce cell expansion, support prolonged cell viability, and enhance mAb 
expression [73,86–90]. Further to this, continuous supplementation in expression cultures of uridine, 
manganese chloride, and galactose demonstrated successful the glycan engineering of expressed 
mAb, where mAb hyper-galactosylation was promoted to enhance complement-dependent 
cytotoxicity (CDC) activity [91]. 
In the manufacturing process of fed-batch, perfusion, and continuous culture systems, media is 
continuously fed in the culture system, whilst parameters such as cell viability, cell density, and 
metabolite levels are monitored in real time until the parameters indicate that it is the optimal time 
to harvest the expressed mAb from the culture supernatant. In perfusion and continuous culture 
systems, a feed is removed from the culture simultaneously to the media addition, the difference 
being that the cell dilution rate in continuous culture is optimized to remain equal or higher than the 
cell growth rate, which allows the perpetuation of mAb expression and requires the continuous 
harvest of the supernatant [92–94]. The harvest of the supernatant requires clarification technologies 
such as the use of precipitants/flocculants (e.g., polyethylene glycol, diethylaminoethyl dextran, 
caprylic acid, and polyethylenimine), high throughput centrifugation, and filtration methods to 
remove cells and biological debris, for the lowering the loading burden in the lead up to mAb capture 
through affinity chromatography [19,95–100]. The mechanical stresses from centrifugation and 
filtration are unavoidable, although they can induce mild mAb product loss through fragmentation 
and aggregation. 
Protein A-ligand-based affinity chromatography is the most robust, efficient, and prevalently 
used mAb capture technology, owing to its selectivity and high affinity to various human Fc, as well 
as its efficient dissociation of captured mAbs at a low pH for reuse. Fragment mAbs and recombinant 
formats based on Fabs and single chain variable fragments (scFv) are unable to take advantage of 
protein A affinity capture, and alternatives have been developed, such as capturing proteins G, M, 
and L, which bind at different mAb epitopes; ion exchange chromatography; and polyhistidine 
tagged capture through immobilized metal chromatography [100–102]. A further advantage of 
affinity chromatography in manufacture is the integration of a viral inactivation step by holding the 
low pH-eluted mAb product prior to further purification steps; however, this applies the mAb 
product to low pH at high concentrations, which can induce mild mAb instability, aggregation, and 
the formation of acidic variants [5,22,100,103,104]. 
Post mAb capture, further polishing steps are required to remove further contaminants such as 
host cell proteins and DNA, as well as leached affinity chromatography ligand- and mAb-
degradation products such as fragments, aggregates, and ionic variants. The polishing steps are 
designed based on the specific properties of the mAb product, such as the isoelectric point and 
molecular weight (MW), to implement appropriate chromatographic technologies such as anion and 
cation exchanges, hydrophobic interaction, and multimodal and size exclusion that will separate the 
mAb product from the manufacture-introduced impurities [22,100,103]. The additional 
chromatographic steps unavoidably apply the mAb product to buffers of varying ionic strength and 
high concentrations, which can again induce mild mAb instability and aggregation. Post polishing 
steps, the purified mAb product undergoes a further viral removal step, such as filtration, and then 
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it undergoes buffer exchange and concentration through ultrafiltration or diafiltration methods to 
prepare the bulk mAb product for formulation [100,105]. 
4. Formulation Strategies and Considerations 
Strategies to improve the formulation of mAbs and mAb-based therapies continues to be an 
ongoing challenge, as is faced with all biotherapeutics. Firstly, whole therapeutic mAbs are 
unsuitable for non-invasive oral, nasal, or pulmonary routes of administration as they are susceptible 
to chemical and enzymatic degradation in the gastrointestinal tract. The bioavailability of mAbs 
through these routes is poor, owing to mAbs’ polar surface charge and relatively large MW, limiting 
transport through mucosal membranes. 
Fragment mAb platforms, together with excipient and PEGylation technologies, have been 
developed to help circumvent transportation limitations for pulmonary delivery, specifically. 
However, physical stresses applied to the mAb (e.g., shear stresses from the aerosolization of liquid 
formulations for a pressurized meter dose and a nebulization delivery, or from the production of dry 
powder for inhalation) pose further challenges of mAb instability, leading to degradation and 
reduced efficacy. [8,26,28]. Few biologics have been successfully approved for pulmonary delivery, 
most notably insulin formulation Afrezza® (MannKind, Westlake Village, CA, USA), and, currently, 
an erythropoietin-Fc fusion and a nanobody-targeting respiratory syncytial virus are in clinical trials, 
showing promise for the further development of this administration strategy for both the systemic 
and localized delivery of mAb-based therapeutics [5,28]. 
Several drug carrier technologies such as microencapsulation, liposome, and nanoparticle 
formulations inherently enhance the stability and control the release of mAbs, which can prolong 
their half-life. These nanocarrier formulation strategies are of intense interest, as they hold promise 
for developing less invasive inhaled formulations of mAb-based therapeutics with superior attributes 
to currently established formulations [41,106–109]. 
The majority of currently approved mAb therapeutics are formulated for IV, although 
commercial interest has directed technologies to develop injectable mAb formulations which has seen 
success in many approved mAb therapies thus far, primarily SC for systemic delivery, along with a 
few intravitreal and intramuscular formulations for tissue-specific indications. Amongst others, anti-
HER2 antibody trastuzumab was originally developed as an IV formulation and was successfully 
repurposed as a SC formulation [110–112], whereas next generation therapies have directly moved 
towards SC formulation, such as with anti-TNF-α antibody adalimumab [113]. Injectable 
administrations offer several advantages over IV administration, especially in the treatment of 
chronic diseases in regards to a reduced burden to allied health services, patient tolerance, and 
adherence to treatment; however, the intrinsic physicochemical properties of mAbs may be 
undesirable for injectable formulation. In considering the low volume, injection pressure, and the 
typically high (>100 mg) effective dose of mAb for injectable delivery, the viscosity and aggregation 
propensity of mAbs become key formulation challenges to address, as they are dependent on mAb 
concentration. Certain mAb therapies are suitable, and others are not based on their solubility, 
viscosity, self-association, intrinsic stability, aggregation, and precipitation profiles. 
Injectable mAb formulations can be further improved with the use of excipients to increase 
solubility, reduce viscosity, and enhance the stability of mAbs. Excipients are considered for a 
formulation based on their physicochemical properties, pharmacokinetics, and safety. For example, 
polysorbates are commonly used in biologics as a stabilizing agent; however, their addition in high 
concentrations can denature proteins and cause adverse side effects such as injection site reactions 
[114–116]. Injectable mAb formulations are co-formulated with recombinant human hyaluronidase, 
specifically as a permeation enhancer for more efficient absorption into tissue, although the inclusion 
of this additional biologic adds further burden to the formulation’s viscosity and propensity to 
aggregate [5,8,25–28,117–123]. Antibody therapies for IV administration are prepared as lyophilised 
powder for reconstitution and further dilution, and injectable administrations are prepared as liquid-
based formulations in pre-filled syringes. Liquid formulations of mAbs are more susceptible to 
physiochemical degradation, are less stable, and have a reduced shelf-life as compared to lyophilised 
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formulations. However, drying technologies to produce lyophilised formulations apply the mAb to 
physical stresses that induce instability and degradation, leading to reduced efficacy [124–126]. 
Long-term stability predictions are elucidated from formulation screening in accelerated 
aggregation studies, as part of the preliminary screening process of generated mAb libraries [127]. 
The stability profiles of mAbs can be greatly affected by the amino acid composition, structure, and 
potential glycosylation in their variable region CDRs that are isolated through the screening and 
maturation process. Elucidating the causes for reduced solubility or increased aggregation 
propensity has to be considered together with the molecular interactions between the mAb and the 
biological target as to not compromise affinity. Computational tools have been developed to elucidate 
amino acids within the mAb CDR structure that have a high propensity to aggregate, and strategies 
for improving solubility and aggregation profiles have been developed through direct amino acid 
substitutions and the strategic addition of glycosylation sites [128–132]. The characterization of mAb 
stability and target interaction for optimization is considered a fundamental step as part of 
preliminary drug discovery, as the applicability for development, manufacture, and formulation of 
the mAb therapeutic is governed by the mAbs stability profile. 
5. Improving mAb Tissue Penetration for Cancer Treatment 
Antibody therapies are currently restricted to invasive parenteral routes of administration for 
maximum bioavailability and systemic distribution; however, delivery to the specific target tissue, 
such as tumors for cancer treatments, continues to be a challenge. Penetration to tissue from blood 
vessels is again poor, owing to mAbs’ polar surface charge and relatively large MW, limiting 
transport through physiological barriers. The efficiency of tissue penetration is further influenced by 
systemic and local mAb clearance rates. Enhancement to mAbs’ affinity to their biological target 
through maturation and strategic mutation technologies have led to faster diffusion rates of mAb to 
target for increased efficacy. However, for tumourous tissue specifically, penetration through tumors 
is restricted by the tumor’s binding site barrier, in which antigens expressed on the tumors periphery 
capture the majority of the mAb released to surrounding tissue; this effect is exaggerated with 
overexpressed antigen. The enhancement of whole mAbs’ affinity beyond 1 nM has specifically 
shown that there is no further improvement of tumor diffusion rates, tissue penetration, and 
accumulation [42,43,133]. An increased affinity of mAbs to cellular targets also leads to the increased 
uptake, internalization, and catabolism of mAbs, which reduces ADCC and increases the mAb 
clearance rate. This mechanism is exploited through the development of high affinity ADCs to target 
the delivery and release of potent drugs, inducing targeted cell death [43–45]. 
Fragment mAb platforms have shown better tissue penetration and biodistribution than whole 
mAb therapeutics; however, a pitfall of smaller peptides lacking an Fc region is a highly reduced in 
vivo half-life and poor retention times. Technologies to improve the half-life of mAb fragments have 
been primarily through PEGylation, along with strategic Fc mutation and glycosylation engineering 
to enhance neonatal Fc receptor (FcRn) recycling. Furthermore, hyper-glycosylation technology has 
been successfully applied in other biotherapeutics, such as with glycosylated erythropoietin 
Aranesp® (Amgen, Thousand Oaks, CA, USA). Conversely, nanocarrier platforms that are relatively 
larger as compared to whole mAbs have demonstrated superior pharmacokinetics and tumor 
retention, as well as previously mentioned enhanced stability and the sustained, controlled release of 
mAbs [41]. These enhanced properties have generated considerable interest in developing the 
systemic delivery of mAb-nanoparticle platforms for superior tumor penetration, as well as targeted 
and sustained therapeutic drug delivery. Further to nanocarriers, additional formulation strategies 
developed for the controlled release of mAbs include hydrogels and crystalline antibodies, which 
have shown success as stable, injectable formulations for development [5,8,15,41–43,134–136]. 
In addition, to further enhance the stability and half-life of other biotherapeutics, recombinant 
technologies allowed their fusion to mAb Fc as to introduce FcRn recycling as a protection 
mechanism, which has innovatively expanded the applicability of mAb-based therapeutic platforms. 
Notable examples include the TNF Receptor–Fc fusion protein Enbrel® (Amgen, Thousand Oaks, CA, 
USA), which acts as an inhibitor to overexpressed TNF-α in autoimmune diseases, and the Factor IX–
Antibodies 2019, 8, 36 11 of 22 
 
Fc fusion protein Alprolix® (Biogen, Cambridge, MA, USA), which is a blood factor supplement for 
hemophiliacs [11,46,133]. 
6. Strategic Modulation of mAb Immune Effector Functions 
The modulation of mAbs effector functions through isotype switching, glycoengineering, and 
strategic mutations have proved advantageous for the development of more effective mAb treatment 
strategies. Antibody binding to Cq1 promotes the complement cascade, FcγR1A/B, FcγR2A, and 
FcγR3A/B receptors to activate immune effector functions; FcγR2B counter-balances the effector 
response, and FcRn prolongs mAb half-life. Binding to these receptors is primarily done through sites 
in the Chinge, CH2, and the conserved glycosylation region in the Fc (N297). 
IgG3 does not efficiently bind to FcRn, which reduces its half-life to approximately seven days, 
as opposed to a 21 day half-life for the other IgG isotypes. In most instances of mAb design, an 
extended half-life is preferred as to prolong the effective dose of a mAb in serum [15]. IgG2 and IgG4 
mAbs have a reduced effector function as compared to IgG1 and are thus used in instances where 
minimal engagement to the immune system is warranted to increase safety of the mAb therapy—
with ADCs reducing off-target cytotoxicity, for instance. Eculizumab (Soliris®, Alexion 
Pharmaceuticals, New Haven, CT, USA) is the first (and thus far only) approved recombinant IgGκ 
2(CH1/Chinge)–4(CH2/CH3) hybrid whole mAb. Further cross-sub-class variant mAb therapies are in 
development, with key amino acid substitutions from the IgG2 and IgG4 sub-classes introduced for 
intentionally suppressed effector functions [4,13]. The removal of the conserved glycosylation site 
through amino acid substitution of N297 or T299 (aglycosylation) has also demonstrated reduced 
effector function; however, this happens at the expense of mAb stability and is therefore not a suitable 
strategy for whole mAb therapeutics [11,14,15,137–140]. 
On the other hand, enhancing ADCC and CDC is useful for engaging the immune system to 
tumor tissues in the absence of a conjugated cytotoxic drug. Certain glycoengineered modifications 
to the conserved glycosylation region in the Fc, such as deficiency in core fucose (afucosylation) and 
hyper-galactosylation, have demonstrated enhanced mAb binding to FcγR3A and Cq1, specifically 
for an enhanced ADCC and CDC effect [13,43]. Afucosylated mAbs benralizumab (Fasenra™, 
AstraZeneca, London, UK) and mogamulizumab (Poteligeo®, Kyowa Hakko Kirin, Tokyo, Japan), as 
well as low fucose content mAb obinutuzumab (Gazyva®, Genentech, San Francisco, CA, USA), are 
currently approved therapies, with several further in development (along with clinical trials), which 
demonstrates the commercial interest and applicability of this technology in improving mAb 
therapeutics through enhancing ADCC. However, the significance of manipulating sialylation in 
mAb therapeutics is a controversial topic, with several reports demonstrating a reduction in ADCC 
and CDC and others reporting no observable difference. This highlights a clear need to characterize 
and define the in vivo efficacy of such manipulation [11,13,14,43]. 
No currently approved mAb therapies contain amino acid substitutions for an improved half-
life through modulated binding properties to FcRn, improved CDC through binding to complement 
factor Cq1, or improved ADCC through enhanced binding affinity to FcγR1A and 3A. However, 
several mutations have been reported, patented, and are in clinical development, demonstrating the 
commercial interest in this technology for improving mAb therapeutics [6,11,13,15,133,137,140–143]. 
For a more comprehensive understanding of mAb engineering strategies for modulated immune 
effector functions, we direct the reader to the following reviews [13–15,140]. 
7. Computational Approaches for Aggregation Prediction and Rational Design of mAbs 
The advancement of in silico analysis of mAb peptide sequences, structures, conformation, and 
their associated biological interaction has been integral to the development of various computational 
tools for characterizing, designing, and optimizing mAb-based therapeutics. The generation and 
continued pursuit of mAb structural data for in silico analysis has led to the development of several 
integral databases, notably IMGT®, serving as a key resource for data mining [144–146]. Molecular 
dynamic (MD) simulation analysis has driven the computational analysis of the discovery and 
characterization of relevant molecular interactions within the mAb molecule, mAb binding to 
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biological targets and mAb surface association with the surrounding environment. These interactions 
can infer intrinsic stability, target binding associations, solubility and aggregation propensity of the 
mAb. MD simulations and free energy calculations from crystal structures remain key for the highly 
specific elucidation of mAb-target intermolecular interactions that correlate to binding affinity, as 
significant interactions such as hydrogen-bond formation can be predicted and determine the 
strength of the molecular associations [147]. However, elucidation of mAb self-association, solubility, 
and aggregation propensity have been driven by the development of computational modelling and 
simulation tools that simultaneously analyses mAb topography and surface polarity. Notably, 
AGGRESCAN3D, TANGO, and PASTA are the most prominent tools for predicting the site specific 
aggregation propensity of mAbs [35,148]. 
The preliminary elucidation of mAb structural data—that being amino acid sequences and 
higher order structure (HOS)—is experimentally derived to produce crystal structures that model the 
solid-state 3D structure of the mAb. Mass spectrometry technologies have come of age to produce 
high throughput and orthogonal analysis to elucidate mAb peptide sequences, oxidation, 
deamidation, and glycosylation heterogeneity, as well as, more recently, for native, destabilized, and 
aggregated HOS elucidation [149,150]. X-ray crystallography technologies have been the underlying 
workhorse for elucidating the crystal structure of mAbs. Producing crystalline mAbs is challenging, 
owing to the complexity of mAb HOS and the degree of mAb conformational heterogeneity. 
However, several complementing technologies have evolved in recent years to ascertain structure 
and interactions, including circular dichroism (CD), infrared (IR) and raman spectroscopy, cryogenic-
electron microscopy, and nuclear magnetic resonance (NMR) spectroscopy [148,150–157]. Of the 
technologies available for HOS elucidation, 2D-NMR and X-Ray crystallography (followed by MS) 
provide the highest sensitivity and local specificity. In comparison, CD, IR, and raman are high-
throughput methods, although they have much lower sensitivity [150,157]. 
Thus far, only four whole IgG antibodies have a successfully determined crystal structure (PDB 
ID: 1HZH, 1IGT, 1IGY, and 5DK3), notably 1HZH as a wholly human IgG1 and 5DK3 as a humanized 
IgG4/κ, both of which have been used as model structures for MD simulations [158]. However, 
fragment mAbs yield much higher success with producing crystal structures, which has led to much 
pursuit and contribution in generating mAb fragments and targetting complexing crystal structure 
libraries for data mining and in silico analysis [159,160]. 
Upon obtaining relevant crystal structures for a candidate mAb, detailed crystal structure and 
MD simulation analysis has been extensively used to elucidate the mAbs intramolecular interactions 
that confer intrinsic stability and intermolecular interactions to confer interactions to biological 
targets and self-association. The particular binding interface of interest is analyzed, and amino acids 
in the mAb structure are identified for substitution that can disrupt molecular interactions in the 
interface in the instance of diminishing target binding and identify potentially unutilized bonding 
sites and polarity mismatches in the interface that can be improved in the instance of enhancing target 
binding. MD simulations are then carried out for the native and substituted mAb structures to 
elucidate any relevant bond formations, interactions, and more favorable binding free energy 
produced by the substituted structure, of which promising candidates can be synthesized and 
validated through in vitro analysis. This predictive approach has been successfully applied to identify 
mutations in mAbs for modulating effector functions, target binding, optimizing affinity capture for 
manufacturing, and, more recently, for designing antibodies de novo from targets of interest [11,161–
165]. Mutations have been specifically identified for enhanced binding to FcγR2A, FcγR3A, and Cq1, 
as well as a reduced binding to FcγR2B for a more pronounced ADCC and CDC effect, an enhanced 
binding to FcRn for an extended half-life, and a reduced binding to FcγRs and Cq1 for a diminished 
ADCC and CDC effect, all of which are transferrable to mAbs of the same isotype sub-class 
[137,141,142]. Further to this, the molecular interactions of glycoengineered mAb variants to FcRs 
have been characterized through MD simulations to corroborate predictions with the observed 
modulated effector functions [13,15,137,141,142]. 
Self-association, solubility, and aggregation propensity are further evaluated by computational 
modelling tools that specifically characterize the topography and surface polarity of mAbs, 
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concurrently analyzing the local spatial arrangement of amino acids in the mAb structure, solvent 
accessibility, and local surface charge [5]. In particular, surface exposed hydrophobicity is sought as 
the lead mechanism for protein self-association driving aggregation propensity, in which 
aggregation-prone regions (APRs) are identified in the mAb structure. The substitution of identified 
APRs to gatekeeper (i.e., polar) amino acids has experimentally demonstrated resistance to 
aggregation and improved solubility, which validates this strategy for improving mAb stability [36–
40,166–170]. The majority of APRs identified are located in biologically relevant mAb regions—those 
being the CDRs and the Fc. Specifically targeting these APRs through mutation may disrupt 
important biological functions and mAb structure. Analyses of the mAbs intermolecular interactions 
are necessary to validate the intrinsic stability of substituted mAb variants; if conformational 
fluctuations are elucidated, then the biologically active interface is likely disrupted. Interestingly, 
mutations for enhancing biological functions have demonstrated a negative impact on mAb solubility 
and stability, further suggesting that the self-association profile of mAbs is linked to its biological 
activity [36,128,171]. 
Aside from direct residue substitution in mAb structures, other strategies reported to 
profoundly interfere with the effects of APRs include isotype switching and the strategic addition of 
N-linked glycans [39,128,172,173]. Additionally, N-linked glycosylation in the CDR regions of mAbs, 
although uncommon, has demonstrated improved solubility and stability profiles of mAbs without 
impacting their target affinity, as compared to the same mAbs with removed CDR glycans [128,174]. 
The rationale behind strategic glycan addition is based on the election of N-linked glycosylation sites 
that have apparent spacial proximity to APRs, with the introduced glycan therefore sterically 
hindering the APR from self-association interactions. The benefits of extending mAb half-life with 
strategic glycan addition, as seen with hyper-glycosylated biotherapeutics (as well as improving mAb 
solubility and stability for improved formulation strategies) has yet to be realized and suggests a very 
intriguing and highly relevant technology for perusal. 
8. Concluding Remarks 
Therapeutic antibodies have come of age as continuing to be a key, dominant technology in the 
biopharmaceutical industry. The repurpose of antibodies to many formats have made them versatile 
to design and tailor highly specialized treatments, including ADCs as a targeted drug delivery 
system, bispecific and fragment mAb platforms for tailored engagement and increased 
bioavailability, and recombinant Fc-fusion proteins for an increased half-life and introduced 
immunological engagement. Further advancements include the modulation of Fc effector functions 
through manipulations of the Fc, either through isotype switching, glycoengineering, or strategic 
mutations in the Fc region, along with the PEGylation of fragment mAbs for enhanced half-life. 
Advancements in discovery, manufacture, and formulation technologies have further propelled the 
success of therapeutic antibodies, notably through expression system development and the transition 
from IV to SC formulations. Human-based expression systems have been extensively used in mAb 
development and are becoming an accepted manufacturing platform for mAb therapeutics. 
Furthermore, cell-free synthesis technology is giving rise to the potential for higher efficiency in the 
manufacture process. 
Though developments for further generation antibody therapies have led to great strides in 
producing improved therapeutic outcomes, many facets of the manufacture process and formulation 
development strategy pose as challenges to be considered. Antibody-based therapies are susceptible 
to chemical and enzymatic degradation through oral, nasal, or pulmonary routes of administration 
and are therefore currently restricted IV or SC delivery. Despite achieving maximum bioavailability 
through IV/SC administration, tissue penetration of mAb-based therapies is poor, which limits their 
local bioavailability, requiring high concentrations to achieve an effective dose. The stability of mAbs-
based therapeutics is a highly pronounced and recurring challenge to be considered, as it affects 
manufacture yield and formulation considerations. Several strategies are in development to improve 
the stability of mAbs in order to potentially produce formulations for pulmonary or oral 
administration. Notably, computational tools have come of age, complementing experimental 
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techniques to derive antibody structure and aggregation prediction. Through these methods, the 
stability and aggregation propensity of mAb-based therapies have demonstrated improvement 
through rational mutation and glycosylation within the framework region, which is potentially 
translatable to all mAbs within the same isotype. Furthermore, nanocarrier technologies have been 
shown to enhance the stability and potentially control the release of mAbs. The refinement of rational 
mAb design coupled with nanocarrier technologies has the potential to overcome these challenges, 
to develop superior treatment strategies, and ultimately to formulate for non-invasive administration 
routes such as pulmonary delivery. 
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Mutant Region Proposed Function
A
CH1
Remove APR by introducing polar amino acid [1]
B Remove APR and introduce glycosylation site [1]
C Ckappa Sterically hinder APR by introducing glycosylation 
site [1]
D
CjoinE
Improve solubility by introducing glycosylation site [2]F
CH1
G Sterically hinder APR by introducing glycosylation 
site [1, 2]H
I Improve solubility and sterically hinder self-
association by introducing glycosylation site [2, 3]
Tm1 (°C)  Tm2 (°C)  Tagg (°C) 
Tmab 68.5 81.3 81.54
A 69.0 79.3 78.51
B 70.5 78.8 82.13
D 71.0 81.9 74.15
E 54.9 68.3 ND
F 69.6 80.5 82.41
G 69.4 80.5 82.22
H 68.6 81.3 64.83
I 69.8 82.5 80.61
Table 1: Surface exposed amino acid residues identified in 
trastuzumab Fab region for substitution.
INTRODUCTION Antibodies like many biologics, are lost in production
and storage due to degradation and aggregation. Current formulation
strategies to enhance stability include addition of stabilising excipients
and lyophilisation.
Trastuzumab (Herceptin®) is used to treat HER2 positive breast
cancers and possesses homology to many antibody therapeutics.
Modifications in the peptide sequence of trastuzumab that prove
successful in enhancing stability may be applied to the whole class of
IgG1 antibodies, which can lead to improved formulation,
administration and treatment strategies.
AIM This study reports on the strategic addition of N-linked glycans to
the Fab region of trastuzumab for the purpose of enhancing its
intrinsic stability.
Table 2: Melting temperature (Tm) and onset of aggregation (Tagg)
of Tmabs and mutants. Intrinsic tryptophan fluorescence and static
light scattering measurements were taken simultaneously over a
temperature ramp. Mutant E became unstable compared to Tmab,
whereas mutants B, F and G showed enhanced intrinsic stability and
resistance to aggregation.
Table 3: Kinetics and binding affinity of Tmab mutants to HER2, FcyR1A and FcγR3A (± SD) measured
through surface plasmon resonance. Single cycle kinetics was performed to assay Tmab and mutants
over a receptor captured surface. With the exception of mutant E (not shown) Tmab and mutants showed
similarity in binding kinetics; the biological functions of the mutants had not been compromised.
DISCUSSION It was found that glycosylated mutants B, F and G
exhibited enhanced intrinsic stability and that all mutants (except E)
retained their biological functions as compared to Tmab. Also, despite
successful mutation, glycan addition in mutant C was unsuccessful,
which is contrary to previous reports on this mutation [1].
CONCLUSION The successful mutants warrant further investigation
and demonstrate the effectiveness of our approach for the
development of highly stable whole therapeutic antibodies. This can
lead to improved formulation, administration and treatment strategies,
and may increase antibody half-life and yield from production
processes.
HER2   KD (pM) FcγR1A    KD (nM) FcγR3A    KD (nM)
Tmab 12.11 ± 2.72 5.05 ± 0.33 1.13 ± 0.32
A 72.97 ± 3.64 2.90 ± 0.01 1.00 ± 0.25
B 34.28 ± 2.01 3.00 ± 0.15 10.67 ± 1.03
C 33.53 ± 15.86 2.59 ± 0.02 3.78 ± 0.46
D 47.56 ± 25.89 2.34 ± 0.26 8.17 ± 1.60
F 54.24 ± 10.24 2.29 ± 0.08 7.01 ± 3.84
G 31.88 ± 2.11 1.25 ± 0.02 5.04 ± 1.47
H ND 3.37 ± 0.22 6.24 ± 1.30
I 83.44 ± 77.77 1.72 ± 0.03 3.81 ± 0.41
Figure 3: Titration of Tmab and mutants to SK-BR 3. Affinity of
Tmab and mutants to surface receptor HER2 were tested in situ
against SK-BR 3 by an endpoint titration assay detected with flow
cytometry. All Tmab mutants retained affinity to HER2 exposed on the
cell surface.
Figure 2: Reducing SDS-PAGE gel of several trastuzumab (Tmab)
mutants. Mutants B, D (not shown), E, F G, H and I showed
glycosylation in the heavy chain. Mutant C was not glycosylated in the
light chain (not shown).
Successful mutation and glycan addition was confirmed through mass
spectrometry (not shown). Glycan addition was unsuccessful for
mutant C, so was excluded from further stability assessment.
Tmab       A          B         G          I           E          H          FkDa
250
150
100
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Figure 1: Crystal structure 1n8z of trastuzumab Fab fragment complexed to extracellular domain of
HER2 receptor. Trastuzumab VH/CH1 (blue), VL/CL (green), HER2 fragment (orange), aggregation prone
region (APR) elected for this study (red) and surface exposed amino acids identified for substitution to an N-
linked glycosylation site (purple).
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Available online 2 December 2016It has been over four decades since the development of monoclonal antibodies (mAbs) using a hybridoma cell
line was ﬁrst reported. Since thenmore than thirty therapeutic antibodies have beenmarketed, mostly as oncol-
ogy, autoimmune and inﬂammatory therapeutics.While antibodies are very efﬁcient, their cost-effectiveness has
always been discussed owing to their high costs, accumulating to more than one billion dollars from preclinical
development through to market approval. Because of this, therapeutic antibodies are inaccessible to some pa-
tients in both developed and developing countries. The growing interest in biosimilar antibodies as affordable
versions of therapeutic antibodies may provide alternative treatment options as well potentially decreasing
costs. As certain markets begin to capitalize on this opportunity, regulatory authorities continue to reﬁne the re-
quirements for demonstrating quality, efﬁcacy and safety of biosimilar compared to originator products. In addi-
tion to biosimilars, innovations in antibody engineering are providing the opportunity to design biobetter
antibodieswith improved properties tomaximize efﬁcacy. Enhancing effector function, antibody drug conjugates
(ADC) or targeting multiple disease pathways via multi-speciﬁc antibodies are being explored. The manufactur-
ing process of antibodies is also moving forward with advancements relating to host cell production and puriﬁ-
cation processes. Studies into the physical and chemical degradation pathways of antibodies are contributing to
the design of more stable proteins guided by computational tools. Moreover, the delivery and pharmacokinetics
of antibody-based therapeutics are improving as optimized formulations are pursued through the implementa-
tion of recent innovations in the ﬁeld.
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Over the past twenty years, therapeutic antibodies have rapidly be-
come the leading product within the biopharmaceutical market. In
2013, therapeutic antibodies represented 50% of the $140 billion taken
by the biopharmaceutical market with sales growing from $39 billion
in 2008 to $75 billion in 2013 [1]. There are currently more than thirty
therapeutic antibodies approved for established markets such as the
United States and Europe with over three hundred antibody-based
products in clinical development [1–3]. Therapeutic antibodies are no
longer full-length, naked mouse antibodies; advancements in antibody
engineering technologies, novel antigen discovery strategies and prog-
ress in deciphering disease pathways have all generated robust interest,
resources and investment in antibody development. In this review, we
will discuss developments in the ﬁeld of therapeutic antibodies, the
growth of biosimilars and pay particular attention to targeting degrada-
tion pathways of antibodies to producemore stable biobetter antibodies
and formulations.
2. Antibody discovery strategies
The generation of early antibodies relied on the immunization of
mice or other mammals with the desired antigen target. This resulted
in multiple antibodies directed at different epitopes of the antigen se-
creted by a mixed population of B cells with each cell secreting only
one speciﬁc antibody (i.e. polyclonal). Unfortunately, secreting B cells
can only replicate a limited number of times, therefore rendering mass
production all but impossible. The ground-breakinghybridoma technol-
ogy developed by Kohler and Milstein allowed antibody secreting cells
from the spleen of immunized animals to be fused with immortalized
non-antibody secreting cells, thus resulting in cells that would divide
continuously when cultivated in permissive conditions [4,5]. Although
the ﬁrst recombinant antibodies were produced using this technology,
including the ﬁrst approved therapeutic antibody muromonab-CD3
(OrthocloneOKT®3) in 1986 for preventing kidney transplant rejection,
hybridoma production presented some drawbacks. Hybridomas can be
labor intensive, low yielding or genetically unstable [6]. More impor-
tantly though, the antibody sequences originated from an immunized
animal and consequently had the potential of triggering an immune re-
sponse in humans. Therefore, further improvements were needed to
yield antibodies more human-like and safe. These technologies have
evolved from chimeric antibodies that is, grafting essential mouse
amino acids needed for antigen binding onto a human antibody frame-
work [7,8], to both in vitro and in vivo techniques for generating human-
ized antibodies.
The XenoMouse™ (Abgenix) and HuMab-Mouse® (Medarex) are
transgenic mice developed in parallel and in both, the endogenous mu-
rine heavy and kappa light chain genes are inactivated and replaced
with the equivalent human germline sequences [9,10]. Injection of anti-
gens into these mice leads to development of ‘fully human’ antibodies
that have undergone mouse somatic hypermutation and selection to
relatively high afﬁnity. Validation of this technology camewith the reg-
ulatory approval of panitumumab (Vectibix®) in 2006; a fully human
antibody directed against epidermal growth factor receptor (EGFR) as
treatment for advanced colorectal cancer [11]. Since then, RANK
ligand-speciﬁc denosumab (Prolia®) has been approved for bone loss
and TNF-speciﬁc golimumab (Simponi®) for rheumatoid arthritis.
An in vitromethod for generating fully human antibodies can be ac-
complished by cloning and screening large libraries of sufﬁciently di-
verse human antibody genes in combination with display technology.The concept of display technology provides a direct physical link be-
tween a gene (genotype) and the encoding antibody fragment (pheno-
type) to allow selection of genes that encode a protein with the desired
binding function. Phage display technology remains the most widely
used in vitromethod for the display of large repertoires and for the se-
lection of high afﬁnity antibodies to biologically relevant targets [6].
Phage display involves the expression of proteins on the surface of ﬁla-
mentous phage via fusion with phage coat protein with the genetic se-
quence packaged within, linking phenotype to genotype selection.
When combined with antibody libraries, phage display allows for
rapid in vitro selection of antigen-speciﬁc antibodies and recovery of
their corresponding coding sequence [12–14]. This system is highly ef-
fective, robust and amenable to high throughput processes for screening
of N1010 speciﬁcities [15]. The diversity of phage display libraries is dis-
tinguishable by source and design: naïve [16], immune [12], synthetic
[17] and semi-synthetic [18]. The technology was ﬁrst demonstrated
for a single chain variable fragment (scFv) [13] with screening of other
formats also introduced including human antigen binding fragments
(Fabs) [19], domain antibodies [20], camelid domain antibodies [21],
single domain shark antibodies [22], diabodies [23] and even whole
IgG [24]. The ﬁrst approved human antibody isolated by phage display
technology was adalimumab (Humira®) which binds the cytokine
TNF. This antibody was ﬁrst selected as a scFv expressed on the surface
of phage and was further engineered in human IgG1 format, providing
major validation for phage display technologies [25]. Adalimumab re-
mains the most lucrative antibody product generating global sales of
$11 billion in 2013 [1]. The number of phage display-derived candidates
currently in clinical development further demonstrates the value of
phage display as an established and reliable drug discovery platform
[26].
Other cell surface methodologies such as bacterial, baculovirus and
yeast display present thousands of copies of the displayed protein on
the cell surface thereby allowing for quantitative screening such as
ﬂow cytometry [27–29]. Yeast display has the additional feature of eu-
karyotic protein folding pathways and as a result, is perhaps the most
ideally suited system for the surface display of mammalian secreted
proteins such as antibodies. Alternatively, ribosome display is used to
screen large scFv and single variable domain libraries containing up to
N1013mutant clones [30]. Themain distinguishing feature of this meth-
od is that large libraries can be generated because the entire procedure
is performed in vitrowithout the need for cell transformations. The ge-
notype and phenotype are linked through ribosomal complexes,
consisting of messenger RNA (mRNA), ribosome and encoded protein.
The in vitro selection of antibodies from antibody libraries based on tar-
get afﬁnity is termed “panning”. The method is an iterative process
whereby the population of target speciﬁc antibodies is enriched relative
to the number of panning rounds.
With the advent of next-generation sequencing (NGS), analysis of
the natural and synthetic repertoires from which libraries have been
constructed has become possible [31–33]. In one application, NGS was
used to identify antigen-speciﬁc IgG antibodies from polyclonal serum
of immunized rabbits andmice when used in combination with afﬁnity
chromatography coupled to LC-MS/MS [34]. The technology has been
used to demonstrate its utility in selecting antibodies with favorable
properties. For example, Reddy et al. found that 21/27 (or 78%) of scFv
they constructed could bind the target antigen with nanomolar afﬁnity
after using NGS data to pair together the most abundant variable heavy
(VH) and variable light (VL) genes from immunized mice [35]. Other
studies have seen similar ﬁndings with natural VH:VL pairing limita-
tions [36] and without the limitation [37]. Interestingly, the method of
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isolated from immunizedmicewas comparedwith a phage panning ap-
proach of the same cDNA [38].While bothmethods provided complete-
ly different sets of antibodies, speciﬁcity and afﬁnities of the antibody
clones were comparable.3. Novel antibodies in approval and preclinical development stages
In 2015, eight therapeutic antibodies were granted market approval
by the United States Food and Drug Administration (FDA) (Table 1).
While full-length and IgG1 antibodies still dominate, a humanized Fab
also gained approval. Five of the eight approvals were to non-
oncology indications with two antibodies entering ‘ﬁrst-in-class’ for
the treatment of hyperlipidemia. The outlook for 2016 has been positive
with six antibodies approved (as of November 2016), including a ﬁrst-
in-class antibody to bacterial target Bacillus anthraxis. A number of
full-length antibodies are currently under biologics license applicationTable 1
Novel full-length antibodies and fragments developed in recent years and their clinical status.
Name Commercial
name
Company Target
Approved by FDA in 2015
Secukinumab Costentyx® Novartis IL-17
Dinutuximab Unituxin® United Therapeutics
Corporation
GD2
Alirocumab Praulent® Sanoﬁ PCSK9
Evolocumab Repatha® Amgen PCSK9
Idarucizumab Praxbind® Boehringer Ingelheim Dabigatran
Mepolizumab Nucala® GlaxoSmithKline IL-5
Necitumumab Portrazza® Eli Lilly EGFR
Daratumumab Darzalex® Janssen Biotech CD38
Approved by FDA in 2016 (as of November)
Reslizumab Cinquil® Teva IL-5
Ixekizumab Taltz® Eli Lilly IL-17a
Obiltoxaximab Anthim® Elusys Therapeutics Bacillus anthrax
Atezolizumab Tecentriq® Genentech PD-L1
Olaratumab (+
Doxorubicin)
Lartruvo® Eli Lilly PDGFRalpha
Bezlotoxumab Zinplava® Merck Clostridium difﬁcile
toxin B
Not yet approved, trials completed
Brodalumab Valeant Pharmaceuticals IL-17R
Bimagrumab Novartis ACVR2B
MABp1 Xilonix XBiotech IL-1alpha
Catumaxomab Removab Trion Pharma EPCAM/CD3
Guselkumab Janssen Biotech IL-23/p19
Dupilumab Sanoﬁ/Regeneron IL-4R
Ongoing Phase III trials
Ocrelizumab Ocrevus Roche CD20
Sirukumab GlaxoSmithKline IL-6
Sarilumab Sanoﬁ/Regeneron IL-6R
Tildrakizumab Sun Pharmaceutical IL-23/p19
Romosozumab Amgen/UCB Pharma Sclerostin
Racotumomab Vaxira Recombio NGcGM3
Clivatuzumab
tetraxetan
hPAM4-Cide Immunomedics Mucin1
Ublituximab TG Therapeutics CD20
Benralizumab AstraZeneca IL-5R
Caplacizumab Ablynx vWF
Lampalizumab Roche CFD
Avelumab Merck/Pfzier PD-L1
Aducanumab Biogen Beta amyloid
Abbreviations: GD=disialoganglioside; PCSK=proprotein convertase subtilisin/kexin; EGFR=
derived growth factor receptor; ACVR = activin receptor; EPCAM= epithelial cell adhesion m
complement factor.(BLA) submission and awaiting FDA approval or have completed
Phase III trials with endpoints met (Table 1).
There is expected to be an inﬂux of antibodies in the coming years
for the treatment of inﬂammatory skin conditions including psoriasis,
encompassing various cytokine targets or their respective receptors;
IL-17a, IL-17R, IL-1α, IL-4R and IL-23 (Table 1). Other promising anti-
bodies based on recent clinical trial results include ocrelizumab and
atezolizumab. Ocrelizumab is a humanized antibody which selectively
targets CD20-positive B cells which based on emerging evidence play
amajor role in activating T cells, the key cell type responsible for inﬂam-
matory damage within central nervous system lesions in multiple scle-
rosis (MS) [39]. Data from three Phase III studies (OPERA I, II and
ORATORIO) show positive results in patients with relapsingMS and pri-
mary progressive MS (PPMS) with superiority to well-established ther-
apy (Rebif®), by reducing the three major markers of disease activity.
Atezolizumab is a monoclonal antibody designed to target PD-L1
expressed on T cells and tumor-inﬁltrating immune cells, preventing
binding to PD-1 and B7.1 to mediate T cell immune responses. PositiveIndication (FDA approved) Format
Psoriasis Whole IgG1 (fully human)
Neuroblastoma (pediatric
patients)
Whole IgG1 (chimeric)
Hyperlipidemia Whole IgG1 (fully human)
Hyperlipidemia Whole IgG2 (fully human)
Anti-coagulation reversal Fab fragment (humanized)
Asthma Whole IgG1 (humanized)
Non-small cell lung cancer
(NSCLC)
Whole IgG1 (fully human)
Multiple myeloma Whole IgG1 (fully human)
Asthma Whole IgG4 (humanized)
Psoriasis Whole IgG4 (humanized)
Anthrax Whole IgG3 (humanized)
NSCLC, Bladder cancer Whole IgG1 (humanized)
Soft tissue carcinoma Whole IgG1
Clostridium difﬁcile infection Whole IgG1 (fully human)
Psoriasis Whole IgG1 (fully human)
Muscle loss and weakness Whole IgG1 (fully human)
Colorectal cancer, Cachexia Whole IgG1 (‘true’ human)
Malignant ascites Whole hybrid of rat IgG2 variable and mouse
IgG2a Fc regions
Psoriasis Whole IgG1 (fully human)
Atopic Dermatitis Whole IgG4 (fully human)
Multiple Sclerosis Whole IgG1 (humanized)
Rheumatoid arthritis Whole IgG1
Rheumatoid arthritis Whole IgG1 (fully human)
Psoriasis Whole IgG1 (humanized)
Osteoporosis Whole IgG2 (humanized)
NSCLC Whole IgG1 (mouse)
Pancreatic cancer Whole IgG1 (humanized)
Chronic Lymphocytic Leukemia Whole IgG1 (chimeric)
Asthma Whole IgG1 (humanized)
Thrombotic thrombocytopenic
purpura
VH-VH (humanized)
Macular degeneration Fab fragment (humanized)
Merkel Cell Carcinoma Whole IgG1 (fully human)
Alzheimer’s Disease Whole IgG1 (fully human)
epidermal growth factor receptor; PD-L=programmeddeath-ligand; PDGFR=platelet-
olecule; NGcGM= N-glycolyl (NGc) gangliosides; vWF = Von Willebrand factor; CF =
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tients with advanced non-small cell lung cancer (NSCLC) show strong
correlation between PD-L1 expression and response rates, suggesting
that measuring PD-L1 may help identify people most likely to respond
to antibody treatment. Atezolizumab has since been granted FDA ap-
proval (after priority review) for treatment of a speciﬁc type of bladder
cancer and NSCLC.
A number of novel formats and treatment options are also likely to
enter the market in 2017. Of note based on novelty, are racotumomab,
ublituximab, MABp1 and caplacizumab. Racotumomab is an anti-
idiotypic mouse monoclonal antibody that mimics N-glycolyl (NGc)
gangliosides, thus triggering responses against tumor antigen
NGcGM3 [40]. The idiotypic antibody acts as a therapeutic vaccine by in-
ducing the immune system to elicit a speciﬁc response. A Phase III clin-
ical trial is ongoing in advanced NSCLC patients.
Ublituximab is a chimeric monoclonal antibody which targets CD20
and has been fragment of crystallization (Fc) engineered with low fu-
cose content to enhance afﬁnity to all allelic variants of FcγIIIa receptors,
demonstrating greater antibody dependent cell cytotoxicity (ADCC)
than rituximab (Rituxan®) and ofatumumab (Arzerra®). This will see
the second glyco-engineered antibody to enter the market (discussed
later in Fc engineered section). Ublituximab is currently being assessed
in Phase III trials in combination with small molecule ibrutinib in pa-
tients with previously treated high-risk Chronic Lymphocytic Leukemia
(CLL). Indeed, 2015 witnessed the ﬁrst FDA approval of a combination
regime of anti-PD-L1 antibodies nivolumab (Opdivo®) and ipilimumab
(Yerzoy®) and is quickly becoming a focus of ongoing research with
both emerging and established therapeutics.
MABp1 is a ‘natural’ antibody cloned from an afﬁnity-matured,
in vivo human immune response, with no sequence modiﬁcations. The
antibody was derived from Epstein-Barr-virus-immortalized B lympho-
cytes derived from an individual with circulating anti-IL-1α, a method
previously described by Garrone and colleagues [41]. This potential
breakthrough ﬁrst-in-class ‘true human™’ monoclonal antibody
targeting IL-1α is being assessed in Phase III clinical trials for late stage
colorectal cancer. The safety results to date suggest a unique safety pro-
ﬁle for this antibody, among the best tolerated therapies used in oncol-
ogy, making it ideally suited for treating advanced cancer patients with
reduced tolerance for toxic therapy [42]. The antibody is also being in-
vestigated in a Phase II trial to correct the metabolic dysregulation un-
derlying the wasting phenotype associated with malignancy by
speciﬁcally targeting IL-1α signaling in the hypothalamus.
A Phase III clinical trial (HERCULES) has been initiated for bivalent
nanobody® (or VHH) caplacizumab targeting anti-von Willebrand fac-
tor (vWF) to treat acquired Thrombotic Thrombocytopenic Purpura
(TTP). This could see the ﬁrst nanobody® to be approved and the
smallest antibody fragment on the market at approximately ﬁfteen
kilodaltons (kDa).
4. Biosimilars, guidelines and challenges
Over the last decade there has been a growing interest from the bio-
pharmaceutical industry to heavily invest in the development of
biosimilars to compete with blockbuster antibodies that are about to
comeoff patent. Biosimilar antibodies are ‘highly similar’ replicate prod-
ucts of a therapeutic antibody that has already received marketing ap-
proval. The proposed biosimilar must be comparable with the
originator referencewith respect to its structure, function, animal toxic-
ity, human pharmacokinetics (PK), pharmacodynamics (PD), clinical
safety, immunogenicity and effectiveness. Biosimilars are therefore ex-
pected to be produced, formulated and administered in the same regi-
men as the approved originator reference, without access to the
proprietary manufacturing information; adding to the technical com-
plexity and challenge of producing a highly similar product. The approv-
al process of a biosimilar is less extensive than for a new therapeutic
antibody; and while there is less emphasis on clinical trials, a highdegree of similarity between the biosimilar and originator reference
must be established through analytical and preclinical evaluation in
order to warrant abbreviated clinical studies [43,44].
The European Medicines Agency (EMA) Committee for Medicinal
Products for Human Use (CHMP) and the FDA are the leading interna-
tional authorities for regulating sales and administration of therapeu-
tics. Other regulating bodies in the world adopt their guidelines, along
with clinical context outlined from the World Health Organization
(WHO) or International Conference of Harmonization (ICH). In
Australia, the Therapeutic Goods Administration (TGA) of the
Australian Department of Health adopts the scientiﬁc guidelines from
the European Union (EU) and ICH in approving biosimilars. A key
issue for the biosimilar approval pathway has been the uncertainty
and evolving nature of the regulatory process. The inconsistencies be-
tween the agencies has led to a marked difference in the numbers of
biosimilar antibodies approved across the different markets (Table 2).
Clinical context from WHO guidelines [45,46]
TheWHO guidelines express as a minimum the requirement of clin-
ically relevant endpoints including PK, PD, efﬁcacy, safety, and immuno-
genicity data to assess biosimilarity. In some circumstances, efﬁcacy
studies are waived if there is sufﬁcient evidence of biosimilarity from
all other non-clinical data. More extensive toxicology and/or clinical
studies are required when differences are identiﬁed to address residual
uncertainties and undesirable immunogenicity.
EMA approach to assessing biosimilarity [47–52]
The EMA guidelines deﬁne a biosimilar as “a biological medicinal
product that contains a version of the active substance of an already au-
thorized original biological medicinal product (reference medicinal
product)” and that “similarity to the reference medicinal product in
terms of quality characteristics, biological activity, safety and efﬁcacy
based on comprehensive comparability exercise” needs to be
established.
The EMA discusses that the stepwise approach for assessing a
biosimilar include a comprehensive physicochemical and biological
characterization and in vitro pharmaco-toxicological studies as
paramount to establishing the quality of the biosimilar. In vivo animal
toxicology, immunogenicity, PK and PD studies may be required de-
pending on the collated non-clinical in vitro evidence. Clinical studies
are to further evaluate safety, PK, PD and efﬁcacy endpoint data. The
EMA review the presented data in a totality of evidence approach.
FDA approach to assessing biosimilarity [53–55]
The FDA scientiﬁc and quality guidelines deﬁne biosimilarity as “that
the biological product is highly similar to the reference product not-
withstanding minor differences in clinically inactive components” and
that “there are no clinically meaningful differences between the biolog-
ical product and the reference product in terms of safety, purity, and po-
tency of a product.” The FDA considers the following differences
between protein products: “(1) primary amino acid sequence; (2)mod-
iﬁcation to amino acids, such as sugar moieties (glycosylation) or other
side-chains; and (3) higher order structure (protein folding and
protein-protein interactions).”
The FDA further discusses the requirement of interchangeability: “To
meet the additional standard of “interchangeability,” an applicant must
provide sufﬁcient information to demonstrate biosimilarity, and also
demonstrate that the biological product can be expected to produce
the same clinical results as the reference product in any given patient
and, if the biological product is administeredmore than once in an indi-
vidual, the risk in terms of safety or diminished efﬁcacy of alternating or
switching between the use of the biological product and the reference
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out such alteration or switch.”
The FDA discusses that the stepwise approach for assessing
biosimilarity include a comprehensive structural and functional charac-
terization, animal toxicity, human PK and PD, clinical immunogenicity,
clinical safety and effectiveness. The FDA adopts a totality-of-the-evi-
dence approach to reviewing the presented evidence, and they require
at least one clinical PK study and, if appropriate, one PD study in the rep-
ertoire of evidence that supports biosimilarity. Clinicallymeaningful dif-
ferences to be addressed include the expected range of safety, purity
and potency of the biosimilar.
A couple of notable aspects between the authorities is the clinical ev-
idence of interchangeability proposed by the FDA, which almost all EU
countries have ruled out with the exception of France [56]. In the con-
text of one or more indications, both authorities advise that if
biosimilarity has been demonstrated for one indication, extrapolation
of clinical data to other indications of the originator reference may be
acceptable. Similarly, due to the structural complexity and heterogene-
ity that comes from the production and puriﬁcation of antibodies, pro-
ducing a biosimilar that is structurally identical to its reference
product is extremely unlikely. Both authorities therefore are aware
that manufacturing conditions can inﬂuence differences in protein
modiﬁcations and higher order structure, such as the glycosylation pro-
ﬁle, which can affect the safety and effectiveness of the protein in its
clinical context. Biosimilarity can be accepted as long as structural and
functional differences are recognized and thoroughly evaluated to pro-
vide sufﬁcient evidence that they are of no clinical relevance. Further-
more, both authorities have considered differences in formulation as a
possible area of consideration during evaluation of a biosimilar. It is pos-
sible that improvements in formulation and/or excipients have oc-
curred since the originator was approved.
To date, four biosimilar antibodies have been approved by the EMA
with the ﬁrst approval in 2013 for the inﬂiximab biosimilar CT-P13
(Table 2). In comparison, the FDA only recently approved three
biosimilar antibodies almost three-years later; and withoutTable 2
Summary of approved biosimilar antibodies worldwide.
Originator Biosimilars in
market
Approving country Year of
approval
Abciximab
(ReoPro®)
Clotinab® Europe 2013
Rituximab
(Rituxan®,
MabThera®)
AcellBia® (BCD-20) Russia 2014
MabTas India
Reditux® South America
Etanar®
Kikuzubam®
Etanercept
(Enbrel®)
BRENZYS® (SB4) Korea 2015
Benepali® Europe 2016
Etacept India
Erelzi® United States 2016
Inﬂiximab
(Remicade®)
Remsima® (CT-P13) Korea, South
America
2012
Inﬂectra® (CT-P13) Europe, United
States
2013,
2016
INFIMAB®
(BOW015)
India 2014
Inﬂiximab Biosimilar Japan
Flixabi® Europe 2016
Trastuzumab
(Herceptin®)
HERTRAZ® India 2013
CANMAB®
HERZUMA®
(CT-P06)
Korea 2014
CREDIMA
HERtiCAD® Korea, Russia 2014,
2016
Adalimumab
(Humira®)
Exemptia® India 2014
Amjevita® United States 2016interchangeability status. Nevertheless, reports from recent clinical
studies are laying the groundwork for the feasibility of ‘switching’
from an originator to a biosimilar antibody [57,58]. Moving forward,
the regulatory approval of biosimilar antibodies will be a global evolu-
tion requiring both biosimilar developers and regulatory agencies to
continuously monitor and adapt. At this stage, biosimilar antibodies
offer cost reductions of 10–30% which has been calculated to lead to
considerable cost savings to healthcare authorities in countries that sub-
sidize costs [59]. The competition offered by lower-cost biosimilars is
expected to increase volume thatmay further drive a reduction in over-
all cost of both originator and biosimilar antibodies [60]. Certainly,
biosimilar antibodies are starting to surge in developing countries
such as India and South America (Table 2).
5. Biobetter antibodies
Despite its success, antibody-based therapy still presents a long list
of important shortcomings that need to be overcome to fully exploit
their full therapeutic potential. Typical drawbacks in antibody-based
therapy include limited efﬁcacy due to poor tissue and tumor penetra-
tion, low in vivo efﬁcacy, cumbersome administration, antibody aggre-
gation, solubility as well as high production costs [61]. The use of
antibody engineering to improve the properties of therapeutic antibod-
ies has advanced greatly in the last decades giving rise to a varied set of
novel formats that offer enhanced attributes for therapeutic and re-
search purposes. These novel molecules are often referred to as
biobetters or next-generation antibodies and include platforms such
as: engineered antibodies for enhanced effector functions, antibody
drug-conjugates (ADC), multi-speciﬁc antibodies and single-domain
antibody fragments (sdAb or nanobodies®) [62,63].
A biobetter can have modiﬁcations to its chemical structure such as
humanization, fusion/conjugation or be glyco-engineered to be less im-
munogenic or more efﬁcacious. For instance, anti-CD20 ocrelizumab
which is currently under review for FDA approval forMS is a humanized
version of rituximab (Rituxan®). A biobetter may be modiﬁed to have
an improved formulation for improved treatment regimen so treatment
is less evasive or have a simpliﬁed manufacturing process. This was
demonstrated with novel subcutaneous (SC) formulations of
trastuzumab (Herceptin®) and rituximab (Mabthera®) developed by
co-formulating the antibody with hyaluronidase, an enzyme that in-
creases the absorption and distribution of the injected product [64]. A
biobetter may be engineered to have higher target afﬁnity, bind at a dif-
ferent epitope or stronger effector function to enhance efﬁcacy and po-
tentially reduce any off-target side effects. Any such improvement
means that the therapeutic has been modiﬁed and incomparable to
the original therapeutic; it is therefore classiﬁed as a new biological
therapeutic and requiresmore laborious testing to obtain regulatory ap-
proval beforemarket entry. In the next section, Fc engineering, ADC and
multi-speciﬁc antibody-based therapies will be discussed.
5.1. Fc engineered antibodies for enhanced effector functions
Antibody engineering has sought to improve the effector function
of antibodies via the Fc region; namely ADCC, complement depen-
dent cytotoxicity (CDC) and PK proﬁle. Speciﬁcally, this has been
mostly explored through modiﬁcations in the amino acid sequence
or the glycosylation pattern in the Fc region to enhance the afﬁnity
towards Fcγ receptors (FcγR) on effector cells [62,65]. The most
prominent and successful technology so far has been the glycosyla-
tion approach, which has seen nearly twenty glyco-engineered
antibodies enter clinical trials with two already approved for clinical
use [66–68]. The ﬁrst success came with the approval of
mogamulizumab (Poteligeo®) in Japan in 2012, developed using
the POTELLIGENT (Kyowa Hakko Kirin) platform which is indicated
for CC-chemokine receptor 4 (CCR4)-expressing T cell leukaemia-
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[69].
An ADCC enhanced version of rituximab, obinituzumab
(Gazyva®) gained approval by the FDA in 2013 under breakthrough
therapy designation [70]. Obinituzumab is an anti-CD20 monoclonal
antibody that was originated by GlycArt Biotechnology (now(a)
(b)
(c)
Fig. 1. Schematic representation of biobetter antibody formats being pursued for clinical develo
297 (Asn-297) in CH2 domains indicated by hexagons. The general structure of N-linked glyco
dotted lines comprising of Fucose (Fuc), N-Acetylglucosamine (GlcNAc), Mannose (Man), Ga
involve defucosylation which refers to the removal of core fucose to enhance Fc-mediated effe
emtansine; Kadcyla®) including N-maleimidomethyl) cyclohexane-1-carboxylate (MCC) link
as discussed in the text including: Triomab or Trifunctional antibody, Dual variable domain
Bispeciﬁc T cell engager (BITE), Dual afﬁnity re-targeting (DART) molecule, Tandem diabody (GlycoMAb) and is approved for CCL [67]. Both POTELLIGENT® and
GlycArt platforms are based on the manufacture of products using
engineered cell lines that yield defucosylated antibodies; a structural
modiﬁcation that removes the core 1,6 fucose from the N-glycans at-
tached to asparagine at amino acid position 297 of human IgG1
thereby greatly enhancing the afﬁnity towards FcγRIII, andpment. (a) Schematic structure of an IgG1 antibody with glycosylation sites at asparagine
sylation is shown inset; core structures indicated by solid lines and variable structures by
lactose (Gal) or N-Acetylneuraminic acid (Neu5Ac). Glyco-engineering of antibodies can
ctor functions. (b) Schematic structure of an antibody drug conjugate (ado-trastuzumab
er and maytansinoid 1 (DM1) payload. (c) Prominent bispeciﬁc formats in development
immunoglobulin (DVD-Ig), Dock-and-Lock (DNL) antigen binding fragments (Fabs),
tandAb) and Immune-mobilizing monoclonal TCRs against cancer (ImmTAC).
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not abundant in the tumor site, and human endogenous IgG can in-
hibit the elicitation of ADCC by therapeutic antibodies. [73] There-
fore, increasing the afﬁnity towards FcγRIII to preferentially
interact with the therapeutic antibody is a valuable approach to im-
prove the efﬁcacy proﬁle. This approach was demonstrated by Zhang
et al. by producing an anti-HER2 antibody with an identical sequence
to trastuzumab but with superior binding afﬁnity to FcyRIIIa and
greater ADCC activity [74]. The antibody was produced using glyco-
engineered Pichia pastoris and the differences were presumed to be
due to absence of fucose in the N-glycans attached to the IgG1
product.
Whereas the glyco-engineering approach generates defucosylated
antibodies with FcγRIIIa-speciﬁc afﬁnity improvement, variants gener-
ated by mutagenesis of Fc amino acid sequence can be enhanced for
multiple FcγR interactions. A number of publications have identiﬁed
speciﬁc Fc mutations to improve binding to the activating receptor
FcγIIIa and reduce binding to the inhibitory receptor FcγIIb with corre-
sponding improvement to ADCC activity [75–77]. The XmAb® concept
is currently being investigated as an anti-CD30 in Phase I trials for Hodg-
kin lymphoma.
In an alternative approach, aglycosylated antibodies (without
glycan structures) can be engineered to display effector functions
that are distinct from those of glycosylated counterparts [78–81].
The use of aglycosylated therapeutic antibodies offers manufactur-
ing advantages by bypassing glycosylation and hence production
can be performed in prokaryotic hosts. On the other hand, the impor-
tance of glycosylation on the structural stability of antibodies has
been demonstrated [82,83]. The ﬁrst aglycosylated antibody to
enter clinical trials, produced in yeast, is humanized rat-derivedTable 3
Overview of ADC developed in recent years and their clinical status.
ADC Format Target Pay
FDA approved
Brentuximab vedotin (Adcetris®) IgG1 (chimeric) CD30 MM
Ado-trastuzumab emtansine (Kadcyla®) IgG1
(humanized)
HER2 DM
Gemtuzumab ozogamicin (Mylotarg® -
withdrawn)
IgG4
(humanized)
CD33 Cal
Phase III
Inotuzumab ozogamicin IgG4
(humanized)
CD22 Cal
Phase II
Enfortumab vedotin
(ASG-22ME)
IgG1 (human) Nectin-4 MM
PSMA ADC IgG1 (human) PSMA MM
Glembatumumab vedotin (CDX-011) IgG2 (human) GPNMB MM
Lifastuzumab vedotin
(DNIB0600A)
IgG1
(humanized)
NaPi2b MM
Pinatuzumab vedotin (DCDT2980S) IgG1
(humanized)
CD22 MM
Polatuzumab vedotin (DCDS4501A) IgG1
(humanized)
CD79b MM
Lorvotuzumab mertansine (IMGN-901) IgG1
(humanized)
CD56 DM
IMMU-130 (Labetuzumab-SN-38) IgG1
(humanized)
CEACAM5 SN-
IMMU-132 (hRS7-SN38ADC) IgG1 (human) TROP-2 SN-
Milatuzumab doxorubicin (IMMU-110) IgG1
(humanized)
CD74 Dox
Indatuximab ravtansine (BT-062) IgG1
(humanized)
CD138 DM
Rovalpituzumab tesirine
(SC16LD6.5)
Undisclosed Fyn3 D6.
Depatuxizumab mafodotin
(ABT-414)
IgG1 (human) EGFRvIII MM
Abbreviations: MMAE=monomethylauristatin; DM=maytansinoid; PSMA= prostate-speci
pendent inorganic phosphate; CEACAM= carcinoembryonic antigen-related cell adhesion moIgG1 otelixizumab directed against CD3 which is being assessed in
Phase II trials for type I diabetes mellitus.
5.2. Antibody drug conjugates (ADC)
ADC comprise one of the foremost antibody-based platforms cur-
rently being pursued for clinical implementation. Indeed, the FDA ap-
proval of brentuximab vedotin (Adcetris®) and a cytotoxin-
conjugated biobetter of trastuzumab, ado-trastuzumab emtansine
(Kadcyla®) in 2011 and 2013 respectively, have eclipsed the clinical
failures of ﬁrst generation ADC. As of early 2016, in addition to the
two ADC available in the market, over forty antibody drug conjugates
are undergoing clinical trials and a plethora of such formats are in pre-
clinical development [3] (Table 3). The achievement of suchmilestones
has been facilitated by the advent of novel ADC technologies and
designs.
While the targeted nature of ADC therapy is expected to reduce
treatment side effects, toxicity still remains an important concern for
ADC. In fact, gemtuzumab ozogamicin (Mylotarg®), a humanized anti-
CD33 antibody conjugated to calicheamicin was the ﬁrst ADC to receive
FDA approval in 2000 for treatment of acute myeloid leukemia (AML).
However, it was voluntarily withdrawn from the market after results
of a Phase III study raised toxicity concerns and showed no beneﬁt com-
pared to standard therapies [84]. Brentuximab vedotin and ado-
trastuzumab emtansine also present signiﬁcant toxicity; both are re-
quired by the FDA to carry a black boxwarning due to the risk (although
only seen in rare cases) of developing progressive multifocal
leukoencephalopathy (brentuximab vedotin) and risk of hepatotoxicity,
cardiac toxicity, and embryo-fetal toxicity (ado-trastuzumab
emtansine). Consequently, there remains a challenge in the ﬁeld toload Linker Lead indications
AE Valine-Citrulline Hodgkin lymphoma, Anaplastic large cell lymphoma
1 Valine-Cirtulline HER2+ breast cancer
icheamicin SS/hydrazone Acute myeloid leukemia
icheamicin SS/hydrazone Acute lymphoblastic leukemia
AE Valine-Citrulline Bladder cancer
AE Valine-Citrulline Prostate cancer
AE Valine-Citrulline Breast cancer
AE Valine-Citrulline Ovarian cancer
AE Valine-Citrulline Non-Hodgkin’s lymphoma (NHL)
AE Valine-Citrulline NHL, diffuse large B cell lymphoma
1 SPP Hematological malignancies
38 Carbonate Colorectal cancer
38 Carbonate Breast cancer
orubicin Hydrazone Multiple myeloma
4 SPDB Multiple myeloma
5 Undisclosed Small cell lung cancer
AF Maleimidocaproyl Glioblastoma
ﬁc membrane antigen; GPNMB= transmembrane glycoprotein NMB; NaPi = sodium-de-
lecule; EGFR = epidermal growth factor receptor.
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over traditional chemotherapy and other targeted therapies. In this re-
gard, great efforts are being directed to implement reﬁnements in
each of the components (targeted antigen, targetingmoiety, linker, pay-
load and conjugation chemistry) to boost the therapeutic potential of
ADC.
Whilemost conjugates in clinical and preclinical development target
cell surface receptors that are overexpressed in solid tumors and B-cell
malignancies (Table 3), novel approaches such as targeting antigens
present in neovasculature or extracellular stromal tissue are being ex-
plored. One main advantage of such approaches is that perfusion into
the tumor is not required since blood serum is in direct contact with
vascular endothelial cells, with exposure of the conjugate to its target
tissue considerably greater than for traditional ADC targeting neoplastic
cells [85–87]. Another attractive feature is that vascular endothelial cells
are less likely to develop resistance mechanisms. Others have also ex-
plored the possibility of targeting cancer stromal cells, aiming to sup-
press tumor proliferation, neovascularization, invasion, and metastasis
which are typically promoted by the tumor microenvironment [88,
89]. Overall, the factors affecting the internalization rate of ADC suggest
that antigen selection is of high importance in determining the efﬁcacy
of the conjugate in a physiological environment.
Conversely, the efﬁcacy of a conjugate is predominantly determined
by its afﬁxed payload. Current ADC feature antineoplastic agents that
have an extremely high potency, usually in the sub-nanomolar range.
Most of these molecules are derivatives of highly potent cytotoxic
drugs that have exquisite potency but at the same time, make them un-
amenable for development as chemotherapeutic agents alone. The cyto-
toxic drugs being employed can be classiﬁed into three major groups
namely, calicheamicins (DNA disruption), maytansinoids and
auristatins (cell cycle interference) [90–93]. Monomethylauristatin E
(MMAE) and monomethylauristatin F (MMAF) are the most widely
used payloads in the current pipeline with another twenty auristatin
conjugates under clinical development [94,95]. Among the maytansine
analogs, DM1 and DM4 are being pursued with more than ten ADC in
clinical trials (Table 3; Fig. 1b). Alternative drug classes such as
duocarmycins and pyrrolobenzodiazepines may also gain popularity
due to their remarkable potency [96,97].
The linker component is amajor determinant of plasma stability of a
conjugate, thus impacting on the efﬁcacy and safety proﬁle. One of the
main reasons for off-target effects is the premature release of cytotoxic
activity outside of target cells. A commonly used approach for coupling
the conjugate to an antibody is via a linker that contains a lysosomal-
speciﬁc protease cleavage site. In this format, the linker is intended to
be cleaved in the lysosome by proteases such as cathepsin B, plasmin
and β-glucoronidase [98,99]. Indeed, the valine-citrulline (Val-Cit) di-
peptide linker, recognized and cleaved by cathepsin B, is currently the
most widely implemented linker technology [100,101]. A novel ap-
proach using non-cleavable linkers has gained popularity since they
could substantially increase blood serum stability. In this modality, the
antibody is digested inside the lysosome upon internalization, releasing
the payload attached to an amino acid residue, yet still retaining its cy-
totoxic activity [102,103]. For example, ado-trastuzumab emtansine,
employs the hetero-bifunctional crosslinker N-succinimidyl-4-(N-
maleimidomethyl) cyclohexane-1-carboxylate (SMCC), creating a
non-reducible thioether linker (MCC) as a spacer between the anti-
HER2 antibody and the maytansine DM1 [104]. Presumably due to in-
creased stability, reduced toxicity has been observed with non-
cleavable linker design relative to conjugates with cleavable linker
[105]. Remarkably, ado-trastuzumab emtansine has displayed superior
in vivo activity in mouse breast cancer models compared to a similar
trastuzumab-DM1 conjugate that differs only in that it contains a disul-
ﬁde reducible linker [106].
The chemical reactions used to couple ADC components can also
play a role in the therapeutic index. The ﬁrst conjugation techniques de-
veloped to create ADC involved a chemical reaction between afunctional group in the linker and a reactive moiety in native amino
acid residues, predominantly the thiol side-chains of partially reduced
cysteines and the epsilon-amino end of lysine residues [107,108]. In
these cases, the conjugation sites and the number of drug molecules
afﬁxed to the antibody are stochastic, resulting in heavily heteroge-
neous conjugates. This heterogeneity undermines the clinical potential
of ADC, since it impacts severely on their toxicity and safety proﬁles.
In terms of potency, the efﬁcacy is compromised by the reduced subset
of ADC with an optimal amount of attached drug to exert a signiﬁcant
cytotoxic effect. Besides the fact that conjugates with low drug-to-
antibody ratios (DAR) have limited efﬁcacy, high DAR also possess
higher toxicity and reduced plasma stability due to increased clearance
rates [109]. This clearly illustrates the critical importance of achieving
an optimal ratio. Despite the shortcomings of stochastic attachments
methods, both cysteine and lysine conjugation techniques have been
utilized in the development of brentuximab vedotin and ado-
trastuzumab emtansine, respectively. A set of alternate novel tech-
niques have been developed to allow for site-speciﬁc conjugation in-
cluding the THIOMAB platform [110], introduction of unnatural amino
acids or enzymatic modiﬁcation of native amino acid side-chains
[111–113] and even glycan attachment through glyco-engineering
[114].
5.3. Bispeciﬁcs
The next novel wave of therapeutic antibodies is predicted to be in
the format of bispeciﬁc antibodies. The concept of bispeciﬁc antibodies
was ﬁrst demonstrated more than twenty years ago, initially by chemi-
cal conjugation of two antibodies [115] then by fusing two hybridoma
cultures [116]. There are now more than ﬁfty different bispeciﬁc for-
mats in development, enabling researchers to adjust and control param-
eters such as size, half-life, stability,ﬂexibility and orientation to achieve
the desired therapeutic outcome. The assembly of antibody chains to ac-
complish the various antibody formats has beenmade possible with an-
tibody engineering techniques including variations of the general
approach [117–119] to novel approaches such as ‘knobs-into-holes’
[120], CrossMab [121], ‘Dock-and-Lock’ (DNL) [122,123] and even hy-
brid domains derived from other immunoglobulin antibodies, via a
technology referred to as strand-exchange engineered domain (SEED)
[124].
The majority of bispeciﬁc antibodies are currently being assessed in
clinical trials and are detailed in Table 4 with a few examples discussed
below based on their mode of action. Referred to as a trifunctional or
triomab is catumaxomab (Removab®), bispeciﬁc to tumor antigen
EPCAM and T cell marker CD3 (Fig. 1c). The antibody acts by recruiting
and activating immune cells; EPCAM targets the tumor, CD3 recruits T
effector cells and the Fc region recruits and activatesmonocytes,macro-
phages, dendritic cells (DC) and NK cells by FcγR binding [125].
Catumaxomab is a hybrid antibody comprised of rat IgG2b binding do-
mains and mouse IgG2a Fc region. Catumaxomab has not yet received
FDA approval (BLA submitted) but has EMA approval for the treatment
of malignant ascites since 2009. The antibody is also in clinical trials for
application in ovarian cancer (II), gastric cancer (II) and epithelial can-
cer (I). Given that catumaxomab is a rat-mouse hybrid, some anti-rat
or anti-mouse IgG responses are observed in patients, though treatment
does not appear to be signiﬁcantly affected. In fact, development of
human anti-mouse antibodies (HAMA) have been shown to contribute
to greater clinical beneﬁt [126].
Another example that achieves effector cell recruitment via a con-
ceptually different formatwithout a Fc region is bispeciﬁc T cell engager
(BiTE®). BiTEs are variable regions in the formof two scFv connected by
ﬂexible linker peptides (Fig. 1c) [127,128]. One scFv is directed at a cell
surface tumor antigen (with higher afﬁnity) and the other scFv binds
CD3 (with lower afﬁnity). The ﬁrst marketed BiTE was blinatumomab
(Blincyto®) which targets CD19 on acute lymphoblastic leukemia
(ALL), approved by the FDA in late 2014 under the accelerated approval
Table 4
Bispeciﬁc antibodies developed in recent years and their clinical status.
Name Company Targets Antibody type Mode of action Indications
FDA approved
Blinatumomab Blincyto® Amgen CD19/CD3 BiTE T cell
recruitment
Philadelphia chromosome-negative
precursor B-cell acute lymphoblastic
leukemia
Clinical trials completed
Catumaxomab Removab® Trion Pharma EPCAM/CD3 Trifunctional/Triomab T cell
recruitment/Fc
effector
Malignant ascites
Phase III
Emicizumab/RG6013/ACE910 Roche Factors XI/X CLC-IgG Two factor
dimerisation
Haemophilia A
MT111/MEDI565 MedImmune CEA/CD3 BiTE T cell
recruitment
Gastrointestinal cancer
Phase II
Vanucizumab Roche Angiopoietin2/VEGF Crossmab Two ligand
inactivation
Colorectal cancer
RG7716 Roche Angiopoietin2/VEGF Crossmab Two ligand
inactivation
Macular degeneration
TF2 IBC
Pharmaceutical/Immunomedics
CEA/Hapten DNL Fab3 Payload
delivery
Small cell lung cancer, Colorectal cancer,
Thyroid cancer
Duligotuzumab Genentech/Roche HER1/HER3 DAF-IgG Two ligand
inactivation
Head and neck cancer, Colorectal cancer
ABT122 Abbott Laboratories TNF/IL-17 DVD-IgG Two ligand
inactivation
Rheumatoid arthritis, Psoriatic arthritis
ABT981 Abbott Laboratories IL-1α/IL-1β DVD-IgG Two ligand
inactivation
Osteoarthritis
SAR156597 Sanoﬁ-Aventis IL-4/IL-13 DVD-IgG Two ligand
inactivation
Idiopathic pulmonary ﬁbrosis
Istiratumab/MM141 Merrimack Pharmaceuticals IGF1R/HER3 IgG-scFv Two ligand
inactivation
Pancreatic cancer
IMCgp100 Immunocore MHC
peptide280-88/CD3
ImmTAC T cell
recruitment
Malignant melanoma
AFM13 Afﬁmed Therapeutics CD30/CD16 TandAb NK cell
recruitment
Hodgkin Lymphoma
Phase I
BI1034020 Boehringer Ingelheim
Pharmaceuticals
Beta amyloid 2
epitopes
Bi-nanobody Undisclosed Alzheimer's Disease
ALX0761 Merck Sereno IL-17A/IL-17F Bi-nanobody Two ligand
inactivation
Psoriasis
LY3164530 Eli Lilly HER1/cMET orthoFab-IgG Two ligand
inactivation
Metastatic cancer
Pasotuxizumab Bayer PSMA/CD3 BiTE T cell
recruitment
Prostate cancer
MGD006 Servier CD123/CD3 DART T cell
recruitment
Acute Myeloid Leukemia
AFM11 Afﬁmed Therapeutics CD19/CD3 TandAb T cell
recruitment
Acute Lymphoblastic Leukemia,
Non-Hodgkin's Lymphoma
MGD007 Servier GPA33/CD3 DART-Fc T cell
recruitment/Fc
effector
Colorectal cancer
Abbreviations: BiTE = bispeciﬁc T cell engager; CLC = common light chain; DNL = dock-and-lock; Fab = antigen binding fragment; DAF = dual acting Fab; DVD-IgG = dual variable
domain immunoglobulin, scFv = single chain variable fragment; ImmTAC = immune-mobilizing monoclonal TCRs against cancer; TandAb = tandem diabody; DART = dual afﬁnity
re-targeting molecule; Fc = fragment of crystallization; EPCAM = epithelial cell adhesion molecule; CEA = carcinoembryonic antigen; VEGF = vascular endothelial growth factor;
TNF = tumor necrosis factor; IGFR = insulin growth factor receptor; MHC = major histocompatibility complex; PSMA = prostate-speciﬁc membrane antigen; GP = glycoprotein;
NK = natural killer.
10 Z. Elgundi et al. / Advanced Drug Delivery Reviews 122 (2017) 2–19program. Blinatumomab is currently undergoing multiple Phase II and
Phase III clinical trials for other B-cell related malignancies [129]. A
major setback for BiTEs is the requirement of continuous intravenous
infusion due to the short half-life inherent to the small size of the mol-
ecule (55 kDa) and the lack of Fc region. Additionally, the treatment
produces signiﬁcant side effects, notably neurotoxicity and symptoms
of cytokine-release syndrome [130]. Despite the challenges, this strate-
gy is being investigated for other targets (CEA, EPCAM, PSMA) and indi-
cations. Other examples of molecules with immune cell recruitment are
dual afﬁnity re-targeting (DART®) [131,132] and tandem diabodies
(tandAb®) (Fig. 1c) [133,134].
Another novel class of bispeciﬁc molecules called immune-
mobilizing monoclonal TCRs against cancer (ImmTAC) further expandsthe variety of potential tumor-speciﬁc antigens, by incorporating solu-
ble T cell receptors (TCRs) that can target intracellular antigens through
recognition of peptide-HLA antigen complexes on the cell surface
(Fig. 1c) [135]. Under current investigation in Phase II clinical trial for
malignant melanoma is IMCgp100. The engineered TCR portion of the
molecule targets the gp100 peptide280–288 antigen, which is
overexpressed and presented by HLA-A2 on the surface of melanoma
cells. The anti-CD3 scFv portion captures and redirects T cells to kill
the melanoma cells.
With the knowledge gained on validated targets and receptor signal-
ing of existing therapeutic antibodies, targeting two antigens to simul-
taneously interfere with two or more signaling pathways is being
pursued to improve therapeutic efﬁcacy. The most advanced molecule
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the combination of HER1 and HER3 as a dual action Fab (DAF)-IgG
[136]. Duligotuzumab is being evaluated in Phase II trial in patients
with head and neck cancer. The dual interference can also be applied
to inﬂammatory conditions. Dual variable domain immunoglobulin
(DVD-Ig™) formats directed at TNF + IL-17 and IL-1α+ IL-1β are un-
dergoing assessment in Phase I studies in patients with rheumatoid ar-
thritis (Fig. 1c) [137]. Other formats being investigated to interfere with
signaling pathways include CrossMabs [121] and bi-nanobodies [138].
Bispeciﬁcs can also serve as vehicles to deliver payloads to tumor
cells. TF2 is a DNL(Fab3) bispeciﬁc antibody that binds to CEA present
on the surface of many solid tumors (Fig. 1c). The antibody comprises
three Fab modules that are stably coupled to each other in a triangular
fashion using the DNL technology. Without a Fc region, these molecules
have a rather short serum half-life which is an advantage for pre-
targeting approaches. TF2 is being evaluated in a Phase I trial in patients
with colorectal cancer using Lutetium-177 or Indium-111 payload for
imaging.
6. Manufacture of antibodies
The discovery and development of a therapeutic antibody can be a
lengthy process, starting with early candidates (“hits”) then selection
of advanced candidates (“leads”). Progress to commercial production
is also lengthy, costly, scientiﬁcally and technically complex, on average
requiring at least 18 months to complete at a cost of approximately
sevenmillion dollars [139,140]. The chemistry, manufacturing, and con-
trols (CMC) activities are a critical element of the antibody development
process, necessary to enable human clinical testing. These tasks include
construction and testing of a production cell line,manufacturing process
for production, aswell as development of suitable analytical methods to
characterize the antibody and ensure that it is safe and has the desired
functional properties [139]. In the following section, certain aspects of
CMC are discussed in the context of new headway and the challenges
faced with the manufacture of novel antibody formats brieﬂy
mentioned.
Therapeutic antibodies aremainly produced inmammalian host cell
lines because of their ability to introduce post-translational modiﬁca-
tions. Chinese hamster ovary (CHO) cells remain the most widely used
cell line for the manufacture of antibodies (20 of 39 FDA approved),
followed by SP2/0 (8/39) and NS0 (7/39) mouse cell lines and hybrid-
omas (2/39). Two of the three Fabs are produced in the bacterial strain
Escherichia coli. As the clinical success of therapeutic antibodies grows,
alternative andmore cost-effective production platforms are being pur-
sued including microbial hosts and plant systems. Microbial cells such
as bacteria and yeast possess many advantages including fast growth,
well-characterised genetics and low cultivation costs.
Antibody production in bacterial systems has focused on frag-
ments due to the lack of post-translation glycosylation required on
the Fc region of full length IgG antibodies, speciﬁcally required for ef-
ﬁcient FcγR interactions. A major advancement was recently
achieved with the expression of active, full-length IgG in the cyto-
plasm of E. coli to generate ‘cyclonals’. Robinson et al. use an
engineered strain with an oxidative cytoplasmic environment to fa-
cilitate and promote the formation of disulﬁde bonds and efﬁcient
IgG folding and assembly [141]. Moreover, molecular engineering
of cyclonal Fc domains with previously identiﬁed Fc mutations en-
abled FcγR interactions [78,79,142]. Conversely, yeast expression of-
fers the advantages of post-translational modiﬁcations, disulﬁde
bond formation as well as secretion of correctly-folded proteins. An-
tibody yields surpassing mammalian systems have been reported for
a glyco-engineered strain of P. pastoris capable of producing human
N-linked glycoproteins [143,144]. Additionally, a series of experi-
ments have demonstrated production of IgG at industrial scale to
be robust and commercially viable [145]. The potential of yeast ex-
pression systems has not yet been fully realised with the mostadvanced antibodies otelixizumab (refer to Fc engineered section)
and clazakizumab in Phase II trials for psoriatic arthritis and rheuma-
toid arthritis.
Plant systems are also generating interest as an alternative pro-
duction platform due to the absence of mammalian pathogens but
too are subject to disadvantages given the different glycosylation
proﬁle to humans, subcellular localisation issues and decreased
yield because of proteolytic degradation. Nevertheless, a number of
antibodies have reached clinical development. For instance, CaroRX
is an antibody that targets Streptococcus mutans and used for treating
cavities, produced in Nicotiana tabacum and approved for use in
Europe [146]. MB66 (or MAPP66) contains a combination of three
monoclonal antibodies produced in Nictiana benthamiana designed
to block distinct mechanisms of HIV which has entered Phase I trials.
The clear advantages of using plant systems is the low cost, scalabil-
ity and relative ease to deploy in developing countries [147,148]. In-
terestingly, a biosimilar of trastuzumab produced in N.benthamiana
is entering Phase I clinical trials. An efﬁcacy study in mice has
shown that biosimilar trastuzumab was as effective as originator
trastuzumab (Herceptin®) in reducing the size and growth rate of
breast cancer tumours [149].
The choice of expression system therefore depends on many factors
in order to guarantee cost-effective high yields andmeet safety criteria;
from discovery stages with the precise sequence and mode of action of
the speciﬁc antibody to development of the manufacturing cell line.
Manufacturing cell lines to yield a therapeutic antibody are initially gen-
erated by vector construction and transfection. A variety of different ex-
pression systems and transfection methods exist [150]. Following
transfection, cells are subjected to a selection procedure where stable
cell lines are cloned and expanded. Several strategies have since evolved
from the limiting dilution approach that utilise automated cell sorting
equipment [151,152]. The screening and selection of stable clones
with desired growth and production characteristics is a critical albeit
time-consuming step in the process. Once conditions are deﬁned, the
process is often transferred to a pilot scale to test scalability andproduce
material for preclinical toxicology studies. Larger scale manufacturing
for production of clinical material is performed under current good
manufacturing practices (cGMP) regulations involving either fed-
batch or continuous perfusion culture [140,153]. For validation pur-
poses, three (United States) or ﬁve (Europe) consecutive full-scale cul-
ture runs are required for BLA approval [154].
Therapeutic antibodies must have very high purity and be sterile,
with the concentration of host cell proteins reduced to parts per million
(ppm), DNA to parts per billion (ppb) and virus levels to less than one
virus particle per million doses [139,155]. The stringent puriﬁcation of
antibodies from mammalian cells is typically accomplished using a
three column chromatography process; protein A afﬁnity chromatogra-
phy as an initial capture step followed by cation exchange (CEX) and
anion exchange (AEX) chromatography [156]. These are followed by a
virus clearance step after which puriﬁed product is concentrated and
diaﬁltered into the ﬁnal formulation buffer. While the antibody is pri-
marily captured during the afﬁnity step, the consecutive ion exchange
processes act as ‘polishing’ steps to remove impurities such as host
cell protein, DNA, aggregates, endotoxin, adventitious and endogenous
viruses [154].With the growing demand and increasingmarket compe-
tition, attention is now being focused on reducing manufacturing costs
and improving process efﬁciency. For example, Protein A afﬁnity chro-
matography contributes a major cost to the puriﬁcation process, there-
fore improved chromatography matrices, speciﬁcally non-afﬁnity
methods are gaining popularity such as; hydrophobic charge induction
chromatography (HCIC), high performance tangential ﬂow ﬁltration
(HPTFF) and MEP HyperCel [157–160].
New manufacturing challenges are being faced as ADC and multi-
speciﬁc antibodies move towards clinical use. In the case of full-length
bispeciﬁc IgG molecules or IgG-like antibodies (i.e. those containing Fc
region), production then puriﬁcation can typically follow that of other
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tion, such as the puriﬁcation of variable regions and other antibody frag-
ments without Fc region, then capture using ion exchange
chromatography (IEX) or hydrophobic interaction chromatography
(HIC) have been reported [161]. In another example, blinutonumab
has been engineered to express a histidine tag which allows the use of
immobilized metal afﬁnity chromatography (IMAC) for the initial chro-
matography step [162]. ADC are complex products comprised of an an-
tibody component, chemical linker and a cytotoxic drug. Several
reaction steps have to be carefully controlled tomanufacture ADC prod-
ucts consistently. Perhaps the greatest challenge in ADCmanufacturing,
is the design of a manufacturing facility capable of generating each part
alone then together and to perform as required. Manufacturing the an-
tibody component is the relatively easy part, because these technologies
are now well-established. Linker chemical technology is rather special-
ized with chemical synthesis involved. Manufacturing the cytotoxin
component is the dangerous, complex, and costly phase. Toxin produc-
tion, both up- and downstream, needs full isolation to prevent release of
toxic product; this would involve extensive use of isolator cabinets and
roomswith careful environmentalmonitoring [163,164]. Moreover, the
use of disposable technology and closed puriﬁcation systems are recom-
mended due to the high level of toxicity of the chemicals used in these
processes [165].
7. Physical and chemical degradation of antibodies
Duringmanufacturing and storage, therapeutic antibodies are at risk
of degradation via a number of pathways. Though these reactions may
be kept under control by appropriate storage and formulation condi-
tions of the ﬁnal product, degradation that occurs during culture, down-
stream processing and in vivo cannot be controlled sufﬁciently. These
degradation events may affect antigen recognition, hamper functionali-
ty and in severe cases lead to immunogenic responses [166–170]. Each
antibody molecule seems to have a unique personality related to its re-
quirements for stability; a phenomenon derived from the fact that dif-
ferences in the CDR between antibodies are primarily dictated by the
surface exposed amino acids that deﬁne antigen speciﬁcity [169]. The
identiﬁcation of degradation prone or unstable regions early in the anti-
body development process would ideally permit re-engineering of
these problematic areas [171–174]. This approach is aided by recent de-
velopments in computational modelling tools that predict regions of in-
terest susceptible to physical, chemical degradation or inﬂuence other
biophysical properties of antibodies. In the next section, degradation
pathways commonly observed in therapeutic antibodies and an over-
view of predictive tools are discussed.
7.1. Aggregation
Protein aggregation is the most common and signiﬁcant type of
physical degradation associatedwith therapeutic antibodies, often lead-
ing to reduced activity and in some cases, formation of immunogenic
products [175,176]. Initial preparations of therapeutic antibodies were
administered by intravenous (IV) infusion formulated at lower protein
concentrations (1–25 mg/ml). As antibody-based therapeutics became
more widely used, high concentration formulations that allow SC injec-
tion (N50 mg/ml) became desirable giving rise to aggregation issues.
Proteins are folded in such away as to internalize hydrophobic domains
and surface expose more hydrophilic domains. As protein-protein con-
tact frequency increases at high concentrations, the opportunity for ag-
gregation formation increases proportionally. Changes in extrinsic
conditions including temperature, pH, salt, shaking, viscosity and con-
centration can transiently expose hydrophobic domains which pro-
motes protein-protein interactions that lead to aggregation events
[177–180]. Non-covalent aggregates can be formed via hydrophobic
and/or electrostatic interactions and may be reversible, while covalent
aggregates are usually formed by disulﬁde bonds and are difﬁcult toreverse. Mechanisms of protein aggregation include: (1) aggregation
of native state monomers; (2) aggregation of monomers with a modi-
ﬁed conformation (non-native); (3) aggregation of chemically-
modiﬁed monomers; (4) aggregation via a nucleation-dependant pro-
cess; and (5) surface-induced aggregation via adsorption of protein to
glass-liquid or air-liquid interfaces [181,182].
7.2. Denaturation
Protein denaturation refers to the partial or complete unfolding
of the native three-dimensional folded protein structure. A dena-
tured antibody often loses its tertiary and perhaps secondary struc-
ture leading to loss of binding afﬁnity and activity if an active site
domain is affected, and may expose aggregation-prone regions lead-
ing to further degradation [178,183,184]. Several intermediate states
may exist between the folded native structure of an antibody mole-
cule and the denatured state, with some intermediates thought to
act as precursors or ‘nuclei’, attracting other protein species to ex-
posed hydrophobic sites and forming irreversible aggregates. Dena-
turation may be induced by a number of stress conditions that arise
during antibody manufacture including changes in solution pH or
temperature, use of organic solvents or chaotropes, high salt concen-
trations, or shear force [177,178,185]. In general, the CH3 domain of
an antibody is often the most stable against denaturation at high
temperatures (highest Tm) while the CH2 domain is least stable
and denatures ﬁrst (lowest Tm) [186].
7.3. Fragmentation
Fragmentation of therapeutic antibodies can be a product of enzy-
matic or non-enzymatic hydrolysis that occurs at the peptide backbone
of a number of regions, such as the hinge region, the CH2-CH3 interface
or a region containing aspartic acid (Asp) or tryptophan (Trp) residues
[177]. Asp-associated hydrolysis is affected bypHand the n+1 residue;
for instance, a serine (Ser), valine (Val) or tyrosine (Tyr) adjacent to an
Asp may increase the rate of Asp-hydrolysis. Hinge region hydrolysis
can occur in the absence of Asp, and occurs most commonly in the
IgG1 isoform [177,187,188]. The rate of hydrolysis is dependent on the
ﬂexibility and the peptide sequence at the hinge, occuringwithin a nar-
row range of residues. Hinge hydrolysis rates are affected by solution
pH, with a minimum rate of hydrolysis observed near pH 6, and higher
rates at a lower or higher pH [177,188]. Fragmentation of full-length an-
tibodies is a common occurrence and generally, cleaved forms are pres-
ent in such low amounts that an effect on efﬁcacy would not likely be
seen.
7.4. Deamidation
Deamidation is the most common chemical degradation pathway of
therapeutic antibodies and results from the hydrolysis of the amide
side-chain of amino acids glutamine (Gln) or asparagine (Asn) [177,
181,189,190]. Hydrolysis of the side-chain can occur at acidic pH
(pH b 4) resulting in the conversion of Asn to Asp and Gln to glutamic
acid (Glu) [177]. However at higher pH, deamidation occurs predomi-
nantly (andmore slowly) via the formation of a cyclic imide intermedi-
ate. For Asn, the cyclic intermediate (succinimide) leads to either the
formation of Asp or an isomer of Asp. A similar process results in the
deamidation of Gln to Glu; although Gln deamidation is much less fre-
quent, due to the lower stability of the 6-membered cyclic intermediate
formed. In short, deamidation events lead to more acidic forms of the
antibody through the acquisition of additional carboxylic acid groups.
Conversely, it is also possible for Asp residues to undergo modiﬁcation
to a succinimide intermediate that produces a basic form of the anti-
body by removal of a carboxylic acid group [189].
A number of factors can affect the rate of deamidation. For instance,
Asn residues are more prone to deamidation if they are present in
Table 5
A representative list of computational tools for prediction of protein aggregation hot spots.
Name Properties
Sequence-based methods
TANGO
[204]
Determines the secondary structure formation propensity
Aggrescan
[205]
Uses amino acid aggregation propensity value
Zyggregator
[207]
Compares a new peptide sequence to the database
PASTA
[208]
Predicts amyloid structure aggregation by looking into
sequences that are likely to stabilize the cross-beta core of ﬁbrils
PAGE
[209]
Uses physicochemical properties for prediction
Structure-based methods
SAP
[173]
Determines spatial effective surface accessible area
LIP
[211]
Measures ratio of polar surface area to apolar surface area of
buried interfaces
AGGRESCAN3D
[212]
Based of original AGGRESCAN server with input from 3D
structure and spatial arrangement of residues
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by a small or ﬂexible residue such as Gly, Ser, threonine (Thr) or Asn
[177,191]. Deamidation rate is also affected by extrinsic conditions in-
cluding pH, temperature, buffer composition and concentration [192].
Gln deamidation is thought to be less common than Asp deamidation
due to the lower stability of the 6-membered cyclic ring intermediate,
which results in a much slower reaction rate [177]. Although Gln
deamidation occurs less frequently, a study found that following incu-
bation at pH9, 7.8% of Gln82 of a recombinant IgG1mAbhad undergone
deamidation, despite no deamidation of this residue occurring at neu-
tral pH [190].
Deamidation of therapeutic antibodies is well characterized both
in vitro and in vivo, and has been shown to decrease the potency, activity
and stability of antibodies [189,191–195]. The deamidation events ap-
pear to be highly selective for individual antibodies. For example, Harris
et al. performed accelerated stability studies at elevated temperatures
with rhuMAB HER2 antibody and found three labile Asn residues in
the CDR region (Asn55, Asn30 and Asn102) [189]. These residues either
formed aspartate, isoasparatate or a stable succinimide intermediate,
resulting in a total of 7 species of the antibody being resolved.
Deamidation of these Asn residues was shown to signiﬁcantly affect
the speciﬁc in vitro activity and potency of rhuMAb HER2.
7.5. Oxidation
Oxidation is another common degradation pathway which can
occur during antibody production, formulation or storage. A number
of amino acid residues may be affected, including methionine (Met),
cysteine (Cys), histidine (His), tyrosine (Tyr) and Trp [177]. Speciﬁc
Met residues within the Fc region (up to four residues) are prone to
oxidation resulting in production of methionine sulfoxide [181,196,
197]. Oxidation of these residues may affect the stability of an anti-
body, Fc-mediated effector function or Protein A binding afﬁnity
which is often used for puriﬁcation from cell culture supernatant
[198]. Wang et al. demonstrated that oxidation of Met252 can result
in N4-fold reduction in the half-life of an antibody in transgenic mice
expressing human Fc neonatal receptor (FcRn). However, this was
only observed when 80% of the antibody existed in the oxidized
form, and not at 40% [199].
Oxidation can be dependent on intrinsic factors such as the de-
gree of surface exposed residues as well as extrinsic factors including
buffer composition, light exposure and pH, although Met oxidation
appears to be almost pH-independent [177,198,200]. Oxidative
stress has been observed during antibody production in mammalian
expression systems where the formation of reactive oxygen species
as a result of hypoxic conditions caused fragmentation of an IgG1 an-
tibody [201].
Tryptophan oxidation of antibodies has been reported following
light exposure. Sreedhara et al. found that light induced oxidation of
surface exposed Trp residues (Trp53, Trp108 and Trp94) in the Fab re-
gion of an IgG1 antibody led to a loss of potency accompaniedwith a so-
lution colour change [196]. In another example, oxidation of a Trp
residue in the H3 CDR loop (Trp135) of a humanized anti-respiratory
syncytial virus (RSV) therapeutic antibody resulted in loss of antigen
binding and biological function [202].
7.6. Computational design tools
In recent years, computational methods used to simulate and devel-
op structural models of proteins have transformed into practical design
tools for the development of biobetter and next-generation antibody
therapeutics [172,203]. Current computational design tools have
evolved to allow rapid identiﬁcation of speciﬁc amino acid sequences
or regions on a protein of interest, that contribute to its observed
in vivo properties such as binding afﬁnity, efﬁcacy, stability and half-
life [203].Some of the early computational tools used for protein modelling
include TANGO, PAGE, AGGRESCAN, PASTA and Zyggregator all of
which rely on the sequence of the protein of interest (Table 5)
[173,204–209]. These computational tools use force ﬁelds such as
CHARMM or AMBER and exploit chemical properties of the amino
acids such as hydrophobicity, β-sheet propensity, charge, and aro-
matic content to predict aggregation hot-spots and residues suscep-
tible to chemical degradation. In some cases, multiple tools can be
used in combination to improve the predictive power. For example,
Wang et al. combined TANGO and PAGE to identify aggregation-
prone motifs and residues susceptible to deamidation or oxidation
of 22 commercial and 20 non-commercial therapeutic antibodies
[210].
Some structure-based computational tools have also been devel-
oped. One such method, Spatial Aggregation Propensity (SAP), predicts
surface exposed aggregation-prone regions of a protein based on hydro-
phobicity, dynamic ﬂuctuations and solvent accessibility of residues and
regions [172]. The tool has been used to simulate entire antibodies and
develop IgG1 antibody variants with enhanced physical stability to the
wild type, by performing single or multiple mutations in either the
Fab or Fc regions [172,174].
Another method developed by Angarica and Sancho predicts aggre-
gation propensity based on the packing density and polarity ratio (ratio
of polar surface area to apolar surface area) of buried interfaces [211].
The tool was designed to characterise “Light Interfaces of high Polarity”
(LIPs) considered to be intrinsically unstable cores. The technology
shows promise as a tool for engineering antibody variants with in-
creased aggregation-resistance, especially as a complimentary method
to surface- or sequence-based tools mentioned above.
One of themost recent developments in computational modelling is
the evolution of AGGRESCAN to AGGRESCAN3D (A3D), an improved
server which addresses many of the limitations of AGGRESCAN and
other sequence-based methods. A3D takes into account the three-
dimensional structure of the protein and the spatial arrangement of
the residues when the protein is in its native folded state [212]. With
the incorporation of a mutation module that allows the easy modelling
of the detected aggregation-prone and surrounding residues, A3D looks
to be a promising tool for predicting problematic regions and the same
time, allowing for re-design of more stable proteins.8. Optimization of antibody bioavailability and delivery
Antibody-based therapies are predominantly delivered intrave-
nously (IV), though an increasing number are now being formulated
and administered subcutaneously (SC). While the IV route offers
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greatly reduce the actual concentration of antibody achieved in tar-
get tissues [213]. What is more, IV infusions are time-consuming
and inconvenient. Ideally, an antibody formulation should be non-
invasive and increase local bioavailability. Limited alternatives
have been implemented in the clinic since formulation requirements
for such delivery often pose signiﬁcant hurdles. For other parenteral
administration routes, such as SC or intramuscular (IM), the most
common limitation is poor antibody solubility at the high concentra-
tions required, given that maximum volume of injection is restricted
to 2 ml and 5 ml, respectively. When compared to IV formulations
which range from 1 to 25 mg/ml, SC and IM products often require
concentrations N100 mg/ml to deliver an effective dose. Further-
more, these delivery routes involve an absorption step to enable sys-
temic circulation. Two main approaches are being pursued to
optimize bioavailability: 1) the design of aggregation-resistant anti-
bodies with higher solubility to prevent precipitation at higher con-
centrations; 2) the use of polymer matrix systems to develop
controlled release formulations and improve PK proﬁle.
As discussed in the previous section, the design of aggregation-
resistant antibodies albeit challenging, has become possible with
the implementation of computational tools and increasing under-
standing of antibody structure and degradation pathways.
Formulation stability has also been improved by using stabilizing
additives such as salts (e.g. citrates, sulfates), amino acids (e.g. gly-
cine) and sugars (e.g. sorbitol, sucrose, trehalose) [177,214–217].
The development of SC and IM products has been successful in
the last decade because of the formulation of large doses in signif-
icantly smaller volumes without aggregation issues [64]. SC and IM
formulations have signiﬁcantly improved patient convenience en-
abling self-administration through the use of pre-ﬁlled syringes, a
feature that is highly advantageous for treatment of chronic dis-
eases. A novel approach to improving SC formulation and PK has
been proposed by Yang et al. whereby, crystalline antibody prepa-
rations of inﬂiximab (Remicade®) and trastuzumab (Herceptin®)
were formulated at 200 mg/ml while maintaining low viscosities
suitable for this delivery route [218]. Animal studies in rats showed
a 2-fold increase of antibody half-life compared to non-crystallized
antibody, demonstrating the potential of crystalline preparations as
controlled release systems. Alginate polymers have also been ex-
plored for controlled release. Schweizer et al. developed two
polyanionic alginate matrices loaded with antibody through elec-
trostatic interactions [219]. Both matrices were delivered to rats
subcutaneously as hydrogels. After comparison with its liquid anti-
body counterpart, no signiﬁcant differences in bioavailability were
reported.
For many pathologies, local delivery could increase efﬁcacy and re-
duce systemic exposure. In such cases, administration routes such as
oral, topical, respiratory and intraocular become highly relevant. Con-
trolled release systems based on polymer matrices are also being tested
in preclinical studies for these delivery routes [213,220]. For instance, li-
posomes and chitosan-alginate microparticles have been employed for
oral delivery in order to protect antibodies from gastric inactivation
and allow release in the small intestine [221,222]. This is being explored
in combinationwith the conjugation of targeting ligands to improve de-
livery and absorption in the gastro-intestinal tract. [223]. For topical ap-
plication, a hydroﬁber dressing/adhesive sheet has been used to apply
inﬂiximab as a gel formulation for wound healing with improvements
in 7/8 patients tested [224]. In another example, a Phase I trial has
been completed with positive results for BIL-010t, a topically adminis-
tered, sheep antibody therapy to treat Basal Cell Carcinoma (BCC). BIL-
010t ointment was self-applied for 28 days; it was noted that 13/20 pa-
tients had decreases in the sizes of their lesionswith onlymild localized
skin reactions reported. The respiratory route has been extensively
studied for treatment of chronic obstructive pulmonary disease, lung
cancer, asthma and other pulmonary pathologies. Liposomes andmicrospheres have shown potential to increase bioavailability of respi-
ratory delivery by preventing proteolysis [225]. The PEGylation of anti-
body fragments was shown to increase lung lumen residence time in a
murine model through decreased clearance of alveolar macrophages
and increased mucoadhesion [226]. Other strategies being investigated
to deliver antibodies via the respiratory tract include IgG-loaded lipid
microparticles and nano-micelles [227–229]. The most advanced mole-
cule in clinical development is ALX-0171, an anti-RSV nanobody admin-
istered through inhalation; demonstrating a positive safety and
tolerability proﬁle in a ﬁrst-in-infant Phase I/II study with an anti-viral
effect observed [230].
Overall, the IV route will likely remain themost prominent adminis-
tration route in development due to ease of formulation. Still, the im-
provement of local bioavailability is an obvious requirement to fulﬁl
the potential of antibody-based therapy, both in terms of efﬁcacy and
patient convenience. As such, strategies such as pursuing alternative ad-
ministration routes and developing appropriate controlled release sys-
tems will gain relevance as their therapeutic potential continues to be
explored in preclinical studies.
9. Conclusions
Antibody-based therapeutics have evolved from murine antibodies
to humanized and fully human antibodies, developed with innovative
technologies such as transgenic mice and phage display. In the coming
years, next-generation antibodies with improved properties and for-
mats including ADC and bispeciﬁcs are expected to gain popularity as
biobetter antibody therapeutics. Major hurdles are being overcome for
biosimilar development following the marketing approval of the ﬁrst
biosimilar antibody by the FDA earlier this year. The advancement of
next-generation biobetters and biosimilars is critical to; 1) reduce the
high cost of therapeutic antibodies encountered over the last thirty
years, 2) address the shortcomings confronted with the use of these an-
tibodies such as poor efﬁcacy and stability and most importantly,
(3) provide greater patient beneﬁt.
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Abstract
Ensuring the successful production of a therapeutic antibody begins early on in the development process. The first stage is vector expression of
the antibody genes followed by stable transfection into a suitable cell line. The stable clones are subjected to screening in order to select those
clones with desired production and growth characteristics. This is a critical albeit time-consuming step in the process. This protocol considers
vector selection and sourcing of antibody sequences for the expression of a therapeutic antibody. The methods describe preparation of vector
DNA for stable transfection of a suspension variant of human embryonic kidney 293 (HEK-293) cell line, using polyethylenimine (PEI). The
cells are transfected as adherent cells in serum-containing media to maximize transfection efficiency, and afterwards adapted to serum-free
conditions. Large scale production, setup as batch overgrow cultures is used to yield antibody protein that is purified by affinity chromatography
using an automated fast protein liquid chromatography (FPLC) instrument. The antibody yields produced by this method can provide sufficient
protein to begin initial characterization of the antibody. This may include in vitro assay development or physicochemical characterization to aid in
the time-consuming task of clonal screening for lead candidates. This method can be transferable to the development of an expression system
for the production of biosimilar antibodies.
Video Link
The video component of this article can be found at http://www.jove.com/video/55153/
Introduction
The success of therapeutic antibodies continues to drive substantial investment into antibody development as a wave of next generation
therapeutics begins. The antibody market is expected to be reshaped by antibody fragments 1, antibody-drug conjugates 2, bispecific antibodies
3 and engineered antibodies with favorable properties 4. Another class gaining pharmaceutical interest are biosimilars. Biosimilar antibodies
are 'highly similar' replicate products of a therapeutic antibody that has already received regulatory approval. A proposed biosimilar must
be comparable with the originator antibody with respect to its structure, function, animal toxicity, clinical safety and effectiveness, human
pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity 5,6.
The approval rates of biosimilar antibodies have been slow due to the strict constraints on the final quality of the product. The exact
manufacturing processes such as specific cell lines and culturing conditions through to the final processing steps can remain proprietary.
What is more, the manufacturing of antibodies inherently involves a degree of variability which can add to the challenge of producing a highly
similar product. A comprehensive physiochemical and biophysical characterization and comparison is quite difficult, yet a number of studies
demonstrating the characteristics of biosimilar antibodies are emerging in the literature 7,8,9.
Generating a therapeutic antibody begins with transfection of mammalian host cells with a vector carrying the genes for the respective antibody.
Vector design, cell line and culture conditions are key considerations for setting up the expression system.
The DNA sequences of antibodies can be sourced from Drug Bank (www.drugbank.ca), IMGT (www.igmt.org) or research publications including
patents. For example, the sequence of trastuzumab is available through Drug Bank (DB ID: DB00072). The amino acid sequence of the variable
regions can undergo gene design and optimization for synthesis in the desired host species. It is important for a biosimilar antibody that no
modification is made to the amino acid sequence. Once synthesized, antibody genes can be subcloned into the appropriate vector of choice.
Human IgG antibodies consist of two identical heavy chains and two identical light chains. Tightly regulated expression of both chains is essential
for optimal production of heterologous IgG protein in mammalian cells 10. Intra- as well as inter-chain disulfide bonds have to be formed and
a number of post-translational modifications have to be introduced during protein biosynthesis. A number of vectors are available that have
been designed specifically to express antibody genes (refer to Table of Materials). These antibody-specific vectors usually express the constant
regions for both heavy and light chains so only the variable regions of each chain require cloning.
Transfection of cells with two independent constructs (co-transfection) is the most common approach for delivering heavy and light chain-
encoding genes. That is, each gene is driven by its own promoter and transcribed as separate antibody chains before being assembled in the
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endoplasmic reticulum. On the other hand, multi-cistronic vectors have internal ribosome entry site (IRES) elements incorporated that allow
expression of multiple genes as a single mRNA transcript with translation permitted from internal regions of the mRNA 11. In this instance, the
heavy and light chain-encoding genes are coupled in an arrangement to achieve co-expression of both antibody chains 10,12.
While transiently transfected cells yield sufficient protein to perform a limited number of experiments, stably transfected cell lines that have
undergone selection for genome integration can deliver higher yields. Higher protein amounts allow for assay development relating to in vitro
characterization and can provide an indication of antibody quality in consideration for downstream applications such as clonal cell line and lead
candidate selection.
The goal of this article is to describe the stable expression and purification of a therapeutic antibody produced in a mammalian expression
system. Indeed, this method can be applied to the expression of a biosimilar antibody. The method can be used for the initial characterization
of antibodies before proceeding on to the critical, albeit time-consuming steps of identifying a desirable clone for larger scale manufacturing.
Moreover, this method can be used to express other proteins and not just antibodies.
The following detailed protocol describes the expression of therapeutic antibody trastuzumab. This consists of preparation of vector DNA
followed by stable transfection in HEK-293 cell line and purification of antibody protein by an automated chromatographic method.
Protocol
NOTE: A suitable mammalian expression vector must be used for this protocol. Here, a single construct containing two expression cassettes is
used (i.e. heavy and light chain expression is driven by separate promoters). Trastuzumab heavy and light chains were previously cloned into the
vector. This vector was a gift from Andrew Beavil, obtained through a not-for-profit plasmid repository 13.
1. Recovery and Scale-up of Vector DNA
NOTE: Vector DNA was received as a soft agar stab culture in Escherichia coli XL-1 Blue strain; vector carries hygromycin resistance.
1. Insert a sterile inoculation stab or loop into the soft agar of the stab culture then streak a Luria Bertani (LB) agar plate prepared with 75 µg/ml
hygromycin for isolated colonies. Incubate the plate at 37 °C for 18-24 hr.
2. Inoculate a single colony into 5 ml Terrific broth (TB) containing 75 µg/ml hygromycin. Incubate the culture at 37 °C for 18-24 hr with 225 rpm
shaking.
3. Use the overnight culture to prepare a glycerol stock of vector DNA by gently mixing 800 µl of culture with 200 µl 80% glycerol in a cryovial
and freeze at -80 °C.
1. Add 100 µl of the overnight culture to 100 ml TB containing 75 µg/ml hygromycin in a baffled shaker flask (i.e. 1/1,000 dilution).
Incubate the culture at 37 °C for 18-24 hr with 225 rpm shaking.
4. After overnight culture, extract and purify the DNA according to manufacturer's instructions of midi/maxi preparation kit with the following
exception; during the final step, elute or resuspend DNA with water (pH 7.0-8.5).
5. Check concentration and purity of DNA by absorbance readings at 260 and 280 nm then store DNA at -20 °C.
 
NOTE: Optional (highly recommended): Sequence DNA using vector-specific primers to confirm identity.
2. Stable Transfection of HEK-293 Cells
1. Grow and maintain HEK-293 cells (suspension cells) according to standard protocols in serum-free media supplemented with 0.1% non-ionic
surfactant in Erlenmeyer flasks. Maintain at 2 x 105 cells/ml and subculture every fourth day. Culture cells at 37 °C with 5% CO2 and 120 rpm
rotation.
 
NOTE: Cells should have been in culture for no less than 4 days and no more than 4 weeks prior to transfection. HEK-293 cells grown as
monolayers in serum-containing media can also be used for this procedure.
2. On the day prior to transfection, seed HEK-293 cells at 3 x 105 cells/ml in wells of a 12-well plate in 2 ml of Dulbecco's Modified Eagle Media
(DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS). On the day of transfection, check that cells have reached
80-90% confluency
3. Dilute DNA and polyethylenimine (PEI) separately in transfection media then mix together.
1. Dilute 1.25 µg vector DNA per well (15 µg for 12 wells) in 300 µl transfection media. Incubate at room temperature for 5 min.
2. Dilute 2.5 µl of 1 mg/ml PEI solution (30 µl for 12 wells; i.e. 1:2 ratio of DNA to PEI) in 300 µl transfection media. Incubate at room
temperature for 5 min.
3. Add diluted DNA to diluted PEI, gently mix and incubate at room temperature for 15 min.
4. Add 50 µl of DNA/PEI mixture dropwise to each well of the plate. Rock the plate gently to distribute the transfection mixture then place the
plate at 37 °C, 5% CO2 for 24 hr.
5. Add 50 µg/ml hygromycin B per well and return plate to 37 °C, 5% CO2 for 10 days.
 
NOTE: By Day 10, un-transfected cells will have died and detached from the surface of the plate, whereas stably-transfected cells will be
viable and attached to the plate.
6. Replace the media in wells with 1/4 volume serum-free media and 3/4 volume DMEM supplemented with 10% FBS (i.e. 0.5 ml serum-free
media + 1.5 ml DMEM = 7.5% final serum concentration) and incubate for 4 days.
7. Replace the media in wells with 1/2 volume serum-free media and 1/2 volume DMEM supplemented with 10% FBS (i.e. 1 ml serum-free
media + 1 ml DMEM = 5% final serum concentration) and incubate for 4 days.
8. Replace the media in wells with 3/4 volume serum-free media and 1/4 volume DMEM supplemented with 10% FBS (i.e. 1.5 ml serum-free
media + 0.5 ml DMEM = 2.5% final serum concentration) and incubate for 4 days.
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9. Replace the media in wells with 2 ml of serum-free media supplemented with 0.1% non-ionic surfactant (i.e. 0% final serum concentration)
and incubate for 4 days.
 
NOTE: Maintain 50 µg/ml hygromycin B selective pressure on cells during serum-free adaptation. Cells adapted to serum-free media detach
from the surface of wells and may cluster in suspension. Refer to step 2.1 for culture conditions with the additional supplement of 50 µg/ml
hygromycin B.
10. Using a pipette, gently mix the suspension cultures in the 12-well plate and pool cells into a separate tube.
1. Using a hemocytometer, enumerate pooled cells and seed in 30 ml serum-free media in a Erlenmeyer flask at 2 x 105 cells/ml. Culture
cells at 37 °C with 5% CO2 and 120 rpm rotation. Subculture and expand every fourth day.
11. Continue to expand culture size to required cell density to obtain 10 vials at 1 x 107 cells/vial for cryopreservation in liquid nitrogen. Freeze
the cells in serum-free media containing 10% dimethylsulfoxide (DMSO).
 
NOTE: Conditioned media containing antibody can be harvested at each subculture to confirm protein production or used to optimize
purification conditions. To harvest conditioned media and maintain cells for subculture, centrifuge the culture at 300 x g for 5 min then filter-
sterilize supernatant through a 0.22 µm filter. Filtered supernatant may be kept at 4 °C for 1-2 weeks or -20 °C for longer term storage.
3. Large Scale Antibody Production from Batch Overgrow Culture
NOTE: Antibody production can be followed on from step 2.11 where existing cells are expanded to the required cell density based on the batch
overgrow culture volume to be setup. Otherwise, cells that have been thawed from cryopreservation begin at this stage once expanded to an
appropriate cell density and volume. Various culture supplements may be used to optimize antibody production; the use of tryptone to increase
antibody yield is demonstrated in this protocol.
1. Seed cells at 2 x 105 cells/ml in 100 ml serum-free media in two Erlenmeyer flasks (to compare antibody yields from un-supplemented and
nutrient-supplemented cultures). Culture at 37 °C, 5% CO2 and 120 rpm.
2. After 24 hr, add tryptone to a final concentration of 0.5% to nutrient-supplemented culture. Equalize volume of un-supplemented culture with
serum-free media.
3. From day 8, perform cell counts of the cultures daily using a hemocytometer to monitor cell viability. Harvest the culture supernatants once
cell viability is less than 80%.
1. Harvest supernatant by centrifugation of the cultures at 3,000 x g for 15 min then filter-sterilize the supernatant (containing antibody)
through a 0.22 µm filter. Store the supernatants at 4 °C (short-term) or freeze at -20 °C (long-term).
4. Antibody Purification by Affinity Chromatography Using an Automated Fast Protein
Liquid Chromatography (FPLC) System
NOTE: The following procedure can generally be applied to most automated systems. Purification can be performed at room temperature or at
4 °C (if FPLC system is kept in a cool room). A series of scouting tests can be performed to identify the optimal purification conditions including
appropriate column matrix, binding buffer, elution buffer and pH to ensure maximum recovery of purified antibody from conditioned media (refer to
Results section). The optimal conditions are dependent on the antibody or protein being purified. Purifications were performed on an automated
FPLC system. Purifications were performed at room temperature using a 5 ml Protein A column.
1. Prepare the following buffers using ultrapure water and adjust to the recommended pH then filter through a 0.22 µm filter.
1. Prepare 1 L of phosphate buffered saline (PBS) pH 7.4 (binding buffer) by mixing the following: 0.14 M NaCl, 0.0027 M KCl, 0.01 M
Na2HPO4 and 0.001 M KH2PO4. Adjust pH if necessary before filtering the buffer.
2. Prepare 500 ml of 0.1 M glycine-HCl pH 2.7 (elution buffer). Adjust pH before filtering the buffer.
3. Prepare 50 ml of 1 M Tris pH 9.0 (neutralization buffer).
2. Ensure all system power and communication connections with computer are made. Devices should be visible in the software 'System Control'
module. Ensure UV cell is set at 280 nm wavelength. Optional: Calibrate pH meter if connected and to be used.
3. Immerse inlet tubes of A, B and sample pump in ultrapure water to wash the system. Purge the pumps with a syringe if there is air in the
tubing or a suspicion of air in the system. Wash the system with water by manual operation via the system controller or via an automated
method. Observe that pressure, conductivity, UV280 tracing and pH remain consistent and that the pressure limit for the column is not
exceeded as per manufacturer's specification.
 
NOTE: Abnormalities may indicate air or blockage in the system that should be addressed before proceeding.
4. In the system controller module, start the flowrate at 1 ml/min manually via pump A in either load (bypassing sample loop) or inject (through
the sample loop) position to begin connecting the column. Disconnect system tubing at the column position inlet and remove the stopper
connected to the column inlet.
1. Allow water to flow from the system tubing dropwise on top of the column then attach the system tubing to the column. Having the
column inlet and inlet fitting overflowing with drops of water ensures a connection free of air bubbles.
5. Attach the column outlet at the downstream outlet and verify all fittings are tightly fastened. With the column now attached to the system, do
not exceed limits for maximum pressure limit and flowrate as outlined in column specifications.
6. Wash column with 5 column volumes (CV) of water. If necessary, continue column wash until UV280 tracing has stabilized.
7. Immerse inlet tubes of A in Binding buffer, B in Elution buffer and sample pump in Binding buffer to equilibrate the system in correct buffers.
Fill the inlet tubes with buffer using PumpWash by manual operation.
8. In the 'Method Editor' module of the software, use the method wizard to setup an affinity chromatography method for the column that is
intended to be used.
 
NOTE: Automated FPLC systems come with methods pre-filled with the recommended settings (i.e. flowrate and pressure limit) and run
steps based on the column (manufacturer, matrix and size) selected for purification.
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1. Use the following run steps for Protein A affinity chromatography:
1. Equilibrate system with 5 CV of Binding buffer and collect flowthrough into waste container.
2. Load sample onto the column (volume to be loaded is specified manually in the method) and collect flowthrough into a separate
container.
3. Wash system with 5 CV of Binding buffer and collect flowthrough into a separate container.
4. Elute column with 5 CV isocratic fractionation using Elution buffer and collect purified antibody sample as fractions by fraction
collector.
5. Equilibrate system with 5 CV of Binding buffer and collect flowthrough into waste container.
9. Once the method has been setup, specify the volume of conditioned media to be applied to the column and save the method.
 
NOTE: The specified volume in the method should be 5-10 ml less than the actual volume to avoid introduction of air during the sample run.
The specified volume used in this protocol is 90-120 ml.
10. Submerge the sample pump tubing into the vessel containing the conditioned media.
11. Prepare a separate container to collect sample flowthrough via the specified outlet tubing.
 
NOTE: It is important to collect the flowthrough in the case an error occurs during the run or the binding capacity of the column is exceeded
requiring the flowthrough to be reapplied to the column or the purification repeated.
12. Prepare collection tubes in the fraction collector. Add 100 µl of neutralization buffer per 1 ml fraction volume. The FPLC system will
automatically elute the fractions into the collection tubes.
13. In the 'System Control' module of the software, open the method to be run.
 
NOTE: The method run is initiated in a series of pages that include checking the variables of the method, fraction collector setup and defining
result file name and storage location.
14. Click START to initiate the run. The run can be monitored in the 'System Control' module.
15. At the completion of the purification run, check the resulting chromatogram in the 'Evaluation' module in the system software.
16. Combine all protein-containing fractions into a separate tube, buffer exchange and concentrate in PBS using a centrifugal filter device with 30
kDa molecular weight cut off. Perform centrifugation steps according to manufacturer's instructions.
17. Measure antibody concentration using bicinchoninic acid assay (BCA) according to manufacturer's instructions.
18. If another purification run is to be performed, prime the sample pump tubing in Binding buffer and repeat steps 4.9-4.14.
19. At the completion of purification runs, immerse inlet tubes of A, B and sample pump in ultrapure water and wash the system and column as
performed in step 3.
20. Submerge A, B and sample pump tubing in 20% ethanol and repeat wash procedure for storage of the system and column.
21. Disconnect the column from the downstream outlet and replace column stopper, then disconnect column at the inlet and replace stopper,
reconnect tubing to the system. Store the column at 4 °C.
Representative Results
Stable production of trastuzumab by transfected HEK-293 cells was confirmed using bio-layer interferometry (BLI) as presented in Figure 1. An
IgG standard curve was generated by measuring the binding rate between an IgG antibody standard and Protein A biosensor (Figure 1A). The
crude supernatant sample was similarly measured, then its concentration interpolated from the standard curve (Figure 1B). The supernatant
concentration was measured to be approximately 25 µg/ml (sampled from 50 ml collected at subculture) two weeks after serum-free adaptation
and prior to setting up cells for overgrow batch cultures.
Supernatant collected at each subculture after serum-free adaptation was pooled and used to optimize purification conditions; scouting of binding
and elution buffers was performed as shown in Figure 2. The steps of purification are depicted in Figure 2A based on UV280 signal. Once
the Protein A column equilibrates, an increase in UV280 signal represents sample loading; this increase is due to supernatant flowthrough
passing through the column (containing unbound proteins which absorb UV light at this wavelength), while antibodies have been captured by
the column. Once the sample has finished loading, the UV280 signal returns to baseline as any remaining unbound proteins are washed away.
Elution occurs as pH decreases to the optimal pH to release the antibodies captured by the column, depicted by an increase in UV280 signal
with eluted antibodies fractionated and collected by the fraction collector. Throughout the sample run, conductivity changes based on the salt
concentration in the buffers whereas system pressure should remain relatively constant. Optimal elution, pH and buffer was scouted first (Figure
2B); it was observed that antibody eluted more efficiently off the column at lower pH using either 0.1 M glycine HCl or citric acid. However, below
pH 2.7 there was no further improvement in the elution profile. In addition, elution peaks with 0.1 M glycine HCl appeared less broadened when
compared with 0.1 M citric acid at similar pH (Figure 2B). Subsequently, 0.1 M glycine-HCl pH 2.7 buffer was used to optimize binding buffer
conditions (Figure 2A). The effect of different binding buffers on elution was also compared (Figure 2A). It was observed that PBS pH 7.4 and
20 mM sodium phosphate pH 7 had comparable elution profiles, while the addition of 3 M NaCl to sodium phosphate buffer (to enhance antibody
binding to the column) was not favorable. Due to the ease of PBS buffer preparation, PBS pH 7.4 was selected as the binding buffer for future
purifications.
The purification chromatograms of batch overgrow cultures are shown in Figure 3; tryptone-supplemented culture is compared to un-
supplemented culture. It was noted that the addition of tryptone to the supplemented culture resulted in an increased UV280 signal during the
sample loading step, compared to the un-supplemented culture. The tryptone-supplemented culture yielded 3.8 mg and the un-supplemented
culture 1.7 mg of trastuzumab, based on protein recovered after buffer exchange and concentration. Quality control of the purified antibody
was confirmed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) as shown in Figure 4. Trastuzumab grown in un-
supplemented and tryptone-supplemented conditions results in similar antibody profiles under non-reducing and reducing conditions. As
expected, a prominent band at approximately 150 kDa confirms correctly folded antibody; other bands represent fragmented forms of the
antibody, a result of disulfide bond breakage and a method-induced artefact. Likewise, two bands at 50 and approximately 25 kDa confirm the
presence of antibody heavy and light chains, respectively.
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Figure 1: Confirmation of protein production by stably transfected HEK-293 cells using bio-layer interferometry (BLI). (A) Standard
curve was generated by measuring binding rate of IgG antibody standard to protein A biosensor over 120 seconds (grey) followed by crude
supernatant sample of PEI-transfected trastuzumab (PEI-Tmab; black). (B) Concentration of antibody protein in crude supernatant (open black
circle) was interpolated from standard curve (closed black circles) by plotting IgG antibody standard concentration versus binding rate. Please
click here to view a larger version of this figure.
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Figure 2: Purification chromatograms of elution and binding buffer scouting experiments. (A) The steps of purification are depicted
according to UV280 signal (blue, green or black lines); sample loading onto the column followed by column wash to wash away unbound
proteins then elution of bound protein from the column. Measurement of pH (red line), conductivity (brown line) and system pressure (grey line)
is monitored throughout the run. Three buffers were tested for optimal binding of trastuzumab to the column and washing away of unbound
protein to maximize elution yield. (B) 0.1 M glycine-HCl (pH 2.5-3.3) and 0.1 M citric acid (pH 2.5-3.5) buffers were tested for optimal elution of
trastuzumab from protein A column. Please click here to view a larger version of this figure.
 
Figure 3: Purification chromatograms of trastuzumab (TmAb) batch overgrow cultures grown with no supplement or supplemented
with tryptone. Stably transfected HEK-293 cells were setup at 2 x 105 cells/ml and cultured for 8 days either un-supplemented (120 ml; black
line) or supplemented with 0.5% tryptone (90 ml; green line). After harvesting, supernatants were purified using PBS pH 7.4 (binding buffer) and
0.1 M glycine-HCl pH 2.7 (elution buffer). Please click here to view a larger version of this figure.
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Figure 4: Analysis of purified trastuzumab by SDS-PAGE. Approximately 2 µg of trastuzumab purified from un-supplemented (-) or tryptone-
supplemented (+) cultures was sampled by 10% SDS-PAGE under non-reduced or reduced conditions. The gel is stained with coomassie R-250.
Please click here to view a larger version of this figure.
Discussion
This protocol details the transfection, stable expression and purification of a therapeutic antibody in HEK-293 cells. Stable expression of
antibody genes is the first step in generating an antibody-producing cell line for the development and manufacture of a therapeutic antibody.
While Chinese hamster ovary (CHO) cells remain the expression platform of choice for therapeutic proteins, the HEK-293 cell line is gaining
prominence with the realization that proteins produced in these cells are a closer match to naturally occurring human proteins, in terms of post-
translational modifications and function 14,15.
Mammalian cell lines including CHO (e.g., CHO-DG44 and CHO-K1) as well as non-immunoglobulin secreting murine B cell lines NS0 and
SP2/0 are predominantly used in biopharmaceutical production. Expression systems based on these cell lines are based on selection processes
whereby high producing clones are induced and selected through incremental addition of a specific selective drug 16,17. The selection process for
a stable clone can therefore be arduous and time-consuming. In comparison to these existing methods, the HEK-293 cell line robustly transfects
with high efficiency. The selection process is simplified and very easily adapts to serum-free suspension culture, making it an ideal expression
system for laboratory scale production of proteins 18.
A limitation of stable transfection is time in which a practical amount of protein can be produced and utilized in experiments. To try and overcome
this, the current protocol describes a culturing step that can achieve substantial amounts of protein within 3-6 weeks of transfection. The
batch overgrow cultures (large scale production) provide the opportunity to produce substantial amounts of antibody for the setup of in vitro
characterization experiments in the lead up to selection of a clonal cell line and lead candidates. This has clear advantages over transient
transfection, which can require higher amounts of DNA and reagents. In addition, the protein yield is not reproducible from batch to batch since
expression is only temporary and determined by transfection efficiency.
The addition of tryptone in this protocol provided an increased yield in protein expression. Addition of tryptone to transfection cultures has
previously been shown to improve protein synthesis 19,20. The tryptone supplemented culture resulted in improved trastuzumab antibody yields
of 40 mg/L versus the un-supplemented culture of 14 mg/L (Figure 3). SDS-PAGE verified that: (1) the antibody was being produced correctly;
and (2) the addition of tryptone did not alter structure based on comparison of the antibody bands under non-reducing and reducing conditions
(Figure 4). The addition of tryptone to the cultures is optional and is particularly used to achieve higher protein yields. Other supplements have
been considered to enhance protein expression such as sodium butyrate and valproic acid 21,22,23.
The first checkpoint of the protocol is the confirmation that protein is being produced by the transfected cell line. This step may be performed any
time after the two-week period of selective pressure used to select stable transformants. A number of methods may be used to confirm protein
production including bio-layer interferometry (Figure 1) or the similar approach of an IgG ELISA. Alternatively, a western blot may be performed
using an anti-IgG detection antibody to identify antibody protein in the crude supernatant or purified sample.
Other researchers have shown that higher transfection efficiency is achieved using adherent cells in serum-containing media 24. The presence
of supplements from animal origin is undesirable for biopharmaceutical production. Therefore, the sequential adaptation to serum-free media
is a critical step in the protocol requiring patience and careful monitoring of cell viability. The 4-day turnover period suggested in this protocol
is a guide and so if problems are encountered at a certain serum concentration, it is recommended that the cells be subcultured 2-3 times
in the previous ratio of serum-containing to serum-free media before continuing with the next ratio. Prior to setting up batch cultures and
cryopreservation of cells, consider that most cell lines are deemed fully adapted after three subcultures in 100% serum-free media.
One of the most crucial steps at the purification stage is the scouting for optimal conditions and buffers to ensure efficient binding of the antibody
to the column and then complete elution off the column (Figure 2). The conditioned media collected at each subculture is useful for this purpose.
In this case, the elution buffer of citric acid pH 3.5 generally recommended for protein A affinity chromatography was unsuitable for elution of
trastuzumab from the column. The scouting experiment using two different elution buffers at various pH clearly showed that even within the
narrow range of pH tested, the degree of elution was affected (Figure 2B).
In terms of downstream processing of the antibody fractions after purification, the antibody can be buffer-exchanged using a desalting column
either by manual or automated operation. Alternatively, dialysis membrane can also be used. Final protein concentration can be determined
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by other protein quantification methods including measurement of the absorbance signal at 280 nm with concentration deduced from Beer
Lambert's Law based on the extinction coefficient of the antibody.
This protocol has successfully produced the antibody protein of trastuzumab by stable transfection of HEK-293 cells. The antibody was purified
and characterized to confirm integrity. The steps in this protocol detailing DNA preparation, stable transfection followed by serum-free adaptation,
large scale production and automated purification can be transferred to producing other proteins.
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Abstract
This study reports the synthesis, characterisation and antimicrobial activity of five novel silver
N-heterocyclic carbene (Ag–NHC) complexes obtained by N-propylphthalimide and
N-methyldioxane substituted benzimidazolium salts with silver oxide. The reactions were
performed at room temperature for 24 h in the absence of light. The obtained complexes were
identified and characterised by 1H and 13C NMR, FT-IR and elemental analysis techniques. The
minimum inhibitory concentration (MIC) of the complexes was determined for E. coli,
P. aeruginosa, E. faecalis, S. aureus, C. tropicalis and C. albicans in vitro through agar and broth
dilution. The results indicated that these complexes exhibit antimicrobial activity. In particular,
complex 3 presented the significant broad spectrum antimicrobial activity.
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Introduction
It has been well established that silver cations (Ag+) have
antimicrobial activity against a broad range of microorganisms1–4.
Ag+ in low concentrations is non-toxic to humans, therefore a
compound that releases Ag+ to the environment in a steady rate
make an effective antimicrobial agent2–10. The effectiveness of a
silver complex as an antimicrobial agent depends on the
bioavailability of Ag+ when the compound is solubilised. Many
factors can influence this bioavailability of Ag+ including the
solubility and ionisation of the compound, the delivery route and
the presence of anions in the environment such as chloride,
bromide and sulphide1–3,7.
It has also been well established that silver N-heterocyclic
carbenes (Ag–NHCs) are a class of organometallic compounds
that are stable in the presence of air or moisture; the release of
Ag+ to the environment is slow and consistent4,5,7,8. As Ag–NHC
complexes can be easily and efficiently synthesised, the charac-
terisation of this class of compounds has generated considerable
interest in order to determine their effectiveness as antimicrobial
agents. From investigations to date, many groups of researchers
have synthesised and determined the biological activity of a broad
range of Ag–NHC complexes10–12. Specifically, compounds
derived from benzimidazole-based NHC ligands have shown
promising antimicrobial activity9,11,13–20 and various studies have
extended their research to anticancer activity6,9,13,14.
The aim of this study was to synthesise novel benzimidazo-
lium-based Ag–NHC complexes (2–6) in the pursuit of finding
biologically active compounds that can be further investigated for
their antimicrobial activity. The complexes (2–6) were charac-
terised by IR, elemental analysis, 1H and 13C NMR. The
antimicrobial activities of the compounds (2–6) were determined
against a panel of non-fastidious bacteria and yeasts. Complexes 3
and 6 were particularly effective against gram negative bacteria
and yeast, with compound 3 having the highest antimicrobial
activity across the panel of microorganisms in comparison to the
other complexes.
Materials and methods
Chemicals and equipment
All reactions were made under argon gas using Standard Schlenk
techniques. All primary chemicals were purchased commercially
from the following suppliers: Merck (Darmstadt, Germany),
Sigma-Aldrich (Aldrich and Fluka, St. Louis, MO), Introgen
(Carlo-Erba, Val de Reuil, France and Acros Organics, Geel,
Belgium) and ThermoFisher Scientific (Alfa-Aesar, Lancashire,
UK). The purchased chemicals include: o-phenylenediamine,
formic acid, dimethylformamide (DMF), hexane, silver oxide, 1-
(chloromethyl)naphthalene, benzyl chloride, 3-methylbenzyl
chloride, 4-methylbenzyl chloride, 2,4,6-trimethylbenzyl chloride,
diethyl ether, dichloromethane and ethyl alcohol. Prior to use, the
solvents were further purified through conventional methods21:
diethyl ether and hexane by distillation over Na and dichlor-
omethane by distillation over P4O10.
Mueller-Hinton Broth was purchased from HiMedia
Laboratories Pvt. Ltd. (Mumbai, India) and RPMI 1640 broth
was purchased from Sigma-Aldrich (Chemie GmbH, Taufkirchen,
Germany).
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The melting points (m.p.) of compounds were performed on an
Electrothermal 9200 melting point apparatus. Elemental analyses
of 2–6 were conducted on a LECO CHNS-932 Elemental
Analyser. FT-IR analyses were done on a Mattson 1000 spectro-
photometer. The NMR spectra of the Ag–NHC complexes were
performed on a Bruker AC300P FT spectrometer. Chemical shifts
() were given in ppm relative to tetramethylsilane.
Synthesis and characterisation of Ag–NHC complexes
(2–6)
The benzimidazolium salts were prepared as follows: KOH
was added to benzimidazole solution in ethyl alcohol and alkyl
halide was added to this solution after 1 h. The solution was
refluxed for 6 h then it was allowed to cool to room temperature.
The precipitated KCl was removed by filtering. The obtained N-
alkylbenzimidazole was purified by crystallization. Subsequently,
alkyl halide was added to the DMF solution of synthesised
N-alkylbenzimidazole and it was stirred for 24 h at 80 C.
Benzimidazolium salts were synthesised and purified by crystal-
lisation in a mixture of ethyl alcohol–diethylether (2:1)17,22–24.
The Ag(I)-NHC complexes (2–6) were synthesised
from N-propylphthalimide and N-methyldioxane substituted
benzimidazolium salts (1) (2 mmol) and Ag2O (1 mmol) in
20 mL dry dichloromethane (Scheme 1). All reactions were
conducted in a Schlenk tube that was wrapped with alumin-
ium foil for 24 h at room temperature. After the completion of
the reactions, the dichloromethane was removed by vacuum to
obtain the crude products. The products were washed twice
with diethyl ether, filtered and recrystallised from dichlor-
omethane–diethylether (2:1) or chloroform–diethylether (2:1)
mixtures at room temperature. The structures of the com-
pounds were confirmed by elemental analysis, FT-IR, 1H and
13C NMR.
Chloro [1-(N-propylphthalimide)-3-benzylbenzimidazol-2-
ylidene] silver(I), 2
Compound 2 was synthesised as described above from 1-(N-
propylphthalimide)-3-benzylbenzimidazolium chloride (2 mmol)
and Ag2O (1 mmol). The reaction provided complex 2 (0.45 g,
72%) as a solid. M.p.: 212–213 C. IR (CN)¼ 1431.2 cm1.
Anal. calcd. for C25H21AgClN3O2 (538.77 g/mol) was determined
as C, 55.73%; H, 3.93%; N, 7.80%. Found C, 55.61%; H, 4.08%;
N, 7.75%.
1H NMR (300 MHz, DMSO-d6), ; 2.40 (p, 2H,
CH2CH2CH2N, J¼ 7.2 Hz); 3.84 and 4.61 (t, 4H,
CH2CH2CH2N, J¼ 7.2 Hz); 5.66 (s, 2H, CH2C6H5); 7.26–7.87
(m, 13H, Ar–H). 13C NMR (75 MHz, DMSO-d6), ; 29.3
(CH2CH2CH2N); 35.4 and 45.5 (CH2CH2CH2N); 53.4
(CH2C6H5); 111.3, 112.3, 123.5, 124.3, 127.2, 128.5, 129.1,
131.9, 133.8, 134.1 and 134.9 (Ar–C); 168.2 (C¼O).
Chloro [1-(N-propylphthalimide)-3-naphthalen-1-yl-
methylbenzimidazol-2-ylidene] silver (I), 3
Compound 3 was synthesised as described above from
1-(N-propylphthalimide)-3-naphthalen-1-yl-methylbenzimidazo-
lium chloride (2 mmol) and Ag2O (1 mmol). The reaction
produced complex 3 (0.51 g, 83%) as a solid. M.p.: 195–196 C.
IR (CN)¼ 1430.5 cm1. Anal. calcd. for C29H23AgClN3O2
(588.83 g/mol): C, 59.15%; H, 3.94%; N, 7.14%. Found C,
59.03%; H, 4.08%; N, 7.15%.
1H NMR (300.13 MHz, DMSO-d6), ; 2.10 (p, 2H,
CH2CH2CH2N, J¼ 7.2 Hz); 3.56 and 4.46 (t, 4H,
CH2CH2CH2N, J¼ 7.2 Hz); 6.10 (s, 2H, CH2C10H7); 6.89–
8.08 (m, 15H, Ar-H). 13C NMR (75 MHz, DMSO-d6), ; 29.4
(CH2CH2CH2N); 35.5 and 47.5 (CH2CH2CH2N); 50.4
(CH2C10H7); 112.8, 123.3, 124.7, 124.9, 125.1, 125.9, 126.7,
127.2, 128.9, 129.2, 130.7, 132.2, 133.6, 133.8, 134.2, 134.6
and 134.9 (Ar–C); 168.5 (C¼O).
Bromo [1,3-bis(N-propylphthalimide)benzimidazol-2-yli-
dene] silver (I), 4
Compound 4 was synthesised as described above from 1-(N-
propylphthalimide)-3-benzylbenzimidazolium chloride (2 mmol)
and Ag2O (1 mmol). The reaction produced complex 4 (0.51 g,
86%) as a solid. M.p.: 246–247 C. IR (CN)¼ 1434.8 cm1.
Anal. calcd. for C29H24AgBrN3O2 (634.29 g/mol): C,
54.91%; H, 3.81%; N, 6.62%. Found C, 54.71%; H, 4.00%;
N, 6.82%.
1H NMR (300 MHz, DMSO-d6), ; 2.51 (p, 4H,
CH2CH2CH2N, J¼ 7.5 Hz); 3.64 and 4.42 (t, 8H,
CH2CH2CH2N, J¼ 7.5 Hz); 7.47–7.85 (m, 12H, Ar–H). 13C
NMR (75 MHz, DMSO-d6), ; 29.3 (CH2CH2CH2N); 35.1 and
45.2 (CH2CH2CH2N); 112.6, 123.1, 124.6, 131.8, 133.4 and 134.4
(Ar–C); 168.2 (C¼O).
Chloro [1-(2-methyl-1,4-benzodioxane)-3-benzylbenzimi-
dazol-2-ylidene] silver(I), 5
Compound 5 was synthesised as described above from 1-(2-
methyl-1,4-benzodioxane)-3-benzylbenzimidazolium chloride
(2 mmol) and Ag2O (1 mmol). The reaction produced complex
5 (0.51 g, 80%) as a solid. M.p.: 166–167 C. IR
(CN)¼ 1454.1 cm1. Anal. calcd. for C23H20AgClN2O2
(499.74 g/mol): C, 55.28%; H, 4.03%; N, 5.61%. Found C,
55.14%; H, 4.21%; N, 5.56%.
1H NMR (300 MHz, DMSO-d6), ; 4.06 and 4.22 (dd, 2H,
OCH2CH(CH2)O, J¼ 9.9 Hz); 4.88 (m, 1H, OCH2CHO); 4.71
and 4.79 (dd, 2H, OCH2CH(CH2)O, J¼ 9.9 Hz); 5.74 (s, 2H,
CH2C6H5); 6.68–7.90 (m, 13H, Ar–H).
13C NMR (75 MHz,
DMSO-d6), ; 49.0 (OCH2CH(CH2)O); 55.6 (OCH2CH(CH2)O);
65.1 (OCH2CH(CH2)O); 71.8 (CH2C6H5); 112.8, 112.9, 117.6,
117.7, 121.9, 122.0, 122.2, 124.6, 124.7, 127.8, 128.5, 129.2,
133.6, 134.4, 136.7, 142.3 and 143.2 (Ar–C).
X-
N
N
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N
N
AgX
R'
1 2-6
R R
Ag2O, CH2Cl2
Antimicrobial activity
Scheme 1. Synthesis of N-propylphthalimide and N-methyldioxane substituted Ag–NHC complexes.
1528 Y. Sarı et al. J Enzyme Inhib Med Chem, 2016; 31(6): 1527–1530
Chloro [1-(2-methyl-1,4-benzodioxane)-3-(4-methylben-
zyl)benzimidazol-2-ylidene]silver(I), 6
Compound 6 was synthesised as described above from 1-(2-
methyl-1,4-benzodioxane)-3-(4-methylbenzyl)benzimidazolium
chloride (2 mmol) and Ag2O (1 mmol). The reaction produced
complex 6 (0.49 g, 77%) as a solid. M.p.: 172–173 C. IR
(CN)¼ 1443.2 cm1. Anal. calcd. for C24H22AgClN2O2
(513.76 g/mol): C, 56.11%; H, 4.32%; N, 5.45%. Found C,
56.03%; H, 4.52%; N, 5.46%.
1H NMR (300 MHz, DMSO), ; 4.07 and 4.20 (dd, 2H,
OCH2CH(CH2)O, J¼ 9.9 Hz); 4.93 (m, 1H, OCH2CHO); 4.75
and 4.81 (dd, 2H, OCH2CH(CH2)O, J¼ 10.8 Hz); 2.30 (s, 3H,
CH2C6H4(CH3)–4); 5.67 (s, 2H, CH2C6H4(CH3)-4); 6.69–7.87 (m,
12H, Ar–H). 13C NMR (75 MHz, DMSO), ; 21.1 (CH2C6H4
(CH3)-4); 49.0 (OCH2CH(CH2)O); 52.2 (OCH2CH(CH2)O); 65.3
(OCH2CH(CH2)O); 71.9 (CH2C6H4(CH3)-4); 112.8, 112.9, 117.6,
117.7, 121.9, 122.2, 124.5, 127.8, 129.7, 133.6, 133.7, 134.4,
137.8, 142.3 and 143.2 (Ar–C); 191.4 (C–Ag).
In vitro antimicrobial activity testing by agar and broth
dilution
The minimum inhibitory concentrations (MICs) for each of the
Ag–NHC complexes were determined on a variety of non-
fastidious bacteria and yeast strains. The Clinical and Laboratory
Standards Institute methods were followed: the agar dilution
protocol was conducted on bacterial strains25 and the broth
dilution protocol was conducted on yeast strains26.
The following strains were used in this study: gram negative
bacteria – Escherichia coli ATCC 25922TM and Pseudomonas
aeruginosa ATCC 27853TM; gram positive bacteria –
Enterococcus faecalis ATCC 29212TM and Staphylococcus
aureus ATCC 29213TM; yeasts – Candida tropicalis and
Candida albicans. All bacterial strains were sourced from the
American Type Culture Collection (Rockville, MD) and all yeast
strains were kindly donated from the Department of
Microbiology, Faculty of Medicine, Ege University (Izmir,
Turkey).
All bacteria were subcultured on Mueller–Hinton Agar and all
yeasts were subcultured in RPMI 1640. For antimicrobial activity
tests, media was supplemented with Ag–NHC complexes and
antimicrobial controls were prepared in serial dilution as
described in the CLSI protocols of the agar25 and broth26 dilution
methods.
Stocks of the compounds 2–6 were prepared in dimethyl
sulfoxide (DMSO) and two-fold serial dilutions of the stocks were
prepared in sterile distilled water. The Ag–NHC complexes were
prepared as an eight-dilution series from 800mg/mL to
6.25mg/mL. Ciprofloxacin, ampicillin and fluconazole were
used as positive control drugs to compare against 2–6.
In preparation for inoculating antimicrobial supplemented
media, the cultures were prepared as a suspension to approxi-
mately 106 CFU/mL. The turbidity of the suspension was
standardised against a McFarlane Number 0.5 turbidity standard.
Antimicrobial supplemented media was inoculated from the cell
suspensions with sterile 10 mL inoculating loops. After inocula-
tion, cultures were incubated at 35 C in static, aerobic conditions,
for 16–20 h for bacterial cultures and 48 h for yeast cultures.
Results and discussion
Synthesis and characterisation
The Ag–NHC complexes can remain stable in the presence of air
and moisture at room temperature, without evidence of decom-
position. Product yields were obtained between 72 and 86%.
Generally, there is a typical proton signal of NCHN in the
range at  9–11 for benzimidazolium salts in the 1H NMR spectra.
However, we did not observed this single signal peak for 2–6. This
result verified the synthesis of the Ag–NHC complexes. The
pentet proton of N CH2CH2CH2C6H5 resonated at  2.40, 2.10
and 2.51 for 2–4, respectively. The triplet proton of N
CH2CH2CH2C6H5 resonated at  3.84 and 4.61 (for 2), 3.56 and
4.46 (for 3), 3.64 and 4.42 (for 4). The aromatic protons of silver
compounds were seen at  between 6.68 and 8.08 ppm in the 1H
NMR. The carbene carbon chemical shift value belonging to
compound 6 was observed at  191.4 ppm in the 13C NMR
spectra. This single signal carbene peak was not observed for
other synthesised new compounds (2–5). Carbonyl carbon was
resonated at low area for example at  168.2, 168.5 and 168.2 for
2–4, respectively. The IR(CN) band was obtained at  1431.2,
1430.5, 1434.8, 1454.1 and 1443.2 for 2–6, respectively.
Antimicrobial activity
Protocols from the Clinical and Laboratory Standards Institute
were conducted to determine the MICs of 2–6 for E. coli,
P. aeruginosa, S. aureus, E. faecalis, C. albicans and C.
tropicalis. The MIC was determined as the lowest concentration
at which the compound prevented visible growth for each
organism.
The results of the MIC values determined for complexes 2–6
are provided in Table 1. The complexes showed varied antimicro-
bial activity against tested microorganisms. In comparison to the
antibiotic controls, all complexes had a higher MIC value:
however complexes 3 and 6 were more effective than the other
complexes. Complex 3, in particular, exhibited the most anti-
microbial activity across the whole panel compared to the other
complexes. Compound 3 was more effective against the yeast
strains C. albicans and C. tropicalis than against the bacterial
strains. The antimicrobial activity of complexes 2 and 4 was the
least effective, having similar activities across all microorganisms.
Table 1. MIC values of the Ag–NHC complexes (2–6) against a panel of non-fastidious microorganisms.
MIC (mg/mL)
Gram negative bacteria Gram positive bacteria Yeasts
Compound E. coli P. aeruginosa S. aureus E. faecalis C. albicans C. tropicalis
2 200 200 200 200 200 200
3 50 50 50 50 25 25
4 200 200 200 200 200 200
5 100 100 100 100 100 100
6 50 50 100 100 50 50
Ampicillin 3.12 – 3.12 1.56 – –
Ciprofloxacin 1.56 3.12 0.39 0.78 – –
Fluconazole – – – – 3.12 3.12
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Complex 5 again exhibited same activities across all microorgan-
isms, although it presented a moderate MIC value. Complexes 2
and 5 both contain a benzyl substituent, although 5 contains a
benzodioxane group and had lower MIC value than 2, which
contains a propyl phthalimide group. This suggests that the
benzodioxane has an effect on the antimicrobial activity of 5.
Complex 3 includes a naphthalene-1-ylmethyl group and its
performance is consistent with a previous work which indicated
that Ag–NHC with naphthalene-1-ylmethyl substituents has
higher antimicrobial activity, especially antifungal activity16.
Complex 6 includes a 4-methylbenzyl group and its performance
is markedly improved compared to a previous work27, in which
the authors demonstrated that their complex which included a 4-
methylbenzyl group had lower antimicrobial activity.
Conclusion
This study describes the synthesis of five novel benzimidazolium
based Ag–NHC complexes (2–6) which were characterised by IR
and elemental analysis, 1H and 13C NMR. The complexes were
evaluated for biological activity against a panel of non-fastidious
bacteria and yeasts. Complexes 3 and 6 were particularly effective
against gram negative bacteria and yeast, with complex 3 having
the highest antimicrobial activity across the panel of microorgan-
isms in comparison to the other complexes.
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